publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
abstract
accept
public
pathogenesi
effect
probiot
dairi
product
contain
lactobacillu
casei
shirota
gut
microbiota
irrit
bowel
syndrom
randomis
placebocontrol
doubleblind
studi
object
hypothes
disturb
intestin
flora
could
factor
onset
persist
ib
complaint
aim
studi
analys
effect
lactobacillu
casei
shirota
lc
faecal
flora
ib
patient
method
randomis
placebo
control
doubl
blind
studi
ib
patient
fulfil
rome
criteria
ii
includ
patient
took
bottl
daili
week
contain
either
lc
placebo
faecal
sampl
collect
intervent
week
end
intervent
week
followup
week
microbi
popul
bacteroid
anaerob
bifidobacteria
coliform
clostridia
lactobacilli
enumer
use
quantit
plate
total
bacteri
count
perform
use
fish
bacteri
dna
analys
quantit
realtim
pcr
detect
atopobium
spp
bacteroidesprevotellaporphyromona
group
clostridium
coccoideseubacterium
rectal
group
clostridium
leptum
subgroup
clostridium
difficil
clostridium
perfringen
desulfovibrio
desulfurican
group
bifidobacterium
spp
statist
analysi
perform
use
mannwhitney
u
test
pair
wilcoxon
test
p
consid
statist
signific
result
signific
differ
total
bacteri
count
seen
treatment
placebo
group
use
quantit
plate
signific
differ
seen
differ
bacteri
group
group
significantli
lower
bacteri
count
seen
group
clostridia
compar
placebo
group
significantli
higher
amount
bifidobacteria
lactobacilli
detect
compar
use
qrtpcr
significantli
lower
count
desulfurican
group
seen
placebo
group
compar
treatment
group
treatment
group
signific
differ
seen
compar
wherea
placebo
group
signific
differ
detect
differ
bacteri
group
differ
sampl
point
analysi
ib
subtyp
level
reveal
differ
microbiota
differ
subtyp
conclus
although
signific
chang
microbiota
seen
intak
lc
treatment
group
differ
microbi
popul
group
signific
interestingli
specif
find
like
associ
specif
ib
subtyp
rather
ib
gener
object
ass
chest
radiographi
find
patient
influenza
viru
infect
review
radiolog
find
patient
confirm
influenza
viru
infect
admit
two
hospit
cantabria
spain
radiolog
find
character
pattern
opac
lung
distribut
presenc
absenc
pleural
effus
hiliar
mediastin
adenopahi
initi
radiographi
abnorm
patient
relat
exclus
influenza
viru
infect
characterist
imag
find
patient
includ
parenchym
consolid
consolid
plu
ground
glass
ground
glass
opac
seventeen
patient
diffus
distribut
opac
bilater
lower
middl
zone
frequent
affect
pleural
effus
patholog
mediastin
lymph
node
seen
initi
radiographi
patient
abnorm
chest
xray
frequent
men
smoker
dyspnoea
pleurit
pain
diarrhoea
conclus
although
patient
influenza
viru
infect
show
normal
chest
xray
abnorm
chest
radiographi
characterist
show
area
consolid
without
ground
glass
affect
bilater
diffus
distribut
predilect
lower
middl
zone
pleural
effus
mediastin
adenopahti
find
seen
initi
radiographi
sever
streptococc
infect
lead
seriou
tissu
damag
myositi
exampl
condit
system
antibiot
therapi
principl
cours
treatment
necrot
soft
tissu
infect
clinic
trial
also
shown
hyperbar
oxygen
hbo
therapi
effect
streptococc
myositi
patient
ozon
known
cytotox
ga
recent
shown
support
immun
system
activ
oxid
mechan
increas
proinflammatori
cytokin
studi
compar
effect
antibiotherapi
hbo
applic
bacteri
growth
wound
recoveri
murin
model
streptococc
myositi
fortyf
male
spraguedawley
rat
divid
five
group
myositi
caus
inocul
ml
mcfarland
streptococcu
pyogen
thigh
region
four
group
sham
group
normal
salin
given
rat
one
four
group
control
wherea
three
group
treat
penicillin
g
mgkg
ml
intraperiton
hbo
oxygen
atm
min
ozon
mgkg
intraperiton
seventh
day
histolog
bacteri
investig
done
soft
tissu
specimen
taken
thigh
region
signific
differ
respons
therapi
three
group
compar
control
group
p
antibiot
ozon
group
also
success
hbo
p
ozon
group
yield
better
result
antibiot
group
p
result
conclud
ozon
therapi
use
addit
antibiot
treatment
seriou
infect
myositi
introduct
mutat
dna
mismatch
repair
mmr
gene
mutsl
equival
hexab
locu
pneumococci
associ
hypermut
phenotyp
variou
bacteri
speci
may
play
signific
role
antibiot
resist
emerg
object
mutat
frequenc
consecut
nonredund
enterococcu
faecali
isol
collect
extrahospit
survey
investig
method
result
detect
mutat
first
approach
base
agar
diffus
method
use
fosfomycin
disk
identif
hypermut
strain
achevi
count
squatter
coloni
grow
inhibit
zone
h
incub
four
strain
coloni
form
unit
within
fosfomycin
inhibit
area
consid
mutat
mutat
frequenc
evalu
agar
medium
without
rifampicin
rate
compris
sd
ie
least
higher
five
test
strain
taken
random
collect
includ
e
faecali
strain
atcc
frequenc
mutat
isol
urin
sperm
fluid
analysi
mutsl
investig
pcr
amplif
sequenc
experi
five
three
amino
acid
aa
substitut
mut
aa
mutl
aa
respect
identifi
comparison
refer
sequenc
genbank
access
addit
nonsens
mutat
arginin
posit
led
inactiv
mut
mutat
associ
hypermut
conclus
mutat
frequenc
clinic
popul
e
faecali
previou
studi
shown
linezolid
mutant
emerg
readili
e
faecali
atcc
ba
et
al
antimicrob
agent
chemoth
hypermut
capabl
strain
detect
simpl
agar
diffus
method
use
fosfomycin
disk
prior
prolong
antibiot
monotherapi
treatment
studi
give
first
evid
associ
mmr
gene
inactiv
mutat
phenotyp
clinic
e
faecali
strain
najibi
b
bakhshi
sattari
alebouyeh
tajbakhsh
tehran
ir
object
infecti
diarrheal
diseas
recogn
second
caus
mortal
among
infecti
diseas
children
less
five
year
enteropathogen
escherichia
coli
epec
play
import
role
caus
agent
children
diarrhea
integron
dna
element
known
carri
genet
cassett
respons
antibiot
resist
object
studi
investig
presenc
resist
gene
cassett
content
class
integron
among
enteropathogen
e
coli
isol
patient
refer
tehran
hospit
method
studi
stool
sampl
collect
enteropathogen
escherichia
coli
detect
use
biochem
serolog
method
confirm
pcr
amplif
eae
gene
isol
genotyp
defin
epec
subject
analysi
class
integron
investig
primer
specif
conserv
integras
gene
int
variabl
resist
gene
cassett
amplifi
sequenc
result
studi
period
case
enteropathogen
escherichia
coli
strain
detect
serotyp
appear
domin
serotyp
twenti
two
strain
appear
harbor
class
integron
among
variabl
region
defin
relat
amplicon
approxim
bp
size
respect
presenc
class
integron
reveal
genet
element
play
import
role
transfer
antibiot
resist
among
strain
studi
may
transfer
resist
aminoglycosid
trimetoprim
gramneg
bacteria
plachoura
galani
z
chrysouli
f
kontopid
panagea
souli
g
petrikko
haidari
gr
object
colistin
resist
salmonella
enterica
associ
mutat
pmrab
two
compon
regulatori
system
control
composit
outer
membran
lipopolysachharid
mechan
recent
describ
colistin
resist
klebsiella
pneumonia
clinic
strain
elucid
basr
homologu
system
pmrab
k
pneumonia
studi
method
colistin
resist
k
pneumonia
strain
isol
clinic
surveil
specimen
patient
colistin
treatment
well
sensit
strain
isol
patient
colistin
use
includ
studi
exact
mic
colistin
determin
etest
strip
sensit
resist
isol
epidemiolog
studi
repetit
extragen
palindrom
rep
pcr
methodolog
basr
bass
gene
respect
resist
suscept
isol
amplifi
pcr
sequenc
primer
use
design
webprim
amplifi
bp
intern
fragment
basr
case
signific
differ
observ
gene
suscept
resist
strain
mutat
observ
bass
gene
one
resist
isol
alreadi
describ
homologu
gene
pmra
colistin
resist
laboratori
strain
salmonella
enterica
howev
mutat
two
compon
regulatori
system
basr
clinic
isol
explain
case
colistin
resist
klebsiella
pneumonia
strain
liakopoulo
k
chatzigeorgi
k
tarpatzi
l
zerva
e
petinaki
larissa
athen
gr
object
investig
mechan
highlevel
methicillinresist
staphylococcu
lugdunensi
isol
materi
method
microorgan
isol
blood
cultur
patient
endocard
identif
speci
level
perform
vitek
system
verifi
molecular
method
base
fbl
gene
suscept
test
variou
antimicrobi
agent
assess
vitek
system
mic
valu
determin
etest
product
penicillinas
perform
nitrocephin
disk
test
presenc
meca
gene
detect
pcr
order
detect
mutat
gene
amplif
follow
sequenc
analysi
done
result
compar
obtain
clinic
lugdunensi
strain
suscept
oxacillin
mic
mgl
isol
despit
highlevel
resist
oxacillin
mic
mgl
carri
meca
gene
overproduct
penicillinas
mutat
detect
howev
mutat
found
alter
posit
insert
posit
four
aminoacid
sayg
mutat
found
suscept
strain
blactam
bind
penicillinbind
motif
ktg
transpeptidas
region
locat
posit
alter
around
motif
possibl
confer
resist
due
reduc
affin
blactam
conclus
first
report
mutat
result
highlevel
methicillinresist
clinic
lugdunensi
isol
escherichia
coli
caus
septic
diarrhoea
calv
itali
emerg
multiresist
clonal
group
marches
e
coppo
r
barbieri
zoppi
c
pruzzo
f
rossi
bergagna
dondo
e
debbia
genoa
turin
object
emerg
antibioticresist
epidem
clone
among
anim
monitor
sinc
clonal
related
among
certain
serogroup
strain
ie
e
coli
capabl
caus
diseas
differ
host
human
includ
shown
although
differ
molecul
employ
crossresist
exist
among
fluoroquinolon
use
human
veterinari
medicin
increas
incid
enrofloxacinresist
e
coli
associ
septic
diarrhoea
calv
recent
observ
northern
itali
aim
studi
investig
phenomenon
method
total
consecut
e
coli
isol
exhibit
reduc
suscept
enrofloxacin
intermedi
resist
resist
caus
septic
diarrhoea
calv
largescal
farm
studi
phylogenet
group
antibiot
suscept
serogroup
determin
rapd
pfge
type
provid
addit
discrimin
result
major
microorgan
carri
resist
two
addit
drug
pattern
fluoroquinolon
ampicillin
cotrimoxazol
tetracyclin
gentamicinthiamphenicol
repres
plasmidmedi
extendedspectrum
ampc
blactamas
includ
plasmidmedi
fluoroquinolon
resist
genet
determin
detect
third
gener
cephalosporin
emerg
activ
antimicrobi
agent
test
suscept
strain
conclus
overal
differ
rapd
profil
differ
serogroup
could
distinguish
among
typabl
strain
indic
substanti
heterogen
suggest
occur
sever
independ
select
event
howev
approxim
one
fourth
strain
belong
serogroup
pfge
reveal
major
clonal
relat
indic
select
clonal
group
sinc
anim
suggest
possibl
sourc
serogroup
e
coli
infect
human
studi
need
clearli
determin
zoonot
potenti
strain
barguigua
bouchakour
talmi
k
zerouali
f
el
otmani
timinouni
casablanca
el
jadida
object
morocco
like
countri
worldwid
grow
problem
ctxm
blactamas
produc
enterobacteriacea
present
studi
sought
character
plasmid
associ
klebsiella
pneumonia
isol
recov
moroccan
commun
method
character
multidrug
resist
region
sequenc
three
plasmid
encod
blactamas
klebsiella
pneumonia
strain
isol
three
moroccan
citi
casablanca
plasmid
el
jadida
plasmid
b
settat
plasmid
c
conjug
mate
attempt
agar
mic
determin
etest
method
antibiot
resist
gene
integron
identifi
pcr
sequenc
result
conjug
transfer
cefotaxim
resist
achiev
strain
carri
kb
plasmid
addit
plasmid
harbour
follow
antibiot
resist
gene
confer
resist
seven
antibiot
class
aac
ibcr
tet
qnrb
gene
plasmid
b
carri
consist
also
aac
ibcr
tet
contrast
plasmid
c
carri
aac
ibcr
tet
gene
present
follow
genet
environ
conclus
knowledg
first
descript
genet
environ
gene
k
pneumonia
moroccan
commun
plasmid
encod
confer
similar
multidrug
resist
phenotyp
suggest
may
share
similar
genet
scaffold
share
featur
plasmid
encod
blactamas
escherichia
coli
canada
icc
abstract
accept
public
macrolid
resist
vitro
select
antibiot
resist
differ
human
isol
lactobacillu
strain
v
rodighiero
e
de
vecchi
r
mattina
celest
toscano
l
drago
milan
object
spread
antibiot
resist
concern
due
increas
rate
isol
multiresist
pathogen
sinc
commens
bacteria
transfer
determin
resist
pathogen
studi
resist
includ
lactic
acid
bacteria
especi
intend
use
probiot
perform
studi
aim
evalu
capabl
antibiot
select
resist
lactobacilli
method
strain
lactobacillu
acidophilu
n
lactobacillu
plantarum
n
lactobacillu
crispatu
n
lactobacillu
casei
n
isol
human
fece
includ
amoxicillinclavulan
erythromycin
tetracyclin
test
minimum
inhibitori
concentr
mic
measur
microdilut
broth
method
suscept
determin
accord
breakpoint
establish
efsa
frequenc
spontan
mutat
calcul
number
coloni
grown
antibioticcontain
agar
plate
per
inoculum
select
resist
perform
mic
peak
serum
concentr
cmax
suscept
isol
serial
subcultur
onto
agar
plate
contain
linear
gradient
antibiot
bacteria
expos
ten
consecut
passag
antibioticgradi
plate
ten
passag
antibioticfre
plate
acquisit
resist
defin
increas
mic
stabl
mutant
reduc
suscept
erythromycin
analys
pcr
detect
presenc
erm
mef
gene
result
resist
macrolid
observ
strain
harbour
ermb
gene
tetracyclin
strain
strain
suscept
amoxicillinclavulan
frequenc
mutat
suscept
strain
n
lower
mic
tetracyclin
show
highest
frequenc
mutat
multistep
select
increas
mic
gener
observ
chang
stabl
strain
test
antibiot
could
select
stabl
resist
speci
molecular
character
resist
mutant
lead
detect
erm
mef
gene
conclus
result
suggest
decreas
suscept
follow
exposur
antibiot
might
occur
lactobacilli
evalu
abil
acquir
resist
common
antibiot
perform
parallel
investig
presenc
resist
determin
strain
intend
human
anim
use
ikeda
h
hanaki
ikedadantsuji
h
matsui
iwatsuki
k
shiomi
naka
k
sunakawa
omura
tokyo
kanagawa
jp
background
patient
suffer
mrsa
infect
often
coinfect
gramneg
bacteria
like
treat
combin
vancomycin
van
blactam
antibiot
howev
combin
therapi
caus
emerg
vanresist
mrsa
design
blactam
antibioticinduc
vanresist
mrsa
bivr
trap
larg
amount
van
lower
free
drug
concentr
milieu
blactam
antibiot
inhibit
peptidoglycan
synthesi
promot
express
autolysin
result
releas
larg
amount
peptidoglycan
fragment
extracellular
milieu
hypothes
peptidoglycan
fragment
gener
action
blactam
antibiot
autolysin
incorpor
cytoplasm
recycl
promot
synthesi
nascent
lipidii
analog
case
escherichia
coli
thu
search
activ
compound
mimic
role
blactam
antibiot
induct
bivr
phenomenon
method
bivr
strain
use
indic
cell
bivr
assay
compound
test
induct
bivr
phenomenon
either
prepar
peptidoglycan
fragment
synthet
compound
test
impregn
paper
disc
diamet
mm
place
van
agar
plate
streak
cell
plate
incub
overnight
test
compound
activ
indic
bivr
cell
grow
around
paper
disc
form
hollow
diamet
measur
nonbivr
cell
show
growth
zone
due
presenc
van
result
purifi
muropeptid
glcnacmurnaclaladisoglnlli
odiacetylmurnlaladisoglnlli
mg
per
disc
yield
mm
respect
growth
zone
peptid
essenti
activ
bivr
induc
activ
undetect
glcnacmurnaclaladisogln
murnaclaladisoglulli
laladisoglulli
conclud
activ
compound
compos
glcnacmurnac
glycan
chain
peptid
c
ludden
corcoran
killeen
keadi
da
costa
cormican
morri
tw
boo
galway
ie
object
emerg
carbapenemresist
enterobacteriacea
cre
becom
signific
public
health
threat
within
divers
group
vimproduc
enterobact
cloaca
increasingli
report
countri
greec
spain
report
evalu
evid
transmiss
carbapenemresist
e
cloaca
cardiothorac
intens
care
unit
cticu
method
clinic
infect
control
microbiolog
data
collat
clinic
specimen
cultur
rountin
method
patient
rectal
swab
environ
screen
cre
isol
identifi
vitek
suscept
test
perform
clsi
disc
diffus
evalu
carbapenemas
conduct
use
modifi
hodg
test
mht
metalloblactamas
mbl
etest
synergi
test
pcr
detect
carbapenemas
gene
analysi
pfge
band
pattern
also
perform
result
carbapenemresist
e
cloaca
cultur
sternal
wound
patient
within
period
patient
receiv
broadspectrum
antibiot
neither
histori
recent
travel
respect
stay
cticu
overlap
day
treat
appropri
antibiot
aggress
infect
control
measur
institut
cre
isol
patient
hospit
environ
medic
equip
time
isol
resist
blactam
includ
carbapenem
gentamicin
tobramycin
suscept
ciprofloxacin
amikacin
colistin
phenotyp
carbapenemas
screen
method
yield
posit
often
inconsist
subtl
result
pcr
confirm
presenc
blavim
isol
pfge
demonstr
indistinguish
band
pattern
conclus
first
report
emerg
vimproduc
e
cloaca
ireland
sternal
wound
infect
organ
also
previous
report
clinic
molecular
data
indic
crosstransmiss
carbapenemresist
e
cloaca
cticu
like
laboratori
detect
vimproduc
enterobacteriacea
remain
challeng
need
activ
surveil
highrisk
patient
warrant
consider
report
highlight
therapeut
infect
control
challeng
pose
organ
reiter
import
prudent
antibiot
usag
aggress
infect
control
measur
introduct
integron
mobil
genet
element
capabl
gene
captur
express
via
sitespecif
recombin
action
promot
integron
play
major
role
dissemin
antibiot
resist
gene
commonli
associ
member
famili
enterobacteriacea
object
find
incid
class
integron
associ
esbl
produc
klebsiella
pneumonia
isol
blood
stream
infect
studi
carri
k
pneumonia
isol
period
two
year
antimicrobi
suscept
test
antibiot
esbl
detect
done
per
clsi
follow
multiplex
pcr
integras
gene
pcr
done
detect
class
class
integron
similarli
class
class
integron
use
specif
primer
sequenc
done
repres
number
strain
result
isol
esbl
produc
blashv
blactxm
common
esbl
posit
isol
carri
class
integron
isol
carri
class
integron
class
class
found
none
class
class
type
sequenc
blast
result
confirm
ident
drug
resist
rate
integron
posit
isol
higher
compar
integron
neg
strain
conclus
higher
percentag
class
integron
associ
esbl
strain
note
first
time
region
also
coexist
class
class
type
increas
higher
risk
multidrug
resist
gene
transfer
rate
find
strongli
suggest
integron
major
role
dissemin
esbl
mediat
resist
among
nosocomi
isol
k
pneumonia
alarcon
e
aznar
espinola
somodevilla
lopezbrea
madrid
es
object
aim
studi
detect
presenc
prophag
induct
lytic
cycl
cultur
clinic
isol
presenc
low
concentr
mitomycin
c
determin
associ
resist
antimicrobi
agent
method
h
pylori
strain
studi
obtain
gastric
biopsi
follow
standard
methodolog
strain
store
use
tigr
use
neg
control
prophag
detect
genom
amoxicillin
clarithromycin
rifampicin
ciprofloxacin
tetracyclin
metronidazol
resist
determin
etest
follow
standard
methodolog
prophag
induct
h
pylori
strain
subcultur
recent
prepar
blood
agar
plate
contain
ngml
mitomycin
c
mgl
vancomycin
mgl
amphotericyn
b
day
incub
plate
examin
presenc
growth
inhibit
plaqu
result
porphag
induct
observ
strain
tigr
detect
inhibit
plaqu
cultur
mitomycin
c
contain
blood
agar
plate
follow
resist
percentag
detect
amoxicillin
clarithromycin
rifampicin
ciprofloxacin
tetraciclin
metronidazol
percentag
resist
analyz
group
strain
without
prophag
resist
higher
group
prophag
follow
antimicrobi
agent
amoxicillin
vs
clarithromycin
vs
ciprofloxacin
vs
metrronidazol
vs
resist
lower
group
prophag
follow
antimicrobi
agent
rifampicin
vs
tetracyclin
vs
conclus
mitomycin
c
contain
blood
agar
plate
easi
method
detect
prophag
carriag
among
h
pylori
strain
high
percentag
h
pylori
strain
show
prophag
detect
mitomycin
c
induct
presenc
prophag
seem
associ
higher
percentag
resist
antimicrobi
agent
frequent
use
treat
infect
produc
h
pylori
object
identifi
resist
mechan
determin
appropri
antibiot
treatment
patient
whose
blood
abdomin
fluid
isol
e
coli
resist
ertapenem
cephalosporin
borderlin
imipenem
meropenem
resist
highlight
problem
detect
difficulti
treatment
multi
drug
resist
gram
neg
organ
method
follow
hospitalis
mi
egypt
requir
itu
care
nile
hospit
patient
repatri
via
airambul
wythenshaw
hospit
cardiac
rehabilit
subsequ
develop
acut
abdomen
secondari
cholycyst
laporotomi
cholecystectomi
carri
cultur
blood
drain
fluid
isol
resist
e
coli
routin
inhous
antibiot
suscept
test
isol
undertaken
vitek
resist
confirm
refer
laboratori
carri
mic
cephalosporin
carbapenem
aminoglycosid
tigecyclin
agent
agar
dilut
potenti
carbapenemas
activ
examin
plate
assay
clover
leaf
test
follow
enzym
identif
pcr
result
pure
growth
e
coli
reduc
carbapenem
suscept
isol
mic
carbapenem
ertapenem
meropenem
imipenem
isol
clover
leaf
posit
carbapenemas
activ
pcr
identifi
isol
panblactamresist
due
ctxm
seen
mic
cefotaxim
potenti
whilst
ceftazidim
fell
isol
sensit
tigecyclin
patient
receiv
day
result
full
recoveri
detail
travel
histori
reveal
visit
tunisia
spain
portug
travel
greec
turkey
past
yr
conclus
previous
identifi
e
coli
uk
detect
carbapenemas
problemat
resist
ertapenem
may
indic
yet
mic
ertapenem
readili
rais
imperm
alon
make
use
singl
maker
uncertain
dissemin
date
geograph
speci
restrict
previous
associ
e
coli
travel
egypt
tigecyclin
concentr
well
gall
bladder
consid
sensit
test
circumst
howev
concern
remain
around
achiev
adequ
serum
level
agent
patient
sever
sepsi
singl
confirm
pathogen
icc
abstract
accept
public
rafi
r
moaddab
tabriz
ir
object
studi
evalu
effect
second
line
drug
mycobacteri
strain
becom
import
past
year
particularli
due
outbreak
caus
multidrug
resist
mdr
strain
mycobacterium
tuberculosi
mt
aim
studi
evalu
invitro
suscept
tuberculosi
mt
mycobacteria
tubercl
bacilli
mott
strain
two
main
second
line
antimycobacteri
agent
ciprofloxacin
ofloxacin
method
studi
invitro
activ
ofloxacin
ciprofloxacin
total
mycobacteri
strain
includ
mycobacterium
tuberculosi
strain
strain
resist
strain
sensit
first
line
drug
mycobacteria
tubercl
bacilli
strain
strain
resist
first
line
drug
investig
proport
method
lowensteinjensen
lj
medium
result
tuberculosi
strain
strain
sensit
first
line
drug
diagnos
suscept
ofloxacin
ciprofloxacin
strain
resist
first
line
drug
one
strain
resist
ofloxacin
strain
found
resist
ciprofloxacin
mycobacteria
tubercl
bacilli
strain
strain
resist
ofloxacin
strain
found
resist
ciprofloxacin
conclus
find
studi
show
ofloxacin
ciprofloxacin
could
effect
use
mycobacterium
tuberculosi
strain
also
mycobacteria
tubercl
bacilli
strain
staphylococcu
aureu
faecal
carriag
among
healthi
human
spain
detect
livestockassoci
genet
lineag
methicillinsuscept
isol
benito
c
lozano
e
zarazaga
c
torr
es
object
determin
rate
aureu
faecal
carriag
healthi
human
spain
perform
genet
character
recov
isol
method
fecal
sampl
healthi
human
recov
la
rioja
spain
septemberdecemb
sampl
inocul
mannitolsaltagar
orsab
plate
aureu
methicillinresist
aureu
recoveri
respect
isol
identifi
biochem
method
nucgen
pcr
antibiot
suscept
profil
determin
diskdiffus
method
antibiot
aureu
isol
submit
spaagrand
mlst
type
presenc
antibiot
resist
gene
msra
msrb
mphc
erma
ermb
ermc
ermf
mupa
virul
factor
gene
lukflukspv
lukelukd
lukm
eta
etb
hla
hlb
hld
hlg
hlgv
studi
pcr
result
aureu
recov
studi
sampl
methicillinsuscept
mssa
high
divers
spatyp
detect
among
isol
type
detect
two
sampl
one
mlst
perform
isol
spatyp
sequenc
type
respect
identifi
isol
suscept
antibiot
test
except
erythromycinclindamycin
isol
ermc
withwithout
ermamphc
tobramycin
mupirocin
isol
ant
mupa
gene
mssa
neg
lukflukspv
gene
encod
pantonvalentin
leucocidin
lukd
gene
identifi
isol
interestingli
strain
harbour
lukd
lukm
gene
five
isol
posit
mssa
other
virul
factor
detect
number
isol
hla
hlb
hld
hlg
conclus
high
preval
high
clonal
divers
mssa
isol
identifi
far
know
first
detect
mssa
faecal
sampl
healthi
human
antimicrobi
resist
vancomycin
heteroresist
mrsa
strain
tertiari
hospit
greec
panayea
souli
galani
karantani
h
giamarel
g
petrikko
athen
gr
methicillin
resist
aureu
strain
caus
varieti
infect
sometim
difficult
treat
spread
hospit
environ
commun
vancomycin
heteroresist
hvisa
mainli
observ
among
strain
esblescherichia
coli
eec
defin
e
coli
resist
third
gener
cephalosporin
suscept
amoxicillin
clavulan
thu
tem
shv
ctxmtype
enzym
molecular
class
enzym
function
group
bushjacobymedeiro
classif
taken
account
itu
consid
differ
time
two
episod
greater
day
isol
present
differ
suscept
pattern
affect
esbl
classif
vitro
growth
competit
carri
fivefold
place
inoculum
two
isol
e
coli
eec
vs
e
coli
antimicrobi
resist
thioglicol
tg
aliquot
subcultur
everi
day
regrowth
tg
coloni
identif
result
total
number
urinari
isol
analyz
belong
differ
patient
isol
categor
eec
number
differ
itu
eec
discard
took
place
end
studi
period
fourth
consecut
itu
mean
time
eec
itu
anoth
eec
itu
day
mean
time
eec
itu
noneec
itu
day
growth
competit
show
greater
decreas
eec
popul
day
conclus
data
suggest
given
time
absenc
antimicrobi
pressur
e
coli
fewer
antimicrobi
resist
outgrow
eec
probabl
due
better
fit
isol
object
examin
pattern
antimicrobi
suscept
acinetobact
calcoaceticusbaumannii
isol
commonli
use
drug
tertiari
care
hospit
riyadh
saudi
arabia
method
retrospect
studi
carri
king
fahad
nation
guard
hospit
kfngh
organ
identifi
test
autom
identif
suscept
system
microscan
walk
away
siemen
antibiot
suscept
test
confirm
etest
ab
biodisk
sweden
procedur
detail
interpret
recommend
clinic
laboratori
standard
institut
clsi
result
total
isol
acinetobact
baumannii
baumannii
avail
analysi
organ
show
high
rate
resist
piptazo
isol
imipenem
meropenem
gentamicin
amikacin
ceftazidim
cefepim
ciprofloxacin
colistin
multidrug
resist
observ
acinetobact
speci
isol
conclus
antimicrobi
resist
acinetobact
baumannii
major
emerg
problem
particularli
intens
care
unit
strict
infect
control
measur
judici
prescrib
antibiot
antibiot
stewardship
program
antibiot
cycl
adopt
control
infect
due
bacteria
patient
admit
intens
care
continu
monitor
antimicrobi
suscept
strict
adher
infect
prevent
guidelin
essenti
elimin
major
outbreak
futur
c
caneira
f
calisto
r
moura
augusto
g
da
silva
j
melo
cristino
duart
lisbon
coimbra
pt
object
tigecyclin
antibiot
use
clinic
set
multidrug
resist
mdr
extend
spectrum
blactamas
esbl
product
promin
due
constant
potenti
emerg
resist
long
term
survey
studi
need
aim
studi
assess
activ
tigecyclin
mdr
esbl
enterobacteriacea
isol
period
ten
year
method
total
isol
escherichia
coli
n
klebsiella
pneumonia
n
collect
hospit
portug
portug
suscept
antimicrobi
agent
determin
disk
diffus
interpret
accord
clsi
guidelin
tigecyclin
imipenem
ciprofloxacin
gentamicin
amikacin
ampicillin
cefotaxim
ceftazidim
cefepim
amoxicillinclavulan
acid
tigecyclin
mic
perform
etest
esbl
identifi
pcr
specif
primer
blactxm
blatem
blakpc
gene
result
accord
breakpoint
propos
clsi
k
pneumonia
e
coli
esblproduc
nonsuscept
tigecyclin
higher
preval
intermedi
suscept
found
klebsiella
e
coli
longitudin
analysi
show
increas
tigecyclin
resist
studi
period
influenc
presenc
ctxmand
temtyp
enzym
howev
first
time
portug
identifi
e
coli
resist
tigecyclin
nine
k
pneumonia
isol
produc
show
reduc
activ
mdr
esblproduc
e
coli
tigecyclin
mic
mgl
k
pneumonia
isol
tigecyclin
mic
mgl
analysi
tigecyclin
mic
show
poor
correl
valu
obtain
disk
zone
diamet
mic
result
concord
discord
data
occur
mostli
intermediatesuscept
zone
conclus
tigecyclin
show
good
activ
mdr
esbl
isol
howev
high
frequenc
isol
intermedi
categori
found
discord
correl
mic
inhibit
zone
diamet
suggest
select
pressur
lead
overal
reduc
suscept
tigecyclin
enterobacteria
instanc
tigecyclin
resist
found
isol
collect
may
indic
indiscrimin
use
tigecyclin
result
indic
use
tigecyclin
hospit
set
care
control
avoid
emerg
resist
r
mend
h
sader
farrel
r
jone
north
liberti
us
object
assess
telavancin
tlv
compar
activ
staphylococci
includ
strain
decreas
suscept
vancomycin
va
teicoplanin
te
europ
eu
tlv
approv
unit
state
us
canada
treatment
adult
complic
skin
skin
structur
infect
csssi
drug
also
review
treatment
complic
skin
soft
tissu
infect
eu
nosocomi
pneumonia
us
eu
method
aureu
sa
coagulaseneg
staphylococci
con
collect
site
countri
includ
turkey
israel
isol
submit
central
laboratori
identif
perform
standard
algorithm
vitek
strain
test
clsi
method
eucast
criteria
appli
avail
result
sa
sssi
bacteremia
respiratori
tract
infect
major
con
bacteremia
tlv
mic
mgl
potent
daptomycin
da
mic
mgl
activ
va
mic
mgl
linezolid
lz
mic
mgl
sa
similar
result
note
con
sa
higher
va
mgl
mgl
te
mic
activ
observ
con
regardless
countri
origin
glycopeptid
conclus
tlv
exhibit
higher
potenc
least
direct
compar
va
da
lz
sa
decreas
glycopeptid
show
higher
tlv
mic
although
strain
inhibit
mgl
concentr
fda
breakpoint
sa
mgl
tlv
activ
sa
con
suggest
drug
option
staphylococc
infect
includ
caus
strain
decreas
glycopeptid
somodevilla
guiu
correa
madrid
es
escherichia
coli
involv
communityacquir
urinari
tract
infect
uti
reason
import
know
antimicrobi
suscept
pattern
order
give
appropri
empir
treatment
uti
aim
studi
evalu
antibiot
resist
e
coli
strain
isol
communityacquir
uti
see
preval
extendedspectrum
blactamas
esbl
produc
strain
commun
method
e
coli
isol
collect
outpati
clinic
evid
communityacquir
uti
period
januari
novemb
hospit
madrid
spain
urin
sampl
cultur
cled
agar
incub
hour
uti
defin
cultur
singl
organ
midstream
urin
specimen
coloni
form
unit
per
millilit
identif
antibiot
suscept
test
made
routin
use
autom
system
microscan
siemen
addit
suscept
test
perform
disk
diffus
method
accord
standard
procedur
studi
reduc
suscept
antibiot
commonli
use
uti
amoxicillin
amoxicillinclavulan
acid
cefuroxim
norfloxacin
ciprofloxacin
trimethoprimsulfamethoxazol
fosfomycin
nitrofurantoin
evalu
addit
extendedspectrum
blactamas
esbl
product
examin
ratio
greater
ceftazidim
ceftazidimeclavulan
acid
minim
inhibitori
concentr
mic
cefotaxim
cefotaximeclavulan
acid
mic
consid
esblposit
result
e
coli
isol
obtain
produc
extendedspectrum
blactamas
isol
present
reduc
suscept
differ
antibiot
evalu
shown
tabl
attach
conclus
studi
show
increas
preval
esbl
coli
communityacquir
infect
almost
e
coli
strain
isol
posit
esbl
high
resist
rate
obtain
quinolon
norfloxacin
ciprofloxacin
esbl
esbl
produc
e
coli
reason
antibiot
use
empir
treatment
communityacquir
uti
countri
howev
low
resist
rate
shown
nitrofurantoin
fosfomycin
esbl
esbl
e
coli
suggest
antibiot
may
good
option
empir
treatment
uti
introduct
antimicrobi
resist
level
high
among
pathogen
bacteria
especi
hospit
aim
studi
determin
antimicrobi
suscept
level
environment
bacteria
nation
park
turkey
total
bacteria
defin
rrna
sequenc
figur
antimicrobi
suscept
bacteria
isol
investig
penicillin
ampicillin
lincomycin
erythromycin
vancomycin
ciprofloxacin
gentamicin
tetracyclin
chloramphenicol
agar
diffus
mic
method
strain
high
mic
lincomycin
chloramphenicol
penicillin
test
inactiv
got
test
b
lactamas
posit
strain
test
esbl
product
strain
high
level
mic
gentamicin
tetracyclin
chloramphenicol
studi
presenc
known
gene
pcr
gram
posit
bacteria
test
presenc
erytromycin
vancomycin
resistanv
gene
follow
gene
test
presenc
erma
ermb
ermc
vana
teta
aacaph
cat
result
among
isol
high
mic
rate
ampicillin
penicillin
gentamicin
chloramphenicol
tetracyclin
ciprofloxacin
respect
among
isol
mic
valu
evalu
lincomycin
erythromycin
vancomycin
among
gram
bacteria
show
high
level
mic
respect
got
test
show
isol
inactiv
penicillin
one
isol
inactiv
chloramphenicol
among
blactamas
strain
one
esbl
produc
isol
high
level
erythromycin
mic
ermb
ermc
erma
isol
high
gentamicin
mic
aacaph
tetracyclin
resist
isol
teta
tetm
gene
neg
vancomycin
resist
isol
vana
vana
isol
e
faecium
st
type
strain
close
one
allel
differ
conclus
antimicrobi
resist
one
main
public
health
problem
use
antimicrobi
select
resist
strain
hospit
also
dispers
antimicrobi
natur
may
caus
select
resist
natur
studi
show
presenc
high
level
antimicrobi
nonsuscept
among
environment
isol
natur
park
effect
environment
resist
strain
public
health
evalu
object
antimicrobi
agent
wide
use
anim
husbandri
treat
infecti
diseas
ensur
anim
welfar
good
qualiti
food
product
well
known
antimicrobi
usag
select
resist
form
bacteria
resist
strain
exchang
human
anim
ecosystem
aim
monitor
resist
select
antimicrobi
agent
commonli
use
sheep
produc
milk
survey
carri
aureu
strain
isol
milk
anim
mastiti
problem
seven
year
farm
method
strain
staphylococcu
aureu
isol
collect
milk
sicilian
livestock
big
problem
ovin
mastiti
isol
fact
use
prepar
autogen
vaccin
iz
sicili
test
antimicrobi
suscept
disk
diffus
test
ddt
follow
agent
ampicillin
amp
amoxicillinclavulan
amc
enrofloxacin
enr
eritromycin
er
penicillin
p
tetracyclin
te
vancomycin
va
oxacillin
ox
oxytetracyclin
ot
accord
clsi
guidelin
result
shown
tabl
number
clone
resist
amp
amc
p
te
ot
antimicrobi
commonli
use
anim
husbandri
increas
resist
er
also
found
low
level
ox
resist
detect
decreas
doubl
increas
tetracyclin
resist
shown
substanti
increas
ot
also
observ
presenc
meca
gene
investig
pcr
result
posit
clone
similar
percentag
consid
period
none
show
resist
va
enr
conclus
find
gener
increas
trend
antibiot
resist
select
drug
impli
select
pressur
act
ecosystem
favour
espans
resist
clone
reason
import
monitor
drug
resist
food
anim
prudent
usag
antibiot
veterinari
field
avoid
major
risk
increas
drug
resist
human
popul
oneyear
result
larg
multicentr
observ
studi
e
mantengoli
f
luzzaro
di
maggio
g
brigant
b
pini
goglio
l
ferrari
p
pecil
tinelli
e
tacconelli
r
cauda
gm
rossolini
siena
lecco
bergamo
cremona
florenc
lodi
rome
object
itali
among
countri
report
increas
resist
rate
expandedspectrum
cephalosporin
esc
enterobacteriacea
product
extendedspectrum
blactamas
esbl
ampctyp
blactamas
cbl
remain
major
mechan
esc
resist
report
molecular
epidemiolog
esbland
cblproduc
enterobacteri
isol
collect
oneyear
larg
multicentr
studi
recent
conduct
itali
proteu
mirabili
reduc
suscept
esc
cefotaxim
andor
ceftazidim
mic
mgl
period
esbl
product
confirm
use
doubledisk
synergi
test
esbl
cbl
determin
character
dna
hybrid
confirm
pcr
sequenc
clonal
related
investig
rapd
result
total
case
infect
caus
enterobacteriacea
reduc
suscept
esc
enrol
e
coli
k
pneumonia
p
mirabili
esbl
product
confirm
isol
cbl
product
observ
esblneg
p
mirabili
among
esbl
produc
ctxmtype
enzym
overal
preval
overal
e
coli
klebsiella
proteu
mostli
belong
group
howev
ctxm
group
also
detect
esbl
includ
temand
shvtype
variant
overal
respect
includ
cbl
belong
lineag
total
repres
clonal
heterogen
observ
among
esbl
produc
speci
although
clonal
expans
phenomena
caus
ctxmproduc
e
coli
observ
cblproduc
p
mirabili
isol
clonal
relat
comparison
previou
studi
remark
evolut
molecular
epidemiolog
escresist
enterobacteriacea
observ
itali
ctxmtype
enzym
becom
predomin
esbl
enzym
group
also
emerg
cbl
significantli
contribut
esc
resist
p
mirabili
sinc
also
recognis
shift
gramneg
pathogen
increas
age
studi
describ
trend
bsi
pathogen
antimicrobi
suscept
year
australian
adult
tertiari
referr
hospit
method
posit
blood
cultur
januari
till
decemb
review
duplic
isol
within
day
primari
cultur
patient
year
age
exclud
patient
haematolog
includ
bone
marrow
transplant
respiratori
includ
lung
transplant
cystic
fibrosi
oncolog
burn
unit
also
exclud
repres
heterogen
popul
coagulas
neg
staphylococci
cn
exclud
possibl
retrospect
differenti
true
infect
contamin
result
found
overal
declin
blood
cultur
posit
rate
per
admiss
similarli
proport
posit
cultur
also
decreas
overal
gramposit
pathogen
isol
patient
aureu
enterococcu
spp
viridan
compar
gramneg
pathogen
patient
e
coli
klebsiella
spp
pseudomona
spp
trend
increas
proport
gramneg
pathogen
year
howev
age
specif
proport
gramposit
gramneg
remain
similar
suggest
relat
overal
age
hospit
popul
proport
aureu
isol
methicillinresist
mrsa
declin
gramneg
suscept
gentamicin
third
gener
cephalosporin
enterobacteriacea
remain
stabl
ceftazidim
resist
also
remain
stabl
suggest
increas
extend
spectrum
blactamas
esbl
produc
organ
conclus
studi
demonstr
import
trend
epidemiolog
bsi
pathogen
time
impact
choic
appropri
antimicrobi
therapi
particularli
elderli
hospit
inpati
popul
blactam
gentamicin
quinolon
remain
effect
antibiot
patient
popul
object
primari
object
studi
determin
lead
factor
influenc
presenc
antimicrobi
residu
environ
rank
predict
environment
concentr
pec
method
mechanist
model
present
determin
antimicrobi
presenc
environ
excel
risk
addon
model
test
six
main
group
antimicrobi
consum
europ
penicillin
pen
blactam
bet
tetracyclin
tet
macrolid
mac
quinolonefluoroquinolon
qf
sulfonamidestrimethoprim
st
model
simul
releas
antimicrobi
environ
integr
effect
antimicrobi
use
metabol
degrad
dilut
input
variabl
unifi
assign
probabl
densiti
repres
inher
uncertainti
variabl
paramet
mont
carlo
simul
model
result
probabl
distribut
pec
antimicrobi
group
use
regress
analysi
result
pec
rank
relat
resist
potenti
chronic
acut
toxic
hazard
quotient
hq
result
model
simul
mean
pec
pen
bet
tet
mac
qf
st
tabl
degrad
main
input
influenc
pen
pec
usag
foremost
bet
st
metabol
critic
input
tet
mac
qf
pec
qf
express
highest
rate
resist
format
potenti
bet
express
moder
hq
remain
antimicrobi
express
low
hq
antimicrobi
group
predict
express
toxic
environ
observ
result
infer
current
antimicrobi
use
lead
level
environ
may
increas
resist
format
legisl
new
antimicrobi
consid
metabol
greatli
influenc
level
emit
environ
indepth
understand
antimicrobi
presenc
environ
lack
specif
regard
lower
limit
minimum
inhibitori
concentr
act
selector
resist
format
use
ecosar
antimicrobi
toxic
refer
valu
limit
bacteria
target
antimicrobi
phylogenet
distinct
cyanobacteria
use
calcul
valu
result
limit
present
accentu
need
research
antimicrobi
environ
develop
antimicrobi
resist
strain
cc
lee
k
wong
rw
lai
tk
ling
hong
kong
hk
object
tigecyclin
first
glycylcyclin
antimicrobi
activ
wide
rang
bacteri
pathogen
particip
global
tigecyclin
evalu
surveil
trial
test
studi
invitro
activ
tigecyclin
report
summar
antimicrobi
suscept
bacteri
pathogen
collect
method
total
gramneg
gramposit
isol
collect
princ
wale
hospit
mic
determin
use
microdilut
tray
purchas
trek
diagnost
system
east
grinstead
uk
interpret
use
clsi
guidelin
tabl
respect
shade
denot
resist
valu
smaller
equal
conclus
tigecyclin
show
excel
activ
gramposit
gramneg
isol
less
activ
acinetobact
spp
p
aeruginosa
ergin
eser
g
ankara
tr
object
penicillin
resist
concomit
erythromycin
resist
risk
factor
mortal
patient
miti
orali
bacteremia
aim
studi
determin
penicillin
macrolid
resist
mechan
invas
miti
orali
bacteremia
strain
isol
patient
haematolog
malign
method
miti
orali
isol
blood
cultur
patient
haematolog
malign
includ
studi
isol
identifi
bd
phoenix
system
penicillin
erythromycin
suscept
perform
etest
vancomycin
clindamycin
cefotaxim
levofloxacin
linezolid
suscept
determin
broth
microdilut
penicillin
erythromycin
resist
gene
ermb
mefa
amplifi
use
pcr
method
bamhi
restrict
enzym
use
discrimin
mefa
mefe
result
patient
age
rang
twenti
fourti
patient
women
thirti
patient
diagnos
myelogen
lymphoblast
leukaemia
fifteen
patient
die
due
solid
cancer
fourteen
eighteen
strain
resist
penicillin
mic
mgl
erythromycin
mic
mgl
respect
rate
resist
clindamycin
cefotaxim
isol
suscept
vancomycin
levofloxacin
linezolid
five
penicillin
resist
isol
carri
three
carri
gene
among
erythromycin
resist
intermedi
exhibit
ermb
mefe
genotyp
conclus
erythromycin
resist
highli
due
ermb
follow
mefe
gene
penicillin
suscept
partial
explain
presenc
gene
among
isol
import
awar
high
level
resist
penicillin
erythromycin
miti
orali
patient
haematolog
malign
emerg
threat
sinc
suscept
empir
antibiot
may
reduc
overal
mortal
trend
antimicrobi
suscept
p
aeruginosa
isol
uti
rti
japanes
hospit
particip
levofloxacin
surveil
group
akira
yoshikazu
kazuhiro
keizo
behalf
levofloxacin
surveil
group
object
pseudomona
aeruginosa
becom
ploblemat
outbreak
multidrugresist
clone
produc
metalloblactamas
mbl
alreadi
taken
nationwid
surveil
fq
antimicrobi
resist
mani
bacteri
clinic
isol
sinc
japan
studi
report
surveil
data
p
aeruginosa
isol
patient
urinari
tract
infect
uti
respiratori
tract
infect
rti
collect
method
total
clinic
isol
isol
uti
isol
rti
collect
center
particip
levofloxacin
surveil
group
japan
antimicrobi
suscept
test
broth
microdilut
method
base
clinic
laboratori
standard
institut
clsi
guidelin
updat
annual
revis
document
publish
result
discuss
uti
suscept
rate
levofloxacin
particularli
increas
time
although
caus
increas
obscur
recent
request
strict
observ
dose
period
probabl
implic
drug
use
review
show
decreas
amount
levofloxacin
use
nationwid
field
urolog
amikacin
ceftazidim
also
show
gradual
increas
suscept
rate
suscept
imipenem
remain
unchang
rate
drug
resist
isol
levofloxacin
ceftazidim
amikacin
imipenem
howev
increas
abruptli
shift
level
approxim
rti
suscept
rate
levofloxacin
amikacin
ceftazidim
imipenem
maintain
constantli
level
approxim
respect
rate
drug
resist
isol
levofloxacin
ceftazidim
amikacin
imipenem
moder
increas
comparison
uti
metalloblactamas
rate
metalloblactamas
produc
isol
uti
rti
respect
alikhani
z
karimi
tabar
p
karami
zamani
farajnia
hamadan
zanjan
tabriz
ir
object
pseudomona
aeruginosa
lead
caus
nosocomi
infect
worldwid
infect
particularli
sever
patient
impair
immun
system
infect
agent
frequent
difficult
treat
natur
resist
speci
abil
acquir
resist
mechan
multipl
group
antimicrobi
agent
resist
p
aeruginosa
strain
broadspectrum
cephalosporin
may
mediat
extendedspectrum
blactamas
esbl
aim
studi
determin
p
aeruginosa
antibacteri
resist
pattern
preval
esbl
produc
strain
veb
gene
method
studi
total
clinic
isol
p
aeruginosa
studi
isol
collect
two
univers
hospit
hamadan
iran
month
assess
current
level
antimicrobi
suscept
suscept
investig
p
aeruginosa
isol
antimicrobi
agent
determin
disc
diffus
method
mueller
hinton
agar
plate
interpret
accord
clinic
laboratori
standard
institut
clsi
recommend
esbl
produc
strain
detect
combin
disk
test
presenc
veb
gene
pcr
result
antibiot
resist
rate
broadspectrum
cephalosporin
monobactam
cefepim
cefotaxim
ceftazidim
aztreonam
ciprofloxacin
imipenem
meropenem
effect
antipseudomon
agent
result
reveal
isol
multidrug
resist
isol
esbl
posit
sixteen
strain
among
esblproduc
strain
amplifi
blaveb
respect
conclus
studi
highlight
need
establish
antimicrobi
resist
surveil
network
p
aeruginosa
determin
appropri
empir
treatment
regimen
bacteri
strain
resist
class
antibiot
continu
emerg
unless
inappropri
use
drug
decreas
continu
educ
infect
control
practic
maintain
high
preval
multidrug
resist
product
esbl
p
aeruginosa
isol
patient
confirm
protocol
consid
issu
consid
hospit
object
determin
epidemiolog
clinic
microbiolog
data
infect
caus
drugresist
streptococcu
pneumonia
drsp
adult
patient
retrospect
studi
adult
patient
pneumococc
infect
hospit
king
chulalongkorn
memori
hospit
bangkok
thailand
carri
januari
decemb
addit
trend
preval
penicillinand
cephalosporinnonsuscept
pneumonia
pnsp
cnsp
institut
analyz
result
pneumococc
isol
patient
pneumonia
primari
bacteremia
mening
respect
male
femal
mean
age
year
rang
year
patient
pneumonia
penicillinsuscept
pneumonia
pssp
penicillinintermedi
pneumonia
pisp
penicillinresist
pneumonia
prsp
cefotaximesuscept
pneumonia
cssp
cefotaximeintermedi
pneumonia
cisp
cefotaximeresist
pneumonia
crsp
respect
patient
primari
bacteremia
pssp
cssp
respect
patient
mening
pssp
prsp
cssp
cisp
crsp
respect
isol
suscept
vancomycin
trend
preval
mening
caus
pnsp
cnsp
institut
summar
tabl
conclus
rel
high
preval
infect
caus
pnsp
cnsp
adult
patient
institut
emphas
urgent
need
strengthen
appropri
use
antimicrobi
strict
infect
control
measur
help
reduc
occurr
drsp
streptococcu
pneumonia
isol
introduct
ankara
eser
h
uludag
altun
g
hascelik
ankara
tr
object
studi
macrolid
resist
mechan
divers
pbp
invas
streptococcu
pneumonia
sp
isol
identifi
patient
admit
hacettep
hospit
introduct
heptaval
pneumococc
conjug
vaccin
turkey
investig
method
invas
sp
clinic
isol
collect
children
adult
admit
ihsan
dogramaci
children
hospit
adult
hospit
hacettep
univers
antimicrobi
suscept
test
isol
perform
six
antimicrobi
agent
penicillin
pen
ceftriaxon
cro
levofloxacin
lev
erythromycin
em
clindamycin
cd
vancomycin
van
broth
microdilut
method
accord
clinic
laboratori
standard
institut
clsi
serotyp
determin
quellung
reaction
specif
antisera
sp
isol
mic
mgml
examin
pbp
gene
pcr
resist
genotyp
em
resist
isol
mic
determin
multiplex
erm
b
mef
pcr
method
sp
rflp
analysi
done
differenti
mefa
gene
result
nondupl
pneumococc
isol
obtain
children
adult
cerebrospin
fluid
csf
blood
isol
csf
isol
mic
pen
mgml
em
resist
mic
found
isol
resist
em
cd
em
resist
isol
ermb
gene
two
mef
e
gene
isol
pen
mic
mgml
togeth
four
three
one
one
one
isol
resist
lev
cro
van
paediatr
age
group
differ
serotyp
adult
group
differ
serotyp
observ
frequent
serogroup
age
group
conclus
although
resist
pen
among
blood
isol
pen
resist
high
among
csf
isol
major
serotyp
associ
pen
resist
csf
isol
serotyp
analysi
pbp
gene
show
predomin
predomin
mechan
macrolid
resist
associ
erm
b
gene
strain
show
coresist
clindamycin
major
case
larg
conjug
plasmid
enterococci
differ
ecolog
nich
scarc
goal
analyz
occurr
tcrb
among
enterococci
differ
ecolog
nich
character
genet
context
gene
method
analyz
e
e
gallinarum
e
casseliflavu
e
hira
enterococci
sp
hospit
human
h
n
healthi
human
hv
n
poultri
p
n
piggeri
environmentswin
pe
n
sewag
river
sr
n
recov
differ
portugues
area
gene
code
cur
abr
search
pcr
mate
assay
perform
repres
tcrb
isol
presenc
tetracyclin
erythromycin
vancomycin
gentamicin
use
differ
receptor
strain
clonal
studi
pfge
smai
mlst
coloc
tcrb
abr
gene
assess
pfge
hybrid
result
tcrb
detect
isol
pe
sr
hv
p
h
efm
efl
speci
cotransf
abr
gene
aac
ieaph
polyclon
popul
detect
among
tcrb
repres
isol
among
efm
pfge
type
correspond
also
ten
efl
pfge
type
detect
common
strain
identifi
within
nich
pfge
ape
h
tcrb
locat
plasmid
efl
efm
tcrb
gene
locat
alon
pe
hv
p
vana
pe
tetl
pe
hv
tetm
pe
hv
ermb
pe
sr
pe
p
tetlermb
pe
hv
tetmermb
pe
sr
tetmtetl
p
vanatetmermb
pe
tetmtetlermb
pe
hv
sr
isol
tetm
tetl
ermb
aac
ieaph
ia
locat
plasmid
cotransf
tcrb
n
cotransfer
tcrb
abr
gene
locat
differ
plasmid
suggest
intens
use
copper
nich
might
favour
select
abr
enterococci
plasmid
transfer
clonal
expans
play
import
role
spread
tcrb
object
nosocomi
infect
remain
main
caus
morbid
mortal
burn
patient
infect
caus
baumannii
emerg
signific
problem
report
burn
unit
baumannii
strain
usual
resist
multipl
antimicrobi
agent
includ
carbapenem
repres
import
option
treatment
acinetobact
infect
caus
multidrugresist
isol
common
mechan
respons
carbapenemresist
carbapenemhydrolysingblactamas
belong
molecular
class
oxa
enzym
also
may
associ
presenc
insert
sequenc
aim
studi
detect
oxa
encod
gene
presenc
method
total
baumannii
strain
collect
burn
unit
bu
special
hospit
krakow
poland
strain
select
studi
carbapenemresist
isol
singl
patient
identif
suscept
test
perform
compact
poland
accord
clsi
criteria
multiplex
pcr
describ
woodford
et
al
appli
detect
oxa
carbapenemas
encod
gene
strain
also
test
presenc
fragment
contain
portion
result
antibiot
resist
rate
piperacillin
piperacillintazobactam
ceftazidim
cefepim
imipenem
meropenem
gentamicin
ciprofloxacin
tobramycin
amikacin
carbapenemresist
isol
contain
intrins
gene
encod
blactamas
belong
group
isol
also
found
encod
gene
respect
insert
sequenc
gene
detect
test
strain
conclus
carbapenem
resist
test
isol
might
associ
express
acquir
oxacillinas
belong
group
extend
express
intrins
oxacillinas
belong
group
support
presenc
insert
sequenc
j
nigri
v
r
valencia
es
object
arcobact
butzleri
associ
human
infect
fluoroquinolon
potenti
drug
treatment
howev
evid
increas
resist
antimicrobi
agent
resist
may
occur
due
mutat
quinolon
resistancedetermin
region
qrdr
gyra
gene
therefor
goal
studi
look
mutat
associ
quinolon
resist
arcobact
isol
method
fortyfour
butzleri
isol
refer
strain
butzleri
dsm
use
studi
arcobact
suscept
ciprofloxacin
levofloxacin
determin
disc
diffus
test
bd
usa
etest
strip
ab
biodisk
sweden
recommend
antibiot
resist
arcobact
disc
diffus
breakpoint
minimum
inhibitori
concentr
mic
valu
determin
recommend
clinic
laboratori
standard
institut
clsi
campylobact
isol
subsequ
analys
order
determin
presenc
mutat
qrdr
gyra
gene
purpos
fragment
gyra
gene
arcobact
spp
amplifi
use
fqrdr
tgg
att
aaa
gcc
agt
tca
tag
tca
tmg
wat
cat
cat
aat
ttg
gwa
primer
final
pcr
product
purifi
sequenc
strand
sistema
l
valencia
spain
result
among
isol
test
sensit
remain
consid
resist
antibiot
disc
diffus
zone
mm
mic
valu
mgml
indic
resist
mic
valu
respect
ciprofloxacin
levofloxacin
rang
mgml
mgml
respect
sensit
isol
resist
isol
present
mic
rang
mgml
antibiot
sequenc
pcr
product
reveal
mutat
posit
gyra
gene
resist
arcobact
isol
mutat
could
caus
quinolon
resist
chang
absent
suscept
isol
studi
show
high
rate
quinolon
resist
arcobact
alway
associ
one
mutat
qrdr
region
gyra
gene
increas
resist
class
antibiot
could
public
health
concern
report
commonli
use
best
perform
fluoroquinolon
arcobact
ergin
eser
n
pakasticali
g
ankara
tr
object
aim
studi
evalu
antimicrobi
suscept
metallo
blactamas
product
mbl
dissemin
oxacillinas
gene
among
multidrug
resist
salmonella
serovar
isol
iran
mr
aghasadeghi
sd
siadat
b
rajaei
f
badmasti
n
sepehri
rad
r
sabohi
javadian
mr
razavi
najar
peerayeh
sm
zahraei
ra
khavarinejad
sm
sadat
moshiri
rahimi
tehran
ir
object
high
level
multidrug
resist
normal
associ
mobil
genet
element
encod
specif
resist
gene
among
genet
element
integron
structur
integr
express
resist
gene
integron
play
import
role
captur
express
exogen
genet
materi
method
eighti
five
epidemiolog
unrel
clinic
isol
salmonellaspp
collect
differ
provinc
iran
isol
serotyp
compris
four
serovar
b
c
test
antimicrobi
suscept
sever
antibiot
isol
screen
presenc
class
integron
use
primer
specif
gene
gene
cassett
insert
variabl
region
class
integron
amplifi
use
cs
cs
primer
pair
pcr
product
extract
agaros
gel
purifi
high
pure
pcr
product
purif
kit
accord
size
ivr
amplifi
one
repres
band
group
sequenc
compar
genbank
sequenc
use
onlin
blast
softwar
wwncbinlmnihgovblast
follow
analysi
sequenc
submit
emblgenbank
databas
result
forti
isol
resist
least
antimicrobi
agent
consid
mdr
salmonella
serovar
isol
isol
present
class
integron
case
isol
multidrug
resist
pcr
assay
dna
sequenc
intern
variabl
region
ivr
class
integron
character
four
gene
cassett
array
includ
kb
kb
kb
eight
ivr
distribut
pattern
mdr
isol
nucleotid
sequenc
gene
gene
gene
gene
cassett
gene
class
integron
deposit
ncbi
genbank
sequenc
databas
access
number
respect
conclus
high
frequenc
mdr
salmonella
serovar
demonstr
antimicrobi
select
pressur
widespread
clinic
set
detect
class
integron
carri
gene
cassett
confer
resist
differ
class
antibiot
aminoglycosid
blactam
trimethoprim
confirm
integronmedi
antimicrobi
gene
cassett
common
mdr
salmonella
serovar
isol
iran
regard
biofilm
product
isol
studi
isol
posit
differ
degre
product
except
two
isol
studi
shown
nontyp
typhimurium
isol
character
multidrug
antimicrobi
resist
encod
class
integron
pfge
analysi
suggest
presenc
multipl
clone
nontyp
clinic
isol
serovar
work
support
ministri
health
slovak
republ
project
molecular
analysi
antibiot
resist
nontyphoid
salmonella
serovar
gajic
v
mijac
lazarev
stanojev
n
opavski
belgrad
rs
object
group
streptococci
ga
common
caus
bacteri
pharyng
penicillin
remain
first
line
therapi
ga
infect
case
allergi
macrolid
use
instead
howev
resist
antibiot
among
ga
popul
rise
mani
european
countri
distribut
resist
pheno
genotyp
well
preval
differ
emm
type
among
macrolid
resist
strain
vari
consider
differ
region
time
therefor
aim
studi
investig
phenotyp
genotyp
emm
type
distribut
among
macrolid
resist
ga
isol
pharyng
patient
serbia
method
fifti
one
ga
isol
exhibit
macrolid
resist
collect
variou
region
serbia
period
phenotyp
erythromycin
resist
iml
cml
phenotyp
evalu
tripl
disk
diffus
test
erythromycin
clindamycin
spiramycin
previous
describ
correspond
resist
gene
mefa
erma
ermb
detect
use
pcr
amplif
emm
genotyp
determin
pcr
primer
follow
previous
publish
protocol
podbielski
cowork
result
ga
isol
major
harbor
mef
erma
ermb
rare
encount
strain
phenotyp
mef
gene
iml
isol
erma
posit
one
harbor
addit
mefa
gene
ermb
present
strain
cml
phenotyp
emm
genotyp
reveal
presenc
differ
emm
type
emm
emm
emm
emm
relat
emm
type
particular
resist
mechan
could
observ
emm
type
isol
mefa
posit
emm
isol
erma
posit
emm
encount
among
isol
harbor
mefa
well
one
erma
posit
strain
one
cml
strain
harbor
none
test
gene
erm
b
posit
strain
emm
emm
type
conclus
data
show
predomin
efflux
mediat
resist
mefa
homogen
emm
type
distribut
among
macrolid
resist
ga
serbia
genotyp
associ
resist
mainli
emm
emm
h
lee
rc
chang
lh
su
ty
lin
ch
chiu
taoyuan
tw
object
total
baumannii
clinic
isol
two
teach
hospit
taiwan
decemb
collect
examin
order
elucid
current
resist
mechan
minimum
inhibitori
concentr
mic
imipenem
ceftazidim
ceftriaxon
check
etest
analysi
isol
primer
specif
resist
gene
blaadc
upstream
region
insert
sequenc
design
pcr
amplif
sequenc
identif
baumannii
isol
genotyp
pulsedfield
gel
electrophoresi
pfge
mortal
data
patient
isol
collect
result
upstream
found
isol
includ
n
n
isol
isol
express
full
resist
imipenem
mic
tabl
found
isol
offer
isol
resist
imipenem
mic
contrast
without
upstream
isol
oxatyp
blactamas
suscept
imipenem
upstream
found
isol
upstream
found
isol
oxatyp
blactamas
offer
isol
full
resist
ceftriaxon
ceftazidim
isol
combin
upstream
oxatyp
blactamas
show
resist
imipenem
ceftazidim
ceftriaxon
without
combin
p
strain
produc
one
blactamas
differ
type
type
blactamas
isoelectr
point
pi
pse
detect
predomin
type
enzym
respons
resist
ampicillin
frequenc
type
blactamas
lower
pse
total
ten
spectrum
blactamas
detect
preval
one
enzym
product
studi
strain
reveal
strain
combin
two
enzym
produc
strain
respect
combin
enzym
reveal
strain
strain
produc
one
enzym
pse
respect
one
strain
enteritidi
produc
three
type
enzym
resist
ampicillin
salmonella
spp
shigella
spp
st
petersburg
northwest
region
russia
mostli
due
product
one
type
blactamas
predomin
type
blactamas
widespread
combin
enzym
detect
strain
demir
n
coplu
h
bayrak
turan
caliskan
b
yalcin
u
cinar
n
atakan
z
karahan
b
esen
kirsehir
ankara
mersin
karabuk
tr
object
pvl
toxin
commonli
associ
commun
acquir
aureu
isol
wide
rang
diseas
includ
skin
soft
tissu
pulmon
infect
well
aim
studi
assess
preval
pvl
toxin
cocarriag
wound
nasal
sampl
method
suscept
c
striatum
strain
erythromycin
clindamycin
analyz
etest
ab
biodisk
solna
sweden
spiramycin
disk
diffus
method
use
type
resist
c
striatum
strain
elucid
doubl
disc
diffus
test
gene
associ
resist
isol
pcr
primer
specif
ermx
mef
gene
region
surround
resist
gene
two
repres
c
striatum
isol
clone
invers
pcr
use
primer
design
sequenc
ermx
allel
transfer
resist
gene
two
c
striatum
strain
e
coli
assay
electropor
conjug
result
analyz
collect
c
striatum
clinic
specimen
respons
case
wound
infect
skin
ulcer
pneumonia
c
striatum
resist
erythromycin
clindamycin
spiramycin
resist
erythromycin
clindamycin
isol
resist
three
compound
gene
ermx
detect
c
striatum
resist
erythromycin
clindamycin
gene
also
found
one
isol
sensit
three
compound
preliminari
result
indic
c
striatum
isol
gene
ermx
chromosom
take
part
transposon
conclus
studi
reveal
high
incid
resist
two
macrolid
clindamycin
c
striatum
clinic
strain
isol
hospit
de
valdecilla
santand
spain
first
result
show
c
striatum
collect
ermx
gene
chromosom
associ
transposon
ripol
mc
turrient
r
tato
l
f
baquero
jc
madrid
santand
es
object
unlik
tem
shv
blactam
plu
blactamas
inhibitor
bbli
resist
variant
among
ctxm
enzym
hitherto
describ
clinic
set
variant
may
exist
phenotyp
pattern
could
confus
irt
irshv
object
work
test
automat
suscept
test
system
wider
blind
expert
analysi
might
identifi
differ
ctxm
harbour
differ
laboratoryintroduc
mutat
confer
increas
mic
bbli
ii
compar
effici
detect
irctxm
enzym
use
clsi
eucast
breakpoint
method
construct
hybrid
plasmid
contain
wildtyp
ctxm
gene
ctxm
laboratoryobtain
code
enzym
resist
inhibitor
transform
isogen
e
coli
laboratori
strain
porin
membran
alter
wildtyp
ompc
kn
ompf
lacz
ompf
lacz
ompc
kn
wildtyp
ctxm
mutat
ctxm
belong
ctxm
carri
chang
previous
describ
confer
increas
bbli
mic
result
wildtyp
ctxm
four
genet
background
correctli
detect
wider
expert
personnel
six
mutat
ctxm
carri
classifi
wider
irt
without
overexpress
tem
esbl
case
expert
personnel
irt
overexpress
tem
overexpress
shv
esbl
three
mutat
two
mutant
classifi
esbl
wider
expert
personnel
use
current
breakpoint
refer
ctxm
alway
identifi
esbl
except
classifi
ir
phenotyp
eucast
breakpoint
variant
coincid
identifi
irt
esbl
use
clsi
eucast
breakpoint
interestingli
classifi
iresbl
use
eucast
clsi
breakpoint
conclus
singl
irctxm
phenotyp
detect
either
automat
system
blind
expert
analysi
suggest
irctxm
variant
could
overlook
clinic
microbiolog
set
use
current
breakpoint
eucast
detect
irctxmesbl
phenotyp
clsi
result
suggest
eucast
must
consid
refer
detect
irctxm
mutant
futur
five
isol
exhibit
high
level
resist
carbapenem
test
mic
mgl
wherea
strain
produc
either
turn
moder
resist
imipenem
mic
mgl
class
carbapenemas
found
collect
among
remain
strain
decreas
suscept
imipenem
mic
mgl
attribut
alter
loss
porin
oprd
imperm
mutant
activ
meropenem
doripenem
gener
better
imipenem
mic
time
lower
conclus
seven
imipenem
nonsuscept
p
aeruginosa
isol
french
icu
produc
mbl
preval
lower
european
countri
nevertheless
epidem
potenti
broadspectrum
blactamas
incit
icu
microbiolog
laboratori
strengthen
surveil
measur
prevent
spread
eser
b
sener
g
hascelik
ankara
tr
object
detect
plasmid
mediat
ampc
blactamas
produc
organ
import
ensur
effect
therapeut
intervent
optim
infect
control
howev
detect
enzym
challeng
laboratori
sinc
reliabl
method
routin
detect
plasmid
mediat
ampc
enzym
readytoeat
salad
import
vehicl
pathogen
commens
bacteria
resist
antibiot
j
campo
l
peix
j
j
pire
silva
c
costa
h
nune
n
pestana
c
novai
p
antun
porto
pt
object
increas
demand
fresh
fruit
veget
caus
expans
market
share
minim
process
veget
along
recogn
food
safeti
problem
analyz
microbiolog
qualiti
portugues
readytoeat
salad
rt
role
spread
bacteria
carri
antibiot
resist
abr
gene
method
rt
n
brand
split
mix
leav
carrot
cornmeal
collect
main
supermarket
evalu
microbiolog
load
qualiti
follow
intern
standard
method
count
aerob
mesophil
coliform
enterococcu
sp
detect
salmonella
sp
listeria
monocytogen
sampl
also
plate
differ
cultur
media
withwithout
ab
preenrich
step
abr
studi
agar
diffus
method
clsi
esbl
express
doubl
disk
synergi
test
ddst
speci
identifi
pcr
gram
posit
api
gram
neg
abr
gene
integron
type
e
coli
phylogenet
group
search
pcr
clonal
mlst
specif
isol
result
high
number
rt
present
poor
microbiolog
qualiti
aerob
mesophil
coliform
e
coli
pathogen
differ
abr
phenotyp
genotyp
seen
gram
posit
gram
neg
bacteria
e
coli
detect
sampl
n
phylogenet
group
present
resist
tetracyclin
teta
andor
tetb
streptomycin
aada
sulfametoxazol
andor
trimethoprim
ampicillin
blatem
nalidix
acid
ciprofloxacin
chloramphenicol
two
integron
type
aada
aada
detect
isol
multidrug
resist
e
coli
n
belong
widespread
fumc
allel
e
coli
highli
divers
identifi
ddst
gave
posit
test
raoultella
sp
sampl
carri
esbl
identifi
among
enterococci
n
abr
seen
tetracyclin
tetm
andor
tetl
erythromycin
ermb
nitrofurantoin
ciprofloxacin
conclus
present
studi
posit
rt
within
spectrum
ecolog
nich
may
reservoirsvehicl
abr
bacteria
gene
clinic
interest
eg
e
esbl
find
worthi
attent
spread
human
ingest
dismiss
plasmid
character
includ
determin
size
content
identif
relaxas
rel
rep
initi
protein
rep
toxinantitoxin
system
ta
pcr
sequenc
hybrid
result
efc
strain
studi
classifi
pfgetyp
st
cluster
n
n
n
n
n
highli
resist
erythromycin
tetracyclin
streptomycin
gentamicin
ciprofloxacin
chloramphenicol
suscept
glycopeptid
plasmid
content
efc
isol
variabl
kb
rang
kb
predomin
belong
differ
plasmid
famili
rcrthetha
ii
repan
par
iii
modul
small
theta
replic
plasmid
rare
found
similar
rep
rel
content
observ
among
isol
cc
mosaic
plasmid
contain
rep
andor
rel
differ
famili
identifi
conclus
efc
isol
harbour
mosaic
plasmid
associ
repan
famili
influenc
particular
plasmid
plasmid
modul
success
major
efc
lineag
distribut
antibiot
resist
gene
among
differ
clonal
lineag
differ
enterococc
speci
remain
establish
vitro
fosfomycin
activ
extendedspectrum
blactamas
produc
escherichia
coli
relat
urinari
tract
infect
demir
turan
kirsehir
karabuk
tr
object
extend
spectrum
blactamas
esbl
produc
e
coli
dissemin
worldwid
import
caus
nosocomi
communityacquir
urinari
tract
infect
uti
increas
resist
rate
antimicrobi
among
isol
limit
choic
treatment
k
klesiewicz
n
szkaradek
gunia
h
marona
budak
krakow
pl
object
aim
studi
determin
antih
pylori
activ
seri
xanthon
deriv
substitut
differ
posit
xanthon
structur
ie
possess
among
piperazin
pyridin
aminoalkanol
allyl
methylamin
ethylamin
alkoxi
fenoxi
carbamyl
moieti
also
chlorin
atom
structur
method
disc
diffus
procedur
kirbybau
method
use
primari
screen
suscept
h
pylori
clinic
strain
isol
patient
atcc
h
pylori
strain
xanthon
deriv
concentr
mgml
addit
compound
give
inhibit
zone
rang
mm
diamet
chosen
quantit
assay
establish
lowest
concentr
inhibit
growth
h
pylori
strain
mic
bacteri
suspens
h
pylori
adjust
yeld
approxim
cfuml
plate
mueller
hinton
agar
hors
blood
nad
plate
oxoid
stock
solut
mgml
substanc
appropri
dilut
dmso
obtain
requir
concentr
mgml
mgml
mgml
filter
paper
disc
place
inocul
agar
surfac
impregn
ul
sampl
solut
antibacteri
activ
express
mean
inhibit
diamet
mm
produc
substanc
lowest
concentr
requir
growth
inhibit
h
pylori
strain
regard
mic
result
similar
two
examin
strain
test
compound
activ
h
pylori
strain
concentr
mgml
stock
solut
two
substanc
exhibit
mm
wide
grown
inhibit
zone
mm
mm
mm
present
substanc
classifi
nonact
mic
xanthon
rang
mgml
mgml
potent
activ
mic
valu
mgml
characterist
compound
conclus
perform
research
antih
pylori
activ
seri
xanthon
deriv
could
state
chlorin
atom
well
allyl
moieti
favor
substitut
xanthon
structur
posit
favor
posit
carbonyl
group
side
chain
respons
partial
loss
activ
studi
necessari
investig
effect
activ
compound
mrsa
dilut
coloni
cultur
hour
pellet
ml
broth
hour
incub
increas
ct
interfer
inhibit
crossreact
mssa
xmsn
assay
copan
mrsab
enrich
broth
increas
number
mrsa
coloni
fold
ct
xmsn
assay
hour
incub
sensit
xmsn
assay
increas
use
pellet
centrifug
ml
mrsab
enrich
broth
object
purpos
studi
research
methicillinresist
staphylococcu
aureu
origin
food
base
pheno
genotyp
method
method
aureu
isol
food
sampl
investig
detect
methicillin
resist
use
meca
specif
pcr
oxacillin
agar
screen
disk
diffus
penicillin
bind
protein
latex
agglutin
blactamas
product
mic
test
mrsa
strain
character
antimicrobi
suscept
product
type
ad
staphylococc
enterotoxin
se
toxic
shock
syndrom
well
biotyp
molecular
type
base
xregion
protein
spa
coagulas
coa
gene
result
aureu
isol
eight
meca
posit
phenotyp
test
show
discrep
comparison
major
mrsa
isol
pbp
produc
multiresist
produc
mrsa
se
produc
mrsa
isol
eight
belong
human
biotyp
three
belong
nh
one
bovin
biotyp
amplif
polymorph
spa
coa
gene
reveal
three
five
distinct
type
respect
food
import
vector
transmiss
antibiot
resist
human
mrsa
isol
recov
differ
sourc
show
genet
phenotyp
similar
pattern
obtain
suggest
contamin
human
origin
occur
food
handl
presenc
nuc
speci
confirm
pvl
toxic
shock
syndrom
toxin
gene
detect
pcr
molecular
type
techniqu
agr
type
spa
type
multilocu
sequenc
type
mlst
perform
clonal
complex
cc
determin
use
eburst
softwar
result
isol
confirm
pvlposit
mssa
fourteen
isol
skin
soft
tissu
infect
ssti
nasal
carrier
necrot
pneumonia
one
orl
infect
sepsi
osteomiel
one
isol
strain
respons
hospitalcommun
outbreak
molecular
type
reveal
isol
belong
four
known
agr
allel
differ
spa
type
differ
sequenc
type
st
follow
eburst
analys
relat
st
group
cc
except
singleton
isol
belong
differ
genet
lineag
common
isol
lineag
isol
isol
three
strain
posit
strain
one
studi
show
great
varieti
pvlposit
mssa
clone
circul
itali
common
differ
countri
find
strain
belong
common
clone
new
lineag
found
also
posit
studi
done
evalu
circul
characterist
pvlposit
mssa
sinc
caus
seriou
infect
similarli
counterpart
pvlposit
mrsa
prove
gb
posit
newborn
colonis
ear
throat
gb
blood
hypervirul
clone
detect
gb
women
gb
newborn
gener
serotyp
iii
preval
type
isol
mostli
ear
newborn
type
ii
vast
major
strain
also
type
iii
strain
belong
clearli
distinguish
pfge
clone
gener
close
relat
one
anoth
conclus
serotyp
iii
shown
preval
neonat
colonis
asymptomat
carrier
also
hungari
clone
gb
identifi
multi
locu
sequenc
type
mlst
recognis
hypervirul
intern
clone
associ
mainli
invas
neonat
infect
compris
asymptomat
carrier
among
pregnant
women
could
transmit
newborn
high
rate
potenti
caus
sever
neonat
infect
result
emphas
necess
regular
screen
pregnanc
also
hungari
k
laub
sz
kardo
k
nagi
dobay
budapest
hu
object
carriag
pathogen
bacteria
staphylococcu
aureu
healthi
individu
well
known
preval
studi
survey
nasal
carriag
student
medic
univers
alreadi
attend
hospit
ward
potenti
sourc
infect
first
studi
kind
hungari
method
eightyeight
aureu
isol
collect
nasal
passag
student
attend
semmelwei
univers
budapest
hungari
speci
ident
confirm
coloni
morpholog
catalas
test
pastorex
test
biorad
nuca
pcr
mrsa
strain
screen
meca
pcr
antibiot
sensit
determin
etest
appli
eucast
breakpoint
genet
related
strain
examin
pfge
result
altogeth
student
hungarian
nonhungarian
sampl
voluntari
base
overal
aureu
carriag
rate
littl
higher
among
hungarian
nonhungarian
group
one
occas
carriag
two
unrel
strain
detect
strain
carri
meca
gene
oxacillin
mic
mgl
respect
strain
fulli
sensit
gentamicin
ciprofloxacin
vancomycin
isol
highlevel
mic
mgl
lowlevel
mic
mgl
erythromycin
resist
isol
resist
clindamycin
base
pfge
pattern
clone
compris
approxim
half
strain
strain
respect
rest
rather
divers
conclus
aureu
carriag
rate
correl
well
intern
data
luckili
mrsa
strain
one
higher
mic
eucast
breakpoint
mgl
highli
resist
also
erythromycin
strain
fulli
sensit
test
drug
isol
gener
sensit
characterist
case
carri
pathogen
strain
prove
genet
divers
usual
mrsa
popul
smaller
clone
indic
presenc
sever
independ
strain
dissimilar
isol
within
group
indic
extens
exchang
student
flora
result
among
clinic
strain
pilu
present
case
seven
deriv
invas
infect
rest
respiratori
specimen
half
came
small
children
half
adult
major
strain
resist
r
macrolid
elev
mic
penicillin
mgl
serotyp
n
n
n
n
n
among
carri
isol
n
pilu
posit
follow
serotyp
n
n
n
n
n
n
n
although
major
carri
strain
sensit
antibiot
nearli
half
pilu
strain
also
r
macrolid
nonsuscept
penicillin
children
previous
vaccin
prevenar
rate
pilu
posit
clinic
strain
correl
well
intern
data
significantli
lower
carri
strain
suggest
pili
requir
invas
rather
mere
colonis
probabl
direct
correl
pili
resist
rather
found
pili
certain
resist
serotyp
almost
vaccinetyp
domin
serotyp
except
strain
conjug
vaccin
seem
quit
effect
prevent
colonis
pilu
posit
strain
henc
prevent
subsequ
invas
bodi
kunda
ankirskaya
l
lubasovskaya
popov
gintsburg
moscow
ru
object
coagulaseneg
staphylococci
con
recogn
aethiolog
agent
import
rang
infect
human
countri
report
increas
con
infect
hospit
patient
resist
methicillin
antibiot
despit
inform
popul
structur
global
epidemiolog
staphylococcu
epidermidi
con
scare
goal
investig
analyz
collect
con
divers
clinic
origin
use
molecular
genotyp
method
con
isol
recov
blood
umbil
wound
conjunct
urin
pulmonari
tissu
antimicrobi
suscept
determin
standard
method
speci
identif
carri
amplif
sequenc
tuf
gene
epidermidi
isol
analyz
multilocu
sequenc
type
mlst
protocol
describ
thoma
jc
et
al
mlst
staphylococcu
haemolyticu
isol
perform
use
origin
primer
set
structur
compon
staphylococc
cassett
chromosom
mec
sccmec
test
pcr
addit
result
identif
con
speci
level
indic
epidermidi
common
speci
isol
follow
haemolyticu
staphylococcu
homini
staphylococcu
warneri
staphylococcu
pasteuri
isol
methicillinresist
among
epidermidi
isol
st
discov
includ
new
new
allel
analys
gene
discov
two
predomin
isol
epidermidi
isol
carri
sccmec
iv
composit
variant
sccmec
mecb
unusu
pattern
two
mec
gene
complex
class
class
b
among
haemolyticu
isol
st
recov
isol
carri
modifi
sccmec
type
iv
comlex
mec
class
b
element
sccmecv
sccmec
isol
typabl
predomin
sccmec
type
found
among
homini
isol
new
type
class
mec
typea
conclus
speci
epidermidi
haemolyticu
homini
warneri
preval
among
test
collect
coagulaseneg
staphylococci
high
level
genet
divers
epidermidi
haemolyticu
isol
discov
isol
epidermidi
epidem
neonat
center
aethiolog
agent
differ
form
infecti
process
con
may
serv
reservoir
new
type
sccmec
intens
care
unit
surgic
ward
accord
friedman
criteria
acquisit
classifi
nosocomi
healthcareassoci
commun
charlson
index
pitt
score
frequent
sourc
intravascular
cathet
infect
bsi
consid
complic
patient
patient
met
criteria
therapeut
failur
bsirel
mortal
patient
isol
studi
differ
antibiot
resist
pattern
combin
resist
ciprofloxacin
tobramycin
erythromycin
preval
broth
microdilut
mic
vancomycin
mgml
isol
respect
etest
mgml
respect
regard
daptomycin
isol
show
mic
mgml
microdilut
although
isol
show
mic
mgml
etest
eighti
percent
isol
group
cluster
pfge
group
e
follow
characterist
isol
spa
agri
sscmeciv
b
isol
spa
agri
sccmeciv
cluster
c
e
isol
predominantli
spa
agrii
sscmeciv
acquisit
predispos
featur
sourc
bsi
complic
bsi
mortal
similar
among
cluster
conclus
isol
mrsa
caus
bsi
area
group
cluster
sscmeciv
agrii
spa
predomin
unabl
find
signific
epidemiolog
clinic
differ
trend
among
cluster
object
communityassoci
mrsa
camrsa
becom
worldwid
phenomenon
studi
investig
molecular
epidemiolog
antibiot
resist
mechan
camrsa
select
clinic
specimen
accord
cdc
criteria
method
nondupl
outpati
isol
classifi
camrsa
juli
juli
institut
identif
suscept
test
carri
wider
system
disk
diffus
method
isol
genotyp
pfgesmai
spa
sccmec
agr
type
presenc
gene
encod
pvl
resist
gene
methicillin
meca
erythromycin
er
clindamycin
cc
erma
ermb
ermc
msra
gentamicin
gm
kanamycin
amikacin
tobramycin
aac
ieaph
ia
ant
ia
aph
msra
gene
found
isol
macrolidestreptogramin
ms
resist
phenotyp
ermc
erma
msraermc
gene
mlsbc
mlsbi
resist
phenotyp
aminoglycosid
resist
gene
detect
ant
ia
aac
ieaph
ia
aph
iii
aac
ieaph
iaaph
iii
five
strain
pvl
posit
sccmec
type
ivc
detect
strain
type
v
strain
type
ii
iva
nontyp
respect
agr
type
ii
identifi
strain
agr
type
agr
type
iii
one
strain
nontyp
spatyp
predomin
follow
spa
type
normal
group
clonalcomplex
sequencetyp
respons
half
nosocomi
mrsa
infect
spain
singl
strain
type
conclus
five
select
camrsa
carri
pvl
gene
correspond
spa
type
classic
communityassoci
remain
camrsa
correspond
spa
type
associ
hospit
environ
suggest
interchang
genet
lineag
mrsa
among
commun
hospit
nich
although
staphylococcu
sciuri
occasion
isol
human
less
known
carriag
bacterium
human
especi
methicillinresist
sciuri
aim
present
studi
provid
analysi
carriag
methicillinresist
sciuri
hospit
patient
healthcar
worker
hcw
nasal
swab
taken
hospit
hcw
clinic
center
serbia
belgrad
oxidas
posit
coloni
staphylococci
identifi
sciuri
bd
phoenix
autom
microbiolog
system
methicillin
resist
confirm
pcr
meca
gene
suscept
antibiot
perform
disk
diffus
method
accord
clsi
recommend
determin
sccmec
type
done
previous
describ
protocol
mec
class
ccr
type
kondo
et
al
pfge
perform
describ
previous
bannerman
et
al
among
hospit
patient
hcw
respect
colon
methicillinresist
sciuri
isol
resist
intermedi
resist
two
antibiot
besid
blactam
antibiot
ie
multidrug
resist
test
strain
suscept
trimethoprimsulfamethoxazol
vancomycin
linezolid
pristinamycin
resist
gentamicin
kanamycin
tobramycin
erythromycin
clindamycin
remain
intermedi
resist
clindamycin
ciprofloxacin
resist
rifampin
intermedi
resist
rifampin
tetracyclin
chloramphenicol
mupirocin
intermedi
resist
fusid
acid
pfge
analysi
reveal
pulsotyp
within
popul
methicillin
resist
sciuri
strain
isol
methicillinresist
sciuri
pfge
cluster
b
e
differ
individu
differ
hospit
differ
ward
indic
successfuli
spread
bacterium
isol
strain
mec
type
ccr
type
carriag
methicillinresist
sciuri
among
hospit
patient
hcw
determin
surprisingli
high
carriag
higher
hospit
patient
hcw
isol
methicillinresist
sciuri
strain
differ
genotyp
phenotipyc
characterist
three
drug
strain
resist
four
drug
strain
cn
resist
four
drug
posit
gene
mec
two
sampl
carri
gene
sensit
oxacillin
disc
diffus
method
reveal
heteroresist
result
studi
show
high
number
staphylococcu
resist
oxacillin
predomin
staphylococc
cassett
chromosom
type
iii
cn
type
ii
aureu
common
hospit
strain
insert
commun
explain
chronic
wound
patient
histori
multipl
hospit
life
great
similar
strain
staphylococcu
found
sensit
drug
test
compar
sampl
found
basic
health
unit
may
indic
presenc
possibl
clone
staphylococcu
sever
patient
result
also
call
attent
high
rate
multidrug
resist
found
strain
isol
patient
predomin
sccmec
type
iii
complic
treatment
infect
incid
orthoped
implantrel
infect
primari
knee
hip
replac
revis
surgeri
essenti
role
develop
paraprosthet
joint
infect
pji
belong
staphylococcu
aureu
aureu
bacteria
enter
spotlight
global
pervas
drugresist
pathogen
deal
prosthet
joint
infect
pji
often
need
start
empir
antibiot
therapi
constant
monitor
resist
chosen
pathogen
allow
good
time
correct
scheme
antibiot
therapi
bring
increas
effici
present
prospect
studi
perform
evalu
frequenc
detect
aureu
etiolog
factor
pji
conduct
test
antibiot
resist
method
examin
record
isol
chosen
tissu
fluid
sampl
patient
pji
antibiot
sensit
aureu
test
agar
dilut
method
resalt
aureu
common
pathogen
pji
year
frequenc
aureu
accordingli
year
preval
methicillinresist
aureu
mrsa
almost
chang
specifi
year
accordingli
figur
summar
result
dynam
analysi
antibiot
resist
aureu
pji
none
strain
vancomycin
linezolid
resist
isol
sensit
fuzid
acid
trimethoprimsulfamethoxazol
rifampicin
fosfomycin
resist
rate
aureu
antibacteri
agent
respect
follow
less
isol
resist
erythromycin
lincomycin
ciprofloxacin
gentamycin
amoxicillin
clavulan
highest
resist
rate
aureu
detect
penicil
oncolog
unit
stem
cell
solid
organ
transplant
observ
number
signific
infect
enterobacteriacea
sensit
amikacin
carbapenem
prospect
examin
first
isol
patient
collect
month
concern
risk
cross
infect
frequenc
isol
whether
empir
therapi
febril
patient
carbapenem
rather
convent
piperacillintazobactam
ceftazidim
ciprofloxacin
without
gentamicin
isol
identifi
speci
level
underw
detail
suscept
test
use
disc
diffus
agar
dilut
mic
determin
autom
walkaway
method
pcr
use
detect
presenc
ctxm
group
escherichia
coli
isol
underw
pcr
phylogroup
result
sampl
outpati
inpati
icu
grew
escherichia
coli
klebsiella
spp
enterobact
cloaca
isol
isol
urin
wound
sputa
icu
screen
swab
blood
cultur
isol
e
coli
klebsiella
spp
e
cloaca
patient
contact
icu
patient
strain
isol
origin
middl
east
uk
nigeria
averag
interv
admiss
detect
first
signific
isol
mean
median
day
pcr
show
isol
belong
ctxm
group
potenti
infer
mic
care
icu
signific
risk
factor
find
ctxm
esbl
produc
pathogen
p
phylogroup
e
coli
strain
reveal
group
group
pathogen
group
pathogen
strain
conclus
mic
pcr
phylogroup
isol
suggest
despit
profil
sensit
consist
amikacin
carbapenem
profil
creat
express
heterogen
resist
mechan
would
preclud
concern
cross
infect
work
characteris
ctxm
group
esbl
cluster
molecular
environ
gene
could
clarifi
resist
mechan
origin
strain
doudoulakaki
nika
p
giakkoupi
papadimitri
papaioann
j
kapetanaki
vatopoulo
e
lebessi
athen
gr
object
enterobact
cloaca
emerg
import
nosocomi
pathogen
neonat
unit
aim
studi
investig
massiv
colon
neonat
esbl
produc
e
cloaca
universityaffili
level
iiiv
neonat
intens
care
unit
nicu
larg
pediatr
hospit
athen
method
routin
surveil
cultur
detect
multidrug
resist
bacteria
throat
rectum
neonat
admiss
weekli
discharg
standard
practic
nicu
environment
sampl
collect
suspect
outbreak
clinic
environment
sampl
process
accord
classic
microbiolog
method
suscept
antimicrobi
test
accord
clsi
guidelin
esbl
detect
phenotyp
method
molecular
type
isol
determin
pfge
digest
genom
dna
xbai
result
august
seven
neonat
found
colon
esbl
produc
e
cloaca
oppos
neonat
found
colon
nicu
stay
nicuacquir
case
one
neonat
colon
upon
admiss
refer
case
last
month
nosocomi
outbreak
due
esbl
e
cloaca
highli
suspect
oneday
survey
perform
twenti
neonat
found
colon
esbl
e
cloaca
report
environment
sampl
found
neg
three
neonat
develop
bacteremia
due
esbl
e
cloaca
studi
period
one
suffer
seriou
underli
condit
die
pfge
analysi
epidem
strain
plu
epidemiolog
unrel
e
cloaca
isol
proven
similar
among
epidem
strain
fact
consist
nosocomi
spread
strict
infect
control
measur
hand
hygien
patient
cohort
shute
nicu
new
admiss
establish
continu
surveil
next
week
show
steadi
declin
number
colon
neonat
hospit
found
colon
conclus
continu
surveil
import
tool
earli
identifi
outbreak
wherea
implement
proper
infect
control
measur
result
contain
outbreak
short
period
time
object
occurr
carbapenemas
produc
gramneg
bacteria
high
clinic
interest
hydrolyz
blactam
agent
includ
carbapenem
recognis
antibiot
choic
esbl
acquir
ampc
produc
usual
resist
antibiot
resist
carbapenem
gener
rare
klebsiella
pneumonia
strain
czech
republ
predominantli
caus
alter
cell
wall
togeth
product
extendedspectrum
andor
ampc
blactamas
end
first
put
kpcproduc
isol
k
pneumonia
submit
confirm
nation
refer
laboratori
antibiot
nation
institut
public
health
pragu
isol
obtain
one
patient
method
mic
antibiot
determin
accord
eucast
recommend
blactamas
identifi
isoelectr
focus
follow
pcr
sequenc
blactamas
gene
gene
environ
determin
pcr
map
sequenc
amplicon
isol
compar
pfge
restrict
xbai
endonucleas
multilocu
sequenc
type
mlst
result
isol
k
pneumonia
obtain
wound
swab
decubitu
urin
patient
formerli
hospit
greek
hospit
carbapenemas
identifi
gene
locat
traspozon
variant
resist
colistin
develop
long
therapi
drug
singl
isol
produc
strain
disappear
object
mark
increas
preval
serotyp
monophas
variant
styphimurium
note
worldwid
recent
year
goal
assess
clonal
relationship
character
antibiot
andor
biocid
resist
portugues
isol
differ
sourc
method
studi
isol
human
n
food
n
environ
n
piggeri
n
serotyp
confirm
pcr
flja
fljb
hin
fljafljb
antibiot
suscept
antibiot
test
disk
diffus
method
clsi
character
antibiot
biocid
resist
gene
class
integron
done
pcr
rflp
sequenc
clonal
establish
mlst
repres
isol
result
isol
resist
antibiot
multidrugresist
mdr
antibiot
express
resist
sulfametoxazol
su
andor
tetracyclin
teta
andor
tetb
streptomycin
aada
andor
strastrb
ampicillin
blatem
chloramphenicol
c
andor
flor
trimethoprim
tr
gentamicin
g
aac
iv
nalidix
acid
kanamicin
three
major
group
isol
mostli
associ
genotyp
could
identifi
assut
type
n
blatem
strastrb
tetb
also
carri
pcod
copper
efflux
gene
assign
slv
ii
mdr
antibiot
type
n
frequent
phenotyp
acgssuttr
n
blatem
aac
iv
aada
teta
carri
unusu
class
integron
associ
qach
addit
class
integron
bp
empti
one
cs
belong
worldwid
spread
phagetyp
iii
cssuttr
type
n
aada
tetb
carri
class
integron
gene
cassett
associ
unusu
sequenc
region
qach
belong
conclus
first
studi
characteris
enterica
serotyp
iin
isol
portug
spread
three
mdr
genotyp
belong
worldwid
spread
clonal
lineag
associ
biocid
resist
determin
pcod
andor
qach
might
account
recent
emerg
success
serotyp
metalloblactamas
mbl
produc
strain
emerg
worldwid
exhibit
particular
relev
europ
dispers
integron
carri
clonal
spread
associ
mbl
gene
transposon
may
contribut
observ
dissemin
rate
aim
analyz
popul
structur
p
aeruginosa
clinic
isol
method
collect
carbapenemresist
p
aeruginosa
isol
deriv
five
hospit
north
centr
portug
p
aeruginosa
isol
character
n
antibiot
suscept
determin
agar
diffus
method
etest
clsi
class
integron
character
pcr
sequenc
clonal
related
studi
pfge
xbai
spei
mlst
http
pubmlstorgpaeruginosa
result
p
aeruginosa
isol
show
multidrugresist
phenotyp
includ
resist
imipenem
mic
mgl
aminoglycosid
ciprofloxacin
carri
gene
cassett
insert
differ
class
integron
frequent
found
isol
gene
found
chromosom
andor
plasmid
locat
isol
clonal
unrel
correspond
pfge
type
hand
differ
sequenc
type
st
found
n
n
n
n
n
n
n
n
close
relationship
singl
doubl
locu
variant
observ
among
st
produc
strain
assign
widespread
st
founder
intern
clonal
complex
contain
mbl
isol
conclus
first
report
character
popul
structur
p
aeruginosa
isol
portug
data
indic
isol
belong
extrem
polyclon
popul
appar
common
ancestri
studi
imper
followup
relev
specif
clone
dissemin
carri
isol
demirelli
sari
f
yazan
c
bulut
g
tuncer
ertem
f
b
oral
n
eren
ankara
tr
francisella
f
tularensi
gramneg
aerob
facult
intracellular
bacterium
distinguish
date
f
tularensi
subsp
tularensi
holarctica
mediasiatica
novicida
f
tularensi
detect
anim
speci
rabbit
hare
small
rodent
eg
vole
field
mice
semiaquat
anim
etc
tularemia
reemerg
diseas
countri
recent
evalu
clinicoepidemiolog
characterist
patient
tularemia
method
prospect
review
clinic
record
patient
diagnos
tularemia
admit
hospit
ankara
januari
decemb
case
definit
patient
suggest
clinic
cours
epidemiolog
come
epizoot
area
posit
serolog
antibodi
francisella
tularensi
result
patient
femal
mean
age
year
includ
studi
nine
patient
live
endem
area
turkey
thirteen
patient
travel
endem
area
among
case
contamin
food
water
commonli
note
exposur
ten
patient
consum
spring
water
one
tick
bite
exposur
thirteen
patient
report
expos
rat
live
around
patient
hous
clinic
symptom
period
patient
rang
day
final
diagnosi
patient
glandular
tularemia
wherea
two
oculoglandular
tularemia
suppur
lymph
node
fourteen
patient
hospit
median
durat
day
rang
day
histori
antibiot
use
avail
patient
patient
treat
blactam
blactamblactamas
inhibitor
antibiot
consid
ineffect
tularemia
among
patient
initi
treat
streptomycin
monotherapi
one
patient
treat
streptomycin
ciprofloxacin
combin
epidemiolog
clinic
find
patient
summar
tabl
conclus
tularaemia
consid
differenti
diagnosi
patient
fever
pharyng
conjunct
cervic
lymphadenopathi
henc
earli
diagnosi
treatment
tularaemia
import
everi
clinician
must
awar
diseas
baranda
camino
j
galan
ro
l
robl
fonseca
martinez
serrano
crespo
sanchez
albacet
es
object
determin
epidemiolog
urinari
tract
infect
uti
multiresist
microorgan
isol
hospit
patient
commun
diagnos
hospit
universitario
albacet
spain
studi
antimicrobi
suscept
drug
commonli
use
infect
method
urin
sampl
process
aerob
cultur
standard
method
januari
decemb
identif
antimicrobi
sensit
test
perform
commerci
wider
system
soria
melguizo
criteria
propos
clsi
follow
detect
multidrug
resist
mechan
consid
multidrugresist
pseudomona
aeruginosa
mrpa
resist
antibiot
follow
ceftazidim
carbapenem
quinolon
aminoglycosid
multiresist
acinetobact
baumannii
mra
isol
sensit
tigecyclin
colistin
urin
sampl
test
posit
mdr
microorgan
isol
extendedspectrum
blactamaseproduc
enterobacteria
esbl
meticilinresist
staphylococcu
aureu
mrsa
mrpa
mra
within
esblproduc
enterobacteria
found
escherichia
coli
klebsiella
spp
proteu
spp
multidrugresist
isol
increas
inpati
commun
total
patient
adult
children
women
antimicrobi
resist
rate
esblproduc
enterobacteria
nalidix
acid
ciprofloxacin
cotrimoxazol
gentamicin
nitrofurantoin
fosfomycin
amocillinclavulan
carbapenem
resist
strain
found
conclus
observ
increas
incid
uti
multiresist
pathogen
studi
period
inpati
patient
infect
acquir
commun
among
inpati
highest
incid
correspond
intern
medicin
geriatr
depart
esblproduc
enterobacteria
frequent
isol
multiresist
organ
carbapenem
aminoglycosid
could
best
choic
empir
treatement
hospit
patient
quinolon
cotrimoxazol
recommend
due
high
resist
rate
observ
highthroughput
dna
sequenc
resist
plasmid
power
approach
identifi
resist
virul
featur
l
villa
c
carta
fortini
carattoli
rome
introduct
highthroughput
dna
sequenc
resist
plasmid
allow
quick
determin
plasmid
content
novel
approach
possibl
identifi
major
characterist
resist
virul
trace
evolut
specif
plasmid
famili
recogn
basi
virul
host
rang
transfer
stabil
sequenc
plasmid
identifi
klebsiella
pneumonia
kp
nosocomi
origin
untyp
pcrbase
replicon
type
pbrt
ii
relev
characterist
epidem
clone
materi
method
procedur
devis
simultan
pyrosequ
multipl
plasmid
gsflx
titanium
use
midtag
barcod
primer
larg
volum
empcr
roch
itali
mobil
dna
element
associ
resist
gene
region
implic
replic
plasmid
host
rang
mainten
toxinantitoxin
plasmid
partit
exclus
properti
transfer
annot
major
plasmid
carri
gene
classifi
untyp
neg
common
replicon
enterobacteriacea
one
plasmid
belong
novel
incr
plasmid
famili
plasmid
famili
character
novel
replicas
gene
previous
identifi
salmonella
montevideo
netherland
associ
gene
et
al
novel
fulli
sequenc
plasmid
confer
resist
blactam
cephalosporin
also
mercur
ion
aminoglycosid
strastrb
sulphonamid
neg
conjug
transfer
locu
suggest
tran
mobil
mediat
coresid
plasmid
ii
entir
plasmid
content
two
kp
strain
one
multidrug
resist
one
suscept
determin
resist
strain
posit
carbapenemas
locat
plasmid
pkpqil
previous
identifi
israel
suscept
contain
virulencelik
plasmid
fiik
type
like
contribut
success
spread
clone
independ
acquisit
antimicrobi
resist
gene
sinc
plasmid
consid
genom
within
bacteri
genom
fulli
sequenc
approach
may
help
identifi
characterist
enhanc
success
spread
specif
plasmid
famili
also
abil
plasmid
support
host
surviv
spread
novai
j
pire
l
peix
porto
pt
object
specif
uticaus
e
coli
clone
link
emerg
spread
abr
gene
complet
virul
profil
upec
clone
assess
lineag
method
collect
includ
n
n
n
n
complex
n
complex
n
n
n
isol
repres
isol
year
period
differ
origin
hospit
healthi
volunt
anim
outpati
environ
locat
n
eu
countri
n
korea
n
usa
n
utiisol
n
esblampc
produc
clonal
related
assess
pfgemlst
phylogroup
identifi
pcr
screen
upec
virul
factor
vf
includ
adhesin
toxin
siderophor
polysaccharid
coat
other
pai
usp
ibea
perform
pcr
describ
expec
isol
identifi
previous
describ
criterium
result
fimh
iuta
trat
found
within
st
number
vf
vari
n
n
n
common
virul
profil
establish
upec
clone
rather
uticaus
isol
expec
isol
n
belong
enrich
kpsmtii
iuta
iha
expec
identifi
nearli
half
occasion
st
pap
allel
papef
papgiii
papc
andor
kpsmtii
besid
iuta
also
significantli
enrich
pap
allel
frequenc
usp
sat
fyua
high
though
varibl
distribut
fyua
sat
among
respect
b
usp
among
produc
hand
specif
vf
found
particular
st
pai
mostli
within
ii
cvac
confin
complex
iii
ibea
identifi
produc
iv
sfadoc
found
v
afadra
detect
isol
conclus
consist
vf
profil
found
within
st
differ
could
explain
origin
pathogenesi
abr
profil
upec
profil
link
presenc
fimh
adhes
iuta
iron
uptak
trat
surfac
exclus
colv
colicin
andor
usp
novai
c
rodrigu
r
branquinho
p
antun
g
ribeiro
l
peix
porto
coimbra
pt
object
emerg
carbapenem
resist
among
esblproduc
isol
increasingli
report
worldwid
aim
character
recent
outbreak
ertapenem
ert
resist
enterobacteriacea
isol
portugues
hospit
method
ertr
n
mic
mgml
imi
mer
suscept
ert
n
presumpt
esblproduc
k
pneumonia
kp
n
e
coli
ec
n
e
asburia
ea
n
e
aerogen
eae
n
e
cloaca
ecl
n
isol
studi
marchaugust
blactamas
product
evalu
phenotyp
test
ief
pcr
blakpc
blandm
blavim
blaimp
blaoxa
blage
blaampc
blatem
blashv
blactxm
gene
sequenc
fals
posit
obtain
carbapenemas
product
phenotyp
assay
confirm
spectrophotometr
strain
identif
antibiot
suscept
test
perform
standard
method
clonal
analysi
includ
pfge
mlst
identif
e
coli
phylogroup
plasmid
content
locat
assess
presenc
class
integron
sul
qnr
qnra
qnrb
qnr
gene
search
describ
porin
ompc
ompf
investig
pcr
sequenc
sdspage
result
seven
ertnon
clone
kp
ec
ea
eae
ecl
mic
mgml
mostli
produc
esblampc
detect
mdr
epidem
clone
n
pfgetyp
urologytranspl
unit
frequent
identifi
throughout
whole
period
includ
ert
n
pfge
b
ertr
n
pfge
b
c
mic
mgml
encod
isol
bla
within
plasmid
n
mic
mgml
sporad
nonesbl
produc
clone
n
pfge
ertr
mic
mgml
ert
differ
unit
detect
end
period
bla
locat
plasmid
one
carbapenemr
eae
one
ecl
mic
mgml
one
eae
mic
mgml
clone
also
identifi
differ
porin
alter
observ
among
ertr
clone
qnrb
kp
ec
qnra
class
integron
sporad
detect
studi
reveal
complex
allodem
scenario
associ
emerg
ertapenem
resist
among
differ
esblampc
enterobacteriacea
widespread
clone
portug
object
kpc
import
group
blactamas
given
spread
nosocomi
set
among
enterobacteriacea
wider
dissemin
found
mostli
plasmid
k
pneumonia
kpcposit
k
pneumonia
kpckp
report
mani
european
countri
first
descript
kpckp
itali
report
publish
report
second
italian
outbreak
discuss
clinic
molecular
featur
method
k
pneumonia
isol
collect
san
gerardo
hospit
monza
analyz
repres
isol
involv
outbreak
antibiot
suscept
test
perform
vitek
mic
imipenem
meropenem
confirm
etest
isol
posit
carbapenemas
product
detect
phenyl
boron
acid
test
clonal
distribut
assess
reppcr
rapd
pfge
mlst
select
isol
subject
pcr
analysi
sequenc
detect
pattern
resist
determin
investig
isol
show
mdr
phenotyp
suscept
colistin
gentamicin
tigecyclin
result
genotyp
techniqu
concord
show
one
isol
clonal
relat
belong
st
isol
confirm
posit
sequenc
addit
investig
strain
posit
one
esbl
addit
isol
show
phenotyp
pattern
presum
relat
epidem
cluster
conclus
novemb
san
gerardo
hospit
kpckp
strain
isol
studi
period
clonal
relat
kpckp
obtain
isol
belong
st
first
describ
italian
kpckp
clone
major
respons
worldwid
spread
resist
determin
molecular
analysi
demonstr
presenc
isol
one
blactamas
kpckp
isol
clonal
relat
outbreak
clone
posit
determin
obtain
patient
transfer
anoth
hospit
differ
clone
repres
except
italian
epidemiolog
scenario
describ
kpckp
belong
reppcr
approach
describ
appear
rapid
robust
techniqu
investig
clonal
relationship
kpckp
l
papst
k
seme
p
gabrijel
b
beovic
ljubljana
si
object
detect
isol
patient
colonis
esblproduc
bacteria
import
measur
prevent
transmiss
resist
bacteria
hospit
prospect
studi
want
determin
anatom
site
esblproduc
escherichia
coli
klebsiella
pneumonia
method
patient
colonis
infect
esblproduc
bacteria
includ
prospect
studi
novemb
novemb
rectal
swab
urin
cultur
throat
swab
perform
patient
wound
swab
obtain
patient
wound
sputum
collect
patient
product
cough
sampl
collect
repeat
everi
month
collect
sampl
inocul
chromogen
agar
select
esblproduc
bacteria
disc
diffus
method
done
k
pneumonia
andor
e
coli
isol
assess
antimicrobi
suscept
profil
isol
result
sampl
collect
done
patient
patient
male
femal
year
old
year
averag
patient
immunosuppress
therapi
chronic
cardiovascular
diseas
diabet
insulin
patient
chronic
kidney
failur
chronic
respiratori
ill
patient
colonis
k
pneumonia
patient
e
coli
patient
isol
least
one
sampl
posit
esblproduc
bacteria
occas
rectal
swab
posit
throat
swab
urin
cultur
occas
sputum
cultur
perform
time
posit
wound
swab
posit
sampl
taken
occas
patient
rectal
swab
neg
esblproduc
k
pneumonia
isol
urin
patient
rectal
swab
initi
sampl
collect
posit
togeth
urin
throat
wound
swab
month
later
howev
urin
posit
site
patient
even
subsequ
occas
result
shown
rectal
swab
posit
patient
colonis
esblproduc
e
coli
k
pneumonia
assum
rectal
swab
appropri
method
routin
screen
colonis
e
coli
k
pneumonia
produc
esbl
howev
patient
urin
may
least
transitori
posit
site
enterobact
cloaca
isol
produc
metalloblactamas
neonat
unit
tertiari
greek
hospit
object
enterobact
cloaca
isol
produc
metallo
blactamas
mbl
regard
emerg
clinic
threat
infect
pathogen
involv
neonat
remain
uncommon
analyz
clinic
characterist
outcom
bloodstream
infect
due
vimproduc
e
cloaca
preterm
neonat
hospit
neonat
unit
tertiari
hospit
greec
method
oneyear
period
jan
neonat
present
bloodstream
infect
due
e
cloaca
exhibit
reduc
suscept
carbapenem
studi
bacteri
isol
identifi
vitek
mic
determin
etest
ab
biodisk
phenotyp
test
perform
use
modifi
hodg
test
combin
edta
disk
test
boron
acid
potenti
disk
test
pcr
use
screen
carbapenemas
gene
blavim
blaipm
blakpc
well
esbl
blactxm
blatem
blashv
plasmidmedi
ampc
gene
dna
sequenc
use
identifi
mbl
type
gene
result
studi
five
prematur
neonat
bloodstream
infect
due
carbapenemnonsuscept
e
cloaca
isol
exhibit
variabl
carbapenem
mic
rang
imipenem
mgml
meropenem
mgml
ertapenem
mgml
isol
remain
sensit
tigecyclin
colistin
two
resist
gentamicin
phenotyp
test
indic
mbl
product
pcr
use
verif
identif
carbapenemas
confirm
presenc
sole
blavim
gene
isol
dna
sequenc
blast
search
identifi
gene
neonat
femal
one
male
mean
age
gestat
w
mean
weight
kg
three
neonat
expos
carbapenem
hospit
prior
report
bloodstream
infect
clinic
record
prematur
neonat
analyz
attribut
mortal
rate
studi
show
prematur
neonat
repres
group
patient
especi
vulner
life
threaten
infect
due
mblproduc
e
cloaca
isol
carbapenem
mic
tend
variabl
strain
earli
detect
remain
challeng
laboratori
time
implement
infect
control
strategi
absolut
necess
order
prevent
spread
mdr
bacteria
object
induc
acquir
ampc
blactamas
confer
resist
blactam
except
cefepim
carbapenem
sinc
previou
studi
display
genet
context
well
character
collect
produc
show
donor
transconjug
two
isol
escherichia
coli
carri
bla
multipl
plasmid
well
chromosom
one
isol
select
analys
better
understand
element
mobil
bla
check
result
obtain
first
studi
reproduc
repeat
conjug
assay
pick
independ
transconjug
coloni
select
ceftazidim
rifampin
plasmid
chromosom
locat
bla
parent
transconjug
select
investig
digest
entir
dna
follow
puls
field
gel
electrophoresi
pfge
probe
label
bla
probe
result
hybridis
analys
bla
probe
among
donor
transconjug
coloni
analys
reveal
bla
gene
carri
plasmid
donor
six
transconjug
test
also
chromosom
case
moreov
multipl
hybridis
band
observ
hybridis
bla
transconjug
conclus
acquir
ampc
blactamas
recent
describ
mobilis
integr
conjug
element
ice
element
capabl
transfer
chromosom
chromosom
via
conjug
bla
present
chromosom
donor
transfer
chromosom
transconjug
hypothes
ice
could
involv
mobilis
bla
gene
e
coli
isol
multi
locu
sequenc
type
mlst
method
discrimin
microbi
isol
partial
sequenc
select
housekeep
gene
bionumer
softwar
wide
use
storag
analysi
mlst
sequenc
use
adapt
plugin
tool
bionumer
automat
assembl
process
sequenc
trace
file
connect
onlin
mlst
databas
retriev
correspond
allel
number
sequenc
type
well
avail
clonal
complex
inform
case
campylobact
jejuni
c
coli
http
pubmlstorg
campylobact
profil
avail
link
clonal
complex
use
bionumer
minimum
span
tree
mst
illustr
interrel
clonal
complex
mst
wellknown
context
mathemat
topolog
set
distanc
given
n
sampl
minimum
span
tree
connect
sampl
way
sum
distanc
branch
tree
minim
principl
maximum
parsimoni
mp
mst
share
idea
evolut
explain
event
possibl
contrast
mp
classic
mst
allow
creation
hypothet
node
reli
state
present
sampl
dataset
explain
relationship
evolut
therefor
mst
applic
studi
focus
short
evolutionari
time
frame
microevolut
complet
dataset
mst
algorithm
present
allow
creation
hypothet
node
total
distanc
tree
reduc
userdefin
number
event
context
mlst
hypothet
node
usual
miss
allel
type
number
singl
locu
variant
slv
present
dataset
introduc
hypothet
allel
type
proven
produc
reliabl
model
noncomplet
sampl
dataset
addit
select
mst
probabl
evolutionari
interpret
among
multipl
equival
solut
degener
tree
bionumer
edit
prioriti
rule
tie
handl
adopt
burst
program
http
wwwmlstnet
data
flow
illustr
process
mlst
trace
file
c
jejuni
c
coli
isol
upgma
dendrogram
mixtur
mlst
profil
c
jejuni
c
coli
base
similar
calcul
categor
coeffici
compar
minimum
span
tree
obtain
use
data
object
fast
techniqu
routin
strain
type
clinic
microbiolog
laboratori
use
tool
report
result
compar
studi
autom
reppcr
wholecel
matrixassist
laser
desort
ionizationtim
flight
mass
spectrometri
malditof
ms
molecularepidemiolog
analysi
nososcomi
carbapenemresist
klebsiella
spp
method
thirteen
klebsiella
spp
k
oxytoca
k
pneumonia
nosocomi
isol
metalloblactamas
produc
analyz
autom
reppcr
diversilab
system
malditof
ms
axima
speci
identif
perform
vitek
system
malditof
antimicrobi
suscept
test
isol
bacteria
assay
use
vitek
system
etest
dna
array
use
detect
kpc
tem
shv
ctxm
extend
spectrum
blactamas
detect
gene
done
pcr
sequenc
result
klebsiella
spp
isol
except
one
k
oxytoca
gene
k
pneumonia
also
blashv
gene
associ
esbl
product
reppcr
use
diversilab
system
show
higher
discriminatori
power
malditof
spectra
analysi
strain
type
combin
use
malditof
speci
identif
diversilab
system
clonal
strain
type
may
use
tool
fast
accur
manag
nosocomi
outbreak
trend
mainli
driven
fluconazol
use
call
closer
monitor
antimycot
antifung
use
resist
object
cefotaxim
wide
use
antibiot
treatment
neonat
infect
dose
blactam
antibiot
continu
infus
suggest
improv
treatment
outcom
compar
intermitt
infus
howev
continu
infus
critic
neonat
fluid
salt
restrict
glucos
often
use
nutrient
suppli
neonat
could
time
serv
good
solvent
cefotaxim
yet
stabil
data
cefotaxim
glucos
lack
restrain
pediatrician
continu
infus
cefotaxim
investig
stabil
cefotaxim
glucos
method
cefotaxim
dissolv
glucos
concentr
mgml
store
room
temperatur
cefotaxim
level
measur
everi
sixti
minut
eight
hour
hour
use
valid
high
perform
liquid
chromatographi
hplc
method
measur
perform
duplic
valu
estim
sampl
subsequ
time
point
calcul
percentag
initi
concentr
recoveri
percent
initi
concentr
defin
signific
loss
use
worldwid
standard
result
rel
concentr
time
curv
shown
figur
hour
cefotaxim
concentr
declin
sem
indic
cefotaxim
stabl
least
hour
glucos
conclus
even
hour
cefotaxim
decreas
limit
stabil
concentr
mgml
dissolv
glucos
glucos
good
solvent
cefotaxim
allow
continu
infus
chang
infus
bag
day
facilit
optim
treatment
allow
glucos
supplement
reduc
nurs
staff
workload
object
analysi
diagnost
accuraci
suspect
origin
bacteremia
prognost
influenc
type
microorgan
adquisit
empir
treatment
origin
bacteremia
evolut
death
materi
method
retrospect
studi
bacteremia
diagnos
year
south
hospit
madrid
analyz
suspect
origin
final
origin
acquisit
microorgan
empir
therapi
evolut
death
result
bacteremia
analyz
congruenc
diagnosi
suspecteddefinit
origin
nosocomi
bacteremia
differ
ci
sig
congruenc
diagnosi
suspecteddefinit
origin
commun
bacteremia
differ
ci
sig
bacteremia
respiratori
origin
percent
apropri
empir
diagnosi
vascular
origin
pneumonia
percent
apropri
empir
diagnosi
nonfer
gramneg
bacilli
coagulas
neg
staphylococcu
mortal
ci
fold
higher
bacterem
inadequ
empir
antibiot
treatment
mortal
group
receiv
inadequ
antibiot
therapi
differ
group
ci
sig
differ
mortal
group
right
wrong
suspect
diagnosi
origin
bacteremia
ci
sig
ci
clinician
high
degre
suspicion
correct
origin
focu
bacteremia
higher
respiratori
origin
lowest
vascular
origin
data
consist
type
microorgan
degre
success
affect
overal
mortal
bacteremia
empir
treatment
object
investig
outcom
patient
treat
colistin
either
iv
inhal
therapi
nosocomi
pneumonia
associ
multidrugresist
mdr
pseudomona
aeruginosa
method
retrospect
studi
intens
care
patient
pneumonia
associ
mdr
p
aeruginosa
receiv
colistin
sulphometh
sodium
colistineb
perform
strain
consid
multidrugresist
resist
least
follow
antibiot
piperacillintazobactam
ceftazidim
cefepim
meropenem
aztreonam
ciprofloxacin
amikacin
administr
mode
predict
mortal
base
score
sofa
score
onset
colistin
treatment
clinic
microbiolog
respons
mortal
episod
infect
analys
non
parametr
kruskalw
fisher
exact
test
use
statist
analysi
respect
predict
mortalitysofa
score
mortal
rate
result
six
patient
receiv
colistin
inhal
treat
parenter
combin
administr
mode
patient
receiv
concomit
therapi
mean
predict
mortal
respect
p
sofa
score
onset
treatment
also
compar
p
clinic
respons
favour
patient
receiv
colistin
inhal
patient
receiv
colistin
parenter
p
patient
colistin
administ
via
inhal
parenter
clinic
respons
favour
patient
p
compar
treatment
group
receiv
colistin
parenter
patient
inhal
therapi
compar
group
without
inhal
therapi
favor
clinic
respons
present
respect
p
none
patient
pseudomona
spp
erad
followup
cultur
patient
parenter
treat
group
die
none
patient
receiv
colistin
inhal
patient
combin
group
eventu
die
p
p
respect
compar
group
receiv
colistin
parenter
conclus
aerosol
colistin
could
benefici
adjunct
treatment
manag
pneumonia
associ
mdr
p
aeruginosa
object
inappropri
use
antimicrobi
drug
associ
increas
hospit
expenditur
emerg
resist
bacteria
unnecessari
sideeffect
concern
antibiot
stewardship
among
main
concern
hospit
infect
control
programm
surgic
antibiot
prophylaxi
guid
establish
hospit
aim
studi
investig
point
preval
antibiot
prophylaxi
surgeri
clinic
evalu
appropri
antibiot
use
studi
conduct
ankara
train
research
hospit
tertiari
care
teach
hospit
hospit
contain
oper
room
oper
perform
within
year
decemb
infecti
diseas
consult
went
oper
room
eight
surgeri
clinic
plastic
reconstruct
surgeri
gener
surgeri
ophthalmolog
earnosethroat
orthopaed
urolog
obstetr
gynaecolog
g
neurosurgeri
investig
prophylact
antibiot
regimen
surgeri
durat
intend
use
antibiot
surgeri
also
includ
questionnair
result
seventytwo
hospit
surgeri
patient
underw
differ
kind
surgeri
use
prophylaxi
cefazolin
sulbactamampicillin
ceftriaxon
frequent
antibiot
use
prophylaxi
four
patient
combin
antibiot
metronidazol
plu
antibiot
use
patient
get
prophylaxi
mean
durat
antibiot
use
day
intend
use
antibiot
prophylaxi
surgeri
day
antibiot
prophylaxi
regimen
inappropri
accord
guidelin
reason
inappropri
follow
wrong
antibiot
wrong
dose
durat
antibiot
spite
need
current
studi
show
high
percentag
inappropri
surgic
prophylaxi
regimen
hospit
main
problem
inappropri
prophylact
antibiot
use
dose
durat
chosen
antibiot
right
conclus
suggest
hospit
infect
control
programm
must
includ
follow
use
establish
guidelin
introduc
seem
effici
object
first
epidem
tularemia
southeastern
serbia
happen
year
period
till
patient
hospit
treat
purpos
studi
analyz
determin
best
therapi
choic
patient
suffer
tularemia
method
hospit
treat
inadequ
treat
adequ
treat
unknown
averag
durat
diseas
hospit
day
antibiot
monotherapi
administr
patient
gentamicin
patient
ciprofloxacin
amikacin
streptomycin
doxycyclin
patient
combin
polyval
success
antibiot
therapi
administr
patient
gentamicin
ciprofloxacin
patient
gentamicin
doxycyclin
ciprofloxacin
doxycyclin
gentamicin
ciprofloxacin
doxycyclin
patient
biggest
success
treatment
cure
notic
patient
combin
gentamicin
ciprofloxacin
doxycyclin
combin
gentamicin
ciprofloxacin
monotherapi
gentamicin
combin
gentamicin
doxycyclin
cure
comparison
number
treat
patient
biggest
success
treatment
combin
gentamicin
ciprofloxacin
monotherapi
gentamicin
outcom
medicamentosu
treatment
patient
total
cure
complic
happen
patient
abscess
lymph
node
without
fistulis
patient
relaps
patient
complic
patient
graphic
relaps
includ
recidivant
lymph
node
enlarg
intak
one
lymph
node
final
outom
conserv
radic
treatment
total
cure
patient
residu
persist
lymphadenopathi
patient
conclus
reason
appear
complic
therapi
tularem
patient
inadequ
initi
antibiot
treatment
late
onset
adequ
antibiot
therapi
possibl
appear
resist
speci
f
tularensi
region
southeastern
serbia
earli
forehand
treatment
restrain
colliqu
lymph
node
recurr
diseas
dissemin
infect
earli
diagnosi
treatment
crucial
prevent
complic
complet
cure
object
varieti
method
improv
antimicrobi
appropri
hospit
aim
studi
investig
influenc
antimicrobi
stewardship
program
antibiot
use
hospit
sant
joan
de
de
martorel
studi
conduct
bedhospit
antibiot
consumpt
monitor
one
year
prior
dinh
j
salomon
j
bru
l
bernard
garch
anneci
tour
fr
object
sever
year
antimicrobi
resist
rate
among
bacteria
continu
rise
limit
therapeut
option
due
shortag
new
antimicrobi
agent
situat
led
renew
interest
old
antibiot
fosfomycin
evalu
efficaci
safeti
fosfomycin
resist
bacteria
especi
critic
ill
patient
method
retrospect
studi
evalu
use
efficaci
fosfomycin
cover
drug
infect
due
multi
resist
bacteria
parenter
fosfomycin
combin
anoth
antibiot
appear
safe
effect
treatment
sever
infect
caus
resist
bacteria
sensit
antibiot
benefit
low
stabl
rate
resist
countri
use
long
time
confirm
studi
substanti
find
object
describ
real
world
clinic
experi
use
daptomycin
dap
treatment
infect
endocard
uk
method
retrospect
nonintervent
review
patient
pt
receiv
dap
uk
institut
particip
european
cubicin
outcom
registri
experi
eucoresm
first
year
registri
efficaci
evalu
investig
end
dap
therapi
cure
improv
failur
nonevalu
data
collect
demograph
antibiot
usag
microbiolog
clinic
outcom
advers
event
pt
treat
januari
august
patient
pt
categoris
sever
complic
uncompl
anatom
site
primari
infect
pt
includ
registri
receiv
least
one
dose
dap
result
pt
mean
age
yr
treat
major
pt
signific
underli
diseas
leftsid
ie
side
involv
rightsid
foreign
bodi
involv
prior
antibiot
receiv
pt
reason
discontinu
therapi
loss
suscept
resist
pt
cultur
obtain
primari
infect
pt
staphylococcu
aureu
frequent
isol
organ
follow
coagulaseneg
staphylococci
streptococcu
spp
heart
valv
replac
pt
surgic
intervent
major
pt
mean
durat
therapi
day
pt
receiv
concomit
antibiot
dap
mgkg
frequent
use
dose
clinic
outcom
success
defin
cure
plu
improv
failur
nonevalu
advers
event
report
regardless
studi
drug
relationship
experienc
pt
mean
time
clinic
improv
day
therapi
stop
advers
event
pt
conclus
despit
number
prior
antibiot
failur
multipl
comorbidit
pt
overal
clinic
success
rate
uk
popul
emerg
evid
dap
use
treat
infect
caus
gramposit
speci
increas
import
ie
particularli
treatment
option
may
limit
data
current
seri
add
bodi
evid
efficaci
dap
leftsid
ie
subject
clinic
improv
na
describ
patient
microbiolog
erad
pa
confirm
patient
though
relaps
na
result
clinic
improv
patient
though
well
toler
three
patient
toler
na
administ
least
col
tob
tabl
show
reduct
mean
number
admissionsyear
mean
lenght
stayyear
day
na
onset
patient
statist
signific
reduct
observ
pa
erad
whole
patient
present
side
effect
time
treatment
mainli
bronchospasm
side
effect
prompt
treatment
interrupt
observ
na
cours
col
tob
gen
na
result
clinic
improv
bq
patient
erad
pa
na
reduc
number
admiss
length
stay
per
year
patient
statist
signific
reduct
observ
patient
achiev
pa
erad
na
prevent
nearli
admiss
per
year
side
effect
observ
patient
toler
na
increas
prescript
broadspectrum
antibiot
regard
facilit
select
multiresist
germ
surveil
outpati
antibiot
use
might
contribut
effort
made
prevent
spread
methicillinresist
aureu
mrsa
within
region
network
eursafeti
healthnet
issu
address
offer
train
session
mrsa
antibiot
awar
gener
practition
cooper
associ
statutori
health
insur
physician
westphalialipp
kvwl
repres
german
part
euregio
region
north
rhinewestphalia
furthermor
possibl
reimburs
mrsa
erad
therapi
outpati
creat
present
data
compar
use
select
antibiot
outpati
care
medic
doctor
euregio
kvwl
region
region
data
outpati
prescript
antibiot
base
defin
daili
dose
ddd
collect
kvwl
analyz
year
order
compar
prescript
differ
antibiot
like
fluoroquinolon
mupirocin
euregio
whole
kvwl
region
use
cochran
armitag
trend
test
altogeth
total
dddday
per
inhabit
prescrib
follow
respect
percentag
prescript
antibiot
fluorochinolon
decreas
significantli
euregio
relat
whole
kvwl
region
contrast
number
mupirocin
prescript
increas
significantli
euregio
kvwl
region
desir
medic
doctor
euregio
region
tend
prudent
antibiot
use
increas
number
mupirocin
prescript
among
outpati
reflect
grow
demand
facilit
new
refund
possibl
increas
implement
mrsa
erad
therapi
outpati
care
region
trend
may
reflect
effect
intervent
observ
routin
data
object
chronic
brucellosi
cb
chronic
fatigu
syndrom
cf
character
collect
nonspecif
symptom
longlast
fatigu
note
object
clinic
diagnost
find
cb
cf
lowmolecularmass
kda
isoform
rnase
l
describ
peripher
blood
mononuclear
cell
pbmc
extract
ratio
two
isoform
rnase
l
kda
propos
potenti
biochem
marker
cf
tiev
et
al
knowledg
rnase
l
never
analyz
cb
patient
aim
studi
determin
ratio
isoform
cb
patient
compar
result
healthi
wellmatch
volunt
cb
group
consist
patient
women
men
mean
standard
deviat
sd
age
year
diagnos
brucellosi
five
year
prior
studi
two
cb
patient
focal
diseas
one
spondyl
one
multifoc
motor
neuropathi
remain
subject
nonspecif
symptom
fatigu
malais
arthralgia
andor
myalgia
five
cb
patient
diagnos
cf
control
group
consist
match
healthi
volunt
women
men
mean
standard
deviat
sd
age
year
pbmc
isol
densitygradi
centrifug
target
protein
probe
use
western
blot
procedur
result
pbmc
extract
subject
give
rise
major
kda
minor
kda
polypeptid
band
ratio
rnase
l
isoform
kda
use
cutoff
allow
discrimin
cb
patient
control
high
sensit
specif
posit
prognost
valu
neg
prognost
valu
mean
amount
ratio
rnase
l
isoform
kda
chronic
brucellosi
patient
higher
healthi
subject
p
chronic
brucellosi
patient
like
show
higher
ratio
two
isoform
rnase
l
kda
healthi
subject
high
kda
ratio
rnase
l
could
distinguish
cb
patient
healthi
subject
object
recent
public
suggest
surgic
site
infect
caus
aureu
half
aris
endogen
flora
studi
evalu
rapid
molecular
identif
aureu
nasal
carriag
patient
undergo
urgent
surgeri
studi
carri
telaviv
medic
center
patient
select
differ
surgic
ward
neurosurgeri
thorac
orthoped
vascular
plastic
surgeri
nasal
swab
patient
collect
use
doubl
swab
one
swab
use
molecular
test
genexpert
xpert
mrsasa
nasal
assay
cepheid
use
confirmatori
cultur
solid
chromagar
mrsa
ii
sheep
blood
liquid
medium
brain
heart
infus
broth
result
patient
sampl
patient
found
carier
aureu
molecular
test
mssa
mrsa
compar
routin
cultur
sensit
specif
molecular
test
respect
posit
predict
valu
ppv
neg
predict
valu
npv
patient
invalid
result
initi
molecular
test
repeat
molecular
test
swab
use
initi
cultur
invalid
result
xpert
mrsasa
nasal
assay
capabl
rapid
accur
detect
mssa
mrsa
nasal
colon
studi
need
order
reduc
invalid
result
csf
sampl
neg
serolog
pcrq
assay
three
month
complet
treatment
patient
resum
month
consid
clinic
improv
associ
antimicrobi
therapi
second
treatment
period
sampl
blood
serum
analyz
pcrq
one
serum
sampl
posit
blood
sampl
neg
last
year
posttreat
followup
analyz
sampl
blood
serum
neg
pcrq
convent
serolog
show
detect
antibodi
titer
brucellacapt
test
show
titer
nowaday
patient
remain
sever
loss
strength
left
hand
right
foot
continu
recev
dose
intraven
igg
monthli
conclus
may
first
report
cb
mmn
neurolog
complic
describ
thank
high
sensit
specif
pcrq
assay
introduct
pseudomona
aeruginosa
opportunist
bacterium
high
antibiot
resist
immunoprophylaxi
immunotherapi
may
consid
desir
way
control
treatment
pseudomona
aeruginosa
infect
flagellin
main
virul
factor
high
homolog
cross
reaction
among
flagellin
pseudomona
aeruginosa
strain
ntermin
domain
flagellin
play
import
role
attach
also
may
play
import
role
induct
protect
immun
respons
studi
aim
produc
rntermin
flagellin
futur
immunolog
effect
would
evalu
anim
compar
nativ
flagellin
materi
method
code
sequenc
flagellin
ntermin
pseudomona
aeruginosa
isol
pcr
clone
vector
e
coli
strain
use
express
host
recombin
protein
purifi
nisepharos
resin
object
chlamydophila
pneumonia
mycoplasma
pneumonia
import
common
caus
communityacquir
pneumonia
highest
incid
c
pneumonia
pneumonia
infect
among
schoolchildren
year
old
symptom
may
mild
nonproduct
persist
cough
malais
fever
sever
ill
occur
lower
respiratori
tract
affect
given
rise
acut
bronchiti
pneumonia
agent
caus
respiratori
infect
difficult
distinguish
clinic
sinc
mani
bacteri
viral
infect
share
clinic
featur
includ
symptom
therefor
import
find
sensit
effect
way
identifi
agent
propos
appropri
antibiot
therapi
current
cultur
serolog
confirm
diagnosi
c
pneumonia
pneumonia
difficult
timeconsum
real
time
pcr
sensit
specif
rapid
technolog
effect
altern
propos
new
realtim
pcr
base
diagnsot
tool
c
pneumonia
pneumonia
diagnosi
method
nucleic
acid
extract
nasopharyng
specimen
use
easymag
magna
pure
compact
roch
extract
system
purifi
nucleic
acid
ad
readytous
chlamyco
pneumo
amplif
premix
c
pneumonia
pneumonia
distinguish
duplex
singl
reaction
tube
amplif
perform
fast
biorad
roch
platform
result
qcmd
european
profici
panel
positiveneg
sampl
correctli
identifi
chlamyco
pneumo
posit
detect
includ
weak
posit
ml
c
pneumonia
ml
pneumonia
analyt
sensit
studi
c
pneumonia
pneumonia
sampl
perform
respiratori
specimen
specif
studi
show
cross
reaction
respiratori
bacteria
virus
high
qualiti
associ
compat
major
extract
real
time
pcr
platform
allow
immedi
integr
chlamyco
pneumo
routin
diagnost
laboratori
g
vrioni
daniil
v
mamali
kimouli
mylonapetropoul
k
themelidigalaki
object
sepsi
seriou
medic
condit
requir
rapidli
administ
appropri
antibiot
treatment
rapid
detect
pathogen
blood
critic
favour
outcom
patient
suspect
sepsi
although
blood
cultur
bc
consid
criterion
standard
diagnosi
bloodstream
infect
take
three
day
final
pathogen
identif
antimicrobi
suscept
test
observ
studi
clinic
impact
commerci
avail
multiplex
pcr
system
icu
patient
suspect
sepsi
analys
method
blood
sampl
patient
presum
sepsi
cultur
bactec
system
becton
dickinson
heidelberg
germani
blood
edta
patient
subject
analysi
lightcycl
septifast
grade
test
lcsf
roch
diagnost
mannheim
germani
two
tertiari
care
centr
lcsf
test
multiplex
realtim
pcr
system
allow
detect
pathogen
speci
level
four
group
pathogen
genu
level
gramposit
gramneg
fungal
microorgan
sampl
pcrdetect
pathogen
actual
impact
clinic
manag
determin
chart
review
furthermor
comparison
time
posit
blood
cultur
result
lcsf
result
made
result
patient
yield
concord
neg
concord
posit
result
one
patient
two
pathogen
detect
molecular
method
e
coli
blood
cultur
vs
e
coli
maltophiliac
albican
lcsf
assay
one
patient
lcsf
posit
neg
blood
cultur
vs
p
aeruginosa
lcsf
assay
lcsf
result
obtain
h
contrast
h
requir
blood
cultur
accord
lcsf
result
initi
therapi
inadequ
five
patient
antibiot
treatment
chang
conclus
rapid
multiplex
pathogen
detect
lcsf
system
complement
tradit
culturebas
method
offer
ad
diagnost
valu
time
detect
caus
pathogen
relev
impact
clinic
manag
subset
patient
clinic
suspect
sepsi
n
brankova
v
levterova
panaiotov
k
tankova
kantardjiev
sofia
bg
bordetella
pertussi
caus
agent
whoop
cough
endem
bulgaria
despit
extens
nationwid
vaccin
sinc
object
goal
studi
investig
incid
pertussi
infect
among
children
adult
capit
citi
sofia
bulgaria
seven
year
period
method
sinc
seven
year
nation
refer
laboratori
molecular
microbiolog
start
molecular
diagnosi
pertussi
target
pcr
marker
select
pertussi
toxin
gene
bp
amplifi
fragment
detect
agaros
gel
dna
extract
nasopharyng
swab
sampl
autom
robot
system
total
sampl
analyz
sampl
patient
clinic
suspect
pertussi
analyz
result
total
sampl
analyz
pertussi
pcr
sampl
posit
neg
pertussi
posit
sampl
repres
capit
citi
sofia
million
inhabit
incid
pertussi
ill
estim
patient
per
inhabit
conclus
children
sofia
high
immun
coverag
acellular
vaccin
appli
sinc
april
whole
cellular
vaccin
previous
appli
highest
preval
pertussi
incid
group
age
year
gdh
posit
cultur
posit
stool
specimen
c
difficil
confirm
case
pcr
sensit
eight
gdh
posit
stool
specimen
remain
neg
cultur
sampl
congruent
posit
pcr
tox
eia
cultur
direct
test
congruent
neg
posit
eia
two
sampl
exclud
sensit
toxinpcr
specif
ppv
npv
genotyp
cdiff
assay
abl
identifi
ribotyp
specimen
specimen
genotyp
cdiff
assay
direct
detect
clostridium
difficil
major
ribotyp
stool
show
rapid
sensit
specif
result
dna
isol
fulli
autom
turnaround
time
includ
hand
time
approxim
hour
dna
isol
hour
amplif
hour
hybrid
assay
provid
inform
ribotyp
toxin
binari
toxin
moxifloxacin
resist
present
avail
commerci
cd
test
object
implement
rapid
molecular
diagnost
bloodstream
infect
could
significantli
improv
speed
diagnosi
therebi
outcom
current
molecular
test
directli
whole
blood
sampl
suboptim
sensit
due
use
small
volum
larger
volum
show
inhibitori
effect
human
dna
molzym
germani
incorpor
pretest
enrich
method
select
elimin
human
cell
may
lead
increas
input
volum
subsequ
diagnost
sensit
investig
use
assay
cohort
patient
sepsi
icu
analys
septicaem
patient
icu
blood
cultur
bc
taken
togeth
bc
n
addit
blood
sampl
edta
taken
sampl
site
analysi
st
assay
consist
pretestenrich
ml
edtasampl
follow
bacteri
lysi
dnaisol
subsequ
amplif
use
univers
primer
gramneg
gramposit
bacteria
amplicon
detect
agarbas
gelelectrophoresi
accord
instruct
manufactur
edtasampl
analys
duplic
sampl
consid
posit
least
one
duplic
posit
result
bc
yield
posit
result
aureu
n
e
faecali
n
cn
e
faecali
n
bacteraemia
diagnos
patient
st
posit
sampl
compar
bc
sensit
posit
bc
total
patient
posit
bc
posit
st
seven
patient
posit
st
neg
bc
patient
clinic
suspicion
bacteri
infect
high
show
posit
bc
septicemia
anoth
time
point
edtasampl
taken
studi
result
might
therefor
repres
addit
yield
sequenc
amplicon
current
perform
provid
speciesspecif
result
control
falseposit
result
use
clinic
practic
molecular
analysi
directli
blood
sampl
implement
assay
may
provid
addit
detect
bacteraem
patient
result
evalu
sequenc
result
gelbas
analysi
applic
may
troublesom
implement
routin
workflow
background
object
respiratori
infect
caus
signific
morbid
mortal
develop
develop
countri
influenza
b
flu
b
rna
virus
famili
orthomyxovirida
spread
regular
epidem
result
death
peopl
worldwid
annual
human
respiratori
syncyti
viru
rsv
neg
singlestrand
rna
viru
famili
paramyxovirida
rsv
major
caus
lower
respiratori
tract
infect
hospit
visit
infanc
childhood
human
metapneumoviru
hmpv
neg
singlestrand
rna
viru
famili
paramyxovirida
may
second
common
caus
rsv
lower
respiratori
infect
young
children
util
proprietari
chemistri
process
develop
novel
room
temperatur
stabl
reagent
use
amplivu
taqman
base
multiplex
rtpcr
assay
detect
flu
b
hmpvrsv
ad
benefit
assay
provid
simplifi
workflow
significantli
reduc
number
endus
manipul
requir
perform
test
attribut
allow
widespread
reliabl
use
molecular
diagnost
detect
respiratori
virus
report
describ
initi
studi
perform
reagent
appli
biosystem
fastdx
cepheid
smartcycl
method
result
test
perform
cultur
isol
clinic
specimen
establish
initi
perform
assay
rna
extract
either
nuclisen
easymag
roch
magna
pure
compact
ul
sampl
ad
reconstitut
master
mix
cultur
influenza
b
isol
detect
respect
clinic
specimen
analyz
presenc
either
rsv
rsv
b
hmpv
abl
detect
rsv
rsv
b
hmpv
specif
sampl
evalu
initi
analyt
sensit
test
variou
virus
indic
detect
limit
less
andor
target
test
isol
common
virus
bacteria
confirm
reagent
cross
reactiv
common
respiratori
pathogen
result
studi
indic
room
temperatur
stabl
reagent
coupl
simplifi
workflow
amplivu
molecular
assay
provid
endus
sensit
specif
assay
detect
flu
b
hmpvrsv
adult
n
immunocompet
n
immunosupress
n
hospit
clinic
suspicion
cmv
infect
univers
hospit
ioannina
greec
screen
cmvigm
antibodi
axsym
abbott
cmvdna
coba
amplicor
roch
viral
load
clinic
data
also
investig
confirm
cmv
infect
two
method
obtain
patient
one
hundr
four
patient
posit
cmvigm
neg
cmvdna
antibodi
hsv
vzv
ebv
also
detect
perform
pcr
extra
case
activ
infect
diagnos
antibodi
could
detect
translat
rise
number
diagnos
activ
cmv
infect
compar
serolog
approach
cmvdna
posit
patient
children
adult
major
underli
diseas
haematolog
malign
pneumon
common
clinic
present
overal
median
viral
load
copiesml
cmv
mononucleosi
copiesml
overal
mortal
rate
major
caus
respiratori
failur
eighteen
pcr
posit
patient
receiv
ganciclovir
treatment
led
mark
decreas
cmv
dna
copi
number
median
time
interv
necessari
obtain
neg
result
implement
treatment
pcr
day
conclus
quant
pcr
cmv
assay
rapid
linear
quantifi
cmv
viral
load
seem
use
diagnosi
manag
affect
patient
predict
diseas
monitor
respons
antivir
therapi
serv
surrog
marker
antivir
resist
clinic
relaps
patient
compar
tradit
serolog
assay
detect
antibodi
cmv
qpcr
offer
signific
advanc
direct
detect
viral
dna
independ
function
humor
immun
system
amplifi
dna
assay
design
compat
transport
via
swab
diluent
bd
probetec
ctgc
q
x
amplifi
dna
assay
q
x
swab
diluent
bd
uvt
copan
utmrt
collect
devic
studi
focus
evalu
perform
hsv
assay
use
simul
specimen
compris
bd
uvt
medium
ad
prefil
q
x
swab
diluent
tube
sampl
prewarm
load
directli
onto
bd
viper
system
dna
extract
amplif
analyt
limit
detect
proport
posit
q
x
q
x
assay
use
clean
bd
uvt
medium
estim
viral
particl
vp
ml
vpml
respect
limit
detect
assay
presenc
extern
anogenit
swab
specimen
matrix
estim
vpml
vpml
q
x
q
x
respect
assay
shown
toler
common
exogen
endogen
substanc
may
present
extern
anogenit
lesion
specimen
includ
limit
blood
mucu
semen
leukocyt
variou
prescript
overthecount
medic
addit
assay
found
crossreact
varieti
bacteria
virus
fungi
could
found
extern
anogenit
lesion
specimen
stabil
hsv
dna
simul
extern
anogenit
swab
specimen
demonstr
ambient
refriger
frozen
temperatur
origin
uvt
specimen
dilut
q
x
swab
diluent
bd
probetec
herp
simplex
virus
q
x
amplifi
dna
assay
offer
excel
analyt
sensit
robust
perform
detect
dna
extern
anogenit
swab
express
bd
uvt
medium
bd
viper
system
softwar
allow
user
test
ctgc
specimen
specimen
within
viper
run
provid
workflow
flexibl
product
sale
investig
use
us
background
hcv
genotyp
use
predict
respons
antivir
therapi
also
optim
durat
treatment
region
region
choic
routin
genotyp
hcv
howev
due
high
level
conserv
limit
abil
discrimin
genotyp
genotyp
subtyp
within
genotyp
newli
develop
versant
hcv
genotyp
assay
lipa
versant
use
sequenc
inform
core
region
allow
distinct
hcv
genotyp
subtyp
b
genotyp
previous
versant
hcv
genotyp
assay
lipa
versant
use
sequenc
inform
studi
result
genotyp
assay
evalu
method
total
hcvposit
sampl
edta
plasma
genotyp
use
versant
accord
manufactur
instruct
comparison
studi
versant
use
hcv
rna
extract
use
nuclisen
extract
run
posit
neg
control
includ
interpret
result
assay
includ
studi
differ
found
genotyp
subtyp
level
taken
account
versant
consid
refer
method
result
tabl
give
overview
result
comparison
studi
test
assay
correl
rate
test
result
specimen
discord
two
assay
genotyp
difficult
discrimin
versant
sampl
discuss
versant
show
improv
identifi
correct
subtyp
genotyp
improv
attribut
addit
inform
avail
core
region
hcv
genom
clinic
manag
patient
infect
genotyp
equal
disagr
among
test
may
present
epidemiolog
consequ
least
versant
error
affect
treatment
dosag
durat
high
preval
observ
women
age
year
probabl
due
increas
suscept
popul
earli
sexual
debut
major
risk
factor
acquisit
hpv
infect
characterist
ascend
agespecif
curv
infect
preval
observ
group
data
support
exist
invers
relationship
age
hpv
infect
preval
addit
vaccin
whole
popul
would
prevent
occur
infect
object
recent
introduct
vaccin
hpv
adolesc
girl
itali
focus
attent
virolog
surveil
age
group
sinc
hpv
one
major
pathogen
sexual
transmit
worldwid
import
extend
surveil
also
adolesc
male
could
next
target
immun
strategi
studi
aim
evalu
hpv
infect
preval
adolesc
femal
male
purpos
molecular
assay
base
urin
sampl
easi
collect
accept
young
individu
appli
detect
genotyp
hpvdna
materi
method
urin
sampl
collect
adolesc
year
attend
commun
clinic
youth
centr
local
sanitari
unit
day
clinic
northern
itali
period
span
septemb
juli
analys
subject
femal
mean
age
year
male
mean
age
year
sampl
centrifug
obtain
cell
pellet
dna
extract
carri
use
commerci
kit
nuclisen
minimag
franc
amplif
gene
fragment
perform
degener
primer
genotyp
perform
restrict
fragment
length
polymorph
techniqu
use
restrict
enzym
rsai
haeiii
ddei
recombin
enzym
biolab
inc
new
england
result
hpvdna
detect
analys
sampl
particular
sampl
collect
femal
male
adolesc
respect
high
lowrisk
genotyp
identifi
highrisk
lowrisk
among
femal
adolesc
infect
due
singl
genotyp
sustain
coinfect
two
infect
found
male
subject
sustain
conclus
data
show
hpv
infect
present
year
old
subject
frequent
femal
male
infect
support
highandor
lowrisk
genotyp
among
could
prevent
avail
vaccin
includ
one
two
type
found
molecular
test
urin
sampl
seem
good
altern
conduct
cervic
swab
especi
young
women
final
method
seem
applic
also
male
popul
aim
studi
evalu
often
underestim
potenti
role
herp
virus
onset
inauspici
evolut
respiratori
patholog
critic
patient
analyz
bronchoalveolar
wash
patient
hospit
sever
acut
respiratori
patholog
intens
care
unit
hospit
catania
sicili
itali
retrospect
studi
use
viral
isol
method
realtim
pcr
respect
viral
replic
activ
clinic
signific
express
term
viral
load
correl
day
patient
assist
ventil
time
analysi
sampl
dna
found
least
one
though
often
two
herp
virus
vzv
cmv
ebv
particular
cmv
ebv
posit
vzv
base
data
rel
find
viral
nucleic
acid
durat
mechan
ventil
statist
signific
associ
found
dna
assist
ventil
day
p
increas
viral
load
case
directli
proport
day
assist
ventil
reach
valu
geqml
compar
geqml
cmv
ebv
preval
herp
virus
find
accompani
substanti
viral
load
would
confirm
import
virus
could
onset
respiratori
patholog
immunocompromis
subject
therefor
introduct
test
detect
mention
virus
diagnost
protocol
would
favor
earli
diagnosi
correct
therapi
could
reduc
rate
mortal
critic
longterm
patient
affect
respiratori
patholog
need
assist
ventil
object
acut
children
respiratori
infect
acri
common
reason
consult
gener
practition
case
aetiolog
unknown
yet
result
antibiot
prescript
object
studi
epidemiolog
respiratori
viru
infect
particular
determin
virusspecif
posit
rate
season
pediatr
age
respiratori
viru
infect
month
period
pordenon
itali
use
multiplex
realtim
pcr
assay
detect
multipl
virus
reaction
method
total
nasopharyng
specimen
collect
symptomat
pediatr
inpati
averag
year
novemb
januari
specimen
split
two
aliquot
one
aliquot
process
use
multiplex
realtim
pcr
test
second
test
adenoviru
use
nest
pcr
total
nucleic
acid
extract
use
biomerieux
easymag
multiplex
realtim
pcr
test
perform
use
diagenod
detect
influenza
viru
ia
influenza
b
viru
ib
respiratori
syncyti
viru
rsv
metapneumoviru
mpv
rhinoviru
rv
parainfluenza
viru
piv
adenoviru
detect
nest
pcr
nanogen
result
specimen
test
posit
least
one
respiratori
viru
includ
rsv
b
rhinoviru
flu
b
parainfluenza
adenoviru
metapneumoviru
pediatr
patient
preschool
age
patient
rsv
mpv
posit
less
year
age
seen
dual
respiratori
viru
infect
patient
one
tripl
viru
infect
term
season
distribut
rv
distribut
across
major
month
rsv
peak
decemb
march
ia
infect
distribut
januari
februari
anoth
atyp
peak
octob
decemb
includ
influenza
ib
show
peach
activ
march
april
piv
peak
novemb
octob
mpv
peak
end
winter
spring
month
adenoviru
infect
distribut
winter
spring
month
conclus
molecular
assay
increas
understand
epidemiolog
respiratori
viral
infect
assist
us
diagnos
etiolog
respiratori
tract
infect
individu
outbreak
situat
remain
neg
sampl
neg
influenza
b
overal
sampl
posit
virus
test
addit
two
differ
patient
coinfect
flu
rhinoviru
enterovirusrhinoviru
coinfect
repres
overal
posit
sampl
averag
age
rang
infect
patient
follow
year
year
respect
rhinoviru
year
year
respect
enteroviru
year
year
respect
conclus
result
show
involv
respiratori
virus
patient
influenzalik
ill
thu
notabl
proport
rhinoviru
infect
found
collect
patient
diagnos
influenza
peak
incid
pandem
data
would
suggest
potenti
indic
rhinoviru
detect
acut
respiratori
diseas
regard
age
gender
distribut
infect
patient
signific
differ
found
virus
test
result
eight
n
women
exclud
studi
incomplet
data
total
women
use
final
analysi
fortyf
patient
found
infect
genit
hpv
expect
viral
preval
higher
among
women
younger
year
age
comparison
age
older
rate
hpv
type
follow
coinfect
multipl
hpv
type
one
woman
largest
number
posit
sampl
herzegovinaneretva
canton
conclus
result
indic
hpv
infect
repres
signific
public
health
concern
herzegovina
detail
knowledg
hpv
type
circul
pattern
specif
local
geograph
area
essenti
appropri
implement
screen
prevent
surveil
campaign
g
gioula
e
chatzopoul
exindari
melid
chatzidimitri
f
chatzopoul
n
malisiova
thessaloniki
gr
object
influenza
virus
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
common
pathogen
caus
acut
respiratori
diseas
children
aim
studi
present
contribut
three
pathogen
influenzalik
ill
ili
children
age
year
old
influenza
season
n
greec
materi
method
pharyng
swab
children
younger
year
present
ili
infect
last
two
influenza
season
examin
influenza
b
rsv
hmpv
one
step
realtim
rtpcr
result
influenza
virus
detect
spesimen
rsv
sampl
hmpv
rsv
influenza
virus
coinfect
observ
eight
case
rsv
hmpv
coinfect
four
case
hmpv
influenza
virus
found
one
case
major
patient
year
old
conclus
result
demonstr
influenza
virus
rsv
hmpv
contribut
ili
present
infect
rate
children
younger
year
old
object
identifi
candida
speci
caus
candidaemia
analyz
fungal
dna
blood
cultur
bottl
posit
yeast
use
low
costeffect
assay
method
dna
extract
hous
protocol
base
organ
solvent
extract
test
addit
step
liquid
nitrogen
incub
follow
mechan
disrupt
process
complet
cell
lysi
puriti
extract
dna
evalu
fifti
blood
cultur
bottl
posit
yeast
process
pcr
assay
amplifi
region
rdna
gene
amplicon
twenti
sampl
sequenc
sequenc
submit
comparison
genbank
databas
ncbi
speci
identif
molecular
yeast
identif
compar
result
provid
convent
method
organ
solvent
extract
protocol
show
good
reproduc
amount
dna
extract
pure
dna
high
pcr
sensit
pg
c
albican
dna
amplif
pcr
assay
therefor
method
use
analyz
clinic
sampl
avail
molecular
speci
identif
show
concord
convent
cultur
howev
molecular
method
could
identifi
one
sampl
mix
infect
caus
c
albican
c
glabrata
convent
cultur
identifi
c
albican
moreov
sampl
identifi
c
parapsilosi
classic
method
molecularli
identifi
c
orthopsilosi
speci
belong
c
parapsilosi
complex
conclus
organ
dna
extract
pcr
assay
sequenc
could
effici
identifi
mix
infect
well
candida
speci
molecularli
identifi
test
easili
implement
routin
laboratori
provid
earlier
low
cost
speci
identif
compar
tradit
method
organ
dna
extract
less
expens
protocol
use
commerci
kit
object
clostridium
difficil
infect
repres
signific
burden
health
care
system
small
larg
outbreak
constantli
present
hospit
environ
pcr
ribotyp
late
associ
outbreak
increas
mortal
morbid
therefor
import
recogn
ribotyp
rapid
possibl
standard
type
method
europ
cultur
c
difficil
faecal
sampl
subsequ
pcr
ribotyp
describ
first
time
modif
pcr
ribotyp
use
direct
detect
stool
sampl
use
emerg
pcr
ribotyp
singl
hospit
method
direct
pcr
ribotyp
stool
sampl
modifi
exist
primer
describ
bidet
et
al
increas
specif
c
difficil
total
c
difficil
cultur
posit
neg
stool
sampl
routin
laboratori
use
valid
method
dna
isol
faecal
sampl
pcr
ribotyp
perform
bidet
new
primer
addit
five
stool
sampl
gener
hospit
detect
c
difficil
posit
presumpt
cepheid
xpert
c
difficil
assay
submit
refer
laboratori
ribotyp
confirm
result
direct
pcr
ribtyp
stool
sampl
possibl
c
difficil
posit
sampl
use
new
primer
sampl
neg
n
band
pattern
weak
analyz
n
case
pcr
ribotyp
determin
directli
stool
ident
pcr
ribotyp
strain
isol
stool
sampl
sensit
posit
sampl
one
c
difficil
cultur
neg
sampl
neg
direct
pcr
ribotyp
modifi
primer
contrast
c
difficil
neg
sampl
react
bidet
primer
five
cepheid
xpert
c
difficil
posit
presumpt
sampl
confirm
ribotyp
direct
ribotyp
well
convent
ribotyp
cultur
isol
direct
cultureindepend
pcr
ribotyp
c
difficil
use
rapid
method
detect
emerg
strain
outbreak
identif
result
eleven
studi
identifi
compar
molecular
assay
mrsa
tradit
cultur
andor
chromogen
agar
total
patient
costeffect
studi
found
pcr
incur
higher
cost
better
outcom
found
multiplex
pcr
cost
effect
among
method
length
icu
stay
day
found
pcr
cost
effect
costbenefit
studi
found
pcr
mrsa
cost
save
found
pcr
cost
save
exist
search
destroy
polici
one
cost
util
analysi
report
pcr
lead
import
mortal
reduct
low
costli
due
hour
chang
empir
antibiot
factor
determin
cost
effect
variou
set
baselin
preval
rate
mrsa
appli
screen
preemptiv
isol
highrisk
patient
avail
cost
isol
last
least
assay
characterist
individu
test
cost
use
pcr
instead
cultur
screen
mrsa
found
cost
effect
andor
costsav
particularli
surgeri
signific
benefit
less
isol
less
overal
hospit
stay
infect
avoid
time
cheaper
treatment
choic
lower
mortal
although
studi
urgent
need
especi
sever
infect
diagnosi
infect
control
team
mrsa
hospit
preliminarili
inform
particular
cost
effect
molecular
assay
tradit
techniqu
accord
hospit
set
object
aim
studi
evalu
genom
divers
differ
among
b
pertussi
strain
collect
patient
respect
vaccin
strain
use
product
dtp
vaccin
object
legionellosi
occur
inhal
contamin
aerosol
expel
wet
cool
system
hot
water
distribut
system
healthcar
facil
despit
prolong
incub
period
cultur
remain
standard
diagnost
method
altern
method
like
antigen
detect
molecular
techniqu
expens
often
unavail
give
inform
regard
legionella
pneumophila
viabil
minor
import
clinic
specimen
major
impact
water
sampl
therefor
public
health
secur
consid
high
mortal
rate
need
specif
treatment
develop
rapid
sensit
specif
method
l
pneumophila
detect
crucial
also
distinct
viabl
nonviabl
cell
water
warrant
therefor
propos
flow
cytometri
protocol
l
pneumophila
detect
clinic
water
sampl
viabil
evalu
latter
method
l
pneumophila
use
protocol
optim
fifti
respiratori
sampl
twenti
water
sampl
previous
analys
immunofluoresc
screen
flow
cytometri
sampl
stain
specif
antibodi
antil
pneumophila
biorad
california
react
extern
membran
protein
found
known
l
pneumophila
serogroup
propidium
iodid
evalu
bacteria
viabil
posit
water
sampl
analysi
made
kill
bacteria
heat
flow
cytometri
analysi
perform
facscalibur
cytomet
bd
bioscienc
sydney
specif
studi
mix
l
pneumophila
suspens
e
coli
aureu
c
albican
type
atcc
strain
accord
protocol
result
l
pneumophila
cell
display
intens
green
fluoresc
indic
bacteria
recognit
specif
antibodi
dead
cell
show
high
intens
fluoresc
channel
correl
achiev
immunofluoresc
flow
cytometri
assay
clinic
water
sampl
viabil
assess
success
conclus
flow
cytometri
prove
sensit
specif
method
detect
l
pneumophila
simultan
assess
viabil
furthermor
use
detect
legionella
environment
specimen
experiment
system
first
time
techniqu
appli
detect
l
pneumophila
clinic
specimen
object
compar
result
commerci
avail
select
cultur
system
isol
mycoplasma
homini
ureaplasma
urealyticum
detect
use
pcr
amplif
materi
method
two
endocerv
swab
collect
case
cohort
infertil
femal
attend
fertil
center
manag
infertil
group
control
group
multiparu
femal
attend
contracept
clinic
group
b
one
swab
subject
cultur
isol
urogenit
mycoplasma
use
commerci
avail
select
cultur
system
biorad
usa
sampl
elut
buffer
pcr
amplif
use
specif
primer
mycoplasma
homini
ureaplasma
urealyticum
result
use
pcr
group
group
b
posit
mycoplasma
homini
group
group
b
posit
ureaplasma
urealyticum
accord
duo
kit
result
case
groupa
one
control
group
b
posit
mycoplasma
homini
case
posit
ureaplasma
urealyticum
group
b
respect
sensit
duo
kit
cultur
system
relat
pcr
found
specif
conclus
studi
confirm
reliabl
mycoplasma
duo
kit
cultur
system
diagnosi
genitourinari
colon
femal
genit
system
mycoplasma
homini
ureaplasma
urealyticum
also
report
higher
sensit
pcr
c
kalunga
lusaka
zm
introduct
ntp
conduct
qualiti
assur
refer
laboratori
past
four
year
determin
qualiti
improv
tb
control
qualiti
improv
process
compon
smear
microscopi
diagnost
servic
analyz
aim
look
way
perman
remov
obstacl
success
direct
sputum
smear
microscopi
remain
cost
effect
tool
diagnos
patient
infecti
tuberculosi
monitor
progress
treatment
case
detect
rate
zambia
fall
short
target
detect
infecti
case
tb
eastern
northern
southern
uth
central
western
luapula
northwestern
method
total
serum
sampl
includ
neg
control
acut
q
fever
patient
serial
dilut
high
posit
sampl
thirteen
laboratori
particip
eight
dutch
q
fever
endem
area
two
dutch
nation
laboratori
three
refer
laboratori
outsid
netherland
six
lab
perform
cfa
perform
ifa
three
inhous
assay
perform
elisa
result
ifa
elisa
cfa
valu
laboratori
use
method
within
close
rang
three
method
correctli
identifi
q
fever
patient
hous
commerci
ifa
well
compar
quantit
titr
reach
differ
could
observ
test
reason
specif
howev
sensit
show
variat
ifa
sensit
test
phase
sensit
igg
igm
respons
combin
phase
antibodi
cfa
perform
well
sensit
phase
phase
igg
elisa
sensit
phase
cfa
phase
igg
igm
elisa
less
sensit
cfa
use
manufactur
instruct
discuss
higher
sensit
ifa
support
serial
dilut
howev
observ
base
limit
number
sampl
refin
use
larger
set
sera
ifa
appear
method
choic
high
sensit
requir
eg
earli
phase
ill
elisa
altern
screen
larg
sampl
number
object
characterist
featur
glucos
oxid
acinetobact
abil
produc
brown
pigment
blood
agar
aim
studi
evalu
natur
brown
pigment
produc
acinetobact
baumannii
method
two
ab
baumannii
strain
isol
diabet
patient
identifi
pcr
restrict
analysi
rrna
spacer
sequenc
use
alui
ndeii
mic
estim
bsac
guidelin
isosensitest
ist
glucos
broth
use
growth
strain
growth
strain
monitor
hour
period
use
ist
broth
glucon
acid
concentr
rang
inhibitori
activ
pigment
produc
strain
check
ditch
plate
method
mic
imipenem
meropenem
ceftazidim
cefepim
respect
strain
strain
posit
blaadc
neg
metalloblactamas
strain
produc
brown
pigment
presenc
glucon
acid
also
grew
better
strain
b
period
hour
presenc
ist
broth
contain
glucon
acid
concentr
rang
neither
strain
produc
pigment
glucos
medium
glucon
acid
ad
excess
increas
pigment
strain
brown
pigment
produc
strain
inhibitori
effect
aureu
ps
aeruginosa
baumannii
e
coli
glucos
dehydrogenas
enabl
strain
form
free
enter
entnerdoudouroff
pathway
henc
pigment
product
seen
strain
glucos
broth
use
side
human
blood
enrich
nutrient
includ
glucon
acid
help
strain
surviv
better
convert
glucon
acid
diketoglucon
lead
format
brown
pigment
surviv
baumannii
glucon
acid
enrich
medium
help
surviv
better
baumannii
b
excess
glucon
acid
strain
lead
brown
pigment
may
offer
protect
antioxid
stress
result
show
strain
multipl
rout
metabol
offer
better
chanc
surviv
strain
b
iyer
reed
stacey
n
virgincar
read
uk
object
prompt
empir
antimicrobi
treatment
blood
cultur
recommend
optim
manag
sepsi
rapid
pathogen
identif
id
antimicrobi
suscept
test
ast
result
permit
earli
streamlin
empir
antimicrobi
treatment
pathogendirect
treatment
potenti
healthcar
benefit
compar
use
vitek
autom
system
id
ast
gramneg
bacilli
gnb
posit
blood
cultur
direct
inocul
blood
cultur
broth
indirect
inocul
pure
subcultur
improv
turnaround
time
microbiolog
analysi
method
mayoctob
consecut
gnb
monomicrobi
posit
blood
cultur
set
set
bottl
includ
studi
vitek
gn
id
ast
enterobacteriacea
card
directli
inocul
bacteri
suspens
prepar
differenti
centrifug
posit
blood
cultur
broth
separ
blood
cell
pellet
bacteria
vitek
gnid
ast
n
nonenterobacteriacea
also
indirectli
inocul
overnight
subcultur
follow
manufactur
instruct
indirect
method
result
consid
gold
standard
api
id
system
use
gnb
identifi
vitek
discrep
ast
result
interpret
major
error
result
direct
method
suscept
indirect
method
resist
r
major
error
opposit
discrep
consid
minor
error
object
season
variat
rate
infect
certain
microorgan
alreadi
describ
higher
incid
rate
warmest
month
remaind
year
aim
studi
detect
season
variat
recoveri
rate
differ
pathogen
posit
blood
cultur
obtain
patient
hospit
method
bloodstream
infect
report
last
five
year
includ
studi
incub
continu
monitor
blood
cultur
system
bactec
becton
dickinson
usa
posit
bloodcultur
inocul
onto
appropri
plate
standard
aerob
anaerob
cultur
incub
c
respect
gramstain
smear
examin
microscop
obtain
valuabl
inform
type
microorgan
present
isol
pathogen
identifi
use
autom
system
vitek
biomerieux
marci
letoil
franc
spot
biomerieux
detect
igm
igg
antibodi
serum
sampl
test
initi
dilut
intens
fluoresc
rickettsia
situat
outsid
cell
consid
posit
reaction
endpoint
titer
obtain
serial
dilut
posit
specimen
sera
show
typic
pattern
fluoresc
titer
igg
andor
igm
antibodi
consid
posit
patient
second
serum
sampl
test
seroconvers
fourfold
titr
increas
result
total
patient
igm
igg
antibodi
rickettsia
found
patient
antibodi
r
conorii
detect
patient
male
femal
addit
antibodi
r
mooseri
found
patient
male
femal
differ
preval
antibodi
rickettsia
age
group
men
signific
howev
highest
preval
antibodi
rickettsia
observ
women
age
year
old
rickettsi
infect
significantli
season
case
appear
summer
month
patient
prefectur
kavala
xanthi
demonstr
high
preval
antibodi
rickettsia
conclus
data
show
wide
distribut
r
conorii
northern
greec
indic
low
frequenc
r
mooseri
men
affect
often
women
increas
incid
diseas
occur
summer
month
especi
eastern
macedonia
thrace
background
antigen
detect
blood
serum
earli
stage
hivinfect
result
viru
replic
later
stage
infect
concentr
decreas
antigen
becom
detect
antibodi
hiv
reveal
antigen
often
longer
detect
result
format
complex
antigen
antibodi
blood
exist
commerci
kit
detect
free
antigen
sensit
level
unabl
determin
low
concentr
antigen
requir
earli
diagnosi
hiv
infect
purpos
work
studi
diagnost
effici
detect
free
bound
antigen
modifi
kit
dseiahivagscreen
increas
sensit
antigen
detect
achiev
dissoci
immun
complex
detect
total
antigen
patient
sampl
materi
method
dissoci
immun
complex
preserv
free
hiv
antigen
develop
sampl
treat
glycin
hydrochlorid
dissoci
immun
complex
follow
neutral
trishydrochlor
acid
reagent
immun
dissoci
design
use
kit
dseiahivagscreen
follow
categori
sera
use
work
sera
posit
eia
pcr
indetermin
immunoblot
ib
well
defin
posit
ib
reaction
sera
hivinfect
patient
result
test
blood
sera
sampl
posit
eia
pcr
indetermin
ib
antigen
detect
sampl
use
kit
dseiahivagscreen
sampl
use
modifi
kit
test
sampl
hivinfect
patient
confirm
ib
reaction
antigen
detect
sampl
use
kit
dseiahivagscreen
addit
sampl
dissoci
immun
complex
strain
biologist
ask
complementari
identif
may
juli
isol
place
eppendorf
tube
contain
waterethanol
mixtur
extract
perform
test
ultraflex
iii
sinc
august
extract
elimin
bacteria
subcultur
day
test
directli
deposit
target
result
total
strain
test
ultraflex
iii
strain
identifi
score
strain
identifi
score
strain
score
obtain
final
identif
obtain
bacteri
isol
avoid
sequenc
moreov
even
strain
valid
identif
obtain
low
score
practic
identif
given
malditof
mass
spectromet
often
help
biologist
orient
identif
carri
addit
test
perform
sequenc
conclus
month
protocol
bacteria
thu
treat
identifi
biologist
convinc
contribut
spectrometri
clinic
bacteriolog
valuabl
time
save
case
therapeut
manag
patient
modifi
adapt
quickli
result
given
mass
spectrometri
object
rapid
antigen
detect
assay
respiratori
syncyti
viru
rsv
antigen
wide
avail
larg
differ
perform
characterist
sensit
vari
henrickson
kj
hall
cb
pediatr
infect
di
j
nov
suppl
evalu
perform
two
commerci
avail
immunochromatograph
assay
binaxnow
rsv
clearview
rsv
inver
medic
method
one
hundr
paediatr
nasopharyng
aspir
collect
store
winter
univers
hospit
antwerp
use
evalu
binaxnow
specimen
also
test
clearview
rsv
result
rapid
assay
compar
combin
immunofluoresc
directli
specimen
andor
cultur
inocul
shell
vial
follow
two
day
incub
vc
consid
gold
standard
true
posit
defin
posit
either
andor
vc
sampl
test
found
posit
rsv
either
andor
vc
sensit
specif
clearview
binaxnow
assay
respect
tabl
signific
differ
sensit
p
specif
p
two
assay
conclus
easi
perform
rsv
antigen
test
compar
perform
facilit
urgent
test
outsid
batch
run
outsid
normal
laboratori
work
hour
order
increas
sensit
neg
result
confirm
object
diagnosi
infect
human
immunodefici
viru
base
detect
antibodi
ab
stage
primari
infect
detect
antigen
viral
rna
object
assess
perform
access
hiv
combo
assay
biorad
access
system
beckman
coulter
term
specif
sensit
serum
plasma
sampl
studi
perform
three
laboratori
virolog
depart
hospit
laboratori
cqfd
ef
nord
de
franc
laboratori
ef
normandi
clinic
evalu
access
hiv
combo
access
system
show
excel
specif
hiv
test
blood
donor
hospit
patient
patient
infect
chronic
stage
infect
also
identifi
posit
perform
fulli
suitabl
hiv
screen
privat
hospit
laboratori
object
campylobact
jejuni
organ
frequent
describ
associ
syndrom
gb
although
infect
c
jejuni
recogn
mainli
cultur
serodiagnosi
often
use
tool
diagnosi
neurolog
complic
reactiv
arthriti
occur
intestin
campylobacteriosi
mani
variou
bacteri
antigen
use
detect
c
jejuni
specif
antibodi
studi
evalu
elisa
four
differ
antigen
prepar
serolog
diagnosi
c
jejuni
infect
patient
gb
method
sera
obtain
six
pediatr
patient
age
rang
year
old
two
male
four
femal
met
establish
clinic
criteria
gb
week
develop
neurolog
symptom
six
patient
diarrhea
episod
pair
serum
specimen
obtain
patient
control
specif
sensit
differ
elisa
use
sera
cultureposit
c
jejuni
patient
blood
donor
serolog
test
c
jejuni
perform
use
one
commerci
elisa
mikrogen
three
homemad
elisa
test
wholecel
antigen
virionserion
lp
antigen
wholecel
antigen
prepar
accord
method
describ
strid
colleagu
result
cutoff
limit
serum
antibodi
homemad
elisa
set
mean
antibodi
titr
determin
sera
blood
donor
exceed
three
standard
deviat
igg
antibodi
diagnost
signific
level
present
patient
four
elisa
test
observ
signific
decreas
igg
antibodi
titr
serum
sampl
obtain
two
patient
chronic
phase
diseas
elisa
lp
antigen
elisa
wholecel
antigen
virionserion
diagnos
igm
antibodi
four
patient
hand
presenc
iga
diagnos
serum
sampl
obtain
acut
phase
two
patient
commerci
elisa
elisa
lp
antigen
result
studi
show
serolog
investig
may
use
tool
identif
c
jejuni
infect
patient
postinfecti
neurolog
complic
therefor
develop
worldwid
avail
standard
elisa
assay
use
serolog
diagnosi
c
jejuni
infect
complic
gb
need
introduct
tradit
clinic
sampl
manual
inocul
spread
onto
agar
plate
lab
technician
use
plastic
platinum
loop
common
streak
pattern
fourquadr
pattern
aim
procedur
isol
discret
coloni
identif
antibiot
suscept
test
kiestra
lab
autom
drachten
netherland
develop
instrument
spread
sampl
perform
bead
electromagnet
field
aim
studi
compar
number
discret
coloni
obtain
manual
spread
automat
spread
perform
inoqula
studi
variat
reproduc
discret
coloni
creat
inoqula
method
bacteria
two
differ
speci
select
enterococcu
faecali
atcc
escherichia
coli
atcc
inoculum
speci
prepar
suspend
bacteria
phosphat
buffer
salin
pb
densiti
mcfarland
use
vitek
densicheck
suspens
e
faecali
use
undilut
suspens
e
coli
dilut
final
inoculum
spread
plate
respect
agar
plate
use
cromogen
agar
call
uriselect
biorad
five
skill
lab
technician
ask
particip
studi
lab
technician
inocul
two
plate
bacteri
suspens
suspens
use
inocul
plate
inoqula
plate
inocul
ml
use
pipett
manual
spread
plastic
loop
fourquadr
pattern
use
plate
incub
ambient
air
hour
discret
coloni
count
result
inoqula
produc
three
time
mani
discret
coloni
e
coli
five
time
mani
discret
coloni
e
faecali
manual
method
tabl
e
faecali
fig
e
coli
fig
amount
discret
coloni
isol
manual
spread
vari
differ
lab
technician
also
notic
variat
number
discret
coloni
produc
inoqula
conclus
inoqula
produc
greater
amount
isol
bacteri
coloni
manual
streak
number
isol
coloni
obtain
manual
spread
vari
differ
lab
technician
reproduc
evalu
differ
inoqula
streak
pattern
need
studi
introduct
chronic
abdomin
pain
childhood
adolesc
common
disturb
patient
famili
consid
differ
etiolog
abdomin
pain
role
helicobact
pylori
unclear
studi
casecontrol
prospect
carri
bandar
abba
patient
age
year
suffer
recurr
abdomin
pain
rap
month
interf
normal
life
style
select
randomli
healthi
preschool
school
children
age
select
control
group
demograph
data
collect
questionnair
physic
examin
group
check
helicobact
pylori
stool
antigen
test
hpsa
result
patient
femal
case
group
suffer
rap
control
group
posit
hpsag
person
borderlin
result
hpsag
posit
male
relat
age
rout
deliveri
child
born
famili
histori
peptic
ulcer
diseas
hpsag
result
differ
significantli
case
control
group
initi
supplement
feed
month
strong
risk
factor
hpylori
infect
object
prenat
hypoxia
lead
nervou
system
patolog
one
side
infecti
process
tendenc
gener
side
use
tandem
marker
intens
care
newborn
pct
biomark
bacteri
infect
marker
brain
damag
method
newborn
day
icu
transport
matern
clinic
gestat
age
week
pct
serum
level
measur
elecsi
immunoassay
result
newborn
hie
ivh
patient
ivh
prenat
pneumonia
case
necrot
coloenter
wherea
patient
hie
aspir
pneumonia
prevail
necrot
coloenter
diagnos
case
pct
level
ngml
hospit
level
directli
correl
pct
level
r
subsequ
assay
made
patient
pct
ngml
case
pct
normal
initi
level
ngml
level
case
decreas
pct
level
treatment
remain
everi
inocul
perform
tripl
blood
agar
plate
experi
repeat
four
time
implement
wasp
routin
microbiolog
laboratori
result
inocul
fifti
urin
sampl
fifti
mrsascreen
sampl
wasp
compar
result
manual
inocul
urin
sampl
ml
plant
blood
agar
mcconkey
agar
plate
four
quadrant
streak
pattern
ten
ml
mrsa
screen
sampl
eswab
plant
chromogen
agar
inocul
tsb
salt
enrich
medium
overnight
incub
enrich
broth
plant
onto
chromogen
agar
plate
wasp
manual
quantit
evalu
autom
streak
ml
loop
show
plate
inocul
wasp
time
coloni
grow
overnight
incub
compar
plate
inocul
ml
use
calibr
pipet
three
atcc
strain
correct
made
cfuml
initi
mcfarland
suspens
although
numer
differ
coloni
count
plate
inocul
wasp
manual
differ
clinic
interpret
observ
test
clinic
sampl
continu
next
week
although
wasp
promis
autom
instrument
plant
streak
bulk
sampl
like
urin
mrsascreen
sampl
microbiolog
laboratori
conscienti
valid
recommend
implement
daili
routin
object
anaerob
bacteria
remain
import
group
human
pathogen
fastidi
microorgan
identif
convent
biochem
method
frequent
tediou
inaccur
malditof
mass
spectrometri
fast
reliabl
technolog
microorgan
identif
shown
use
microorgan
identif
cultur
sampl
compar
correl
biochem
identif
malditof
mass
spectrometri
anaerob
bacteria
identif
sepsi
caus
varieti
differ
group
infecti
etiolog
earli
adequ
antimicrobi
therapi
correl
posit
clinic
outcom
recent
year
matrixassist
laser
desorptionion
time
flight
malditof
mass
spectrometri
fingerprint
becom
power
tool
microbiolog
diagnost
direct
identif
microorgan
posit
blood
cultur
shorten
diagnost
significantli
enabl
earlier
specif
therapi
aim
studi
compar
two
differ
method
sampl
prepar
malditof
directli
posit
blood
cultur
versu
convent
cultur
current
gold
standard
first
part
studi
posit
blood
cultur
investig
use
tube
separ
gel
bd
enrich
microorgan
serum
follow
standard
ethanolform
acid
protein
extract
prepar
bacteri
extract
second
part
studi
maldi
sepsityp
kit
bruker
dalton
use
prepar
bacteri
extract
posit
blood
cultur
gramneg
bacteria
gramposit
bacteria
correctli
identifi
use
separ
tube
compar
cultur
speci
level
use
maldi
sepsityp
kit
bruker
dalton
gramneg
bacteria
gramposit
bacteria
correctli
identifi
overal
identif
biotyp
score
studi
significantli
higher
gramneg
septityp
bd
compar
gramposit
bacteria
septityp
bd
alter
algorithm
interpret
biotyp
score
gramposit
bacteria
increas
rate
identif
germ
handson
time
higher
method
use
tube
separ
gel
thu
protocol
suitabl
method
analysi
blood
stream
infect
better
result
observ
bruker
dalton
sepsityp
kit
object
natriuret
peptid
compos
famili
peptid
present
diuret
vasoconstrict
properti
associ
left
heart
ventricl
function
especi
amino
end
end
brain
natriuret
peptid
ntprobnp
secret
heart
ventricl
due
dilat
heart
failur
high
level
ntprobnp
also
observ
bacteri
infect
sepsi
procalcitonin
pct
calcitonin
propeptid
level
increas
seriou
bacteri
infect
result
increas
level
ntprobnp
crp
observ
episod
increas
pct
valu
found
episod
highest
level
observ
ntprobnp
respiratori
truck
infect
bacteremia
pct
respiratori
infect
bacteremia
crp
bacteremia
venou
cathet
infect
statist
signific
correl
observ
ntprobnp
crp
p
correl
observ
ntprobnp
pct
crp
pct
signific
correl
observ
isol
bacteria
ntprobnp
pct
crp
respiratori
truck
posit
cultur
found
statist
signific
correl
ntprobnp
crp
p
also
pct
crp
p
ntprobnp
level
significantli
correl
crp
level
sever
infect
signific
correl
isol
bacteria
posit
cultur
ntprobnp
pct
crp
result
pct
higher
patient
sepsi
patient
sir
due
noninfecti
etiolog
p
pct
level
increas
significantli
sever
ill
highest
level
observ
patient
septic
shock
p
patient
die
follow
period
group
nonsurvivor
patient
aliv
end
day
n
discharg
cure
n
period
group
survivor
total
patient
die
first
day
pct
level
patient
avail
pct
level
higher
nonsurvivor
p
p
p
p
respect
chang
pct
level
time
analyz
signific
decreas
observ
survivor
pct
valu
avail
n
p
cutoff
valu
neg
predict
valu
npv
pct
differenti
sepsi
sir
due
non
infecti
etiolog
accuraci
patient
sir
exclud
patient
sepsi
npv
pct
mortal
follow
cutoff
valu
npv
accuraci
cutoff
valu
npv
accuraci
conclus
think
pct
import
marker
guid
clinician
differenti
diagnosi
sepsi
prognost
k
behera
tk
mohanti
ss
layek
kumaresan
patbandha
haryana
object
mastiti
continu
costli
diseas
modern
dairi
farm
detect
subclin
stage
immens
worth
term
anim
health
economi
present
studi
undertaken
evalu
potenti
valu
acut
phase
protein
serum
amyloid
haptoglobin
detect
clinic
subclin
mastiti
correl
ph
electroconduct
zebu
sahiw
perform
evalu
access
hiv
combo
assay
unicel
dxi
e
roux
n
groleau
c
chandeli
f
margotteau
c
stoia
duhamel
b
roussel
c
bonchamp
v
potel
nogu
cottin
r
falcoubriatt
flecheux
marn
la
coquett
steenvoord
fr
object
new
autom
hiv
combo
assay
develop
biorad
qualit
detect
antigen
antibodi
group
mno
use
unicel
dxi
immunoassay
system
beckman
coulter
purpos
studi
evalu
perform
new
assay
term
sensit
specif
precis
method
studi
perform
unicel
dxi
immunoassay
system
analyt
sensit
estim
dilut
studi
afssap
panel
nibsc
panel
standard
clinic
sensit
evalu
test
subtyp
variant
sampl
commerci
posit
sampl
hospit
patient
sampl
seroconvers
panel
includ
earli
seroconvers
sampl
clinic
specif
studi
sampl
blood
donor
select
neg
hospit
patient
sampl
non
select
hospit
patient
sampl
precis
studi
studi
follow
clsi
guidanc
analysi
sampl
neg
sampl
low
posit
sampl
medium
posit
sampl
antigen
result
specif
found
blood
donor
sampl
select
neg
hospit
patient
sampl
non
select
hospit
patient
sampl
analyt
sensit
obtain
nibsc
equal
iuml
estim
pgml
afssap
panel
clinic
sensit
posit
sampl
includ
antibodi
antigen
seroconvers
sensit
gave
perform
accord
state
art
earli
seroconvers
sampl
detect
intraassay
interassay
precis
found
posit
sampl
conclus
evalu
access
hiv
combo
highest
throughput
unicel
dxi
immunoassay
system
show
excel
perform
term
global
specif
analyt
sensit
clinic
sensit
precis
new
access
hiv
combo
fulli
suit
screen
hiv
hospit
privat
laboratori
ib
indetermin
neg
result
addit
test
high
sensit
eia
antigen
detect
major
sampl
also
evalu
viral
load
costeffect
analysi
includ
calcul
cost
identifi
one
case
hiv
infect
reliabl
differ
determin
mannwhitney
criterion
result
analyz
sera
ib
indetermin
neg
result
antigen
detect
respect
posit
sampl
viral
load
detect
case
viral
load
exce
sensit
level
use
assay
copiesml
median
copiesml
sampl
indetermin
ib
result
copiesml
sampl
neg
ib
result
hivstatu
confirm
test
patient
median
time
confirm
ib
day
patient
indetermin
neg
ib
result
come
repeat
test
falseposit
result
due
error
preanalyt
phase
object
eucast
disk
diffus
antimicrobi
suscept
test
method
fastidi
organ
base
muellerhinton
fastidi
agar
mhf
pilot
studi
anaerob
bacteria
grow
well
enough
mhf
permit
antimicrobi
suscept
test
decid
investig
whether
brucella
blood
agar
supplement
hemin
vitamin
k
bba
recommend
antimicrobi
suscept
test
anaerob
bacteria
gradient
strip
might
also
suit
disk
diffus
method
bacteroid
fragili
atcc
bacteroid
thetaiotaomicron
atcc
test
etest
gradient
strip
piperacillintazobactam
meropenem
metronidazol
clindamycin
bba
accord
manufactur
instruct
correspond
disk
eucast
disk
strength
includ
plate
twelv
plate
incub
anaerob
environ
co
h
n
hour
antimicrobi
agent
two
differ
day
intra
inter
day
variabl
etest
result
compar
accept
rang
two
strain
refer
agar
dilut
test
clsi
guidelin
twelv
plate
disk
also
incub
etest
result
within
accept
rang
intra
inter
day
variabl
dilut
step
zone
diamet
mean
rang
shown
tabl
n
maximum
differ
two
mean
mm
maximum
rang
mm
overal
growth
better
zone
smaller
conclus
small
intra
inter
day
variabl
observ
disk
diffus
bba
test
antimicrobi
agent
whether
small
variabl
reproduc
clinic
isol
whether
resist
isol
separ
wild
type
zone
diamet
distribut
bacteroid
fragili
group
remain
investig
also
impact
differ
temperatur
need
evalu
h
iakar
n
balaban
b
yalcin
u
cinar
e
guner
eksioglu
n
atakan
b
esen
kirsehir
ankara
mersin
karabuk
tr
object
heterogen
express
methicillin
resist
aureu
make
phenotyp
test
difficult
slow
aim
studi
compar
result
phenotyp
genotyp
method
use
methicillin
resist
determin
suscept
antibiot
use
skin
soft
tissu
infect
method
outpati
inpati
aureu
strain
isol
skin
soft
tissu
infect
includ
studi
patient
classifi
commun
acquir
hospit
acquir
cdc
criteria
methicillin
resist
determin
oxacillin
cefoxitin
disk
diffus
dd
confirm
oxacillin
salt
screen
agar
test
meca
pcr
suscept
test
antimicrobi
includ
clindamycin
cli
erythromycin
eri
gentamicin
gen
penicillin
pen
mupirocin
mup
rifampin
rif
tetracyclin
tet
trimethoprimsulphametoxasol
sxt
teicoplanin
tec
determin
data
compar
chisquar
fisher
exact
test
use
spss
result
meca
detect
outpati
inpati
ha
strain
show
higher
posit
castrain
p
ideal
spread
pattern
creat
evenli
spread
growth
uniform
circular
inhibit
zone
pattern
mm
distanc
lap
full
length
primari
streak
ml
mcf
suspens
suffici
speci
except
enterococcu
spp
requir
inoculum
volum
ml
less
inoculum
ml
increas
diamet
inhibit
zone
inoculum
densiti
mcf
yield
larger
inhibit
zone
inoculum
mcf
densiti
effect
sirinterpret
antibioticbacteria
combin
possibl
use
inoqula
inocul
spread
agar
plate
suscept
test
accord
new
eucast
guidelin
signific
differ
sirinterpret
includ
speci
compar
inhibit
zone
manual
spread
spread
inoqula
use
inoculum
much
lower
densiti
recommend
increas
size
inhibit
zone
effect
sirinterpret
antibioticbacteria
combin
bacteri
cell
incub
filter
mullerhinton
broth
exponenti
phase
expos
microgram
per
millilit
ciprofloxacin
saldrich
hour
sever
fluoresc
dye
test
order
obtain
best
approach
subject
propidium
iodid
saldrich
nm
nucleic
acid
stain
penetr
cell
sever
lesion
membran
ie
dead
cell
bi
acid
trimethin
oxonol
saldrich
nm
lipophil
anion
abl
diffus
across
depolar
membran
sybr
green
molecular
probe
nm
fluoresc
dye
bind
doubl
strand
dna
flow
cytometr
analysi
perform
stain
probe
dark
minut
convent
colonyform
unit
cfu
assay
perform
suspens
analyz
flow
cytometri
result
propidium
iodid
abl
discrimin
suscept
resist
strain
test
incub
time
sybr
green
abl
clearli
discrimin
suscept
strain
present
decreas
fluoresc
intens
drug
concentr
time
depend
manner
suscept
strain
compar
viabl
nontreat
bacteri
cell
even
hour
treatment
correl
convent
cfu
assay
flow
cytometri
success
achiev
conclus
one
hour
versu
hour
enough
character
suscept
ciprofloxacin
stain
sybr
green
flow
cytometri
prove
excel
accur
method
repres
altern
approach
evalu
suscept
bacteria
ciprofloxacin
object
detect
extend
spectrum
blactamas
esbl
laboratori
led
rise
use
carbapenem
worldwid
mani
laboratori
reli
autom
system
perform
task
reliabl
result
crucial
import
assess
perform
one
system
microscan
walkaway
system
siemen
panel
screen
tool
detect
esbl
product
rang
enterobacteriacea
object
eucast
aim
set
european
breakpoint
antimicrobi
resist
streamlin
method
antimicrobi
suscept
test
ast
increas
compar
result
differ
laboratori
laboratori
ast
perform
microbroth
dilut
disk
diffus
dd
accord
clsi
guidelin
moment
bd
diagnost
discontinu
product
certain
noneucast
panel
decid
implement
eucastguidelin
breakpoint
dd
automat
test
time
studi
describ
drawback
encount
implement
guidelin
routin
microbiolog
laboratori
besid
breakpoint
sever
antibiot
test
lab
lack
eucastguidelin
eg
temocillin
enterobacteriacea
ceftazidim
acinetobact
erythromycin
enterococci
practic
issu
encount
includ
unavail
requir
disk
plate
compani
moment
implement
also
phoenix
eucastpanel
fit
complet
eucaststrategi
antibiot
rang
includ
new
breakpoint
recommend
eg
erythromycin
enterococci
rifampicin
staphylococci
due
issu
complet
qualiti
control
test
consecut
day
perform
use
atcc
strain
nctc
strain
zone
diamet
measur
daili
train
microbiologist
compar
rang
provid
eucast
tabl
qc
target
aler
sa
identif
methicillin
mr
detect
directli
blood
cultur
bottl
minut
method
prospect
studi
consecut
staphylococc
strain
test
primari
plate
evalu
prospect
studi
bnsa
evalu
strain
repres
mrsa
clone
circul
world
inocul
artifici
blood
cultur
bactalert
fa
fn
ml
fresh
human
blood
cfuvial
incub
bactalert
automat
prospect
studi
clinic
blood
cultur
bottl
posit
gramposit
cocci
includ
immunochromatograph
result
compar
phenotyp
result
vitek
phoenix
discrep
result
check
pcr
result
test
test
interpret
sa
mssa
n
mrsa
n
se
sp
ppv
npv
respect
coagulas
neg
staphylococci
cn
mscn
n
mrcn
n
se
sp
ppv
npv
fals
posit
observ
sa
cn
mrsa
mrcn
isol
detect
primari
cultur
test
posit
mrsa
mrcn
subcultur
two
remain
mrcn
detect
induct
around
cefoxitin
disc
could
retest
test
bnsa
evalu
bnsa
blood
cultur
bottl
pair
aeroana
remain
neg
strain
posit
prospect
studi
bnsa
se
sp
ppv
npv
respect
sa
accur
detect
cn
yield
fals
posit
result
se
sp
ppv
npv
sa
mssa
n
mrsa
n
cn
se
sp
ppv
npv
respect
conclus
sa
present
relev
ppv
npv
enabl
earli
consider
mr
directli
primari
cultur
cn
test
accept
ppv
low
npv
improv
would
probabl
requir
optim
protocol
bnsa
evalu
studi
well
preliminari
result
prospect
studi
appear
promis
object
requir
accept
fact
infecti
diseas
respons
challeng
health
system
increas
immun
coverag
materi
method
februari
juli
incl
case
measl
regist
hospit
univers
clinic
infecti
diseas
town
plovdiv
laboratori
test
conduct
standard
methodolog
viru
serolog
paramet
investig
region
public
health
institut
data
statist
process
spss
analysi
system
use
parametr
method
gaussian
distribut
nonparametr
need
signific
differ
interv
accept
p
guarante
confid
result
discuss
highest
incid
measl
repot
april
may
hospit
patient
mainli
mediumheavi
form
diseas
observ
treat
children
year
measl
complic
pneumonia
found
patient
pronounc
respiratori
failur
need
oxygen
therapi
fellow
antibiot
receiv
complic
case
xray
control
achiev
lungaffect
observ
complic
nervou
system
patient
age
month
year
measl
complic
mening
two
case
viral
enceph
one
year
old
boy
meningomyel
conclus
outbreak
measl
plovdiv
region
put
reason
challeng
organiz
financi
legal
socialleg
aspect
epidemiologist
infecti
diseas
particular
healthcar
system
countri
whole
neurolog
complic
rare
analyz
studi
benign
end
antibodi
hepat
b
core
antigen
confid
interv
posit
hepat
b
surfac
antigen
confid
interv
antihepat
c
posit
confid
interv
antibodi
hepat
posit
antibodi
hiv
conclus
although
popul
theoret
low
risk
hbv
hcv
hdv
infect
result
higher
expect
accord
age
rang
found
recruit
posit
hiv
base
preval
serolog
marker
recommend
vaccin
hbv
infect
prevaccin
screen
object
determin
preval
predictor
hepat
c
viru
hcv
infect
associ
risk
factor
infect
among
inmat
bulgarian
prison
studi
carri
among
inmat
fifth
biggest
bulgarian
prison
men
n
women
n
juvenil
correct
institut
n
anonym
crosssect
data
collect
prison
agre
particip
studi
interview
use
standard
questionnair
includ
demograph
imprison
histori
hcv
relat
risk
behavior
item
thereaft
blood
drawn
particip
test
antihcv
antibodi
hcvrna
discard
serum
sampl
test
also
presenc
hepat
b
core
antibodi
antihbc
hepat
b
surfac
antigen
hbsag
hepat
antibodi
antihdv
antibodi
human
immunodefici
viru
hiv
object
shigatoxin
produc
escherichia
coli
stec
import
caus
foodborn
diseas
transmit
human
primarili
consumpt
contamin
food
raw
undercook
ground
meat
product
raw
milk
report
first
occurr
stec
austria
method
biochem
identif
serotyp
virul
test
done
nation
refer
centr
escherichia
coli
descript
investig
perform
order
describ
outbreak
identifi
outbreak
genesi
outbreak
involv
person
male
index
isol
year
old
previous
healthi
male
fecal
specimen
taken
intens
care
haemolyt
uraem
syndrom
hu
april
graz
second
isol
year
old
tyrolean
patient
specimen
receiv
april
patient
suffer
discharg
slime
bowel
irregular
follow
wateri
diarrhea
patient
attend
book
fair
graz
day
onset
ill
innsbruck
two
work
colleagu
consum
appet
bred
variou
handmad
spread
exhibit
booth
two
colleagu
fell
ill
diarrhea
one
innsbruck
one
munich
germani
stool
specimen
test
anoth
stool
isol
june
year
old
male
treat
hu
vienna
fourth
isol
latter
patient
wife
age
develop
bloodi
diarrhea
three
day
husband
discharg
hospit
fifth
stool
isol
year
old
patient
diarrhea
graz
specimen
receiv
may
five
isol
sorbitolfer
posit
hlya
neg
eae
analys
pfge
use
xbai
restrict
enzym
yield
pattern
indistinguish
clearli
differ
five
stec
provid
german
nation
consult
laboratori
hu
diseas
associ
austrian
stec
isol
conclus
report
emphas
stool
sampl
patient
hu
must
test
techniqu
sole
use
sorbitolmacconkey
media
direct
persontoperson
transmiss
underlin
import
instruct
famili
member
need
postdefecatori
handwash
five
six
remain
patient
consumpt
unidentifi
contamin
handmad
spread
produc
distribut
graz
area
like
sourc
infect
adher
abil
siderophor
amylas
caseinas
better
express
nacl
amylas
siderophor
nacl
amylas
better
express
nacl
siderophor
caseinas
show
best
express
thereaft
vf
express
gradual
decreas
till
nacl
adher
hela
cell
decreas
higher
salin
test
strain
prove
high
resist
broad
rang
ph
amylas
caseinas
better
express
ph
siderophor
ph
higher
glucos
concentr
inhibit
express
amylas
caseinas
incub
condit
exhibit
influenc
vf
express
molecular
detect
vf
gene
evidenc
ecpda
echeld
test
strain
densitometr
analysi
electrophoret
band
obtain
multiplex
pcr
show
differ
intens
suggest
number
case
lipas
dnase
gene
could
lost
great
percent
bacteri
popul
conclus
result
prove
high
adapt
abil
aquat
enterobacteri
strain
differ
stress
condit
express
virul
determin
even
limit
environment
condit
demonstr
role
paramet
preserv
virul
gene
pool
water
object
chlamydia
trachomati
ct
detect
self
obtain
vagin
swab
sv
firstcatch
urin
fcu
two
separ
assay
result
highest
sensit
laboratori
howev
onesampl
test
perform
reason
cost
effici
improv
onesampl
test
assess
laboratori
perform
three
differ
test
approach
find
sensit
onesampl
test
procedur
sv
versu
fcu
versu
combin
specimen
fcusv
method
women
visit
std
clinic
age
ask
particip
studi
client
ask
take
fcu
sv
dual
swab
fcu
sv
fcusv
combin
test
ct
strand
displac
amplif
assay
sda
becton
dickinson
probetec
et
system
maryland
usa
polymeras
chain
reaction
pcr
roch
diagnost
inc
coba
amplicor
system
california
usa
client
least
one
three
sampl
type
sv
fcu
svsfcu
combin
test
posit
ct
naat
regard
ct
posit
comparison
standard
result
total
femal
includ
ct
preval
ct
detect
rate
sv
fcu
svsfcu
combin
respect
result
naat
sda
pcr
analyz
togeth
detect
rate
significantli
differ
sampl
type
test
sole
discord
naat
result
within
differ
sampl
type
found
ct
posit
result
conclus
result
show
detect
rate
svsfcu
combin
equal
fcu
sv
alon
sv
accept
feasibl
specimen
femal
moreov
sv
costeffect
sampl
type
std
clinic
popul
therefor
conclud
sv
specimen
choic
detect
ct
femal
result
ten
patient
men
women
includ
match
control
mean
age
year
ie
common
distant
site
infect
one
patient
develop
spondyl
patient
predispos
condit
distant
site
infect
mitral
valv
insuffici
bicuspid
aortic
valv
atrioventricular
septal
defect
discu
protrus
five
patient
preced
dental
procedur
case
remov
dental
plaqu
calculu
none
patient
receiv
antibiot
prophylaxi
preoper
ten
patient
activ
oral
infect
foci
often
untreat
periodont
like
caus
spontan
bacteraemia
patient
report
childhood
infect
control
p
wbc
count
ml
admiss
median
maximum
lo
day
median
conclus
patient
predispos
medic
condit
seem
suscept
distant
site
infect
caus
mutan
major
predispos
factor
studi
materi
cardiac
structur
abnorm
patient
subsequ
develop
ie
distant
site
infect
result
highlight
import
oral
health
patient
cardiac
abnorm
support
use
antibiot
prophylaxi
dental
care
oral
infect
foci
patient
especi
colonis
mutan
background
antibiot
resist
term
frequent
use
clinician
discuss
patient
howev
patient
clinician
may
share
assumpt
mean
term
object
aim
explor
patient
interpret
term
antibiot
resist
consid
implic
strategi
reduc
overus
antibiot
design
qualit
interview
studi
particip
adult
patient
nine
european
citi
recent
consult
primari
care
clinician
symptom
lower
respiratori
tract
infect
lrti
approach
semistructur
interview
conduct
particip
follow
consult
data
subject
framework
analysi
domin
theme
network
antibiot
resist
aros
develop
resist
bodi
barrier
antibiot
effect
individu
loss
respons
less
commonli
patient
correctli
conceptualis
antibiot
resist
properti
bacteria
nevertheless
overus
antibiot
strong
central
concept
almost
patient
explan
whether
view
resist
locat
either
bodi
bacteria
patient
awar
link
antibiot
use
antibiot
resist
identif
misinterpret
antibiot
resist
locat
bodi
could
lead
clinicianpati
discuss
public
health
intervent
much
clearer
locat
mechan
antibiot
resist
explain
transfer
societ
relev
rather
focus
individualis
risk
therebi
emphasis
public
health
argument
prudent
use
antibiot
object
diarrhoea
remain
one
main
sourc
morbid
mortal
world
enteroaggreg
escherichia
coli
eaec
increasingli
recogn
emerg
pathogen
caus
diarrhoea
develop
industri
countri
romania
real
contribut
eaec
diarrhoea
diseas
burden
known
lack
routin
eaec
detect
protocol
clinic
microbiolog
laboratori
aim
present
studi
determin
preval
faecal
carriag
eaec
romanian
children
sporad
acut
diarrhoea
method
e
coli
isol
origin
stool
sampl
collect
diarrheal
episod
children
five
year
age
previous
found
neg
enter
pathogen
salmonella
spp
shigella
spp
yersinia
enterocolitica
campylobact
spp
diarrheagen
e
coli
pathotyp
includ
studi
specimen
one
biochem
confirm
e
coli
isol
screen
pcr
presenc
eaecassoci
gene
aat
aggr
aap
asta
eaec
isol
evalu
use
pcrbase
protocol
phylogenet
background
test
antimicrobi
suscept
disk
diffus
method
molecular
approach
reveal
e
coli
isol
carri
least
two
eaecassoci
gene
target
frequent
detect
gene
aat
isol
aap
isol
twentynin
isol
harbour
concurr
aat
aggr
aap
gene
almost
half
carri
also
asta
gene
eaec
isol
deriv
phylogenet
group
isol
rest
belong
group
isol
isol
isol
twentyfour
eaec
isol
express
resist
five
extendedspectrum
blactamas
produc
eaec
isol
fluoroquinolon
suscept
studi
reveal
eaec
pathotyp
might
signific
caus
sporad
diarrhoea
among
children
romania
result
provid
addit
support
reconsider
local
diagnost
surveil
strategi
l
p
p
p
sk
materi
dimens
poverti
roma
nation
minor
particularli
notic
sphere
live
especi
segreg
settlement
illeg
hut
mostli
built
wood
iron
wast
flat
metal
stock
materi
obtain
wast
dump
surround
countrysid
devast
environ
access
basic
infrastructur
electr
tap
water
mostli
use
water
well
stream
sewerag
system
wast
dispos
mani
case
influenc
bad
health
statu
troubl
hygien
accord
offic
govern
plenipotentiari
roma
issu
slovakia
approxim
roma
settlement
present
often
locat
rural
commun
without
necessari
basic
infrastructur
accord
sever
studi
mani
settlement
often
built
loos
soil
lack
drink
water
sewag
wast
pit
landfil
sanitari
facil
lack
garbag
dispos
settlement
concentr
small
area
larg
number
peopl
peopl
whose
health
statu
unsatisfactori
aim
aim
studi
describ
categor
differ
clinic
pictur
patient
neurobrucellosi
clinic
present
demograph
laboratori
data
patient
materi
method
hospit
record
patient
brucellosi
follow
retrospect
review
clinic
result
patient
neurobrucellosi
patient
classifi
four
group
mening
group
n
case
subacutechron
mening
one
case
acut
mening
encephalomyel
group
n
one
case
meningoencephalomyel
one
case
cerebellar
abscess
one
case
transvers
myeliti
polyradicular
group
n
one
case
miller
fisher
syndrom
other
n
one
case
intradur
abscess
ten
patient
femal
nine
patient
male
mean
age
patient
year
patient
fever
patient
neck
stiff
patient
unconsci
state
patient
underw
lumbar
punctur
lp
accord
cerebrospin
fluid
csf
analys
mean
leukocyt
count
mean
glucos
level
mgdl
mean
protein
level
mgdl
standard
tube
agglutin
test
show
brucellosi
patient
underw
lp
microorgan
detect
four
patient
blood
cultur
one
patient
csf
cultur
cranial
nerv
involv
five
case
frequent
sixth
cranial
nerv
involv
patient
recov
sequel
paraparesi
hear
loss
dementia
sphincter
dysfunct
patient
recov
complet
conclus
although
neurobrucellosi
frequent
accompani
subacutechron
mening
may
mani
differ
clinic
pictur
classic
triad
mening
fever
neck
stiff
unconsci
state
rare
seen
brucellosisrel
mening
brucellosi
kept
mind
patient
unexplain
neurolog
find
region
brucellosi
endem
addit
classif
brucellosi
reflect
locat
nervou
system
involv
clinic
pictur
pathogenesi
need
object
oral
candidiasi
opportunist
infect
oral
caviti
common
among
elderli
studi
carri
order
evalu
colon
oral
caviti
candida
speci
oral
candidiasi
institution
noninstitution
elderli
method
total
elderli
includ
institution
elderli
nurs
home
male
femal
mean
age
noninstitution
elderli
male
femal
mean
age
specimen
isol
oral
caviti
steril
swab
copan
zagreb
croatia
surfac
oral
mucosa
inocul
isol
medium
sabouraud
dextros
agar
cultur
incub
hour
case
growth
plate
consid
neg
discard
count
colonyform
unit
record
oral
caviti
consid
colon
candida
spp
case
posit
microbiolog
analysi
normal
oral
mucos
appear
diagnosi
oral
candidiasi
establish
take
account
clinic
appear
pseudomembran
candidiasi
erythemat
candidiasi
denturerel
stomat
candidaassoci
lesion
posit
microbiolog
analysi
diagnosi
made
accord
number
coloni
describ
budtzjorgensen
result
altogeth
institution
elderli
studi
colon
candida
spp
result
statist
differ
compar
noninstitution
elderli
p
result
investig
also
show
increas
number
institution
elderli
oral
candidiasi
compar
noninstitution
one
institution
elderli
noninstitution
elderli
p
conclus
result
studi
show
higher
preval
colon
oral
caviti
candida
spp
well
oral
candidiasi
institution
elderli
compar
noninstitution
elderli
four
patient
diagnosi
infecti
diseas
durat
definit
diagnosi
begin
initi
symptom
vari
longer
week
less
day
mean
hospit
day
day
day
follow
consult
patient
transfer
depart
need
disciplin
support
nine
patient
depart
die
atyp
present
infecti
diseas
common
elderli
patient
import
problem
delay
miss
diagnosi
long
hospit
period
data
reveal
neither
lack
fever
direct
diagnosi
noninfecti
diseas
unconsci
constant
symptom
cn
infect
elderli
patient
detail
investig
differenti
diagnosi
import
geriatr
patient
object
main
aim
studi
evalu
role
microbi
air
contamin
risk
surgic
site
infect
ssi
hip
knee
arthroprosthesi
control
adher
guidelin
antimicrobi
prophylaxi
project
fund
italian
ccm
centro
controllo
malatti
ministri
health
method
hospit
invit
join
project
gisio
member
ssi
surveil
conduct
accord
helic
protocol
version
microbi
air
contamin
evalu
patient
area
rest
oper
passiv
sampl
determin
index
microbi
air
contamin
ima
pasquarella
et
al
case
also
activ
sampl
determin
coloni
form
unit
cfu
surgic
antimicrobi
prophylaxi
refer
brief
cours
antimicrobi
agent
initi
oper
begin
webbas
data
collect
procedur
adopt
use
three
electron
data
form
two
year
project
start
juli
preced
threemonth
pilot
studi
assess
overal
feasibl
programm
project
includ
far
hospit
oper
room
accord
ventil
system
place
unidirect
airflow
turbul
air
ventil
mix
total
surgic
procedur
hip
knee
arthroprosthesi
includ
decemb
mean
durat
oper
minut
hip
minut
knee
arthroprosthesi
ima
valu
rest
follow
rang
median
surgic
procedur
follow
valu
regist
rang
median
total
patient
receiv
antibiot
prophylaxi
minut
hour
hour
incis
frequent
administ
antimicrobi
agent
cefazolin
tobramycin
teicoplanin
although
one
year
followup
implant
request
ssi
surveil
studi
depict
epidemiolog
scenario
complex
network
risk
factor
ssi
embed
alreadi
highlight
potenti
area
improv
air
qualiti
antibiot
prophylaxi
brucellosi
chronic
granulomat
infect
caus
intracellular
bacteria
endem
diseas
mediterranean
countri
turkey
brucellosi
show
involv
mani
system
seem
respons
high
incid
relaps
identifi
studi
rct
case
seri
case
report
elig
inclus
review
studi
boric
acid
compar
either
nystatin
azol
terconazol
flucytosin
itraconazol
clotrimazol
ketoconazol
fluconazol
buconazol
miconazol
monotherapi
boric
acid
studi
studi
mycolog
cure
rate
vari
patient
treat
boric
acid
four
includ
case
seri
report
statist
signific
outcom
regard
cure
mycolog
clinic
rate
none
includ
studi
report
statist
signific
differ
recurr
rate
regard
advers
effect
caus
boric
acid
use
vagin
burn
sensat
case
water
discharg
treatment
vagin
erythema
identifi
studi
conclus
find
suggest
boric
acid
safe
altern
econom
option
women
recurr
chronic
symptom
vagin
convent
treatment
fail
due
involv
nonalbican
candida
speci
azoleresist
strain
object
object
present
survey
studi
yersinia
enterocolitica
infest
drink
surfac
water
northwestern
greec
method
period
month
novemb
total
number
water
sampl
examin
presenc
enterocolitica
water
sampl
collect
area
epiru
northwestern
greec
includ
sampl
drink
water
sampl
lake
water
sampl
marin
water
drink
water
sampl
tapwat
collect
hous
three
differ
municip
area
lake
water
sampl
collect
two
lake
pamvoti
voulkaria
repres
two
differ
ecosystem
pollutedurban
ruralunpollut
use
recreat
activ
marin
water
sampl
collect
five
differ
point
sourc
ionian
sea
includ
area
recreat
activ
aphaawwa
standard
method
examin
water
wast
water
employ
detect
enterocolitica
bacteri
indic
total
microbi
flora
coliform
fecal
coliform
enterococci
result
enterocolitica
isol
two
sampl
marin
water
two
sampl
lake
water
posit
sampl
isol
pollut
aquat
environ
urban
lake
amvrakiko
golf
isol
enterocolitica
coincid
increas
number
total
coliform
cfuml
enterococci
cfuml
enterocolitica
strain
isol
drink
water
sampl
conclus
find
present
survey
underlin
presenc
enterocolitica
marin
lake
water
indic
microbiolog
pollut
potenti
threat
public
health
contamin
aquat
environ
use
recreat
activ
also
absenc
enterocolitica
drink
water
sampl
examin
area
prove
efficaci
chlorin
practic
object
aim
present
studi
report
event
tick
invas
premis
blood
transfus
unit
btu
gener
hospit
follow
unusu
climat
condit
spring
summer
northwestern
greec
method
first
week
juli
larg
number
tick
appear
extern
intern
wall
insid
premis
btu
hatzikosta
gener
hospit
ioannina
caus
uneasi
unit
medic
paramed
personnel
btu
locat
next
microbiolog
clinic
biochemistri
laboratori
btu
variou
clinic
none
surround
laboratori
clinic
report
appear
tick
also
confirm
situ
inspect
inspect
extern
wall
btu
build
reveal
larg
number
tick
presenc
number
bird
nest
mani
crack
wall
result
tick
specimen
collect
microbiolog
depart
medic
school
ioannina
identifi
belong
ixod
spp
greek
ornitholog
societi
call
identifi
nest
swallow
belong
mostli
speci
delichon
urbica
btu
build
surround
hospit
build
swallow
speci
delichon
urbica
host
haematophag
tick
belong
famili
ixodida
appar
nest
sourc
tick
astonishingli
enough
move
toward
btu
premis
nowher
els
hospit
build
swallow
nest
hospit
build
year
revisit
everi
spring
bird
habitat
howev
appear
larg
number
tick
correl
earlier
spring
high
temperatur
heavi
rainfal
continu
middl
juli
favor
weather
condit
work
well
crack
old
build
wall
result
multipl
establish
tick
hospit
wall
btu
purpos
studi
plan
indic
clinic
cours
termin
brucellosi
region
recent
year
compar
literatur
studi
base
review
medic
record
adult
patient
older
year
follow
diagnosi
brucellosi
march
octob
demograph
data
diseas
diagnosi
cours
treatment
termin
data
patient
record
result
patient
includ
male
averag
age
includ
analysi
statist
signific
relationship
advanc
age
develop
spondyl
arthriti
respect
p
p
besid
frequenc
splenomegali
neurobrucellosi
among
young
popul
found
high
statist
signific
respect
p
p
case
spondyl
common
involv
lumbar
vertebra
also
statist
signific
relationship
high
esr
spondyl
sacroilli
viscer
abscess
p
respect
studi
sad
see
nt
signific
chang
frequenc
diseas
complic
time
osteoarticular
involv
particularli
presenc
spondyl
search
advanc
age
patient
meticul
scan
complic
laboratori
paramet
patient
age
durat
symptom
may
help
identifi
complic
case
arthropodborn
infect
confirm
case
lyme
diseas
mediterranean
spot
fever
qfever
thirti
two
eufor
soldier
test
posit
brucellosi
four
confirm
case
hemorrhag
fever
renal
syndrom
report
case
sexual
transmit
diseas
viral
hepat
c
signific
problem
deploy
incid
rate
infecti
diseas
conflict
rel
low
combin
factor
presenc
comprehens
infrastructur
medic
care
extens
prevent
medicin
effort
sever
fortuit
circumst
nevertheless
eufor
militari
personnel
crowd
uniqu
stressor
subject
respiratori
diarrheal
diseas
outbreak
diseas
brucellosi
hemorrhag
fever
renal
syndrom
qfever
caus
potenti
biolog
weapon
agent
preval
background
campylobact
recognis
caus
agent
bacteri
infecti
diarrhoea
remain
one
preval
bacteri
enteropathogen
industri
countri
campylobact
infect
gener
foodborn
diseas
object
aim
report
studi
campylobact
case
record
decad
well
suscept
campylobact
isol
antibiot
also
frequenc
diseas
accord
age
sex
season
estim
method
total
campylobact
strain
isol
patient
acut
gastroenter
hospit
infecti
diseas
hospit
thessaloniki
select
skirrow
medium
use
skirrow
medium
blood
agar
infus
antibiot
vancomycin
polymixinb
trimethoprim
incub
microaerophil
condit
follow
isol
select
media
identif
carri
use
biochem
profil
campylobact
strain
furthermor
campylobact
strain
test
suscept
antibiot
ampicillin
gentamicin
tobramycin
cephalothin
ceftriaxon
ciprofloxacin
nalidix
acid
cotrimoxazol
erythromycin
use
kirbybau
method
result
strain
c
jejuni
c
coli
total
strain
isol
male
femal
furthermor
strain
isol
children
age
year
adult
addit
leucocyt
found
stool
specimen
peak
campylobact
infect
studi
spring
month
summer
month
increas
fluoroquinolon
cotrimoxazol
resist
nalidix
acid
ciprofloxacin
cotrimoxazol
respect
among
campylobact
isol
observ
erythromycin
macrolid
consid
drug
choic
low
resist
conclus
campylobact
major
caus
bacteri
enter
follow
salmonella
northern
greec
frequent
isol
c
jejuni
age
specif
infect
rate
highest
children
less
two
year
old
campylobacteriosi
occur
much
frequent
spring
summer
month
erythromycin
still
effect
antibiot
therapi
campylobact
infect
background
associ
chlamydia
pneumonia
atherosclerosi
hypercholesterolaemia
subject
absenc
convent
risk
factor
unclear
studi
done
determin
whether
c
pneumonia
seroposit
associ
increas
intima
media
thick
imt
carotid
arteri
hsc
reactiv
protein
crp
oxid
stress
subject
hypercholesterolaemia
method
fiftytwo
hypercholesterolaem
subject
recruit
health
screen
programm
organ
institut
subject
inclus
criteria
includ
baselin
ldlc
mmoll
subject
diabet
hypertens
sever
obes
smoke
primari
hypercholesterolemia
presenc
acut
inflamm
creactiv
protein
unit
exclud
igg
iga
c
pneumonia
measur
microimmunofluores
test
igg
titr
iga
consid
seroposit
imt
far
wall
carotid
arteri
measur
bmode
ultrasound
hscrp
measur
immunoturbidimetr
method
use
autom
analys
isoprostan
oxid
stress
marker
quantifi
liquid
chromatographi
mass
spectrometri
result
seroposit
c
pneumonia
detect
hypercholesterolaem
subject
signific
differ
imt
hypercholesterolaem
subject
c
pneumonia
seroposit
compar
c
pneumonia
seroneg
subject
mean
mm
vs
mm
p
hscrp
show
statist
signific
differ
c
pneumonia
seroposit
seroneg
individu
mean
hscrp
sd
mgdl
vs
p
contrast
signific
differ
observ
compar
isoprostan
marker
oxid
stress
serostatu
c
pneumonia
mean
sd
pgml
vs
p
conclus
data
demonstr
seroposit
c
pneumonia
increas
oxid
stress
associ
increas
carotid
imt
hscrp
subject
hypercholesterolaemia
absenc
convent
cardiovascular
risk
factor
object
rapid
reliabl
identif
three
potenti
toxigen
corynebacterium
speci
corynebacterium
diphtheria
c
ulceran
c
pseudotuberculosi
usual
essenti
diagnosi
treatment
diphtheria
diphtherialik
diseas
classic
differenti
suspect
isol
done
biochem
test
time
consum
may
often
give
unclear
result
recent
matrix
assist
laser
desorptionion
time
flight
malditof
mass
spectrometri
ms
shown
allow
identif
isol
microorgan
within
minut
therefor
fast
altern
speci
differenti
method
use
matrix
assist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
comparison
classic
microbiolog
api
coryn
molecular
method
rpob
sequenc
corynebacterium
strain
result
potenti
toxigen
corynebacterium
spp
strain
collect
german
nation
consiliari
laboratori
diphtheria
period
ten
year
correctli
identifi
malditof
ms
strain
biochem
identif
api
coryn
yield
ident
result
rpob
gene
sequenc
twelv
strain
show
unreli
ambigu
api
result
concordantli
identifi
rpob
sequenc
malditof
ms
except
one
isol
c
tuberculostearicum
conclus
test
corynebacteria
correctli
identifi
malditof
ms
compar
rpob
gene
sequenc
moreov
posit
neg
predict
valu
identif
potenti
toxigen
corynebacterium
speci
malditof
respect
conclus
conclus
speci
identif
potenti
toxigen
corynebacterium
spp
accomplish
malditof
ms
within
min
appli
suspici
coloni
scenario
malditof
ms
technolog
might
use
rapid
screen
method
help
decid
whether
suspici
coloni
analyz
presenc
tox
real
time
pcr
propos
algorithm
fast
reliabl
diagnosi
diphtheria
incorpor
malditof
ms
realtim
tox
pcr
elek
test
scrub
typhu
caus
orientia
tsutsugamushi
acut
febril
ill
character
fever
rash
myalgia
sever
complic
rare
recent
case
scrub
typhu
sever
complic
acut
respiratori
distress
syndrom
septic
shock
acut
renal
failur
myocard
mening
increasingli
report
fulmin
myocard
character
critic
ill
present
howev
affect
patient
recov
pharmacolog
therapi
mechan
circulatori
support
may
better
longterm
prognosi
patient
form
myocard
adult
patient
scrub
typhu
present
normal
ekg
admiss
hypotens
period
subsequ
develop
chest
pain
th
hospit
day
invers
ekg
diffus
ventricular
dyskinesia
echocardiographi
appear
hospit
day
report
case
acut
fulmin
myocard
adult
scrub
typhu
complic
led
sever
cardiogen
shock
death
streptococcu
sui
sui
swine
pathogen
respons
mening
septicemia
pneumonia
endocard
sinc
first
case
report
human
infect
denmark
human
infect
sui
report
mani
countri
especi
southeast
asia
high
densiti
pig
report
patient
septic
arthriti
bacteremia
caus
sui
best
knowledg
case
sui
isol
joint
fluid
rare
first
case
report
sui
infect
korea
organ
confirm
phenotyp
character
rrna
sequenc
analysi
korean
femal
present
fever
arthralgia
headach
seen
secondari
referr
center
korea
aspir
joint
fluid
blood
cultur
reveal
growth
sui
biotyp
identifi
vitek
gpi
api
strep
system
usa
organ
suscept
penicil
vancomycin
rrna
sequenc
blood
cultur
isol
show
homolog
sui
subsp
sui
report
genbank
although
fever
subsid
subsequ
blood
joint
cultur
neg
antibiot
therapi
swell
pain
left
knee
joint
persist
plan
receiv
total
knee
replac
object
tickborn
enceph
tbe
infecti
zoonot
diseas
present
central
europ
rare
itali
last
year
continu
increas
diseas
morbid
observ
endem
countri
case
occur
year
report
first
paediatr
case
describ
itali
case
report
first
year
old
boy
came
remark
involv
central
nervou
system
week
flulik
syndrom
non
tickbit
report
daili
consumpt
nonpasteur
milk
refer
lumbar
punctur
reveal
clear
cerebrospin
fluid
csf
polymorphonuclear
pleocytosi
glucos
protein
content
normal
boy
receiv
treatment
dexamethason
ceftriaxon
ampicillin
acyclovir
regress
symptom
within
hour
tbe
specif
serolog
blood
csf
posit
serolog
borrelia
burgdorferi
reveal
past
infect
diagnosi
mening
form
tbe
boy
normal
neurolog
outcom
second
year
old
boy
came
onset
walk
difficulti
myalgia
leg
heavi
fatigu
nausea
day
fever
headach
note
remov
two
tick
day
start
symptom
clinic
present
slight
instabl
march
heel
blood
examin
reveal
leuconeutropenia
thrombocytopenia
elev
aminotransferas
level
signific
creatin
kinas
increas
serolog
common
virus
bacteria
also
borrelia
burgdorferi
neg
first
tbe
serolog
posit
igm
day
posit
igm
igg
need
treatment
spontan
regress
symptom
describ
first
pediatr
tbe
case
document
itali
gener
diseas
transmit
tick
genu
ixod
even
alreadi
describ
sporad
case
nonpasteur
cow
milk
manifest
typic
diphas
febril
cours
flulik
syndrom
first
phase
involv
central
nervou
system
second
phase
first
case
tick
bite
known
boy
often
fed
nonpasteur
milk
dairi
product
peculiar
second
case
short
incub
period
absenc
second
phase
infect
show
children
imposs
defin
singl
clinic
pictur
character
tbe
sever
clinic
form
background
clostridium
sordellii
c
sordellii
gramposit
anaerob
bacillu
report
rare
caus
fatal
toxic
syndrom
medic
abort
portug
legal
therapeut
abort
week
gestat
approv
report
case
young
patient
underw
medic
induc
abort
die
c
sordellii
toxic
shock
syndrom
case
summari
women
underw
medic
induc
abort
mean
mg
oral
mifepriston
follow
mg
vagin
misoprostol
present
matern
hospit
emerg
five
day
receiv
mifepriston
complain
lipothimia
night
abdomin
cramp
admiss
conscient
afebril
hypotens
hour
later
develop
rapid
onsetsepsi
mark
leukocitosi
whitecellsml
neutrophil
hemoconcentr
hematocrit
hemoglobin
sever
metabol
acidosi
patient
underw
hysterectomi
uteru
biopsi
cultur
anatomopatholog
analysi
request
patient
transfer
intens
care
unit
die
present
emerg
microbiolog
laboratori
direct
examin
gramstain
smear
uterin
biopsi
show
larg
gram
posit
rod
biopsi
inocul
appropri
agar
plate
medium
incub
aerob
anaerob
h
later
anaerob
cultur
posit
coloni
smear
gram
stain
show
gram
posit
rod
c
sordellii
identifi
semiautom
system
vitek
biomerieux
anc
card
anaerob
corynebacterium
card
discuss
fatal
case
posabort
c
sordellii
sepsi
distinct
clinic
featur
develop
report
studi
gram
stain
uterin
biopsi
good
rapid
mean
presumpt
result
help
diagnos
c
sordellii
identifi
uterin
biopsi
cultur
semiautom
system
differ
studi
use
anticlostridium
speci
immunochem
assay
pcr
assay
perform
formalin
fix
uterin
tissu
posautopsi
conclus
improv
diagnosi
gram
stain
cultur
endometri
biopsi
specimen
good
approach
earlier
recognit
diseas
etiolog
object
oropharyng
form
tularemia
known
common
particularli
eastern
european
countri
includ
turkey
aim
studi
evalu
patient
tularemia
make
point
diseas
method
februari
august
five
patient
unilater
cervic
mass
admit
outpati
clinic
preliminari
diagnosi
tularemia
diagnosi
tularemia
confirm
microagglutin
test
pcr
result
patient
oropharyng
tularemia
suspicion
contamin
water
ingest
age
patient
rang
three
male
two
femal
initi
stage
diseas
patient
gener
symptom
fever
headach
malais
sore
throat
last
two
week
gener
symptom
disappear
cervic
lymph
node
start
swell
patient
blactam
antibiot
administ
three
differ
center
admiss
clinic
howev
nt
respons
treatment
admiss
unilater
cervic
submandibular
lymphadenopathi
malais
detect
patient
one
patient
suppur
lymphaden
spontan
drainag
leukocytosi
found
one
patient
elev
esr
three
elev
crp
three
patient
lymph
node
aspir
perform
fluctuat
detect
f
tularensi
could
grown
cultur
howev
f
tularensi
subsp
holarctica
dna
detect
four
lymph
node
aspir
convent
pcr
microagglutin
test
posit
four
patient
titr
three
patient
one
patient
patient
treat
streptomycin
doxycyclin
ciprofloxacin
doxycyclin
combin
week
period
due
delay
initi
treatment
one
patient
receiv
second
cour
antibiot
insuffici
respons
first
therapi
continu
suppur
lymphaden
sever
complic
observ
conclus
tularemia
kept
mind
differenti
diagnosi
patient
fever
pharyng
tonsil
cervic
lymphadenopathi
especi
unrespons
blactam
antibiot
endem
region
earli
treatment
proper
antibiot
start
work
evalu
clinic
parasit
statu
malaria
caus
fever
among
patient
admit
militari
fever
hospit
thirti
six
patient
includ
twenti
alreadi
diagnos
malari
patient
recruit
peac
keep
mission
forc
africa
sixteen
case
present
prolong
fever
come
differ
locat
egypt
result
show
elgab
elahmar
area
cairo
extens
infest
region
might
due
chang
ecolog
pattern
sinc
year
environment
condit
favour
breed
flare
mosquito
elsharkia
elfayoum
governor
g
next
order
might
due
increas
rural
area
agricultur
project
reestablish
plasmodium
vivax
main
speci
among
local
acquir
patient
import
patient
come
back
egypt
africa
especi
sudan
p
falciparum
howev
p
falciparum
also
present
case
el
fayoum
governor
p
oval
p
malaria
encount
interest
case
recruit
ardelgolf
heliopoli
area
high
social
hygien
standard
condit
appli
elnozha
elgidida
case
includ
runway
airport
malaria
local
transmiss
diseas
attribut
infect
mosquito
transport
long
haul
flight
two
local
acquir
case
malaria
posit
bone
marrow
smear
neg
peripher
blood
examin
howev
thick
blood
film
sensit
patient
clinic
parasitolog
cure
one
patient
die
best
therapeut
respons
local
acquir
malaria
infect
monotherapybas
one
chloroquin
mefloquin
background
catscratch
diseas
csd
caus
bartonella
hensela
benign
selflimit
diseas
immunocompet
children
histori
contact
cat
organ
commonli
found
blood
cat
felid
classic
present
tender
swollen
region
lymph
node
without
papul
site
initi
infect
immunocompromis
patient
howev
sever
form
present
occur
diagnosi
usual
possibl
serolog
histopatholog
case
summari
kuwaiti
girl
previous
healthi
admit
fever
abdomin
pain
nausea
gener
weak
arriv
trip
egypt
five
day
earlier
histori
diarrhea
vomit
urinari
symptom
rash
examin
patient
look
ill
oral
temperatur
abdomin
tender
guard
initi
blood
investig
show
wbc
esr
mmh
creactiv
protein
crp
mgl
urea
mmoll
creatinin
umol
urinalysi
show
presenc
rbc
wbc
cultur
neg
diagnosi
append
made
appendicectomi
perform
patient
howev
continu
run
high
grade
fever
therapi
piperacillintazobactam
taz
metronidazol
initi
clinic
respons
observ
ct
abdomen
show
mesenter
paraaort
lymphadenopathi
multipl
splenic
lesion
suspicion
enter
fever
prompt
chang
taz
ceftriaxon
blood
cultur
brucella
agglutin
spot
test
widal
test
neg
sever
antibiot
cours
includ
antitb
antifung
tri
none
help
improv
condit
final
splenectomi
lymph
node
biopsi
done
patholog
report
conclud
multipl
splenic
granuloma
pictur
suggest
csd
serolog
howev
prove
neg
ifa
titr
igg
igm
histori
contact
cat
egypt
elicit
patient
patholog
report
avail
dramat
improv
condit
follow
splenectomi
best
knowledg
first
case
csd
report
kuwait
recommend
consid
csd
differenti
diagnosi
children
present
puo
lymphadenopathi
splenic
involv
despit
sever
antibiot
cours
includ
recommend
csd
patient
show
defervesc
splenectomi
perform
object
salmonella
one
common
caus
bacteri
foodborn
diseas
worldwid
recent
enterica
serovar
emerg
among
common
serovar
isol
human
mani
countri
serovar
consid
monophas
variant
serovar
typhimurium
greec
monophas
serovar
firstli
record
human
isol
total
isol
increas
sharpli
next
two
year
frequent
serotyp
total
isol
result
shown
tabl
phage
type
use
typhimurium
type
phage
identifi
differ
pt
commonli
identifi
pt
b
eightysix
percent
isol
express
resist
ampicillin
sulphonamid
streptomycin
tetracyclin
rtype
assut
without
addit
resist
c
pfge
analysi
identifi
uniqu
profil
ah
eightyeight
percent
strain
repres
three
profil
b
c
share
similar
conclus
combin
phenotyp
genotyp
characterist
frequent
pattern
appear
one
phage
type
rtype
assut
plu
addit
resist
close
relat
pfge
profil
b
c
follow
pattern
phage
type
rtype
assut
without
addit
resist
close
relat
pfge
profil
b
c
result
consist
possibl
presenc
two
differ
clone
enterica
serovar
prevail
human
pig
isol
greec
similar
data
record
sever
european
countri
background
use
implant
cardiac
devic
perman
pacemak
ppm
continu
increas
infect
complic
insert
devic
manag
pacemak
endocard
gener
requir
surgic
remov
entir
system
brucella
sui
uncommon
caus
endocard
previous
report
associ
ppm
year
old
gentleman
inuvik
nunavut
canada
ppm
year
evalu
syncop
univers
alberta
hospit
edmonton
canada
investig
reveal
evid
cardiac
lead
veget
transesophag
echocardiogram
preoper
blood
cultur
intraop
cultur
taken
laser
lead
extract
becam
posit
brucella
sui
mic
mgl
ciprofloxacin
doxycyclin
rifampin
upon
question
patient
subacut
histori
constitut
symptom
report
hunt
skin
butcher
canadian
carib
rangif
tarandu
patient
brother
hunt
partner
treat
b
sui
infect
year
previous
patient
treat
laser
lead
extract
combin
oral
antimicrobi
therapi
doxycyclin
rifampin
month
follow
blood
cultur
neg
discuss
brucella
sui
type
known
pathogen
canadian
carib
herd
hypothesis
cutan
exposur
skin
butcher
ingest
undercook
meat
result
zoonot
transmiss
organ
patient
caus
bacteraemia
secondari
seed
pacemak
wire
literatur
search
first
report
case
pacemak
endocard
due
b
sui
import
clinician
awar
possibl
zoonot
transmiss
b
sui
patient
expos
carib
canadian
north
risk
secondari
infect
underli
foreign
bodi
ppm
clinician
also
remind
alert
microbiolog
lab
brucella
suspect
pathogen
allow
appropri
biosafeti
precaut
neisseria
meningitidi
agent
bacteri
mening
classifi
differ
serogroup
base
immunolog
reactiv
capsular
polysaccarid
serogroup
b
c
among
predomin
serogroup
turkey
b
c
serogroup
n
meningitidi
encount
frequent
caus
menigococc
mening
meningococc
vaccin
contain
serogroup
c
use
prevent
recruit
fatal
diseas
till
may
administr
quadrival
vaccin
consist
serogroup
implement
emerg
menigococc
mening
case
caus
serogroup
present
first
known
menigococc
mening
case
caus
n
meningitidi
serogroup
x
sinc
start
quadrival
meningococc
vaccin
administr
recruit
serogroup
x
emerg
caus
meningococc
diseas
suscept
popul
suppress
serogroup
includ
quadrival
vaccin
result
mass
vaccin
campaign
impli
mass
vaccin
program
sole
prevent
diseas
total
improv
environment
condit
especi
riski
popul
also
essenti
prevent
diseas
background
arcanobacterium
haemolyticum
ah
extrem
rare
caus
infect
endocard
present
unusu
case
superinfect
ah
primari
staphylococcu
aureu
sa
mitral
valv
endocard
hepat
bc
posit
intraven
drug
user
ivdu
protract
cours
multiorgan
impair
patient
success
treat
case
studi
ivdu
male
transfer
emerg
unit
neighbour
hospit
intens
care
hospit
februari
sign
sever
sepsi
seizur
ct
head
reveal
small
pariet
bleed
lumbar
punctur
nonconclus
ctpa
neg
pulmonari
embol
show
extens
non
occlus
thrombu
superior
vena
cava
systol
murmur
prompt
transesophag
echo
reveal
mitral
regurgit
veget
follow
isol
meticillinsensit
sa
grown
two
set
blood
cultur
patient
treat
flucloxacillin
iv
week
satisfactori
respons
patient
start
get
intermitt
pyrexia
elev
crp
wcc
mild
renal
hepat
impair
blood
cultur
ah
singl
bottl
consid
signific
dose
fluclox
increas
pyrexia
rais
inflammatori
marker
impair
renal
function
prompt
biopsi
reveal
focal
necrot
glomerulonephr
vibrio
vulnificu
human
pathogen
frequent
transmit
human
via
raw
oyster
isol
major
raw
oyster
shellfish
harvest
subtrop
area
summer
season
woman
diabet
mellitu
liver
cirrhosi
present
emerg
depart
gener
edema
one
month
mental
chang
day
diagnos
v
vulnificu
septicemia
treat
ceftazidim
doxicyclin
also
isol
v
vulnificu
sea
water
outbreak
sea
season
summer
v
vulnificu
septicemia
emerg
jeju
island
associ
climat
chang
island
first
report
relationship
clinic
environment
isol
accord
climat
environment
chang
jeju
island
korea
icc
abstract
accept
public
observ
radiograph
pattern
area
consolid
often
associ
patchi
interstiti
infiltr
fatal
case
observ
consolid
airbronchogram
diffus
alveolar
infiltr
extens
involv
lung
presenc
bilater
opac
interstiti
infiltr
lobar
consolid
patchi
infiltr
associ
poor
prognosi
patient
abnorm
ct
find
greater
risk
intub
ventil
icu
admiss
death
normal
ct
patient
similar
ct
find
variou
outcom
improv
discharg
death
conclus
chest
ct
find
may
signific
predict
clinic
outcom
manag
diseas
eg
initi
antibiot
patient
influenza
infect
ct
find
alon
exactli
predict
outcom
risk
factor
consid
object
g
glutamyl
transferas
ggt
enzym
present
cell
membran
mani
tissu
high
ggt
level
use
prognost
factor
alcohol
liver
diseas
metabol
syndrom
cardiovascular
diseas
liver
cancer
liver
metastasi
differ
cancer
crimean
congo
hemorrhag
fever
emerg
turkey
last
year
elev
alanin
amino
transferas
alt
aspart
amino
trasnsferas
ast
level
use
sever
criteria
prognost
factor
fatal
manag
cchf
howev
observ
associ
ggt
level
cours
diseas
studi
aim
figur
relat
serum
ggt
level
cchf
effect
surviv
method
patient
laboratoryconfirm
diagnosi
cchf
includ
studi
serum
ala
ast
gama
glutamyl
trasnferas
ggt
retrospect
investig
record
two
paramet
use
evalu
relat
cchf
ggt
serum
ggt
level
serum
astggt
ratio
ast
elev
promin
featur
cchf
alt
elev
astggt
ratio
chosen
marker
result
total
patient
includ
total
femal
mean
age
year
year
mean
hospit
stay
patient
day
day
remark
laboratori
find
follow
mean
minmax
wbc
platelet
ast
ggt
ul
compar
serum
level
ggt
fatal
non
fatal
case
mean
ggt
level
statist
significantli
higher
fatal
case
day
admiss
serum
ast
level
also
found
higher
day
fatal
group
mean
ggt
level
continu
increas
cours
diseas
figur
astggt
ratio
investig
ratio
first
day
admiss
day
higher
serum
ggt
level
promin
laboratori
find
non
fatal
case
figur
posit
correl
detect
higher
astggt
ratio
mortal
conclus
serum
ggt
level
use
prognost
factor
cchf
howev
increas
ggt
level
recoveri
period
cchf
yet
fulli
explain
therefor
studi
need
area
research
background
crimean
congo
hemorrhag
fever
seriou
viral
hemorrhag
fever
immunopathogenesi
diseas
clear
enough
yet
interleukin
il
pivot
cytokin
strongli
stimul
cellular
immun
activ
humor
immun
tdepend
tindepend
antigen
immunoregulatori
function
may
play
role
promot
endogen
protect
respons
infect
andor
contribut
patholog
result
unregul
cytokin
express
pathogen
induct
elicit
interferong
product
natur
killer
cell
contribut
earli
defens
certain
bacteri
parasit
viral
infect
tschudin
sutter
r
frei
dangel
goldenberg
af
widmer
basel
ch
object
actinobaculum
schaalii
gramposit
facult
anaerob
coccoid
rod
classifi
new
speci
formerli
belong
speci
actinomyc
sui
grow
slowli
therefor
easili
overgrown
bacteria
often
found
concomitantli
sinc
actinobaculum
schaalii
routin
investig
hospit
whenev
presenc
suspect
due
detect
minut
grey
coloni
blood
agar
plate
neg
reaction
catalsa
object
studi
determin
clinic
signific
actinobaculum
schaalii
identifi
microbiolog
laboratori
last
year
method
consecut
isol
actinobaculum
schaalii
obtain
computer
databas
clinic
microbiolog
laboratori
patient
whose
cultur
bodi
site
yield
pathogen
analyz
observ
tini
coloni
gramposit
catalaseneg
rod
trigger
molecular
identif
base
partial
rrna
gene
sequenc
infecti
diseas
specialist
review
medic
chart
collect
data
regard
underli
diseas
clinic
manifest
antibiot
therapi
clinic
outcom
stavrian
v
kalogeri
e
koukou
tsipou
pagoni
athen
gr
object
bnp
pct
crp
well
known
index
critic
ill
patient
sepsi
septic
shock
purpos
studi
determin
marker
serum
level
increas
sepsi
predict
outcom
valuabl
prognost
marker
retrospect
examin
patient
febril
bacteri
infect
admit
depart
period
two
year
one
histori
establish
cardiac
failur
diagnost
sepsi
base
clinic
laboratori
data
measur
bnp
pct
crp
blood
sampl
taken
first
two
day
hospit
outcom
determin
survivor
nonsurvivor
result
femal
male
patient
among
patient
survivor
nonsurvivor
signific
increas
bnp
level
nonsurvivor
patient
vs
bnp
level
survivor
patient
also
pct
mean
level
higher
nonsurvivor
group
vs
survivor
group
final
mean
level
crp
survivor
nonsurvivor
conclus
studi
bnp
pct
level
measur
soon
admiss
increas
significantli
sepsi
seem
valuabl
prognost
marker
outcom
patient
differ
crp
mean
level
two
group
signific
cirkin
guzel
n
baykam
meneks
yilmaz
kocagul
celikba
eren
gok
h
esen
yaprakci
b
dokuzoguz
ankara
tr
introduct
influenza
pandem
caus
higher
morbid
mortal
among
pregnant
women
gener
popul
underscor
medic
commun
urgent
need
data
regard
safe
effect
use
medic
pregnanc
although
benefit
treatment
appear
outweigh
theoret
risk
antivir
use
data
newborn
born
mother
took
medic
pregnanc
studi
aim
investig
clinic
characterist
influenza
pregnant
women
follow
health
statu
newborn
mother
deliveri
method
twenti
pregnant
women
clinic
symptom
diagnosi
influenza
includ
studi
octob
januari
studi
popul
follow
deliveri
newborn
evalu
complic
associ
infect
medic
result
twenti
hospit
patient
pandem
influenza
pregnant
mean
age
thirteen
pregnant
women
trimestr
trimestr
trimestr
admit
hospit
although
patient
patholog
respiratori
auscult
find
pregnant
patient
accept
chest
xray
test
bilater
patchi
alveolar
opac
two
requir
mechan
ventil
one
mechan
ventil
pregnant
woman
die
second
day
hospit
six
patient
nt
accept
get
antivir
medic
one
pregnant
women
got
antivir
medic
oseltamivir
prematur
birth
week
deliveri
term
complic
detect
newborn
week
life
conclus
although
earli
evid
suggest
pregnant
women
may
higher
risk
sever
complic
includ
stillbirth
novel
benefit
treatment
appear
outweigh
theoret
risk
antivir
use
earli
antivir
therapi
may
bring
clinic
benefit
pregnant
patient
f
carletti
brozzi
c
eleni
n
polici
g
dalterio
scicluna
c
castilletti
di
caro
g
autorino
demetrio
g
cardeti
rome
object
juli
llama
farm
central
itali
exhibit
skin
lesion
differ
site
evolv
nodul
crust
crater
morpholog
typic
pox
lesion
farm
present
mani
speci
bird
local
exot
mammal
goat
cattl
pig
donkey
hors
none
show
mention
symptom
method
one
moribund
femal
euthanis
sampl
collect
laboratori
analysi
skin
lesion
process
electron
microscopi
techniqu
two
mammal
cell
line
vero
use
viru
isol
attempt
total
viral
dna
extract
homogen
crust
vero
cell
supernat
realtim
pcr
target
crmb
gene
sequenc
phylogenet
analysi
perform
identifi
viru
viral
bacteri
diseas
consid
differenti
diagnosi
result
transmiss
electron
microscopi
reveal
brick
particl
typic
orthopoxvirus
cpxvantibodi
detect
llama
human
sera
farmer
realtim
pcr
gave
posit
result
crust
cell
supernat
phylogenet
analysi
two
poxviru
gene
ha
crmb
confirm
cowpoxviru
infect
homolog
cpxvguwi
strain
isol
germani
outbreak
symptom
describ
among
anim
human
be
farm
news
cpxv
report
itali
origin
infect
llama
born
farm
contact
exot
mammal
declar
owner
suppos
viru
introduc
farm
bred
mice
use
food
bird
prey
mice
came
german
farm
sold
infect
rat
zoo
mongoos
recent
result
affect
cpxv
beltram
c
castilletti
troi
arzes
e
ndip
nganyuo
lapa
di
caro
b
del
pin
capobianchi
udin
rome
veneto
object
r
toma
malet
b
font
espasa
l
falguera
j
prat
fontan
sabadel
es
introduct
object
transrect
ultrasound
guid
prostat
biopsi
truspb
techniqu
choic
diagnosi
prostat
cancer
consensu
antibiot
dose
durat
prophylaxi
main
object
studi
calcul
incid
postbiopsi
bacteremia
pb
know
microorgan
antibiot
suscept
evalu
effect
differ
antibiot
prophylaxi
use
hospit
pb
incid
base
prophylaxi
regimen
ciprofloxacin
cotrimoxazol
tobramycin
lower
incid
pb
ciprofloxacin
group
statist
signific
p
versu
cotrimoxazol
p
versu
tobramycin
global
incid
pb
escherichia
coli
isol
episod
ciprofloxacin
prophylaxi
effect
regimen
lower
pb
howev
suscept
e
coli
isol
nt
optim
take
account
e
coli
suscept
ceftriaxon
use
antibiot
new
prophylaxi
regimen
could
reduc
pb
incid
object
object
studi
evalu
healthcar
worker
hcw
complianc
hand
hygien
guidelin
issu
world
health
organ
assess
knowledg
regard
percept
toward
hand
hygien
also
search
associ
observ
complianc
variou
factor
method
studi
conduct
evaggelismo
hospit
tertiari
care
gener
hospit
athen
greec
march
june
complianc
data
collect
base
direct
overt
hcw
observ
patient
care
anonym
selfadminist
questionnair
use
collect
inform
knowledg
percept
use
data
collect
form
questionnair
provid
result
observ
session
averag
durat
min
record
hand
hygien
opportun
total
averag
complianc
complianc
significantli
higher
among
physician
among
nurs
vs
p
profession
categori
doctor
vs
nurs
type
indic
contact
vs
contact
day
observ
take
day
vs
day
activ
index
found
correl
strongli
complianc
knowledg
questionnair
complet
averag
number
correct
answer
knowledg
question
sd
differ
significantli
among
age
group
profession
categori
depart
ward
hcw
answer
correctli
question
percept
questionnair
complet
behavior
belief
favor
hand
hygien
seem
strong
produc
posit
attitud
toward
behavior
norm
belief
also
rel
favor
respect
hand
hygien
control
belief
hcw
felt
big
effort
requir
perform
good
hand
hygien
accord
hcw
view
effect
action
improv
hand
hygien
hospit
make
alcoholbas
handrub
alway
avail
point
care
patient
empower
regard
least
effect
measur
conclus
complianc
rate
evaggelismo
hospit
low
compar
studi
carri
greec
countri
doctor
nurs
level
knowledg
satisfactori
low
perceiv
behavior
control
seem
exert
strong
influenc
hcw
behavior
action
need
taken
involv
combin
system
chang
educ
motiv
oral
care
chlorhexidin
influenc
bacteri
epidemiolog
incid
nosocomi
pneumonia
intens
care
unit
z
yang
chen
cai
yj
yang
sy
zhao
zq
che
c
zhu
wj
zhou
zhong
f
jing
ez
chen
shanghai
cn
object
investig
effect
oral
hygien
chlorhexidin
influenc
bacteri
epidemiolog
incid
nosocomi
pneumonia
intens
care
unit
method
patient
admit
stay
polyval
icu
chines
tertiari
care
teach
hospit
enrol
studi
may
april
preintervent
period
protocol
oral
hygien
consist
metronidazol
morn
boil
water
even
chang
chlorhexidin
glucon
twice
daili
sinc
may
bacteri
epidemiolog
nosocomi
pneumonia
np
ventil
associ
pneumonia
vap
studi
statist
analysi
perform
sa
result
five
hundr
fortytwo
patient
admit
icu
may
april
four
hundr
eightyseven
patient
screen
patient
episod
np
vap
patient
intub
deviceday
occur
preintervent
period
patient
np
vap
patient
intub
deviceday
intervent
period
signific
differ
intub
patient
sex
vs
p
age
vs
p
median
icu
stay
vs
p
ventilatorday
vs
p
overal
rate
cathet
relat
pneumonia
vap
rate
np
episod
per
ventilatorday
episod
per
patientday
preintervent
intervent
period
respect
among
bacteria
isol
first
year
g
mrsa
g
nonferment
bacteria
intervent
period
among
bacteria
g
mrsa
g
nonferment
bacteria
mrsa
non
ferment
bacteria
distribut
signific
differ
studi
period
vap
conclus
oral
hygien
chlorhexidin
twice
daili
chang
littl
bacteri
distribut
np
icu
compar
preintervent
period
howev
slightli
decreas
incid
vap
episod
per
catheterday
incid
np
patientday
observ
intervent
period
suggest
possibl
benefit
oral
hygien
ventil
patient
icu
period
b
period
c
period
period
e
compar
period
period
b
cefazolin
cefotiam
administ
prophylaxi
dose
continu
day
includ
day
surgeri
moreov
nonscreen
preemptiv
isol
cohort
nspei
c
appli
patient
undergo
endotrach
intub
tracheotomi
admit
singl
room
isol
multipl
patient
similar
condit
one
room
cohort
regardless
whether
mrsa
isol
sinc
august
howev
idea
evidencebas
medicin
ebm
spread
japan
choic
stop
nspei
c
nspei
c
confirm
evid
sinc
mrsa
becom
isol
postop
patient
even
often
nspei
c
strictli
institut
dose
period
prophylact
antibiot
postop
infect
shorten
extend
isol
rate
mrsa
digest
surgeri
could
significantli
reduc
report
herein
method
prevent
isol
mrsa
two
decad
howev
nspei
c
stop
period
c
implement
prophylact
antibiot
administ
day
surgeri
period
period
e
prophylact
antibiot
administ
day
object
infect
prosthes
surround
tissu
one
seriou
complic
orthoped
surgeri
infect
caus
staphylococci
especi
staphylococcu
aureu
nowaday
aureu
often
complet
resist
blactam
methicillinresist
aureu
mrsa
mostli
connect
resist
antibiot
eg
lincosamid
quinolon
exchang
implant
temporari
implant
antibioticcontain
spacer
mode
choic
treatment
biofilmassoci
infect
vitrostudi
aim
determin
antimicrobi
activ
antibioticcontain
specimen
time
period
three
month
method
specimen
prepar
commerci
avail
bone
cement
without
antibiot
mg
gentam
mg
gentamicin
mg
clindamyc
cement
addit
cement
contain
mg
gentamycin
supplement
mg
mgg
vancomycin
specimen
place
nutrient
broth
five
test
strain
methicillinsuscept
aureu
mssa
mrsa
epidermidi
bacteri
growth
visibl
broth
specimen
remov
bacteria
attach
surfac
specimen
count
specimen
soak
nutrient
broth
phosphat
buffer
salin
eluat
taken
determin
antimicrobi
activ
mean
agar
diffus
test
result
cement
contain
gentamicin
clindamycin
show
higher
antimicrobi
activ
mssa
epidermidi
comparison
cement
contain
gentamicin
specimen
infect
start
experi
specimen
gentamicin
clindamycin
inhibit
biofilm
format
act
antimicrobi
mssa
strain
epidermidi
strain
day
cement
gentamicin
also
combin
clindamycin
effect
mrsa
strain
supplement
vancomycin
abl
inhibit
growth
mrsa
strain
concentr
mg
activ
day
microbiolog
diagnosi
exclud
fast
possibl
infect
mrsa
infect
caus
mssa
combin
gentamicin
clindamycin
recommend
treatment
mrsa
applic
vancomycincontain
cement
seem
necessari
pseudomona
aeruginosa
acinetobact
baumannii
use
superson
wave
plasma
irradi
nakano
fujimura
sato
h
takan
watanab
sendai
jp
object
nosocomi
infect
caus
acinetobact
baumannii
pseudomona
aeruginosa
problem
worldwid
known
bacteria
contamin
water
suppli
environ
faucet
sink
bath
hospit
long
time
extrem
difficult
sanit
strain
environ
aim
present
studi
evalu
bactericid
effect
biofilmform
strain
use
superson
wave
plasma
irradi
clinic
isol
baumannii
standard
strain
p
aeruginosa
use
studi
form
biofilm
squar
stainless
steel
plate
ad
tsb
bacteri
suspens
mcfarland
incub
anaerob
condit
stainless
plate
ad
water
tank
irradi
superson
wave
khz
minut
wherea
plasma
flow
gener
dielectr
barrier
discharg
air
kvpp
k
hz
irradi
anoth
plate
biofilmform
bacteria
minut
irradi
plate
cultur
mh
agar
plate
oc
bactericid
effect
observ
use
scan
electron
microscop
sem
abovement
cultur
method
result
strain
baumannii
p
aeruginosa
except
biofilmform
strain
steril
superson
wave
minut
howev
biofilmform
strain
steril
minut
hand
strain
steril
within
minut
plasma
irradi
without
biofilm
burst
bacteria
plasma
irradi
confirm
use
sem
studi
result
show
plasma
irradi
effect
steril
hospit
environment
contamin
p
aeruginosa
baumannii
babak
sm
zahraei
z
pezeshki
z
nokhodian
b
ataei
atai
isfahan
ir
object
nosocomi
infect
creat
hospit
result
health
care
worker
hand
main
rout
microorgan
transmiss
hand
wash
import
measur
prevent
spread
infect
complianc
hand
hygien
hh
among
healthcar
worker
gener
low
less
studi
aim
determin
accept
level
hand
hygien
isfahan
hospit
design
intervent
increas
awar
motiv
perform
among
healthcar
worker
method
cross
section
studi
conduct
three
larg
hospit
isfahan
public
train
medic
center
public
medic
center
privat
medic
center
total
seven
train
observ
differ
work
shift
three
hospit
select
work
day
two
differ
week
everi
day
eight
session
consid
session
observ
monitor
healthcar
worker
routin
activ
check
list
five
indic
touch
patient
procedur
procedur
bodi
fluid
exposur
risk
touch
patient
touch
patient
surround
observ
base
world
health
organ
guidelin
four
differ
profession
group
physician
nurs
student
other
consid
studi
hh
complianc
calcul
number
posit
hand
hygien
actionsnumb
total
hand
hygien
indic
base
indic
profession
group
result
total
observ
indic
gener
hh
complianc
rate
statist
signific
three
differ
hospit
respect
rate
observ
among
nurs
group
student
group
pvalu
less
among
variou
indic
highest
rate
complianc
observ
procedur
bodi
fluid
exposur
risk
pvalu
less
conclus
studi
hand
hygien
complianc
rate
hospit
studi
low
need
plan
improv
phadebact
monoclon
antibodi
type
boul
diagnost
ab
hud
sweden
perform
isol
penicillinas
product
perform
use
nitrocephin
method
result
isol
wiiwiii
ib
serovar
yield
invitro
suscept
ceftriaxon
mic
spectinomycin
mic
three
isol
resist
penicillin
mic
penicillinas
produc
strain
twenti
eight
isol
yield
reduc
suscept
penicillin
mic
thirti
one
isol
resist
penicillin
yield
reduc
suscept
penicillin
five
isol
resist
ciprofloxacin
qrng
mic
five
isol
three
yield
penicillin
reduc
suscept
pattern
two
resist
penicillin
six
resist
tetracyclin
mic
trng
ciprofloxacin
resist
isol
male
subject
seven
distinct
antimicrobi
suscept
pattern
observ
isol
rate
obtain
studi
popul
conclus
ciprofloxacin
penicillin
resist
increas
cephalosporin
resist
observ
local
continu
antimicrobi
surveil
paramount
ongo
distinct
link
phadebact
monoclon
type
isol
antimicrobi
suscept
pattern
j
wojkowskamach
romaniszyn
chmielarczyk
b
wojcikstojek
b
gryglewska
grodzicki
pobiega
pb
heczko
cracow
pl
nosocomi
infect
wellknow
public
health
problem
mani
consequ
like
medic
econom
ethic
etc
inform
epidemiolog
microbiolog
use
basi
legisl
special
program
infect
prevent
control
hospit
long
term
facil
ltcf
unfortun
known
situat
polish
ltcf
aim
work
analyz
epidemiolog
infect
multidrug
resist
organ
among
resid
one
ltcf
result
resid
resid
day
pd
includ
studi
period
studi
resid
wheelchair
disabl
bedridden
disori
time
andor
space
averag
age
prospect
epidemiolog
surveil
carri
train
profession
use
mcgeer
definit
incid
densiti
per
pd
object
foreign
bodi
extern
fixat
prosthesi
infect
caus
signific
morbid
mortal
orthoped
surgeri
silver
ion
coat
metal
extern
fixat
reduc
bacteri
colon
consequ
infect
method
studi
metal
extern
fixat
use
titanium
extern
fixat
coat
silver
ion
contain
calcium
phosphat
base
ceram
powder
use
electrospray
method
implant
coat
hydroxyapatit
way
remain
extern
fixat
without
coat
induc
experiment
infect
staphylococcu
epidermidi
clinic
isol
slime
factor
use
studi
cfuml
suspens
clinic
isol
tryptic
soy
broth
prepar
follow
h
incub
quantit
cultur
bacteria
determin
silver
ion
atom
absorpt
perform
broth
quantit
cultur
bacteria
extern
fixat
perform
addit
microscop
examin
possibl
antibacteri
efficaci
implant
due
silver
ion
coat
investig
week
day
week
accordingli
implant
glass
tube
diamet
cm
place
shake
incub
rpm
implant
rins
distil
water
asept
condit
week
result
bacteri
growth
statist
higher
broth
contain
titanium
extern
fixat
compar
broth
media
contain
silver
ioncoat
hydroxyapatiteco
extern
fixat
hour
p
p
respect
releas
bacteria
silver
ioncoat
fixat
statist
less
compar
hydroxyapatiteand
titaniumco
fixat
p
p
respect
mic
level
silver
ion
powder
mgml
cn
free
silver
ion
detect
broth
media
use
method
detect
threshold
low
ppm
electron
microscopi
observ
less
bacteria
adher
silver
ioncoat
extern
fixat
observ
bacteria
releas
silver
ioncoat
extern
fixat
surround
liquid
result
silver
ion
coat
metal
extern
fixat
bacteri
colon
reduc
significantli
effect
may
help
prevent
postop
infect
caus
extern
fixat
commonli
use
orthoped
oper
invivo
evalu
effect
warrant
ips
core
curriculum
infect
control
practition
submit
nation
repres
ask
score
grade
item
curriculum
meet
held
udin
result
graduat
futur
endors
strategi
discuss
meet
coordin
group
elabor
final
document
document
sent
ncpict
final
approv
ncpict
particip
process
approv
document
result
propos
european
core
compet
aim
help
standard
infect
controlhospit
hygien
profession
ichhp
compet
europ
design
implement
train
cours
accord
differ
nation
context
facilit
mutual
recognit
compet
across
europ
provid
opportun
ichhp
review
perform
plan
profession
develop
provid
opportun
health
care
institut
organ
evalu
need
term
profession
human
resourc
document
organ
three
main
area
programm
manag
qualiti
improv
infect
control
consist
differ
profession
task
common
infect
control
doctor
nurs
except
one
relat
antibiot
prescrib
profession
task
compet
classifi
foundat
practic
appli
newli
appoint
ichhp
staff
littl
previou
experi
expert
practic
ichhp
confid
experienc
compet
conclus
achiev
consensu
document
european
infect
controlhospit
hygien
core
compet
howev
ensur
make
ae
posit
impact
necessari
spread
endors
relev
stakehold
object
assess
influenc
new
carbapenembas
deescal
strategi
antimicrobi
therapi
treatment
infecti
complic
sever
burn
injuri
resist
nosocomi
gramneg
bacteria
method
retrospect
analysi
antibiogram
burn
patient
admit
burn
care
unit
bcu
sensit
common
gramneg
pathogen
implement
deescal
strategi
treat
infecti
complic
thermal
burn
burn
care
unit
increas
suscept
multidrugresist
gramneg
pathogen
potenti
benefit
reduc
overal
cost
treatment
due
direct
cost
antibiot
treatment
shorten
length
stay
hospit
without
increas
mortal
rate
background
first
largescal
studi
focus
preval
ltbi
laboratori
personnel
especi
intermedi
incid
set
method
recruit
laboratori
personnel
perform
quantiferontb
gold
intub
test
qftg
tuberculin
skin
test
tst
agreement
qftg
tst
analyz
risk
factor
posit
test
assess
result
qftg
posit
enrol
laboratori
personnel
tst
posit
cutoff
mm
agreement
two
test
fair
kappa
confid
interv
age
durat
health
care
profess
significantli
associ
posit
qftg
tst
result
univari
analys
multivari
logist
regress
analys
household
contact
tb
patient
p
laboratori
section
microbiolog
p
chemistryimmunolog
p
significantli
associ
posit
qftg
result
conclus
data
show
high
preval
ltbi
laboratori
personnel
emphas
import
ltbi
screen
health
care
worker
qftg
seem
superior
tst
ltbi
screen
panayea
g
petrikko
armaganidi
h
giamarel
chaidari
athen
gr
object
copper
shown
antimicrobi
properti
use
hospit
surfac
minim
environment
contamin
pathogen
bacteria
investig
effect
two
copper
alloy
surviv
vim
andor
kpcproduc
multidrug
resist
mdr
enterobacteriacea
method
mdr
clinic
isol
screen
product
vim
kpc
carbapenemas
use
edtaimipenem
boron
acidmeropenem
synergi
test
respect
gene
confirm
pcr
specif
primer
assess
antimicrobi
properti
copper
coupon
cm
cm
copper
alloy
b
contain
respect
steril
inocul
ml
bacteri
suspens
cfuml
incub
room
temperatur
hour
coupon
place
steril
neutral
broth
difco
vortex
broth
serial
dilut
quantit
cultur
recoveri
viabl
bacteria
lower
limit
detect
cfuml
stainless
steel
c
polyvinylchlorid
coupon
use
control
mean
viabl
count
cfuml
incub
time
interv
coupon
compar
statist
analysi
reduct
viabl
count
start
inoculum
character
bactericid
activ
result
thirteen
isol
includ
k
pneumonia
e
coli
enterobact
spp
produc
either
vim
kpc
test
hour
mean
viabl
bacteri
count
coupon
decreas
respect
reduct
produc
coupon
b
hour
respect
control
c
reduc
bacteri
count
hour
respect
bactericid
effect
detect
coupon
b
hour
respect
viabl
bacteria
could
recov
test
strain
incub
coupon
hour
strain
hour
incub
coupon
b
copper
alloy
reduc
number
viabl
carbapenemaseproduc
bacteria
significantli
hour
produc
bactericid
effect
hour
effect
cuzn
data
suggest
use
copper
surfac
materi
hospit
could
aid
diminish
environment
reservoir
mdr
gramneg
pathogen
r
guner
hasanoglu
kesk
tasyaran
ankara
tr
object
central
venou
cathet
cvc
usag
becom
frequent
intens
care
unit
icu
besid
mechan
complic
cathet
relat
bloodstream
infect
crbsi
frequent
prevent
costli
high
mortal
morbid
although
essenti
icu
patient
urinari
catheteris
also
bring
risk
cathet
relat
urinari
tract
infect
cruti
aim
decreas
crbsi
cruti
rate
observ
educ
feedback
infect
rate
reward
perform
observ
intervent
studi
educ
train
hospit
ankara
turkey
twelv
neurologyneurosurgeri
ten
coronari
six
cardiovascular
surgeri
nine
gener
icu
bed
studi
carri
three
phase
preintervent
intervent
postintervent
six
month
preintervent
period
perform
educ
meet
icu
doctor
nurs
educ
program
highlight
prevent
bundl
urinari
cathet
uc
cvc
relat
infect
observ
cvc
uc
checklist
followup
chart
crbsi
cruti
diagnosi
perform
accord
cdc
definit
six
month
educ
staff
depart
decreas
infect
rate
promis
award
pay
rais
result
studi
period
cvc
uc
insert
patient
cathet
day
respect
observ
indic
cvc
peripher
intraven
access
problem
haemodialysi
insert
site
jugular
subclavian
cvc
insert
emerg
condit
mean
lenght
catheteris
day
complianc
maximum
barrier
precaut
rate
correl
doctor
educ
year
common
displac
reason
cvc
exitu
discontinu
indic
complianc
prevent
bundl
mean
lenght
catheteris
day
relationship
clinic
insert
cathet
complianc
maximum
barrier
precaut
cvc
uc
decreas
crbsi
rate
cruti
rate
studi
show
educ
feedback
infect
rate
reward
effect
reduc
crbsi
cruti
rate
continu
educ
essenti
maintain
low
infect
rate
c
carrilho
jc
pascual
garcia
ra
belei
ns
paiva
nj
cornetta
rl
oricolli
c
grion
pelisson
sf
costa
londrina
br
object
report
outbreak
carbapenemresist
enterobacteria
univers
hospit
control
measur
mortal
associ
pathogen
conclus
carbapenemresist
enterobacteria
great
challeng
concern
control
treatment
outbreak
take
place
frequent
intens
care
unit
nearli
half
patient
manifest
infect
mortal
among
infect
patient
high
c
p
rodriguezcundin
ml
gonzalezmartinez
debenito
ab
campoesquisabel
r
teira
g
marcano
santand
es
object
methicillinresist
staphylococcu
aureu
mrsa
one
import
multidrugresist
bacteria
surveil
control
must
prioriti
hospit
set
aim
studi
describ
incid
mrsa
hospit
implement
prevent
control
programm
programm
prevent
control
implant
nosocomi
mrsa
outbreak
incid
base
bundl
recommend
identif
isol
control
incident
case
earli
detect
condit
carrier
record
incident
case
databas
comput
record
link
hospit
inform
system
allow
us
detect
hospit
readmiss
colonizedinfect
patient
patient
isol
immedi
result
programm
implement
gradual
increas
incid
observ
last
six
year
expens
communityassoci
mrsa
incid
nosocomi
mrsa
kept
around
frequent
locat
infect
nosocomi
mrsa
year
alway
low
respiratori
tract
infect
without
pulmonari
condens
follow
primari
bacteraemia
communityassoci
mrsa
cutan
infect
patient
isol
detect
mrsa
daili
averag
isol
patient
repres
hospit
bed
occup
detect
nosocomi
mrsa
outbreak
hospit
incid
nosocomi
mrsa
kept
rate
around
import
emphas
decreas
proport
nosocomi
mrsa
isol
wherea
communityassoci
mrsa
increas
dynam
record
connect
hospit
inform
system
allow
us
identifi
control
colonizedinfect
patient
entri
hospit
object
retrospect
evalu
result
detect
mrsa
commerci
pcr
genohm
becton
dickinson
compar
cultur
mrsa
one
year
use
two
geriatr
ward
bed
intens
care
unit
bed
bed
commun
hospit
impact
mrsa
epidemiolog
also
evalu
method
patient
screen
admiss
geriatr
ward
intens
care
unit
swab
taken
nose
perineum
pool
test
pcr
inocul
chromogen
agar
detect
mrsa
enrich
broth
cultur
made
sampl
arriv
friday
even
weekend
examin
pcr
patient
isol
soon
mrsa
posit
result
pcr
cultur
known
hand
genohm
pcr
test
rather
low
sensit
posit
predict
valu
compar
cultur
even
cultur
ideal
two
site
enrich
introduct
pcr
meant
reduc
transmiss
mrsa
henc
reduct
infect
faster
isol
speed
test
deduc
data
polici
impact
decreas
nosocomi
mrsa
infect
guleri
r
palmer
l
moorhous
staff
n
harper
j
lickiss
blackpool
uk
background
blackpool
victoria
larg
district
teach
foundat
trust
hospit
nw
england
oper
success
comprehens
cdi
contain
programm
special
emphasi
antibiot
stewardship
real
time
programm
monitor
initi
like
root
caus
analysi
cdi
communityacut
trust
multidisciplinari
audit
surveil
present
find
innov
pilot
project
multidisciplinari
cdi
perform
manag
meet
mcpm
aim
spearhead
trust
cdi
programm
futur
aim
mcpm
includ
team
work
problem
solv
real
time
shopfloor
troubleshoot
rais
profil
awar
friendli
interact
session
result
use
inform
regularli
monitor
strateg
action
plan
record
one
p
aeruginosa
panr
strain
sensibl
colistin
mayseptemb
unexpect
high
incid
vre
report
aflp
analysi
vre
strain
document
genet
relationship
two
differ
group
isol
isol
show
similar
aflp
pattern
differ
genet
relat
isol
data
suggest
possibl
person
person
transmiss
correct
measur
case
vre
document
gramneg
outbreak
record
period
result
show
new
increas
gramneg
infect
progress
antimicrobi
resist
high
discriminatori
aflp
method
fast
enough
allow
realtim
monitor
outbreak
permit
addit
prevent
measur
clostridium
difficil
detect
identif
colonis
subclin
overt
diseas
fm
awadelkariem
c
malon
h
gough
h
oconnor
stevenag
uk
background
detect
c
difficil
toxin
observ
problemat
fals
neg
result
meant
patient
test
repeatedli
symptomat
among
reason
poor
neg
predict
valu
labil
natur
toxin
limit
avail
technolog
newer
sensit
technolog
introduc
pcr
technolog
reduc
rate
fals
neg
elimin
need
multipl
sampl
recent
year
combin
infect
control
measur
cdad
rate
reduc
dramat
howev
success
brought
front
signific
high
fals
posit
rate
especi
ultrasensit
new
technolog
wellestablish
toxinproduc
c
difficil
colonis
young
children
older
patient
histori
repeat
prolong
hospitalis
need
new
approach
determin
clinic
valu
posit
result
object
studi
design
assess
concord
differ
toxin
assay
clinic
present
antigen
positivetoxin
neg
patient
method
twenti
six
antigen
positivetoxin
neg
stool
sampl
techlab
eia
gdh
ag
toxin
includ
studi
patient
multipl
sampl
identifi
sampl
test
use
vida
eia
cultur
ribotyp
cepheid
genexpert
pcr
cytotox
assay
clinic
present
follow
data
analys
assess
clinic
signific
result
result
patient
altern
explan
transient
diarrhoea
eg
lax
found
toxinneg
eia
howev
sampl
posit
pcr
produc
cytotox
effect
follow
cultur
isol
number
ribotyp
conclus
result
suggest
combin
clinicallaboratori
interpret
valu
current
epidemiolog
set
highli
sensit
technolog
pcr
may
detect
presenc
toxin
gene
case
colonis
subclin
presenc
c
difficil
data
suggest
sampl
found
antigen
posit
toxin
neg
eia
presenc
altern
clinic
caus
diarrhoea
treat
colonis
howev
patient
monitor
close
isol
diarrhoea
limit
environment
contamin
p
nikou
e
giannitsioti
athanasia
drakou
e
koratzani
v
sakka
k
kouvela
kanellaki
fragkou
gm
gourgouli
g
kouko
p
panagopoulo
e
paramythiot
plachoura
v
spyropoulo
h
giamarel
papadopoulo
k
kanellakopoul
athen
gr
object
chronic
foot
osteomyel
cfo
diagnost
therapeut
challeng
appropri
regimen
length
antimicrobi
therapi
cfo
occur
ground
diabet
foot
df
studi
aim
evalu
factor
influenc
success
outcom
patient
pt
cfo
without
df
patient
method
pt
cfo
retriev
databas
pt
bone
joint
infect
follow
refer
clinic
demograph
df
foot
vascular
neurolog
complic
charcot
joint
gangren
assess
follow
standard
definit
diagnosi
cfo
base
upon
clinic
imag
laboratorymicrobiolog
evalu
complet
restor
paramet
consid
cure
chisquar
mann
whitney
test
appli
categor
continu
variabl
respect
logist
regress
analysi
factor
predict
outcom
perform
result
dfo
pt
n
male
median
age
iqr
comorbid
n
includ
diabet
mellitusdm
n
insulin
depend
n
rheumat
arthriti
n
non
dm
vascular
diseas
n
vascular
n
neurolog
n
dm
complic
charcot
joint
n
gangren
n
amput
n
orthoped
devic
n
pt
median
iqr
time
infect
onset
treatment
month
sinu
tract
ulcer
fever
found
pt
respect
microbiolog
document
dfo
base
intraop
cultur
n
prone
bone
aspir
sampl
n
gram
posit
bacteria
includ
mrsa
mrse
gram
neg
bacteria
account
among
polymicrobi
case
aureu
plu
p
aeruginosa
esrcrp
baselin
abnorm
pt
combin
antimicrobi
therapi
given
pt
includ
fluoroquinolon
n
fulli
revers
advers
event
note
median
iqr
treatment
durat
month
howev
treat
month
month
month
median
follow
month
cure
analysi
demonstr
independ
relat
advers
outcom
p
conclus
normal
n
predict
pt
outcom
strict
glycem
control
mandatori
manag
pt
dfo
object
rapid
routin
screen
patient
methicillinresist
staphylococcu
aureu
mrsa
import
improv
chromogen
media
detect
mrsa
within
hour
purpus
studi
evalu
abil
two
chromogen
media
oxoid
ii
agar
oxoid
ltd
basingstok
uk
marcyletoil
franc
detect
mrsa
surveil
specimen
method
brillianc
chromid
test
use
six
strain
mrsa
atcc
hvisa
atcc
hgisa
atcc
two
strain
mssa
atcc
strain
e
faecali
e
coli
rest
strain
isol
patient
laboratori
strain
collect
one
two
coloni
test
strain
third
subcultiv
inocul
brillianc
chromid
patient
sampl
process
skin
nose
throat
swab
sent
ami
transport
medium
sampl
inocul
toddhewitt
enrich
broth
thb
blood
agar
ba
brillianc
chromid
first
sampl
inocul
follow
order
thb
ba
brillianc
chromid
next
sampl
inocul
differ
order
thb
ba
chromid
brillianc
plate
inspect
incub
plate
inspect
incub
denimblu
coloni
brillianc
green
coloni
chromid
process
accord
clsi
guidelin
antimicrobi
suscept
test
perform
dnase
coagulas
posit
strain
posit
result
methicillinresist
screen
mrsa
strain
accord
clsi
guidelin
denimblu
green
coloni
dnase
coagulas
neg
regardless
result
methicillinresist
screen
consid
fals
posit
cn
dnase
coagulas
posit
oxascreen
neg
coloni
consid
fals
posit
mssa
result
mrsa
strain
produc
denimblu
green
coloni
follow
hour
incub
tabl
one
discrep
result
obtain
patient
sampl
coloni
denimblu
brillianc
yellow
chromid
mrsa
confirm
case
strain
mssa
e
faecali
e
coli
fail
grow
chromogen
media
conclus
agar
fast
easi
use
reliabl
requir
addit
cost
access
everi
microbiolog
laboratori
comparison
rapid
pcr
method
aim
compartment
immun
respons
ascit
fluid
seem
import
especi
spontan
bacteri
periton
sbp
aim
studi
determin
pattern
cytokin
synthesi
ascit
fluid
af
cirrhot
patient
without
sbp
patient
method
prospect
studi
cirrhot
patient
asciti
admit
univers
hospit
patra
may
decemb
patient
separ
two
group
group
patient
sbp
b
group
patient
without
sbp
cirrhosi
diagnos
basi
typic
clinic
laboratori
ultrasonograph
find
andor
liver
biopsi
upon
admiss
paracentesi
ascet
fluid
perform
ascit
level
tnfa
stnfri
stnfrii
measur
use
elisa
method
data
present
deviat
compar
use
test
p
valu
consid
signific
result
characterist
patient
sbp
vs
without
sbp
age
vs
malefemal
ratio
vs
ethanol
use
vs
viral
hepat
vs
cryptogen
vs
noon
ascit
concentr
individu
cytokin
group
vs
group
follow
vs
vs
tgfa
vs
stnfri
vs
stnfrii
vs
vs
vs
multivari
analysi
show
signific
p
differ
level
stnfrii
two
group
ascit
level
tnfa
stnfrii
stnfri
higher
level
lower
ascit
fluid
patient
sbp
differ
signific
remark
express
patient
either
without
spontan
bacteri
periton
demonstr
increas
cytokin
product
ascit
fluid
cirrhot
patient
level
antiinflammatori
cytokin
stnfrii
significantli
increas
patient
sbp
seem
therefor
ascit
fluid
antiinflammatori
respons
characterist
sbp
might
compromis
final
outocom
enterobacteriacea
site
introduct
extendedspectrum
blactamas
esbl
produc
organ
belong
import
multiresist
pathogen
hospit
recent
esbl
also
spread
commun
worldwid
carrier
esblproduc
enterobacteriacea
remain
colon
prolong
period
possibl
repres
import
sourc
spread
knowledg
bodi
site
commonli
colon
pathogen
therefor
great
import
order
develop
appropri
screen
scheme
aim
studi
therefor
determin
frequenc
colon
bodi
site
conclus
urin
rectum
site
commonli
colon
esblproduc
enterobacteriacea
follow
inguin
fold
three
site
therefor
consid
screen
esbl
carriag
perform
throat
swab
wound
sampl
posit
less
specimen
suggest
site
use
screen
howev
consid
individu
patient
decolon
regimen
perform
e
zamora
cuenca
bustinza
carrillo
e
b
padilla
p
e
bouza
madrid
es
assess
knowledg
cdc
guidelin
prevent
central
venou
cathet
cvc
relat
infect
recommend
healthcar
worker
hcw
inform
knowledg
pediatr
neonat
intens
care
unit
picu
nicu
scarc
compar
data
knowledg
physician
nurs
medicalnurs
student
object
compar
differ
profession
group
order
assess
hcw
knowledg
guidelin
prevent
cvcrelat
infect
picu
nicu
larg
teach
institut
distribut
multiplechoic
questionnair
hcw
unit
novemb
may
also
record
particip
demograph
data
correct
answer
score
incorrect
answer
creat
individu
group
score
adequ
respons
rang
result
collect
questionnair
picu
nicu
respect
return
medic
staff
medic
resid
nurs
staff
replac
nurs
nurs
student
nurs
assist
overal
mean
score
profession
categori
statist
signific
differ
mean
score
nurs
assist
medicalnurs
staff
moreov
year
experi
associ
better
score
vs
particip
receiv
train
session
last
year
better
score
vs
conclus
result
show
room
improv
hcw
knowledg
prevent
cvc
infect
simpl
easytoobtain
score
help
evalu
impact
educ
intervent
bundl
clinic
epidemiolog
nosocomi
infect
powi
vap
uti
bsi
background
aim
studi
investig
risk
factor
associ
high
antibiot
resist
rate
belong
gram
posit
neg
organ
isol
use
epidemiolog
analysi
method
casecontrol
studi
patient
extend
spectrum
b
lactamas
produc
organ
patient
amp
c
produc
organ
patient
nonesbl
organ
patient
gram
posit
organ
conduct
subsidi
care
hospit
provinc
demograph
comorbid
antibiot
usag
analys
patient
result
esbl
ampc
produc
microorgan
isol
patient
belong
age
age
group
risk
factor
includ
hospitalis
comorbid
found
higher
esbl
group
compar
esbl
group
hospitalis
last
three
month
found
risk
factor
resist
gener
cephalosporin
correl
esbl
product
resist
mani
antibiot
gener
use
ampir
treatment
p
pearson
correl
r
except
piperacillintazobactam
p
esbl
product
significantli
higher
k
pneumonia
p
e
cloaca
e
sakazakii
baumannii
strain
gram
neg
strain
reveal
tabl
hospitalis
singl
signific
risk
factor
patient
mrsa
vancomycin
resist
enterococcu
isol
discuss
hospitalis
comorbid
caus
colonis
impair
immun
import
risk
factor
esbl
produc
microorgan
relat
infect
studi
reveal
although
antibiot
usag
includ
gener
cephalosporin
quinolon
cite
risk
factor
esbl
relat
infect
found
signific
statist
studi
piperacillintazobactam
could
thought
option
treat
resist
gram
neg
infect
associ
k
pneumonia
e
cloaca
e
sakazakii
baumannii
whose
esbl
rate
frequent
higher
local
set
carbapenem
opt
seriou
patient
comorbidit
consequ
immun
infect
control
program
import
factor
increas
antibiot
resist
rate
object
infect
patient
traumat
brain
injuri
tbi
associ
prolong
hospitalis
advers
outcom
acknowledg
predispos
risk
factor
may
help
decreas
morbid
mortal
conduct
retrospect
cohort
studi
determin
incid
bacteriolog
risk
factor
develop
infect
tbi
record
patient
year
old
admit
head
injuri
crete
univ
med
ctr
abstract
data
analys
spss
result
patient
men
median
age
analyz
two
hundr
fifti
eight
patient
admiss
underw
surgic
procedur
burrhol
common
procedur
median
durat
surgeri
hour
patient
kind
drain
insert
two
hundr
fourteen
infect
observ
major
infect
lower
respiratori
tract
mainli
ventil
associ
pneumonia
vap
follow
surgic
site
infect
ssi
fifti
three
admiss
complic
least
one
ssi
superfici
deep
common
ssi
wound
infect
cohort
patient
underw
neurosurgeri
lower
glasgow
coma
scale
gc
admiss
prone
admit
intens
care
unit
bear
drain
also
prone
develop
mening
ssi
increas
mortal
multivari
analysi
show
ssi
develop
independ
associ
perform
procedur
p
presenc
concomit
infect
name
vap
p
urinari
tract
infect
p
insert
lumbar
p
ventricular
drain
p
cerebrospin
fluid
csf
leak
p
mening
independ
associ
prolong
hospitalis
p
insert
lumbar
p
ventricular
drain
p
predomin
acinetobact
spp
vap
pathogen
wherea
gram
organ
especi
coagulaseneg
staphylococci
remain
preval
ssi
conclus
respiratori
tract
infect
common
among
patient
head
injuri
devicerel
commun
csf
environ
prolong
hospitalis
independ
risk
factor
ssi
mening
preval
pathogen
must
determin
upon
institut
basi
establish
proper
treatment
life
threaten
infect
object
rate
hospitalacquir
infect
vari
episod
per
hospit
admiss
continu
major
problem
caus
high
morbid
mortal
significantli
increas
length
hospit
cost
treatment
purpos
studi
evalu
hospitalacquir
infect
duzc
univers
hospit
turkey
studi
carri
duzc
univers
hospit
preval
hospitalacquir
infect
hospit
prospect
evalu
total
inpati
search
one
year
follow
period
infect
episod
detect
hospit
patient
n
preval
rate
patient
hospitalacquir
infect
incid
densiti
patient
day
common
hospitalacquir
infect
primari
site
pneumonia
follow
urinari
tract
infect
surgic
site
infect
bacteremia
infect
hospitalacquir
infect
seen
frequent
depart
neurolog
intern
medicin
neurosurgeri
gener
surgeri
urolog
orthoped
infecti
diseas
pediatr
hospitalacquir
infect
rate
intens
care
unit
preval
microorgan
pseudomona
spp
escherichia
coli
staphylococcu
aureu
acinetobact
spp
coagulaseneg
staphylococci
enterobact
spp
object
greec
particip
artemi
global
surveil
programm
sinc
octob
order
studi
epidemiolog
candida
strain
hospit
monitor
suscept
fluconazol
voriconazol
use
low
cost
reproduc
accur
standard
vitro
test
method
strain
isol
patient
sever
candida
infect
bodi
site
hospit
locat
collect
identifi
analyz
suscept
investig
disk
diffus
test
accord
clsi
method
test
result
read
interpret
record
biomic
plate
reader
system
result
total
candida
strain
record
promin
speci
c
albican
yearfrequ
rang
follow
c
glabrata
rang
c
parapsilosi
rang
except
year
frequenc
observ
speci
togeth
frequenc
sensit
c
albican
fluconazol
equal
voriconazol
versu
strain
respect
c
glabrata
respect
percentag
c
parapsilosi
resist
strain
speci
isol
miscellan
bodi
fluid
upper
respiratori
tract
blood
deriv
icu
surgic
ward
year
c
albican
strain
resist
fluconazol
voriconazol
previou
year
resist
respect
compar
increas
resist
strain
note
also
c
glabrata
versu
previou
year
fluconazol
versu
voriconazol
c
parapsilosi
versu
versu
respect
remain
speci
show
increas
rate
conclus
candida
speci
isol
hospit
promin
c
albican
follow
c
glabrata
c
parapsilosi
frequenc
isol
strain
vari
year
year
without
clear
trend
howev
increas
strain
resist
fluconazol
voriconazol
observ
last
four
year
result
confirm
need
monitor
local
epidemiolog
antifung
suscept
candida
strain
order
optim
empir
target
therapi
especi
critic
ill
patient
introduct
aim
hydatid
cyst
infect
echinococci
still
repres
seriou
problem
endem
region
especi
middl
east
mediterranean
countri
australia
ruptur
hydatid
cyst
commonli
give
rise
allerg
phenomena
includ
anaphylact
shock
ruptur
cyst
occur
spontan
surgeri
well
due
trauma
describ
patient
trauma
present
emerg
depart
scant
physic
sign
case
report
girl
admit
emerg
depart
fall
motorcycl
minut
previous
complain
pain
head
two
minor
trauma
face
present
glasgow
coma
scale
blood
pressur
mmhg
puls
rate
beat
per
minut
temperatur
physic
examin
normal
except
mild
abdomin
tender
evid
injuri
secondari
survey
otherwis
normal
white
blood
cell
count
eosinophilia
absent
laboratori
test
within
normal
limit
underw
head
neck
comput
tomographi
without
sciagraph
fluid
examin
gener
urticaria
develop
progress
examin
stop
fluid
resuscit
methyloprednisolon
diphenylhydramin
administ
intraven
condit
stabil
underw
abdomen
comput
tomographi
determin
caus
abdomen
pain
free
fluid
usual
exclud
intraperiton
bleed
one
ruptur
cyst
right
lobe
liver
anoth
cyst
measur
mm
thin
wall
left
lobe
liver
patient
turn
ruptur
hydatid
cyst
immedi
taken
oper
room
gener
surgeon
drainag
capitonag
cyst
perform
patient
treat
albendazol
three
month
six
month
followup
remain
well
without
complic
conclus
ruptur
hydatid
cyst
rare
occur
spontan
follow
seriou
injuri
even
minor
trauma
anaphylaxi
frequent
caus
death
case
hydatid
cyst
ruptur
echinococcu
liver
cyst
suspect
case
anaphylaxi
uncertain
etiolog
acut
vascular
collaps
gener
cutan
erythema
urticaria
edema
suggest
anaphylaxi
hydatidosi
especi
endem
area
rodriguez
guardado
g
martin
l
casado
f
perez
rodriguez
v
carcaba
j
carton
oviedo
es
introduct
travel
visit
friend
rel
vfr
typic
demonstr
travel
behaviour
pattern
render
high
risk
acquisit
prevent
infect
pretravel
servic
rare
sought
vfr
wherea
misconcept
possess
lifelong
immun
malaria
make
less
like
receiv
adher
antimalari
chemoprophylaxi
recommend
object
analyz
adher
group
measur
prophylaxi
health
problem
result
travel
method
vfr
travel
attend
tropic
medicin
referr
unit
interview
questionnair
investig
use
malaria
prophylaxi
vaccin
knowledg
dietari
hygien
measur
travel
vfr
defin
immigr
perman
establish
spain
temporarili
travel
place
origin
analyz
immigr
mean
time
travel
day
travel
seneg
equatori
guinea
ecuador
bolivia
venezuela
brazil
cameroon
colombia
ethiopia
patient
receiv
health
advic
travel
travel
nt
receiv
vaccin
carri
antimalaria
chemoprophylaxi
use
safe
water
one
use
repel
twentyeight
patient
ill
return
home
twentysix
patient
diarrhea
trip
fever
frequent
reason
consult
case
diarrhea
due
parasit
infect
eight
patient
malaria
case
due
p
falciparum
two
p
vivax
conclus
vfr
group
high
risk
import
diseas
due
poor
adher
vaccin
prophylaxi
measur
present
immigr
visit
friend
rel
vfr
constitut
signific
group
travel
malaria
import
develop
countri
subsaharan
africa
destin
carri
highest
risk
urgent
need
increas
health
travel
advic
group
travel
statist
data
analysi
use
descript
analyt
method
mannwhitney
u
test
wilcoxon
signedrank
test
spearman
rank
correl
coeffici
valu
p
consid
statist
signific
result
within
year
patient
treat
trihinellosi
around
men
averag
age
mostli
urban
region
sourc
infect
known
case
caus
found
domest
anim
durat
diseas
make
diagnosi
averag
day
durat
hospitalis
last
day
lethal
outcom
diseas
end
well
patient
patient
diseas
complicationstwo
hepat
one
neurotrichinellosi
neurolog
consequ
two
patient
myocard
one
develop
deep
venou
thrombosi
compar
group
patient
without
complic
statist
signific
differ
shown
time
intak
food
appear
symptom
p
durat
diseas
diagnost
treatment
effect
frequenc
complic
p
statist
signific
correl
durat
sick
diagnosi
made
durat
hospitalis
p
conclus
although
trihinellosi
rare
diseas
still
repres
signific
medic
problem
need
remind
time
diagnosi
begin
treatment
affect
shorten
hospitalis
time
recoveri
influenc
frequenc
complic
spain
could
potenti
area
europ
develop
spread
emerg
diseas
tropic
due
characterist
import
migratori
flow
analyz
clinicalepidemiolog
characterist
infecti
diseas
import
immigr
develop
countri
north
spain
method
retrospect
descript
studi
immigr
develop
countri
live
spain
conduct
demograph
data
detail
countri
origin
time
spain
clinic
syndrom
diagnos
analyz
result
countri
origin
ecuatori
guinea
seneg
ecuador
bolivia
nigeria
guineaconakri
marrueco
brazil
mean
time
spain
day
common
syndrom
abdomin
pain
diarrhea
cutan
syndrom
fever
frequent
diagnos
intestin
parasit
filariasi
chaga
diseas
malaria
schistosomiasi
frequent
intestin
parasit
entamoeba
histolytica
strongyloid
spp
trichuri
trichiura
uncinaria
spp
patient
one
parasit
two
parasit
three
parasit
parasit
patient
subsaharian
africa
patient
diagnos
filariasi
ecuatori
guinea
frequent
perstan
filariasi
loa
loa
onchocerca
volvulu
conclus
increas
migratori
flow
key
factor
develop
spread
emerg
pathogen
inform
diseas
essenti
earli
diagnost
treatment
intestin
parasit
frequent
diseas
follow
filariasi
malaria
chaga
diseas
object
world
health
organ
determin
leishmaniasi
consid
one
import
zoonot
diseas
turkey
transmiss
l
infantum
dog
vector
human
percentag
posit
dog
studi
accord
previou
studi
perform
turkey
sinc
high
proport
infect
dog
asymtomat
diagnosi
leishmania
infect
seriou
problem
parasitolog
method
present
complex
interfer
nnn
cultur
low
sensit
see
parasit
fix
glass
slide
giemsa
stain
difficult
therefor
real
time
pcr
effect
especi
differenti
diagnosi
subclin
asymptomat
dog
cho
j
chung
j
ahn
k
chang
j
chai
kang
kim
h
jeoung
cheon
jeoung
e
choi
seoul
kr
morbid
travel
diarrhea
td
still
high
studi
examin
incid
common
pathogen
characterist
td
among
korean
travel
visit
southeast
asian
countri
perform
prospect
studi
involv
korean
travel
diarrheal
diseas
februari
april
stool
sampl
examin
questionnair
done
arriv
enterotoxigen
escherichia
coli
etec
found
td
case
follow
enteroaggreg
escherichia
coli
eaec
vibrio
parahaemolyticu
noroviru
detect
rate
classic
td
higher
men
patient
shorter
durat
trip
patient
drank
liter
water
per
day
p
p
p
respect
posit
stool
cultur
rate
higher
men
hospit
patient
consum
impur
water
raw
food
p
p
p
respect
higher
sever
diseas
correspond
significantli
higher
cultur
posit
rate
p
consid
possibl
pathogen
addit
etec
patient
td
visit
southeast
asia
travel
need
educ
risk
factor
associ
td
marincu
l
negrutiu
iacobiciu
mare
neghina
l
marincu
r
neghina
timisoara
iasi
ro
object
diarrhea
import
caus
morbid
mortal
worldwid
although
etiolog
remain
unknown
mani
case
present
studi
aim
establish
etiolog
spectrum
pathogen
caus
diarrhea
group
refuge
arriv
center
immigr
timisoara
romania
method
retrospect
analyz
medic
record
immigr
hospit
diarrhea
clinic
infecti
diseas
timisoara
diagnosi
establish
base
epidemiolog
aspect
acut
onset
follow
collect
individu
consumpt
food
inadequ
physic
organolept
properti
store
poor
condit
even
expir
physic
examin
fever
repeat
shiver
nausea
vomit
headach
multipl
wateri
diarrhea
fetid
stool
tenesmu
abdomin
colic
pyrosi
dizzi
paresthesia
lower
limb
laboratori
test
erythrocyt
sediment
rate
blood
count
fibrinogen
c
reactiv
protein
glycemia
blood
cultur
lingual
swab
throat
swab
stool
cultur
stool
parasitolog
examin
natremia
kalemia
calcaemia
medic
explor
abdomin
ultrasound
electrocardiographi
data
epidemiolog
survey
collect
institut
public
health
timisoara
data
statist
process
use
epi
info
softwar
analges
antipyret
antispasmod
antacid
twelv
case
receiv
antibiot
therapi
prior
hospit
admiss
thu
complic
detect
etiolog
agent
patient
favor
outcom
conclus
knowledg
etiolog
diarrhea
among
immigr
patient
allow
proper
implement
target
therapi
prophylaxi
measur
order
limit
diarrheal
morbid
person
risk
marincu
l
negrutiu
iacobiciu
mare
neghina
l
marincu
r
neghina
timisoara
iasi
ro
object
scabi
highli
contagi
parasit
dermatosi
worldwid
distribut
may
caus
signific
morbid
larg
nosocomi
outbreak
present
studi
aim
analyz
clinic
epidemiolog
characterist
scabi
hospit
patient
infecti
diseas
method
data
retrospect
collect
medic
chart
patient
found
scabi
lesion
clinic
infecti
diseas
timisoara
posit
diagnosi
establish
base
epidemiolog
aspect
recent
travel
famili
collect
outbreak
sex
multipl
partner
physic
examin
lesion
papul
pustul
burrow
nodul
occasion
urticari
papul
plaqu
patognomon
distribut
interdigit
web
space
hand
perimalleolar
periumbil
region
rib
horizont
gluteal
creas
radiocarp
joint
intens
gener
skin
itch
night
diagnosi
confirm
either
microscop
identif
mite
skin
scrape
dermoscopi
patient
follow
treatment
precipit
sulfur
appli
topic
entir
trunk
extrem
everi
hour
day
disinfect
carri
linen
person
item
result
studi
group
patient
rural
inhabit
p
live
urban
area
six
famili
outbreak
occur
rural
region
scabi
mainli
associ
respiratori
diseas
liver
diaseas
intestin
diseas
psychiatr
disord
urinari
infect
scabi
lesion
follow
pattern
edemat
urticariform
papul
case
papulovesicular
lesion
case
escori
due
scratch
case
scratch
relat
superinfect
lesion
streptococc
staphylococc
bacteria
case
common
form
scabi
evidenc
patient
wherea
case
atyp
cours
diseas
p
patient
favour
outcom
follow
therapi
precipit
sulfur
associ
symptomat
medic
calcium
antihistaminc
antibiot
bacteri
superinfect
individu
hygien
disinfect
studi
clinic
epidemiolog
characterist
scabi
hospit
patient
infecti
diseas
allow
earli
diagnosi
parasitosi
well
time
implement
effect
prophylact
measur
background
cryptosporidium
sp
taxonomi
gone
number
chang
last
three
decad
initi
singl
speci
c
parvum
number
clonal
genotyp
loos
correspond
specif
vertebr
host
propos
current
nomenclatur
suggest
cryptosporidi
organ
oocyst
size
um
number
cryptic
speci
identifi
base
molecular
genotyp
believ
facilit
better
understand
transmiss
epidemiolog
factor
object
studi
design
assess
valu
clinician
epidemiologist
new
cryptic
speci
whether
inform
would
improv
practic
method
isol
posit
cryptosporidium
oocyst
auramin
stain
type
pcr
result
molcular
speciat
analys
clinic
data
age
travel
histori
contact
anim
sporad
part
outbreak
result
studi
isol
type
c
parum
c
homini
c
meleagridi
c
feli
trend
two
isol
egypt
greec
identifi
c
homini
isol
pakistan
st
lucia
identifi
c
parvum
may
repres
epidemiolog
differ
variou
travel
desin
one
patient
c
parvum
shigella
sonnei
isol
would
strongli
suggest
contamin
water
sourc
infect
second
patient
c
feli
campylobact
sp
isol
patient
recent
acquir
kitten
possibl
pathogen
contribut
diarrhoea
campylobact
caus
diarrhoea
presenc
c
feli
oocyst
primari
pathogen
felin
host
may
repres
oocyst
pass
patient
gut
rather
tissu
invas
conclus
identif
cryptosporidi
isol
either
genotyp
one
cryptic
speci
allow
better
understand
potenti
sourc
studi
need
confirm
trend
seen
studi
object
purpos
studi
compar
neosensitab
method
clsi
refer
broth
microdilut
document
method
test
suscept
candida
spp
isol
five
antifung
agent
amphotericin
b
fluconazol
itraconazol
ketoconazol
voriconazol
method
studi
broth
microdilut
method
perform
accord
clsi
recommend
neosensitab
method
perform
accord
manufactur
instruct
neosensitab
rosco
diagnostica
taastrup
denmark
c
parapsilosi
atcc
use
qualiti
control
strain
result
total
isol
candida
spp
c
albican
n
c
tropicali
n
c
parapsilosi
n
c
glabrata
n
c
dubliniensi
n
c
krusei
n
c
famata
n
c
lusitania
n
c
pelliculosa
n
evalu
method
mic
rang
found
mgml
mgml
mgml
mgml
mgml
amphotericin
b
fluconazol
itraconazol
ketoconazol
voriconazol
microdilut
method
respect
isol
suscept
voriconazol
method
nineti
one
isol
determin
suscept
two
c
albican
found
suscept
dose
depend
sdd
five
c
krusei
n
c
glabrata
n
c
albican
n
found
resist
fluconazol
method
nineti
two
isol
determin
suscept
six
c
krusei
n
c
albican
n
found
sdd
itraconazol
method
agreement
two
method
three
antifung
agent
studi
two
c
albican
c
glabrata
eight
c
albican
n
c
krusei
n
c
glabrata
c
tropicali
isol
determin
resist
amphotericin
b
ketoconazol
method
respect
one
c
albican
three
c
albican
n
c
glabrata
isol
intermedi
amphotericin
b
ketoconazol
neosensitab
method
strain
suscept
antifung
standard
method
situat
minor
error
calcul
amphotericin
b
ketoconazol
neosensitab
method
neosensitab
method
may
altern
easi
method
clinic
laboratori
determin
suscept
yeast
isol
c
tascini
leonildi
ciullo
e
tagliaferri
f
menichetti
pisa
object
studi
activ
antifung
agent
candida
spp
strain
isol
invas
candidiasi
assess
fungicid
activ
amphotericin
b
caspofungin
anidulafungin
fungicid
activ
azol
studi
consid
fungistat
method
strain
candida
spp
isol
invas
candidiasi
pisa
hospit
period
studi
mic
strain
perform
sensititr
method
manufactur
instruct
well
without
growth
yeast
subcultur
order
measur
fungicid
activ
amphotericin
b
caspofungin
anidulafungin
minim
fungicid
concentr
mfc
drug
defin
reduct
inoculum
result
thirtythre
candida
spp
isol
includ
studi
thirti
strain
isol
blood
liver
abscess
vertebr
osteomyel
periton
among
strain
c
albican
strain
candida
nonalbican
strain
c
parapsilosi
c
glabrata
c
tropicali
c
krusei
mic
mic
strain
shown
tabl
antifung
agent
except
amphotericin
b
increas
mic
candida
nonalbican
strain
increas
sever
dilut
respect
c
albican
strain
shown
tabl
amphotericin
b
mgl
mgl
instead
valu
echinocandin
superior
especi
candida
nonalbican
conclus
candida
nonalbican
strain
elev
mic
antifung
agent
amphotericin
b
fungicid
activ
superior
echinocandin
especi
among
candida
nonalbican
strain
activ
might
use
clinic
ground
studi
h
bernhardt
knoke
g
schwesing
j
bufler
j
bernhardt
greifswald
berlin
rostock
de
object
investig
antifung
effect
anidulafungin
voriconazol
vrc
biofilm
mic
valu
differ
candida
speci
small
tube
system
continu
flow
cultur
method
carri
experi
strain
strain
c
albican
ca
c
glabrata
cgl
c
tropicali
ct
c
krusei
ck
c
parapsilosi
cp
c
orthopsilosi
co
c
metapsilosi
cm
c
lusitania
cl
c
guilliermondii
cgui
blood
cultur
isol
grown
small
tube
v
ml
peptoneyeast
extract
mm
mgl
vrc
mgl
suppli
low
flow
rate
mlh
flow
tube
within
h
biomass
product
glucos
concentr
metabol
activ
ph
plankton
cfu
measur
mic
test
perform
etest
rpmi
morpholog
adher
fungal
cell
assess
microscop
stain
lactophenol
cotton
blue
result
tube
system
develop
biofilm
vari
speci
strain
took
place
day
continu
input
product
stop
case
sensibl
speci
like
ca
ct
metabol
activ
measur
glucos
concentr
seldom
reach
begin
concentr
could
partli
shown
continu
input
vrc
differ
strain
cp
show
differ
result
increas
resist
long
term
trial
day
biofilm
strain
low
suscept
like
cp
strain
candidaemia
strain
cl
cgui
stop
growth
input
vrc
also
metabol
activ
conclus
small
tube
system
model
get
inform
biofilm
differ
candida
strain
condit
long
term
cultiv
suppli
low
nutrit
similar
real
condit
batch
cultur
protocol
result
studi
period
total
episod
candidemia
occur
patient
account
global
incid
inpati
median
age
patient
year
male
common
speci
isol
c
albican
episod
follow
c
parapsilosi
episod
c
glabrata
c
tropicali
episod
c
guilliermondii
episod
c
krusei
episod
c
dubliniensi
c
norvegensi
episod
studi
period
incid
candidemia
increas
inpati
p
c
glabrata
c
krusei
fungemia
occur
frequent
patient
admit
intens
care
unit
p
isol
result
suscept
voriconazol
posaonazol
amphotericin
b
three
echinocandin
suscept
rate
fluconazol
itraconazol
respect
antifung
agent
test
follow
fluconazol
mgdl
itraconazol
mgdl
mgdl
voriconazol
mgdl
posaconazol
amphotericin
b
mgdl
caspofungin
mgdl
anidulafungin
mgdl
micafungin
mgdl
conclus
candidemia
still
frequent
complic
among
hospit
patient
observ
progress
increas
studi
period
trend
could
due
increas
immunocompromis
patient
admit
institut
particular
hematolog
patient
solid
organ
transplant
recipi
surgic
patient
admit
intens
care
unit
nevertheless
c
albican
remain
preval
speci
resist
rate
antifung
agent
low
k
serefhanoglu
f
timurkaynak
f
kurt
azap
h
arslan
istanbul
ankara
tr
object
object
prospect
observ
multicent
studi
describ
factor
associ
bloodstream
infect
bsi
candida
nonalbican
nac
speci
compar
candida
albican
bsi
antifung
suscept
pattern
intens
care
unit
icu
patient
studi
conduct
adult
medicalsurg
icu
two
univers
hospit
adult
patient
icuacquir
bsi
due
candida
exclud
patient
neutropenia
malign
aid
includ
potenti
factor
occur
day
candidemia
includ
demograph
characterist
comorbid
exposur
antibiot
antifung
icurel
factor
ie
tpn
invas
procedur
outcom
determin
antifung
suscept
test
perform
use
broth
microdilut
assay
method
describ
clinic
laboratori
standard
institut
result
clinic
characterist
patient
present
tabl
seventysix
case
candidemia
due
c
albican
nac
spp
distribut
first
three
nac
spp
c
tropicali
c
glabrata
c
parapsilosi
multivari
logist
regress
analysi
factor
show
presenc
glucocorticosteroid
treatment
central
venou
cathet
variabl
independ
associ
bsi
due
nac
compar
bsi
due
c
albican
ci
ci
respect
total
patient
die
within
day
diagnosi
candidemia
mortal
rate
higher
nac
c
albican
bsi
vs
candidemia
due
nac
spp
independ
associ
death
p
except
one
c
lusitania
strain
resist
amphotericin
b
four
c
glabrata
strain
fluconazol
suscept
dose
depend
candida
speci
suscept
fluconazol
caspofungin
voriconazol
amphotericin
b
conclus
presenc
central
venou
cathet
glucocorticosteroid
treatment
significantli
associ
bsi
due
nac
bsi
due
nac
significantli
associ
death
compar
bsi
due
c
albican
invitro
activ
fluconazol
encourag
agent
efficaci
inexpens
safe
drug
continu
play
import
role
manag
invas
candidiasi
kofteridi
dimopoul
valachi
maraki
thanasia
v
theodorakopoul
aristeid
n
spernovasili
g
samoni
heraklion
crete
gr
object
candiduria
encount
cancer
patient
pt
signific
defin
howev
may
indic
urinari
tract
infect
uti
invas
infect
studi
aim
determin
signific
candiduria
neoplast
pt
patient
method
adult
pt
neoplasia
posit
urin
cultur
candida
admit
oncolog
haematolog
depart
univers
hospit
heraklion
greec
retrospect
review
result
seventi
one
pt
candiduria
identifi
male
median
age
rang
underli
diseas
solid
tumor
hematolog
malign
frequent
risk
factor
use
urinari
cathet
nephrostomi
follow
antimicrobi
treatment
corticosteroid
anatom
malform
urinari
tract
neutropenia
diabet
mellitu
fever
present
admiss
nineteen
pt
dysuria
flank
pain
vomit
promin
clinic
featur
pt
respect
uti
establish
criteria
present
among
posit
urin
cultur
c
albican
isol
nonalbican
c
tropicali
c
parapsilosi
c
glabrata
c
famata
c
guilliermondii
c
lusitania
blood
cultur
obtain
posit
howev
pt
candida
blood
death
occur
pt
candiduria
factor
associ
death
includ
diseas
progress
sepsi
syndrom
candida
spp
present
blood
pt
die
pt
die
advanc
neoplasia
conclus
factor
predispos
candiduria
includ
urinari
cathet
nephrostomi
prior
use
antimicrobi
agent
corticosteroid
anatom
malform
urinari
tract
diabet
mellitu
candiduria
rare
associ
candidemia
howev
associ
high
mortal
probabl
occur
pt
advanc
neoplasia
object
dermatophytos
consid
one
major
public
health
problem
mani
part
world
distribut
vari
differ
countri
geograph
area
depend
sever
factor
studi
conduct
investig
aetiolog
agent
clinic
variant
dermatophytos
western
greec
period
method
total
sampl
skin
scale
nail
hair
fragment
obtain
patient
suspect
dermatomycos
refer
laboratori
clinic
microbiolog
univers
hospit
ioannina
greec
caus
agent
identifi
direct
microscopi
cultur
result
dermatophyt
isol
patient
mainli
adult
common
type
infect
onychomycosi
follow
tinea
pedi
tinea
corpori
tinea
cruri
tinea
capiti
tinea
manum
tinea
facei
forti
seven
patient
dermatophyt
isol
two
differ
site
infect
frequenc
type
tinea
higher
male
femal
male
exceed
femal
case
tinea
corpori
tinea
facei
trichophyton
rubrum
preval
dermatophyt
speci
isol
posit
sampl
follow
mentagrophyt
microsporum
cani
epidermophyton
floccosum
violaceum
trichophyton
spp
gypseum
speci
tonsuran
verrucosum
schoenleinii
occasion
isol
conclus
region
trichophyton
rubrum
common
aetiolog
agent
type
dermatophytos
except
tinea
capiti
tinea
facei
epidemiolog
data
collect
would
serv
refer
futur
research
mani
factor
contribut
chang
preval
dermatophytos
alter
pass
time
background
voriconazol
vrz
remain
first
line
therapi
invas
aspergillosi
aspergillu
speci
resist
azol
prognosi
aspergillosi
remain
poor
antifung
combin
could
interest
test
vitro
combin
anidulafungin
ani
vrz
azol
suscept
resist
aspergillu
spp
two
differ
method
method
thirti
clinic
isol
aspergillu
spp
five
variou
aspergillu
speci
identifi
btubulin
sequenc
test
anivrz
combin
evalu
use
checkerboard
ck
base
clsi
broth
microdilut
method
use
agar
diffus
techniqu
etest
ck
final
inoculum
ml
mic
mec
record
visual
fraction
inhibitori
concentr
index
fici
interpret
synerg
fici
interact
fici
antagonist
fici
test
run
duplic
etest
mic
vrz
ani
determin
alon
well
combin
combin
ani
strip
place
agar
remov
vrz
strip
appli
demarc
left
previou
strip
synergi
antagon
defin
respect
decreas
increas
dilut
result
mic
result
use
ck
method
interact
vrz
ani
mec
endpoint
tabl
except
nidulan
isol
antagon
shown
use
etest
interact
observ
isol
accord
endpoint
use
antagon
synerg
observ
calidoustu
isol
respect
conclus
overal
vitro
interact
shown
vrz
ani
azol
suscept
resist
aspergillu
isol
use
differ
techniqu
confirm
result
vivo
warrant
cavl
arendrup
sulim
holm
l
nielsen
sd
nielsen
jd
knudsen
ne
drenck
jj
christensen
hk
johansen
copenhagen
odens
herlev
hvidovr
dk
object
studi
investig
diagnost
issu
underli
host
factor
manag
outcom
factor
danish
fungaemia
patient
method
isol
clinic
inform
collect
six
centr
isol
episod
patient
includ
correspond
nation
episod
result
speci
distribut
vari
age
prior
antifung
treatment
isol
intrins
reduc
fluconazol
suscept
p
clinic
specialti
c
glabrata
c
krusei
haematolog
ward
versu
p
colonis
sampl
predict
invas
speci
case
speci
identif
blood
cultur
posit
vari
system
speci
procedur
thu
cultur
drawn
via
arteri
line
c
glabrata
need
longer
incub
case
concomit
bacteraemia
less
common
use
bactalert
compar
bactec
system
versu
p
patient
undergon
surgeri
icu
patient
malign
diseas
mortal
vari
age
increas
age
p
speci
numer
highest
c
krusei
lowest
c
parapsilosi
candida
speci
sever
underli
diseas
icu
patient
versu
p
choic
time
initi
therapi
versu
patient
c
glabrata
receiv
caspofungin
versu
fluconazol
p
initi
antifung
choic
deem
suboptim
upon
speci
identif
case
would
current
guidelin
follow
conclus
high
proport
danish
fungaemia
patient
sever
ill
receiv
suboptim
initi
antifung
treatment
optimis
diagnosi
therapi
possibl
aim
describ
role
prepar
voriconazol
eye
drop
manag
fungal
kerat
method
retrospect
observ
case
seri
involv
patient
cultur
proven
fungal
kerat
april
march
attend
cornea
clinic
tertiari
care
eye
hospit
eastern
india
among
fungal
kerat
case
case
identifi
analysi
ulcer
size
organ
treatment
modal
mic
valu
analyz
voriconazol
use
either
topic
ac
wash
ml
intrastom
ml
result
among
case
show
heal
corneal
scar
format
underw
therapeut
keratoplasti
case
requir
topic
use
case
requir
intracamer
use
case
requir
intrastom
administr
among
filament
fungi
aspergillu
sp
respond
well
follow
fusarium
sp
unidentifi
sp
equal
penicillium
sp
scedosporium
sp
cladosporium
sp
among
case
undergo
therapeut
keratoplasti
candida
kerat
maximum
case
follow
case
fusarium
sp
case
aspergillu
sp
case
alternaria
sp
penicillium
sp
relat
ulcer
size
respons
voriconazol
therapi
obtain
ulcer
size
mm
remain
case
ulcer
size
mm
minim
inhibitori
concentr
voriconazol
mgml
aspergillu
sp
mgml
fusarium
sp
candida
sp
show
resist
activ
upto
voriconazol
conclus
voriconazol
promis
activ
filament
fungi
may
prove
use
manag
fungal
kerat
show
respons
candida
kerat
centr
narkwiboonwong
k
trakulhun
k
watanakijthavonkul
p
paocharern
singsakul
wongsa
n
woracharoensri
n
worasilchai
chindamporn
panoi
methipisit
p
sithinamsuwan
bangkok
th
report
thalassem
patient
suffer
cerebr
pythiosi
left
common
carotid
pythiosi
arteri
aneurysm
septic
embol
evolv
brain
abscess
left
anterior
cerebr
arteri
territori
first
case
world
pythium
insidiosum
involv
left
common
carotid
arteri
produc
septic
emboli
caus
pythiosi
brain
abscess
man
develop
nasal
congest
whitish
discharg
left
nostril
three
week
admiss
develop
high
grade
fever
one
week
later
complain
occipit
headach
follow
focal
seizur
start
right
hand
develop
secondarili
gener
toniccon
seizur
comput
tomographi
scan
brain
perform
cm
hypodens
lesion
note
left
frontopariet
region
intraven
ceftriaxon
gmday
metronidazol
mgday
prescrib
one
week
later
fever
still
persist
rightsid
weak
worsen
person
past
medic
histori
patient
diagnos
bthalassemia
haemoglobin
e
diseas
pertin
physic
find
high
grade
fever
signific
left
carotid
bruit
right
facial
palsi
spastic
right
hemiparesi
mri
brain
show
larg
rimenhanc
brain
lesion
left
hemispher
mra
show
multipl
aneurysm
left
common
intern
carotid
arteri
serum
test
antibodi
pythiosi
use
differ
techniqu
elisa
immunodiffus
western
blot
result
test
posit
also
prescrib
itraconazol
terbinafin
p
insidiosum
antigen
immunotherapi
patient
eventu
die
brain
herniat
autopsi
reveal
gross
pu
left
frontal
area
left
common
intern
carotid
arteri
also
found
cm
diamet
aneurysm
pu
wright
stain
show
hypha
infrequ
septat
branch
tissu
cultur
brain
confirm
diagnosi
pythiosi
isol
organ
proof
polymeras
chain
reaction
pcr
specif
primer
cox
ii
region
discuss
could
nt
erad
infect
brain
tissu
well
infect
carotid
arteri
area
brain
carotid
arteri
involv
harm
resect
cerebr
pythiosi
differenti
diagnos
brain
abscess
thalassem
patient
earli
recognit
prompt
surgic
treatment
consid
reduc
mortal
morbid
bronchoscop
patient
abpa
prior
ia
copd
aspergillu
bronchiti
compar
uk
standard
method
process
respiratori
cultur
modifi
plate
instead
high
volum
cultur
rang
ml
avg
plate
sabouraud
dextros
agar
real
time
pcr
mycassay
aspergillu
preced
dna
extract
use
mycxtra
kit
sensit
assay
genom
follow
extract
effici
sputum
sampl
obtain
bronchoscopi
procedur
materi
obtain
split
highli
mucoid
materi
liquid
materi
possibl
approxim
equal
volum
materi
use
pcr
cultur
method
result
sampl
cultur
aspergillu
neg
routin
cultur
neg
high
volum
cultur
neg
pcr
clinic
cutoff
ct
posit
ct
valu
sputum
sampl
split
posit
pcr
posit
high
volum
cultur
cfu
bal
sampl
aspergillu
cultur
neg
sampl
pcr
posit
patient
highest
pcr
yield
initi
bronchoscopi
trap
aspir
often
discard
contain
lignocain
one
patient
hypha
charcotleyden
crystal
visibl
sampl
patient
abpa
cfu
grown
high
volum
cultur
uk
standard
method
cultur
grossli
suboptim
aspergillu
spp
need
revis
improv
cultur
method
may
valu
sputum
inferior
real
time
pcr
use
mycxtra
dna
extract
system
mycassay
aspergillu
assay
bronchoscopi
sampl
consider
variabl
diagnost
yield
sputum
may
superior
spiliopoul
c
bartzavali
ed
anastassi
christofid
patra
gr
object
evalu
perform
multiplex
pcr
mpcr
method
detect
dermatophyt
gener
specif
rubrum
compar
convent
method
microscopi
cultur
diagnosi
tinea
unguium
method
total
nail
sampl
clinic
suspect
tinea
unguium
examin
direct
microscop
examin
cultur
well
mpcr
method
dermatophyt
pcr
kit
ssi
diagnostica
denmark
dna
clinic
rubrum
isol
use
posit
control
mpcr
includ
two
step
extract
primer
mix
contain
two
primer
pair
direct
toward
gene
encod
chitin
synthetas
detect
dermatophyt
gener
pcr
product
intern
transcrib
spacer
detect
rubrum
pcr
product
bp
intern
control
pcr
product
two
posit
control
dermatophyt
rubrum
genom
dna
describ
case
dissemin
sporothrix
schenckii
infect
man
underli
hairi
cell
leukemia
man
initi
treat
immun
suppress
presum
autoimmun
inflammatori
disord
develop
dissemin
sporotrichosi
involv
skin
lung
eye
immmun
impair
previous
unrecognis
hematolog
malign
hairi
cell
leukemia
degre
dissemin
sever
organ
schenckii
isol
blood
cultur
use
standard
autom
cultur
techniqu
infect
initi
refractori
antifung
therapi
tradit
amphotericin
b
part
due
drug
toxic
treatment
liposom
amphotericin
b
oral
posaconazol
along
treatment
underli
leukemia
result
dramat
clinic
improv
residu
evid
infect
immunolog
defect
associ
malign
well
manag
refractori
sporotrichosi
review
grown
sabouraud
dextros
agar
sda
hour
look
macroscop
morpholog
sda
microscop
morpholog
corn
meal
agar
differenc
saccharomyc
cerevisia
yeast
chromogen
medium
candida
test
assimil
sugar
biorad
risk
factor
studi
previou
use
antibioticantifung
probiot
base
cerevisia
hospit
immunosuppress
follow
clinic
microbiolog
criteria
prove
infect
colon
result
risk
factor
nt
brake
differ
head
due
difficulti
ensur
patient
receiv
saccharomyc
cerevisia
ultralevura
found
patient
admit
chronic
diarrhea
elderli
hospit
receiv
probiot
commun
imposs
know
vagin
cervic
due
cerevisia
main
infect
use
azol
antibiot
treat
infect
isol
blood
steril
sampl
invas
infect
unifi
criteria
decid
patient
given
ultralevura
prevent
infect
studi
phenotyp
genotyp
factor
yeast
relat
abil
invad
host
antifung
test
establish
epidemiolog
criteria
treatment
complic
know
origin
cerevisia
p
mehta
r
mehta
mv
raghavendra
rao
balaramiah
iban
abdallah
sirt
ly
object
fungal
kerat
one
major
caus
ulcer
sight
threaten
infect
cornea
incid
usual
underestim
studi
never
carri
part
world
object
studi
determin
incid
associ
etiolog
risk
factor
region
conclus
contrari
popular
percept
low
incid
fungal
kerat
region
high
incid
found
studi
attribut
increas
trend
toward
farm
activ
region
predispos
peopl
veget
injuri
season
variat
throughout
year
region
lead
alter
tear
film
could
major
predispos
factor
increas
use
contact
lens
also
predispos
user
contact
len
relat
infect
diabet
mellitu
found
patient
predispos
factor
preval
individu
fungi
dantindelafoulhouz
lucasdav
duma
foss
r
collomp
nice
fr
candidaemia
import
caus
morbid
mortal
hospit
especi
among
sever
patient
past
decad
epidemiolog
antifung
therapi
evolv
univers
hospit
commit
sinc
multidisciplinari
approach
help
diagnosi
treatment
invas
fungal
infect
ifi
initi
focus
costli
treatment
objectif
studi
trend
epidemiolog
suscept
antifung
use
hospit
method
patient
blood
cultur
yield
yeast
januari
decemb
includ
patient
data
epidemiolog
suscept
treatment
intervent
antifung
team
collect
computer
patient
record
mycolog
laboratori
pharmaci
result
patient
includ
period
diversif
yeast
speci
observ
signific
reduct
candida
albican
vs
rate
resist
fluconazol
exceed
among
strain
candida
first
strain
candida
parapsilosi
resist
caspofungin
isol
first
line
antifung
treatment
establish
accord
local
recommend
antifung
team
interven
nearli
patient
continu
initi
antifung
treatment
propos
deescal
therapi
patient
die
underlyng
sever
ifi
conclus
work
underlin
local
specif
term
epidemiolog
import
decreas
candida
albican
compar
litteratur
term
multidisciplinari
manag
ifi
among
propos
studi
includ
systemat
monitor
candidaemia
antifung
team
meet
wathev
drug
search
possibl
nosocomi
caus
sever
infect
j
salvo
gilseta
jm
c
ezpeleta
pamplona
zaragoza
es
object
increas
presenc
immigr
latin
america
increas
travel
contin
increas
incid
icc
abstract
accept
public
histoplasmosi
spain
aim
review
case
histoplasmosi
diagnos
hospit
method
review
diagnost
method
employ
clinic
characterist
case
histoplasmosi
diagnos
last
six
year
case
report
diagnos
case
three
hiv
posit
male
year
one
patient
femal
year
treat
immunosuppress
drug
south
america
spectrum
diseas
hiv
posit
patient
one
liver
diseas
one
pulmonari
one
gastrointestin
two
good
outcom
spite
treatment
amphotericin
b
rapidli
progress
multiorgan
failur
die
femal
liver
histoplasmosi
also
good
clinic
respons
treatment
case
amphotericin
b
mgkgday
two
week
follow
itraconazol
laboratori
diagnosi
carri
histolog
pa
pasdiastas
stain
microbiolog
studi
cultur
pcr
directli
three
case
isol
h
capsulatum
var
capsulatum
microbiolog
diagnosi
thank
direct
pcr
tissu
conclus
infect
peopl
histoplasmosi
remain
asymptomat
develop
seriou
clinic
form
depend
level
exposur
patient
immun
statu
usual
sever
form
seen
hiv
posit
patient
occur
seri
case
also
possibl
patient
immunosuppress
therapi
countri
histoplasmosi
import
infect
necessari
high
index
suspicion
perform
detail
histori
get
diagnosi
infect
consid
differenti
diagnosi
immunosuppress
patient
hiv
posit
immunosuppress
therapi
origin
endem
area
histori
stay
sn
khostelidi
yv
borzova
ra
araviyskiy
ts
bogomolova
va
zinserl
zjuzgin
nv
vasilyeva
nn
klimko
saint
petersburg
ru
object
kaya
alpcavu
turhan
tasbakan
h
pullukcu
b
ertugrul
senol
b
cetin
sayinkutlu
metin
avci
g
mermut
v
avkanoguz
n
object
incid
zygomycosi
increas
due
immunosuppress
recent
year
aim
evalu
case
zygomycosi
eight
center
retrospect
method
zygomycosi
patient
collect
zygomycosi
diagnos
cultur
posit
andor
histopatholog
find
addit
clinic
find
clinic
form
zygomycosi
describ
basi
organ
involv
rhinoorbitocerebr
cutan
pulmonari
gastrointestin
dissemin
dissemin
infect
defin
infect
noncontigu
site
result
femal
five
male
subject
mean
age
year
major
case
case
immunocompromis
patient
mainli
diabet
mellitu
case
seven
patient
receiv
corticosteroid
treatment
common
symptom
clinic
sign
patient
fever
n
retroorbit
pain
n
common
form
rhinoorbitocerebr
fungemia
intens
care
unit
fiveyear
studi
two
centr
e
paramythiot
f
frantzeskaki
antoniad
g
kallitsi
haritid
f
klouva
e
trika
h
giamarel
plahoura
panagea
l
zerva
g
petrikko
armaganidi
athen
gr
object
candidemia
frequent
encount
nosocomi
set
particularli
intens
care
unit
icu
caus
consider
morbid
mortal
increas
incid
nonalbican
candida
speci
could
also
import
aim
present
studi
record
epidemiolog
risk
factor
mortal
strain
suscept
antifung
drug
clinic
microbiolog
retrospect
studi
fungemia
episod
regist
two
medicalsurg
icu
record
research
laboratori
depart
intern
medicin
microbiolog
depart
attikon
univers
hospit
microbiolog
depart
thriassion
hospit
use
order
identifi
patient
medic
record
retriev
special
form
complet
patient
includ
demograph
inform
concomit
condit
apach
ii
sofa
sever
score
day
icu
admiss
risk
factor
within
preced
day
data
colon
candidemia
relat
inform
result
attikon
hospit
teach
tertiari
care
hospit
medic
surgic
icu
thriassion
hospit
tertiari
care
hospit
icu
bed
studi
period
total
pt
hospit
icu
among
patient
develop
fungemia
median
patient
age
year
median
icu
length
stay
day
medic
caus
admiss
present
case
speci
isol
c
albican
c
parapsilosi
c
tropicali
cspp
c
glabrata
nonalbican
spp
median
time
elaps
icu
admiss
candidemia
day
mean
apach
ii
score
day
admiss
overal
mortal
attribut
mortal
ostroski
predict
rule
posit
patient
urin
lung
colon
present
multipl
site
colon
fifteen
pt
submit
intraabdomin
oper
fifteen
pt
receiv
tpn
prior
candidemia
episod
caspofungin
commonli
introduc
treatment
conclus
compar
blood
infect
fungemia
common
among
patient
often
lethal
high
apach
ii
score
admiss
multipl
site
colon
combin
abdomin
surgeri
rais
high
suspicion
index
prophylact
therapi
start
nonalbican
speci
rise
isol
may
august
juli
octob
caus
onychomycosi
dermatophyt
isol
conclus
confirm
diagnosi
consid
essenti
bad
treatment
predispos
advanc
invas
dermatophyt
andor
mold
assay
sensibl
antifung
area
nazli
tasbakan
h
pullukcu
sipahi
yamazhan
b
arda
izmir
tr
object
studi
aim
review
systemat
publish
mucormycosi
case
turkey
method
publish
mucormycosi
case
turkey
nation
intern
medic
literatur
last
fifteen
year
retriev
three
nation
ulakbim
turkish
medic
literatur
medlin
plexu
two
intern
databas
pubm
scienc
citat
index
expend
sci
keyword
mukor
mukormikoz
use
nation
databas
mucor
mucormycosi
ad
turkey
intern
databas
data
relat
age
gender
comorbid
sign
diagnost
tool
therapeut
modal
mortal
analys
retriev
articl
result
data
total
mucormycosi
patient
femal
male
age
definit
diagnosi
invas
fungal
infect
accord
criteria
european
organ
research
treatment
cancer
eortc
obtain
report
intern
nation
could
achiev
full
text
two
report
publish
intern
databas
three
report
nation
databas
term
common
clinic
find
common
symptom
swell
eye
face
follow
headach
fever
opthtalmoplegia
loss
vision
neurolog
sign
common
comorbid
diabet
follow
hematolog
malign
corticosteroid
usag
sequenceanalysi
infect
fungal
strain
show
two
mutat
tandem
repeat
gene
promot
treatment
posaconazol
trough
level
microgml
blood
postmortem
tissu
posaconazol
concentr
indic
aucmic
ratio
tabl
cultur
result
posaconazol
drug
concentr
blood
tissu
sampl
obtain
autopsi
efficaci
aucmic
posaconazol
probabl
could
achiev
patient
plasma
level
microgml
would
requir
achiev
pharmacodynam
target
fumigatu
strain
posaconazol
mic
imposs
achiev
current
posaconazol
formul
posaconazol
use
caution
invas
aspergillosi
caus
strain
attenu
posaconazol
suscept
drug
exposur
may
inadequ
result
therapeut
failur
mj
gomezlopez
core
jl
rodrigueztudela
cuencaestrella
murcia
majadahonda
es
background
list
uncommon
fungal
speci
caus
human
infect
grow
convent
method
classif
base
morpholog
biochem
physiolog
featur
proven
ineffect
accur
identifi
speci
candida
haemulonii
report
among
uncommon
yeast
decreas
suscept
antifung
agent
caus
human
diseas
review
identif
antifung
suscept
result
collect
clinic
isol
c
haemulonii
method
total
isol
receiv
institut
period
evalu
one
isol
blood
nine
strain
recov
superfici
site
identifi
morpholog
biochem
test
addit
molecular
identif
done
sequenc
ribosom
dna
domain
suscept
test
follow
recommend
propos
eucast
result
total
isol
discrimin
phenotyp
strain
classifi
unidentifi
accord
biochem
profil
one
strain
misidentifi
candida
sake
object
candida
spp
fourth
common
pathogen
caus
nosocomi
blood
stream
infect
invas
infect
immunocompromis
serious
ill
patient
method
two
retrospect
data
set
patient
time
period
period
period
respect
evalu
patient
whose
data
includ
studi
diagnos
candidemia
univers
hospit
vienna
referr
centr
aim
studi
identifi
chang
epidemiolog
clinic
manifest
outcom
two
group
demograph
dissemin
term
age
gender
etc
analys
well
differ
underli
diseas
period
durat
hospitalis
time
candida
albican
isol
blood
cultur
determin
progress
candidemia
success
therapi
mortal
rate
two
period
evalu
result
period
significantli
patient
proven
candidemia
found
intens
care
unit
period
significantli
medic
ward
main
hospitalis
durat
isol
candida
day
period
day
period
period
two
third
patient
diagnos
immunocompromis
period
patient
die
consequ
candidemia
later
persist
fungal
infect
patient
underli
diseas
bacteri
sepsi
thirtyseven
patient
receiv
antifung
therapi
remain
untreat
fiftyfour
percent
treat
patient
die
oppos
percent
patient
without
therapi
period
patient
die
consequ
candidemia
later
persist
fungal
infect
underli
diseas
patient
bacteri
sepsi
fortyf
deceas
patient
receiv
antifung
therapi
remain
untreat
fiftyfour
percent
die
treat
group
percent
group
without
treatment
conclus
although
much
progress
made
treatment
candida
albican
mortal
patient
still
high
decreas
candida
infect
better
tool
diagnosi
guidelin
manag
awar
pathogen
absolut
essenti
tortorano
prigitano
c
ossi
grancini
e
casari
g
viola
g
giuliani
mella
longo
r
passerini
facchini
tejada
passera
g
delvecchio
e
sala
c
sturla
ceraminiello
c
cavanna
c
bezzi
longo
arghittu
l
mr
sala
p
clerici
grossi
p
pedroni
g
c
bonetti
g
brigant
remain
associ
mainli
even
reduc
rate
surgeri
case
vs
previou
studi
intens
care
treatment
vs
shift
speci
caus
fungaemia
demonstr
comparison
two
period
proport
due
c
albican
decreas
increas
c
glabrata
c
tropicali
note
proport
c
parapsilosi
remain
unchang
decreas
crude
mortal
day
observ
highest
mortal
rate
detect
patient
c
tropicali
c
albican
bloodstream
infect
present
studi
reveal
increas
incid
candidaemia
mainli
age
subject
increas
proport
isol
decreas
suscept
fluconazol
c
lacroix
gicquel
f
morio
j
lambert
accoceberri
e
bailli
g
desoubeaux
e
collin
l
feghoul
n
f
gabriel
f
gay
andrieu
j
guitard
c
hennequin
c
kauffmann
lacroix
lauzin
b
sendid
lortholari
bougnoux
pari
nant
bordeaux
tour
lill
poitier
fr
object
prospect
multicentr
observ
studi
conduct
franc
compar
epidemiolog
candida
spp
isol
high
risk
patient
intens
care
unit
icu
haematolog
unit
hu
renal
transplant
unit
rtu
method
januari
februari
candida
spp
isol
patient
hospit
medic
surgic
icu
adult
paediatr
hu
rtu
french
univers
hospit
collect
c
albican
identifi
use
chromogen
agar
media
screen
bichrodubl
sofibel
identifi
c
dubliniensi
c
krusei
c
glabrata
identifi
kruseicolor
sofibel
glabrata
rtt
sofibel
respect
candida
spp
identifi
use
unequivoc
identif
use
rdna
sequenc
done
c
glabrata
c
parapsilosi
c
kefyr
c
inconspicuanorvegensi
identif
score
vitro
antifung
suscept
determin
etest
first
isol
candida
sp
differ
bodi
site
test
patient
c
glabrata
isol
nonsuscept
caspofungin
c
guilliermondii
n
c
parapsilosi
n
conclus
epidemiolog
studi
conduct
short
period
time
allow
us
point
differ
candida
spp
isol
differ
clinic
unit
bodi
site
local
epidemiolog
must
consid
appropri
empir
antifung
therapi
mahelova
f
ruzicka
v
hola
votava
brno
cz
commonli
isol
yeat
candida
albican
well
yeast
colon
gastrointestin
tract
human
reservoir
develop
infect
bodi
site
new
speci
candida
genu
identifi
classifi
candida
dubliniensi
speci
share
mani
phenotyp
similar
c
albican
lead
misidentif
underestim
primarili
isol
identifi
sampl
hivposit
individu
aid
patient
suffer
oral
candidiasi
mani
public
report
preval
oropharynx
occurr
c
dubliniensi
human
fece
sampl
test
rare
c
dubliniensi
routin
identifi
clinic
laboratori
czech
republ
aim
studi
evalu
incid
c
dubliniensi
human
clinic
materi
especi
stool
sampl
three
common
phenotyp
method
use
discrimin
c
dubliniensi
c
albican
color
coloni
chromagar
candida
inabl
grow
coloni
morpholog
staib
medium
identif
c
dubliniensi
verifi
polymeras
chain
reaction
speciesspecif
primer
pair
univers
primer
pair
experi
took
place
decemb
decemb
collect
almost
sampl
gastrointestin
tract
isol
airway
oropharynx
origin
identifi
laboratori
c
albican
two
three
isol
identifi
c
dubliniensi
incid
oropharynx
airway
significantli
higher
stool
sampl
signific
find
lie
primarili
fact
small
number
public
deal
particular
clinic
specimen
mani
public
incid
c
dubliniensi
clinic
materi
publish
czech
republ
acknowledg
work
support
ministri
educ
youth
sport
candoni
e
simeon
caira
mazzucco
r
fanin
l
pagano
udin
rome
background
acut
myeloid
leukemia
aml
patient
high
risk
invas
fungal
diseas
ifd
report
reallif
experi
po
prophylaxi
aml
also
compar
perform
po
prophylaxi
histor
well
match
control
group
aml
pt
receiv
prophylaxi
fluconazol
fluco
itraconazol
itra
patient
result
fiftyf
unselect
consecut
aml
pt
receiv
po
prophylaxi
mg
daili
jan
oct
median
age
popul
yr
rang
case
given
chemotherapi
anthracyclin
cytarabin
po
start
neutrophil
pmn
count
less
ml
stop
pmn
recoveri
median
durat
sever
neutropenia
pmn
lower
ml
day
rang
case
oral
mucos
grade
iiiii
ctc
common
toxic
criteria
pt
receiv
proton
pump
inhibitor
activ
diagnost
work
made
case
galactomannan
assay
standard
chest
xray
thorac
ct
scan
case
fever
fuo
last
hour
median
durat
po
prophylaxi
day
rang
pt
requir
parenter
empir
preemptiv
antimycot
therapi
experienc
proven
ifd
fusarium
solani
fungemia
aspergillu
sp
pneumonia
mortal
ifd
relat
po
well
toler
pt
experienc
mild
drug
relat
side
effect
case
po
discontinu
due
side
effect
intoler
report
compar
pt
receiv
po
histor
control
group
aml
pt
receiv
fluco
itra
prophylaxi
jan
jun
signific
differ
observ
underl
diseas
statu
age
ifd
risk
factor
day
sever
neutropenia
day
prophylaxi
instead
signific
differ
breakthrough
ifd
po
group
vs
control
group
p
day
parenter
antymicot
therapyn
vs
conclus
reallif
experi
confirm
po
prophylaxi
feasibl
safe
well
toler
effect
prevent
ifd
unselect
aml
patient
high
risk
pt
requir
parenter
antimycot
therapi
experienc
breakthrough
ifd
also
confirm
po
effect
fluco
itra
antifung
prophylaxi
aml
pt
toyoda
k
ciepli
nguyen
pittsburgh
us
background
diagnosi
invas
asperigllosi
ia
limit
poor
sensit
specif
microbiolog
cultur
inabl
convent
histopatholog
test
distinguish
ia
invas
fungal
infect
ifi
caus
nonaspergillu
mould
aspergillusspecif
immunohistochemistri
ihc
situ
hybrid
ish
could
facilit
direct
diagnosi
ia
within
tissu
method
ihc
ish
perform
deparaffin
formalinfix
section
previous
diagnos
case
proven
ifi
slide
interpret
pathologist
blind
diagnosi
ihc
primari
aspergillu
antibodi
abcam
secondari
antirabbit
antibodi
detect
avidin
biotin
complex
visual
use
liquid
dab
ish
commerci
synthes
lock
nucleic
acid
probe
aspergillu
detect
use
antiflourescein
ap
poli
stain
tissu
section
use
determin
area
tissu
studi
result
tissu
section
avail
patient
ia
fumigatu
niger
nonspeci
section
avail
patient
ifi
due
fungi
zygomyc
candida
dactylaria
gallopava
ia
sampl
obtain
tissu
biopsi
lung
upper
airway
vocal
cord
autopsi
sampl
serial
section
one
patient
ia
due
fumigatu
exclud
studi
posit
control
stain
neg
sensit
ihc
ish
ia
respect
ihc
fals
neg
pt
ia
due
fumigatu
specif
ihc
ish
test
neg
section
associ
ifi
due
nonaspergillu
fungi
ihc
associ
signific
level
nonspecif
background
stain
section
could
analyz
compar
ish
conclus
data
pilot
studi
suggest
aspergillusspecif
ihc
ish
facilit
diagnosi
ia
exclud
ifi
due
nonaspergillu
fungi
ish
superior
ihc
limit
fals
neg
result
nonspecif
background
stain
current
assess
ihc
ish
prospect
nonfix
tissu
object
invas
pulmonari
aspergillosi
ipa
among
patient
chronic
obstruct
pulmonari
diseas
copd
increas
frequenc
associ
mortal
exceed
seri
conduct
studi
find
approxim
incid
ipa
patient
hospit
acut
exacerb
copd
aecopd
true
mortal
identifi
potenti
factor
associ
mortal
retrospect
includ
patient
admit
aecopd
isol
aspergillu
last
year
ipa
defin
accord
bulpa
criteria
chart
retrospect
review
patient
classifi
probabl
ipa
colon
result
identifi
patient
admit
last
year
aecopd
aspergillu
isol
thirtyseven
copd
stage
iiiiv
fortysix
male
median
age
fiftyf
patient
increas
dyspnoea
radiolog
alter
mostli
new
infiltr
chest
xray
thirtynin
receiv
mg
steroid
admitt
receiv
mgday
past
month
twenti
patient
one
aspergillu
isol
twenti
four
patient
receiv
voriconazol
median
day
day
crude
mortal
patient
copd
stage
iiiiv
older
vs
year
p
higher
mortal
vs
p
similarli
patient
copd
stage
iiiiv
receiv
frequent
high
dose
steroid
vs
p
frequent
increas
dyspnoea
admitt
vs
p
neither
daili
dose
steroid
voiconazol
therapi
associ
increas
mortal
multivari
analysi
increas
dyspnoea
significantli
associ
mortal
conclus
copd
patient
stage
iiiiv
increas
mortal
ipa
although
lower
describ
author
neither
previou
high
steroid
dose
admitt
associ
mortal
object
diagnosi
pneumocysti
jirovecii
pneumonia
pcp
affect
variou
type
immunocompromis
patient
time
problemat
sought
evalu
diagnost
accuraci
bdglucan
bdg
diagnosi
pcp
metaanalysi
relev
studi
identifi
pubm
scopu
elig
studi
report
bdg
diagnost
data
case
document
pcp
control
condit
exclud
case
invas
fungal
infect
healthi
control
perform
bivari
metaanalysi
sensit
specif
construct
hierarch
summari
receiv
oper
characterist
hsroc
curv
result
twelv
studi
includ
metaanalysi
bdg
data
provid
pcp
case
control
pool
confid
interv
sensit
specif
bdg
respect
posit
neg
likelihood
ratio
respect
area
hsroc
curv
object
studi
assess
pilot
antifung
prevent
strategi
base
itraconazol
level
consecut
high
risk
patient
aim
reduc
empir
treatment
patient
underw
chemotherapi
allogen
stem
cell
transplant
haematolog
malign
receiv
itraconazol
suspens
prophylaxi
studi
ongo
method
neutropen
febril
episod
refractori
day
broad
spectrum
antibiot
initi
day
one
studi
patient
serum
galactomannan
assay
eia
twice
week
trough
itraconazol
level
measur
day
one
fever
still
febril
day
hrct
scan
chest
perform
antifung
treatment
requir
given
well
defin
clinic
microbiolog
radiolog
criteria
present
invas
fungal
diseas
conclus
incid
probabl
proven
ifd
three
patient
possibl
ifd
die
receiv
iv
antifung
therapi
patient
overal
subtherapeut
itraconazol
level
strategi
reduc
rate
antifung
use
l
chishimba
rn
niven
j
cooley
dw
den
manchest
uk
background
object
allerg
bronchopulmonari
aspergillosi
abpa
sever
asthma
fungal
sensitis
saf
progress
allerg
fungal
lung
diseas
current
treatment
itraconazol
itra
associ
failur
rate
advers
event
ae
littl
known
respons
rate
appropri
treatment
voriconazol
vori
posaconazol
posa
studi
assess
effect
vori
posa
second
third
line
therapi
conduct
retrospect
audit
adult
asthmat
patient
fulfil
diagnost
criteria
either
abpa
saf
patient
previous
receiv
itraconazol
vori
mgday
posa
mgday
adjust
tdm
given
least
month
toler
clinic
radiolog
immunolog
evalu
use
assess
respons
defin
respons
improv
symptom
either
fungal
serolog
radiolog
abnorm
rate
clinic
respons
failur
advers
effect
ae
mo
treatment
analyz
coexist
diagnos
aspergillu
antibodi
titr
vori
posa
level
lung
function
use
covari
result
patient
abpa
n
saf
n
male
median
age
yr
patient
fail
itra
n
develop
ae
n
low
serum
conc
n
itra
resist
n
cours
therapi
analys
vori
posa
posa
cours
preced
vori
resist
clinic
respons
voriconazol
observ
mo
mo
mo
compar
mo
posa
vori
pt
ae
requir
discontinu
mo
compar
posa
patient
vori
ae
includ
gi
upset
skin
photosensit
blister
visual
light
flash
insomnia
visual
hallucin
depress
adren
suppress
peripher
neuropathi
eye
irrit
vivid
dream
dizzi
headach
transient
mild
posa
ae
includ
insomnia
gi
upset
mild
liver
impair
among
discontinu
relaps
one
mo
month
conclus
voriconazol
posaconazol
safe
effect
treatment
option
second
line
antifung
therapi
saf
abpa
larger
prospect
studi
requir
capetti
n
zanchetta
melzi
p
zucchi
l
carenzi
cossu
gismondo
g
rizzardini
milano
background
new
method
measur
rna
lower
level
detect
patient
whose
viremia
classifi
undetect
level
new
cutoff
studi
tri
assess
factor
relat
deeper
rna
suppress
among
subject
rescu
therapi
method
versant
rna
assay
kit
kpcr
siemen
procedur
kinet
polymeras
chain
reaction
kpcr
revers
transcript
rt
direct
quantif
rna
rang
detect
copiesml
copi
system
still
see
signal
ss
signal
ns
suggest
viru
concentr
sampl
case
extrem
low
select
adher
patient
salvag
therapi
darunavirraltegravirbas
regimen
deep
salvag
patient
match
patient
late
lopinavirbas
regimen
experienc
patient
b
two
popul
n
b
n
homogen
age
vs
year
b
p
baselin
tcell
vs
p
rna
copiesml
vs
p
time
viral
suppress
vs
week
p
howev
group
averag
treatment
line
mean
gss
group
b
scatter
around
line
gss
p
subject
group
group
b
reach
ns
viremia
p
reach
ns
viremia
seem
correl
lower
baselin
viral
load
ns
vs
log
copiesml
ss
p
even
baselin
gss
vs
p
also
cell
nadir
vs
p
zenith
rna
log
copiesml
vs
p
predict
ns
respons
overal
fair
proport
subject
rescu
therapi
ns
viral
load
late
treatment
line
associ
wors
virolog
outcom
relationship
extrem
viral
load
suppress
ns
latent
infect
tcell
pool
investig
three
case
low
ai
detect
sera
longstand
hiv
infect
high
ai
averag
differ
b
nonb
genotyp
conclus
result
may
relev
implic
understand
complex
mechan
matur
immun
respons
hiv
expand
studi
patient
recent
infect
treat
patient
order
confirm
preliminari
data
control
chronic
steroid
therapi
variou
reason
mainli
copd
two
control
obes
conclus
although
hiv
associ
immunosuppress
may
initi
predict
sever
clinic
cours
influenza
result
suggest
evolut
differ
hivinfect
peopl
found
higher
frequenc
smoke
among
hiv
patient
odd
ratio
strike
also
high
occurr
copd
group
without
differ
exclud
hcv
coinfect
patient
liver
diseas
none
hiv
patient
chronic
diseas
unlik
control
ai
papadopoulo
b
ferwerda
v
sakka
l
galani
antoniad
kavatha
p
panagopoulo
g
poulak
k
protopapa
jw
van
der
meer
netea
ej
giamarellosbourbouli
athen
gr
nijmegen
nl
object
adaptorlik
maltirap
adaptor
protein
bridg
activ
tolllik
receptor
stimul
exogen
endogen
ligand
investig
associ
presenc
snp
mal
risk
sever
infect
individu
human
immunodefici
viru
hiv
infect
snp
determin
cohort
infect
greek
patient
analysi
preval
snp
relat
infecti
complic
evalu
one
hundr
thirti
two
patient
bear
wild
type
wt
haplotyp
heterozyg
ht
snp
four
homozyg
ho
variant
allel
patient
carri
wt
haplotyp
experienc
infect
compar
ht
patient
one
ht
patient
p
ns
individu
nadir
count
cellsmm
carri
variant
demonstr
decreas
odd
ratio
seriou
infect
compar
carri
wildtyp
genotyp
vs
p
six
patient
develop
bcell
nonhodgkin
lymphoma
two
among
patient
bear
wt
haplotyp
four
among
patient
bear
ht
haplotyp
p
conclus
studi
suggest
protect
effect
mal
snp
seriou
infect
infect
individu
low
cell
count
h
leder
achermann
tingu
f
stenner
j
fehr
zurich
ch
februari
yearold
man
human
immunodefici
viru
hiv
infect
refer
hospit
fever
weak
diarrhea
past
three
month
suffer
sever
febril
episod
extens
workup
previou
hospitalis
reveal
caus
hiv
diagnos
despit
excel
virolog
respons
antiretrovir
treatment
undetect
plasma
viral
load
patient
remain
sever
immunosuppress
cellsml
admiss
reduc
gener
condit
febril
normal
heart
rate
low
blood
pressur
multipl
margin
enlarg
lymph
node
enlarg
spleen
laboratori
test
show
pancytopenia
elev
creactiv
protein
acut
renal
failur
vast
examin
bacteria
mycobacteria
helminth
protozoa
remain
neg
upper
lower
endoscop
bowel
examin
tissu
biopsi
show
evid
diseas
fluorodeoxyglucos
fdg
positron
emiss
tomographi
scan
reveal
patholog
fdguptak
lymphat
tissu
immunohistochem
examin
posit
human
herp
viru
type
latencyassoci
nuclear
antigen
figur
allow
diagnosi
multicentr
castleman
diseas
mcd
treatment
rituximab
etoposid
valganciclovir
six
cycl
start
ten
month
later
patient
free
new
febril
episod
work
fulltim
ct
scan
reveal
decreas
size
number
lymph
node
mcd
associ
lymphoprolif
diseas
consid
possibl
caus
episod
fever
diseas
present
vari
wide
optim
treatmentregim
yet
establish
improv
immun
system
treatment
underli
diseas
crucial
antivir
agent
success
investig
promis
approach
treatment
select
case
rituximab
antineoplast
agent
etoposid
vinblastin
highli
activ
prevent
evolut
mcd
toward
lymphoma
unspecif
find
mcd
difficult
diagnos
set
episod
fever
malais
present
case
mcd
extrem
challeng
establish
diagnosi
assum
mcd
still
underestim
even
though
import
ever
mcd
diagnos
time
new
promis
therapeut
approach
exist
object
hepat
b
viru
hbv
infect
frequent
sever
hivinfect
patient
gener
popul
assess
impact
nurs
intervent
improv
immun
hbv
patient
swiss
hiv
cohort
studi
shc
intervent
conduct
one
center
intervent
center
center
use
compar
control
center
method
shc
particip
seroneg
hbsag
antihbc
januari
includ
studi
group
follow
june
non
immun
patient
antihb
iul
patient
unknown
immun
elig
nurs
intervent
consist
document
hbv
serostatu
patient
previous
miss
inform
provid
vaccin
dose
minim
interv
month
nonimmun
patient
measur
vaccin
effect
month
dose
provid
second
cours
vaccin
nonrespond
result
total
patient
seroneg
hbsag
antihbc
includ
intervent
control
center
respect
figur
number
patient
absent
immun
decreas
intervent
center
control
center
p
number
patient
undocu
immun
decreas
intervent
center
control
center
p
conclus
hbv
immun
hiv
popul
insuffici
switzerland
significantli
improv
nurs
intervent
hiv
antibodi
posit
sixti
six
patient
hbsag
check
one
posit
fifti
nine
patient
viral
load
measur
viru
genotyp
check
ast
measur
patient
patient
hbsag
posit
test
request
specialist
team
patient
hiv
serolog
check
patient
posit
hcv
antibodi
check
patient
hbv
viral
load
check
ast
measur
patient
one
patient
posit
hbv
hcv
hiv
conclus
hiv
test
hepat
b
c
patient
far
univers
howev
appli
test
second
blood
born
hepat
viru
patient
laboratori
current
recommend
referr
gastroenterolog
servic
case
posit
viral
hepat
b
c
marker
report
extend
includ
consid
test
blood
born
virus
includ
hiv
result
suggest
substanti
number
request
come
specialist
team
hospit
suggest
may
involv
patient
investig
warrant
establish
target
educ
fusion
process
human
immunodefici
viru
type
mediat
surfac
protein
transmembran
protein
facilit
viral
entri
glycoprotein
must
bind
cellsurfac
alter
conform
reveal
site
coreceptor
attach
trigger
conform
rearrang
glycoprotein
mediat
fusion
viral
host
cell
membran
therefor
interact
critic
viruscel
fusion
region
bind
target
broadli
neutral
antibodi
antibodi
target
recogn
highli
conserv
epitop
overlap
region
antibodi
one
four
known
human
monoclon
antibodi
identifi
effici
neutral
broad
array
primari
isol
vitro
protect
viral
challeng
vivo
goal
project
evalu
potenti
target
viruscel
fusion
inhibit
singl
domain
antibodi
graft
highli
conserv
epitop
recogn
antibodi
done
use
amino
acid
loop
graft
highli
stabl
rabbit
singl
domain
vl
antibodi
design
potenti
construct
test
bind
elisa
assay
solubl
fac
analysi
use
hela
jurkat
cell
line
highli
specif
exhibit
high
bind
condit
test
preliminari
inhibit
assay
perform
jurkat
cell
human
lymphocyt
cell
line
presenc
construct
show
appar
inhibit
indic
bind
alon
suffici
block
viruscel
fusion
steric
effect
due
presenc
larger
molecul
may
necessari
fusion
inhibit
test
celltocel
inhibit
assay
standard
jurkat
cell
line
inhibit
assay
interact
differ
molecul
evalu
inhibit
potenti
conclus
appear
promis
target
valuabl
mediat
biopharmaceut
fill
gap
cch
fever
project
propos
creat
multidisciplinari
collabor
research
environ
bring
togeth
select
competit
advantag
oper
capac
appropri
high
secur
research
facil
refer
center
clinic
sampl
endem
area
intern
network
e
xperienc
research
multidisciplinari
research
consortium
facilit
progress
sever
key
research
area
field
program
mainli
focu
develop
sensit
biosaf
stateofart
diagnost
tool
cchfv
ii
gather
forc
resourc
europ
build
biobank
clinic
sampl
iii
build
comprehens
databas
consist
clinic
laboratori
surveil
data
iv
take
advantag
uniqu
stateofart
tool
progress
toward
vaccin
candid
specif
antivir
biotreat
v
dissemin
appropri
knowledg
health
care
worker
endem
region
contribut
capac
build
achiev
provid
tool
local
european
public
health
author
prevent
counter
futur
outbreak
monitor
spread
diseas
thank
establish
novel
uniqu
tool
resourc
patient
examin
gynecologist
drawn
biopsi
materi
cervic
canal
uteru
blood
serum
patient
time
relaps
pcr
method
fluoresc
immunoassay
use
detect
biopsi
materi
immunoglobulin
g
serum
respect
also
urinalysi
urin
cultur
done
patient
treat
acyclovir
result
patient
histori
episod
luti
per
year
common
complaint
frequent
pain
urin
itch
burn
observ
relationship
luti
relaps
menstrual
cycl
woman
gynecolog
examin
display
abnorm
chang
patient
urinalysi
reveal
increas
amount
epitheliocyt
urin
cultur
neg
biopsi
materi
cervic
canal
uteru
neg
patient
luti
symptom
found
high
level
immunoglobulin
g
blood
serum
three
week
later
antibodi
g
titer
increas
twice
patient
treat
acyclovir
mg
three
time
day
five
day
suppress
therapi
acyclovir
mg
twice
day
given
month
full
cours
treatment
one
patient
complain
luti
patient
frequent
episod
per
year
luti
symptom
normal
urinalysi
herp
genitali
suspect
fluoresc
immunoassay
may
use
case
receiv
neg
pcr
result
result
studi
patient
enrol
due
marinum
infect
among
thirti
isol
three
repetit
isol
two
patient
accord
criteria
clinic
outcom
mention
method
patient
outcom
success
eight
fail
one
lost
followup
statist
fail
lost
followup
pool
success
group
success
group
mean
age
success
group
mean
age
twelv
patient
either
fish
tank
contact
fish
hobbi
two
shrimp
contact
one
play
swim
pool
one
receiv
intraarticular
steroid
inject
three
patient
got
minor
superfici
trauma
extrem
eight
document
contact
histori
success
group
patient
ever
receiv
surgic
debrid
notsuccess
group
patient
receiv
surgic
debrid
fisher
exact
p
conclus
taiwan
first
studi
unravel
relationship
clinic
outcom
suscept
test
bacteri
strain
optim
antimycobacteri
regimen
well
establish
drug
report
success
agent
fail
agent
studi
identifi
risk
factor
treatment
failur
durat
prescrib
clarithromycin
rifampicin
ethambutol
doxycyclin
differ
success
group
notsuccess
group
pulmonari
ntm
infect
appear
uniform
diseas
clinic
radiolog
present
vari
seem
independ
mycobacteria
speci
involv
none
patient
progress
deterior
due
ntminfect
four
patient
cure
opinion
result
achiev
thorough
interdisciplinari
discuss
idboard
consid
clinic
present
comorbid
expect
drugtox
led
final
favour
outcom
patient
comparison
test
vivo
tst
invitro
igra
ppd
demostr
igra
perform
better
tst
cell
cellsml
tst
use
detect
immunolog
respons
tubercular
infect
case
immunodefici
l
gkaravela
foka
sevdali
f
kolonitsi
spiliopoul
ed
anastassi
spiliopoul
patra
gr
object
increas
number
tuberculosi
case
southwestern
greec
observ
reemerg
diseas
combin
isol
multidrugresist
strain
intensifi
need
rapid
diagnost
method
mycobacteria
rate
mycobacteria
isol
system
barri
alsomili
f
buba
u
yusuf
n
al
anazi
riyadh
sa
object
compar
baselin
post
treatment
valu
patient
tuberculosi
control
analyz
sequenti
count
treatment
subject
method
twenti
eight
consecut
adult
patient
diagnos
differ
clinic
form
tuberculosi
recruit
elig
patient
enrol
base
compat
symptom
tb
posit
mycobacterium
tuberculosi
base
zielnielsen
smear
andor
cultur
relev
specimen
determin
bactec
system
andor
lowensteinjensen
cultur
method
control
select
reli
absenc
histori
suggest
tuberculosi
neg
tuberculin
test
subject
control
screen
hiv
ensur
neg
use
enzymelink
immunosorb
assay
elisa
recombin
immunoblot
assay
riba
flow
cytometri
studi
done
per
protocol
patient
control
exclud
follow
condit
form
immunodefici
syndrom
diabet
mellitu
chronic
kidney
diseas
concurr
use
immunosuppress
medic
inform
consent
sought
subject
control
enrol
result
twenti
eight
consecut
patient
vari
form
tuberculosi
enrol
baselin
count
patient
mean
significantli
reduc
compar
match
control
p
valu
pretreat
post
treatment
valu
patient
significantli
differ
record
follow
versu
p
valu
baselin
count
significantli
reduc
p
valu
valu
patient
control
respect
howev
improv
count
treatment
baselin
count
versu
treatment
p
valu
studi
show
significantli
lower
baselin
count
among
patient
tuberculosi
compar
control
count
significantli
rose
toward
normal
end
treatment
therefor
conclud
tuberculosi
associ
lymphoenia
independ
notabl
caus
count
revers
may
indic
success
treatment
object
compar
use
tuberculin
skin
test
tst
interferong
ifng
releas
assay
use
three
specif
antigen
quantiferon
tb
gold
tube
diagnosi
tuberculosi
infect
tbi
indic
treatment
health
care
worker
method
conduct
prospect
transvers
studi
health
personnel
came
routin
health
care
studi
may
june
screen
tst
qft
cellesti
australia
risk
factor
regist
questionnair
patient
posit
result
tst
qft
screen
also
chest
xray
tst
perform
mantoux
method
posit
test
defin
indur
nonvaccin
mm
vaccin
peopl
qtf
made
accord
manufactur
specif
consid
vaccin
person
present
suggest
scar
cdc
recommend
follow
interpret
qft
agreement
tst
qft
assess
cohen
kappa
coeffici
result
studi
health
care
worker
women
gener
hospit
jerez
averag
age
year
sd
vaccin
bcg
tst
done
person
previou
posit
tst
tst
posit
qft
nonvaccin
peopl
wherea
vaccin
peopl
tst
posit
qft
posit
agreement
tst
qft
kappa
ci
among
non
vaccin
group
defin
posit
test
tst
mm
indur
agreement
kappa
ci
agreement
kappa
ci
vaccin
group
two
indetermin
result
detect
qft
indic
tbi
treatment
made
tst
risk
situat
modifi
case
accord
qft
test
prescrib
treatment
tbi
qft
patient
indic
accord
tst
agreement
tst
qft
low
vaccin
nonvaccin
peopl
qft
better
tst
recent
tuberculosi
infect
diagnosi
health
care
worker
high
specif
interfer
booster
qft
better
indic
treatment
tuberculosi
infect
studi
address
ifng
seroconvers
revers
health
care
worker
followup
health
care
personnel
need
came
screen
tuberculosi
infect
screen
chest
xray
tst
qft
cellesti
australia
risk
factor
regist
questionnair
tst
perform
mantoux
method
posit
test
defin
indur
nonvaccin
mm
vaccin
peopl
qft
made
accord
manufactur
specif
consid
vaccin
person
present
suggest
scar
cdc
recommend
follow
interpret
qft
treatment
tbi
agreement
tst
qft
assess
cohen
kappa
coeffici
result
agreement
tst
qft
among
nonvaccin
patient
kappa
ci
redefin
posit
test
tst
indur
mm
agreement
rose
kappa
ci
agreement
vaccin
peopl
kappa
ci
qft
tst
result
frequent
disagr
nonvaccin
peopl
qft
indetermin
patient
neg
tst
prescrib
treatment
tbi
qft
patient
indic
accord
tst
indic
tbi
treatment
made
tst
risk
situat
modifi
case
accord
qft
test
agreement
tst
qft
good
non
vaccin
intraven
drug
user
agreement
tst
qft
low
vaccin
intraven
drug
user
even
tst
consid
posit
mm
criterion
qft
test
better
tool
identifi
infect
individu
reduc
number
unnecessari
tbi
treatment
background
global
control
tuberculosi
hamper
slow
insensit
diagnost
method
particularli
detect
drugresist
form
immunocompramis
patient
earli
detect
tuberculosi
essenti
reduc
overal
mortal
morbid
well
elimin
diseas
transmiss
complex
infrastructur
need
sensit
method
limit
access
effect
risk
factor
longterm
treatment
lymph
node
tuberculosi
jp
lanoix
guimard
n
ettahar
grannec
c
flateau
c
chapuzet
p
tattevin
jl
schmit
amien
renn
tourco
caen
lill
rouen
fr
introduct
lymph
node
tuberculosi
lntb
frequent
extrapumonari
tuberculosi
tb
author
report
huge
differ
durat
treatment
instead
recommend
month
antitb
therapi
conduct
retrospect
multipl
centr
studi
aim
describ
clinic
factor
prolong
antitb
drug
materi
method
includ
retrospect
patient
present
least
lntb
period
seven
hospit
north
franc
tb
diagnos
either
cultur
histolog
clinic
suspicion
improv
antitubercular
drug
five
univers
hospit
particip
exclud
treatment
durat
analysi
patient
bone
neurolog
involv
result
patient
includ
men
africa
born
median
age
year
extrem
hiv
infect
patient
diagnos
hiv
posit
time
tb
diagnosi
mean
cell
forti
two
patient
anoth
tb
localis
bone
neurolog
involv
superfici
lymph
node
cervic
localis
four
patient
die
lost
follow
durat
treatment
analysi
undertaken
patient
median
durat
month
extrem
treatment
significantli
longer
hiv
posit
patient
p
patient
tb
localis
lymph
node
p
patient
loss
weight
p
patient
present
new
lymph
node
treatment
p
treatment
significantli
shorter
complic
occur
main
caus
treatment
prolong
non
favour
evolut
seven
patient
present
relaps
treat
month
month
month
one
month
relaps
conclus
lntb
treat
much
longer
recommend
treatment
length
accord
recommend
recommend
suggest
month
suffici
extrapulmonari
tb
except
bone
neurolog
tb
factor
associ
treatment
durat
hiv
infect
loss
weight
tuberculosi
localis
preval
aetiolog
pathogen
asymptomat
bacteriuria
type
diabet
patient
without
microalbuminuria
daniil
papazafiropoul
konstantopoul
sotiropoulo
e
balampani
kokolaki
bousboula
pappa
petropoul
piraeu
gr
object
preval
asymptomat
bacteriuria
asb
diabet
patient
high
especi
women
aim
studi
evalu
preval
identifi
aetiolog
pathogen
asb
patient
type
diabet
mellitu
without
microalbuminuria
method
total
patient
without
recruit
studi
patient
overt
diabet
nephropathi
nephropathi
caus
symptom
urinari
track
infect
use
antimicrobi
drug
last
day
exclud
studi
microalbuminuria
diagnos
measur
albumin
excret
rate
aer
radioimmunoassay
ria
method
pharmacia
pharmacia
upjon
diagnost
ab
uppsala
sweden
midstream
clean
void
urinari
specimen
collect
urinalysi
examin
gram
stain
cultur
blood
macconkey
agar
detect
uropathogen
isol
pathogen
incub
identifi
use
ii
bd
diagnost
system
germani
api
system
vitek
compact
biomerieux
franc
result
preval
asb
increas
diabet
patient
compar
diabet
patient
without
versu
p
respect
escherichia
coli
preval
pathogen
isol
diabet
patient
without
versu
p
respect
follow
proteu
mirabili
versu
p
respect
klebsiella
spp
versu
p
respect
conclus
asb
preval
among
patient
main
caus
agent
e
coli
screen
asb
warrant
diabet
patient
especi
pyuria
detect
urin
analysi
sinc
asb
found
risk
factor
develop
symptomat
urinari
tract
infect
result
kp
strain
reveal
variou
suscept
imipenem
meropenem
strain
resist
ertapenem
suscept
gentamicin
tetracyclin
tigecyclin
colistin
strain
produc
belong
clone
patient
mean
age
year
rang
clinic
diagnosi
nine
acut
leukemia
one
chronic
lemphogen
leukemia
one
aplast
anemia
one
non
hodgkin
lymphoma
durat
patient
hospit
day
isol
kp
strain
three
patient
simultan
isol
kpc
strain
urin
cultur
observ
two
patient
bacteremia
found
colon
intestin
kpc
strain
four
patient
develop
first
bacteremia
intestin
colon
follow
neutropenia
observ
eight
patient
absolut
number
neutrophil
isol
kpc
strain
patient
treat
combin
blactam
antibiot
aminoglycosid
isol
treatment
chang
colistin
tigecyclin
andor
gentamycin
respons
poor
ten
patient
twelv
die
kpc
infect
conclus
bacteremia
produc
kp
hematolog
patient
high
mortal
consist
seriou
medicalnurseri
problem
addit
alreadi
exist
high
bacteria
resist
damci
istanbul
tr
object
identifi
risk
factor
contribut
treatment
respons
prognos
sever
diabet
foot
infect
materi
method
april
octob
prospect
studi
conduct
diabet
foot
studi
group
sever
diabet
foot
infect
result
total
patient
includ
studi
mean
age
rang
year
forti
three
patient
male
eighti
patient
diabet
ten
year
patient
previou
hospit
stay
previou
antibiot
use
within
last
three
month
durat
wound
infect
four
week
patient
purul
discharg
leucocytosi
found
patient
patient
elev
crp
level
five
fold
patient
classifi
wagner
stage
wagner
stage
thirti
three
patient
present
osteomyel
etiolog
identifi
patient
gram
neg
bacilli
isol
gram
posit
cocci
isol
grew
mix
bacteria
ten
microorgan
isol
esbl
produc
gram
neg
bacilli
three
mrsa
nine
mrse
seven
multidrug
resist
mdr
p
aeruginosa
three
mdr
baumannii
mean
durat
hospit
day
patient
underw
debrid
amput
perform
patient
major
amput
case
conclus
complet
clinic
improv
observ
patient
durat
diabet
ten
year
p
higher
fever
p
exist
purul
discharg
p
higher
wagner
stage
wound
p
elev
crp
level
fold
p
infect
mdr
bacteria
p
requir
amput
p
prolong
hospit
stay
p
neg
predictor
treatment
success
prognosi
method
cmv
seroposit
patient
age
whose
donor
also
seroposit
undergon
renal
transplant
januari
june
includ
studi
data
patient
record
retrospect
use
followup
form
form
includ
follow
inform
age
gender
primari
diseas
cold
ischemia
time
type
transplant
immunosuppress
treatment
scheme
durat
valganciclovir
use
advers
effect
cmv
antigenemia
level
whether
cmv
infect
diseas
develop
transplant
prophylaxi
group
vgc
n
administ
group
n
vgc
administ
short
time
iv
gansiklovir
administ
patient
receiv
antithymocyt
globulin
atg
treatment
iv
ganciclovir
administ
treatment
patient
follow
use
cmv
antigenemia
test
time
month
patient
follow
month
transplant
data
evalu
use
chisquar
test
test
independ
group
spss
softwar
demograph
characterist
rtr
receiv
vgc
prophylaxi
similar
total
atg
dose
significantli
higher
prophylaxi
group
group
determin
although
signific
rate
cmv
infect
develop
lower
patient
prophylaxi
administ
result
case
hmpv
pneumonia
identifi
australian
haematolog
unit
spring
case
separ
adjac
room
rais
possibl
nosocomi
transmiss
lymphopenia
present
complic
chemotherapi
anaplast
larg
cell
lymphoma
case
one
autolog
peripher
stem
cell
transplant
multipl
myeloma
case
two
mrsa
hmpv
identifi
bronchoalveolar
lavag
bal
fluid
respiratori
intub
ventil
intens
care
manag
requir
progress
respiratori
failur
whilst
maxim
therapi
mrsa
infect
bilater
ground
glass
infiltr
progress
nodular
confluent
parenchym
chang
salvag
treatment
ribavirin
start
week
symptom
onset
ribavirin
intraven
follow
intraven
total
day
case
one
patient
clear
viru
respiratori
tract
progress
complic
cerebrovascular
accid
second
patient
develop
extens
air
space
consolid
cavit
hmpv
detect
pcr
week
treatment
ribavirin
conclus
hmpv
infect
associ
signific
morbid
poor
outcom
lymphopenia
risk
factor
infect
hmpv
adult
patient
receiv
treatment
hematolog
malign
coinfect
mrsa
occur
neutrophil
recoveri
hypogammaglobulinaemia
may
contribut
sever
infect
ribavirin
well
toler
late
treatment
intraven
ribavirin
seven
day
erad
viral
shed
one
patient
may
contribut
clinic
virolog
cure
hmpv
may
detect
respiratori
secret
greater
week
adult
patient
haemopoeit
malign
implic
infect
control
measur
independ
risk
factor
pbsi
prior
blood
transfus
reveal
protect
factor
ci
empir
inappropri
antimicrobi
treatment
given
patient
pbsi
mbsi
p
infectionrel
mortal
patient
pbsi
mbsi
p
differ
durat
hospit
overal
mortal
observ
conclus
pbsi
repres
signific
percentag
bsi
among
patient
malign
although
inappropri
empir
antimicrobi
treatment
given
higher
percentag
patient
pbsi
mbsi
differ
durat
hospit
overal
mortal
observ
recognit
risk
factor
pbsi
knowledg
microbiolog
import
select
appropri
empir
antimicrobi
treatment
may
result
improv
outcom
result
sixtyon
uti
episod
diagnos
patient
sixtynin
percent
patient
femal
rang
age
year
one
uti
episod
seen
patient
three
lead
uropathogen
e
coli
klebsiella
spp
enterococci
e
coli
detect
episod
klebsiella
spp
detect
episod
enterococci
detect
episod
twentyon
e
coli
isol
esbl
posit
antimicrobi
resist
rate
esbl
neg
esbl
posit
e
coli
isol
shown
tabl
risk
factor
determin
hospit
time
diagnosi
hospit
within
month
recent
within
month
antibiot
use
urinari
catheter
conclus
risk
factor
urinari
tract
infect
caus
esbl
produc
bacteria
among
renal
transplant
recipi
similar
patient
group
nearli
half
uropathogen
e
coli
strain
esbl
posit
renal
transplant
recipi
high
percentag
resist
pathogen
caus
difficulti
manag
patient
multidrug
resist
bacteria
increasingli
isol
transplant
recipi
caus
high
morbid
mortal
aim
studi
determin
disribut
etiolog
agent
bacteri
infect
seen
earli
period
liver
transplant
retrospect
studi
conduct
patient
underw
orthotop
liver
transplant
consecut
januari
octob
baskent
univers
hospit
microbiolog
document
bacteri
infect
seen
first
month
liver
transplant
includ
studi
total
nineti
liver
transplant
perform
studi
period
twenti
eight
bacteri
infect
episod
diagnos
patient
within
day
transplant
oper
twelv
infect
intraabdomin
gram
neg
gram
posit
catheterrel
gram
neg
gram
posit
urinari
tract
infect
gram
neg
gram
posit
ventil
associ
pneumonia
gram
neg
gram
posit
total
episod
caus
gram
neg
bacteria
remain
caus
gram
posit
bacteria
strain
suscept
colistin
tigecyclin
defin
extens
drug
resist
xdr
seven
isol
gram
neg
strain
klebsiella
pneumonia
esbl
posit
xdr
strain
escherichia
coli
esbl
posit
strain
acinetobact
baumannii
xdr
strain
pseudomona
aeruginosa
distribut
gram
posit
pathogen
enterococcu
faecium
vancomycin
resist
methicillin
resist
coagulas
neg
staphylococci
methicillin
sensit
staphylococcu
aureu
methicillin
resist
staphylococcu
aureu
total
bacteremia
episod
detect
secondari
primari
incid
colon
infect
multidrug
resist
bacteria
particularli
gram
neg
strain
increas
throughout
world
data
regard
transplant
patient
limit
common
usag
extend
spectrum
antibiot
among
patient
preoper
postop
phase
undoubtedli
predispos
difficultto
treat
infect
infect
rate
seen
earli
postop
period
obtain
studi
compar
previou
one
high
percentag
multidrug
resist
strain
alarm
issu
communityacquir
infect
includ
cap
sepsi
std
c
trachomati
significantli
frequent
isol
sexual
partner
vs
discharg
vs
dysuria
vs
leukocyt
gram
stain
vs
u
urealyticum
signific
differ
age
vs
find
signific
differ
rest
issu
studi
find
signific
differ
rest
isol
microorgan
conclus
urethr
frequent
young
men
sexual
partner
discharg
leukocyt
gram
stain
n
gonorrhoea
frequent
isol
hsh
sexual
partner
pain
discharg
like
symptom
leukocyt
gram
stain
c
trachomati
isol
men
sexual
partner
dysuria
leukocyt
gram
stain
u
urealyticum
frequent
youngest
men
microbi
etiolog
periton
dialysi
pd
relat
periton
seem
vari
wide
children
data
adult
scarc
object
studi
determin
microbi
etiolog
correl
leucocyt
wbc
count
cultur
result
well
concord
cultur
gram
stain
pd
relat
case
periton
children
adult
review
record
patient
whose
periton
dialys
n
sent
lab
microbiolog
antwerp
univers
hospit
januari
august
microbi
etiolog
wbc
count
gram
stain
antibiot
treatment
analyz
per
episod
adult
children
includ
episod
microbi
etiolog
base
cultur
result
first
sampl
gram
stain
perform
leucocyt
count
exceed
per
logist
linear
regress
use
addit
mix
effect
model
repeat
patient
effect
determin
degre
correl
wbc
count
posit
cultur
episod
adultpediatr
periton
sampl
cultur
posit
isol
gram
posit
g
gram
neg
anaerob
yeast
etiolog
found
cultur
taken
antimicrobi
treatment
gram
stain
show
predomin
morphotyp
concord
cultur
result
adult
g
mainli
coagulas
neg
staphylococci
cn
aureu
viridan
streptococci
children
predomin
pathogen
e
faecali
cn
coryneform
aureu
preval
pathogen
adult
e
coli
e
cloaca
k
pneumonia
p
aeruginosa
nonferment
children
frequent
e
cloaca
p
aeruginosa
nonferment
signific
differ
wbc
count
found
cultur
sampl
adult
p
conclus
microbi
etiolog
found
major
case
gram
posit
relat
case
periton
frequent
adult
gram
neg
children
distribut
pathogen
also
differ
concord
gram
stain
cultur
appear
low
final
significantli
less
leucocyt
cultur
neg
dialys
compar
cultur
posit
dialys
intern
pmen
clone
equal
exceed
fit
strain
despit
accumul
antibiot
resist
rudolf
n
michaylov
van
der
linden
l
hoy
kp
klugman
welt
mw
object
small
number
global
pneumococc
clone
defin
pneumococc
molecular
epidemiolog
network
pmen
domin
popul
antibioticresist
pneumococci
remain
unclear
pmen
clone
spread
success
despit
scientif
paradigm
loss
biolog
fit
price
acquisit
resist
aim
studi
detect
pmen
clone
relat
clinic
isol
adult
patient
communityacquir
pneumonia
cap
collect
german
capnetz
surveil
studi
compar
unrel
clone
term
antibioticresist
biolog
fit
clinic
paramet
method
multilocu
sequenc
type
mlst
data
use
defin
related
pmen
clone
clinic
pneumococc
isol
related
defin
share
allel
loci
fit
determin
measur
growth
curv
bacteri
growth
measur
micropl
reader
optic
densiti
nm
interv
five
minut
period
hour
compar
bacteri
growth
analys
maximum
slope
curv
experi
repeat
nine
time
statist
analysi
perform
chisquar
test
fisher
exact
test
categori
variabl
ttest
analysi
varianc
anova
continu
variabl
result
analys
pneumococc
isol
isol
show
close
relationship
global
pmen
clone
isol
equal
exceed
fit
isol
without
relationship
pmen
clone
vs
p
constitut
antibioticresist
isol
survey
clinic
paramet
show
promin
signific
differ
group
conclus
success
intern
pmen
clone
base
combin
resist
fit
may
result
endur
strain
despit
reduct
antibiot
usag
new
vaccin
interrupt
transmiss
resist
strain
continu
attent
replac
nonvaccin
serotyp
develop
vaccin
broader
coverag
necessari
object
aim
studi
compar
occurr
genit
chlamydia
trachomati
genit
mycoplasma
ureaplasma
semen
sampl
fertil
infertil
men
kuwait
total
nondupl
semen
sampl
collect
infertil
control
men
seen
infertil
clinic
matern
hospit
studi
inform
consent
semen
analysi
perform
accord
guidelin
world
health
organ
specimen
examin
presenc
ureaplasma
urealyticum
mycoplasma
homini
mycoplasma
genitalium
chlamydia
trachomati
pcr
use
publish
specif
primer
biodata
age
nation
marit
statu
care
record
result
frequenc
genit
u
urealyticum
homini
genitalium
c
trachomati
semen
sampl
respect
mix
infect
detect
infertil
particip
posit
u
urealyticum
homini
respect
semen
sampl
show
statist
signific
differ
mean
sperm
concentr
vital
percentag
total
progress
rapid
progress
motil
comparison
control
fertil
particip
p
similar
statist
signific
differ
note
infertil
fertil
men
posit
genitalium
c
trachomati
p
infect
infertil
men
marri
less
year
significantli
higher
infect
fertil
men
length
marriag
infect
caus
urogenit
pathogen
common
among
infertil
men
fertil
men
may
possibl
play
role
part
etiolog
male
infertil
part
world
genit
mycoplasma
chlamydi
infect
may
neg
influenc
semen
qualiti
object
pleural
empyema
seriou
infect
character
accumul
pu
pleural
space
us
patient
suffer
empyema
year
mortal
mani
studi
address
risk
factor
outcom
empyema
reli
hospit
discharg
diagnosi
code
record
health
care
databas
valid
diagnosi
pleural
empyema
danish
nation
registri
patient
dnrp
randomli
select
hospit
inpati
north
denmark
region
firsttim
discharg
diagnosi
pleural
empyema
retriev
review
medic
record
estim
posit
predict
valu
ppv
empyema
diagnosi
definit
empyema
defin
frank
pu
aspir
pleural
space
posit
gram
stainsubcultur
pathogen
microorgan
pleural
fluid
andor
autopsi
diagnosi
empyema
patient
clinic
symptom
suggest
empyema
associ
compat
radiograph
featur
eg
pleural
thicken
locul
andor
septat
pleural
effus
meet
criteria
definit
empyema
classifi
probabl
empyema
result
could
retriev
medic
record
sampl
patient
empyema
classifi
definit
empyema
case
anoth
patient
classifi
probabl
empyema
case
patient
whose
empyema
diagnosi
reject
eight
pneumonia
one
pulmonari
abscess
one
pulmonari
tuberculosi
one
sarcoidosi
two
emphysema
overal
ppv
empyema
diagnosi
ci
ppv
ci
includ
definit
case
ppv
empyema
diagnos
ci
ci
ci
respect
indic
major
chang
code
valid
occur
studi
period
ppv
decreas
slightli
patient
age
year
patient
age
year
uniformli
high
regardless
studi
period
hospit
depart
type
caus
empyema
high
overal
ppv
indic
good
agreement
code
pleural
empyema
medic
record
registrybas
discharg
code
may
suitabl
sourc
data
pleural
empyema
epidemiolog
research
introduct
nocardia
rare
pathogen
caus
predominantli
pulmonari
andor
skin
soft
tissu
infect
sinc
immunosuppress
one
main
predispos
factor
nociardi
infect
may
increas
rise
number
patient
immunosuppress
therapi
eg
solid
organ
bone
marrow
transplant
data
futher
risk
factor
clinic
cours
treatment
nocardi
infect
limit
case
report
small
case
seri
aim
establish
regist
nocardia
infect
germani
switzerland
netherland
method
retrospect
analysi
microbiolog
proven
pulmonari
nocardia
spp
infect
hospit
germani
netherland
defin
detect
nocardia
spp
respiratori
sampl
radiolag
chang
sign
symptom
pulmonari
infect
result
twentyon
case
pulmonari
nocardiosi
could
identifi
male
femal
mean
age
year
addit
pulmonari
involv
dissemin
diseas
detect
patient
cerebr
abscess
format
eleven
patient
pulmonari
comorbid
n
copd
n
bronchiektasi
n
cystic
fibrosi
n
asthma
n
posttb
twelv
patient
identifi
caus
immunosuppress
hematolog
dieseas
malign
drug
induc
immunosuppress
diabet
mellitu
patient
test
hiv
neg
time
sampl
avail
microbiolog
result
day
case
proven
cultur
patient
addit
pcrsequenc
perform
n
farcinica
n
n
abscessu
n
n
asteroid
n
n
nova
n
carnea
n
cyriacigeorgica
n
otitidiscaviarum
n
paucivoran
n
pathogen
isol
bal
n
sputum
n
biopsi
n
tracheobronchi
aspir
n
abscess
aspir
n
patient
receiv
cotrimoxazol
treatment
mean
durat
treatment
week
one
patient
die
conclus
pulmonari
nocardiosi
remain
rare
diseas
although
immunosuppress
eg
drug
induc
immunosuppress
malign
major
risk
factor
also
occur
patient
without
obvious
impair
immunocompet
patient
frequent
suffer
chronic
pulmonari
diseas
copd
delay
vitro
growth
nocardia
spp
may
lead
misdiagnosi
underestim
nocardiosi
patient
without
typic
risk
factor
prospect
studi
predictor
earli
death
bacteraemia
dc
lye
pada
ng
r
llorin
kee
lee
p
krishnan
barkham
b
ang
singapor
sg
object
inact
empir
antibiot
occur
patient
bacteraemia
mortal
discharg
blood
cultur
servic
start
april
ensur
activ
antibiot
within
day
blood
cultur
collect
prospect
bacteraemia
studi
februari
june
note
mortal
discharg
decreas
death
occur
posit
blood
cultur
notifi
aim
studi
patient
earli
death
clinic
predictor
method
patient
die
earli
death
late
death
posit
blood
cultur
notifi
compar
earli
death
survivor
univari
multivari
analysi
perform
independ
predictor
earli
death
result
patient
case
bacteraemia
patient
die
earli
death
male
compris
median
age
year
charlson
score
staphylococcu
aureu
occur
methicillinresist
mrsa
escherichia
coli
klebsiella
pneumonia
carri
extendedspectrum
blactamas
proteu
mirabili
candida
speci
univari
analysi
earli
death
vs
late
death
age
year
odd
ratio
confid
interv
ventilatori
support
multivari
analysi
independ
predictor
earli
death
vs
survivor
pneumonia
aor
ci
inact
empir
antibiot
aor
ci
hypotens
aor
ventilatori
support
aor
ci
studi
show
hypotens
patient
need
ventilatori
support
pneumonia
inact
empir
antibiot
like
die
blood
cultur
could
notifi
crucial
ensur
adequ
empir
antibiot
cohort
coba
ctgc
test
siemensvers
ctgc
dna
assay
kpcr
detect
chlamydia
trachomatisneisseria
gonorrhoea
object
abbott
realtim
ar
method
compar
roch
coba
amplicor
rca
detect
chlamydia
trachomati
ct
neisseria
gonorrhoea
gc
urin
sampl
siemen
versant
sv
third
test
minor
seri
urin
sampl
ar
sv
autom
system
short
handsontim
tecan
miniprep
use
dna
extract
rca
method
ct
test
urin
sampl
gc
urin
sampl
rca
ar
sampl
taken
year
test
rca
within
day
collect
frozen
minor
select
includ
frozen
urin
sampl
ar
also
test
within
day
collect
rcaand
svmethod
result
ar
detect
ctposit
rca
among
sampl
correl
ctposit
neg
result
gctest
rca
found
confirm
posit
sampl
ar
ar
detect
ctposit
sampl
rca
correl
sv
respect
test
gave
sampl
ctneg
ctposit
rca
sv
detect
sampl
neg
sv
posit
rca
rca
compar
ar
ar
neg
posit
rca
sv
ar
test
sampl
ctneg
sv
ctposit
sampl
rca
detect
ctneg
sampl
arand
rca
method
detect
gcsampl
posit
conclus
rca
use
dna
extractor
sensit
contamin
two
manual
pipet
may
risk
falseposit
also
possibl
falseneg
sampl
inabl
detect
new
variant
ct
nvct
unlik
ar
sv
sampl
store
frozen
may
effect
result
ar
need
sampl
volum
less
sv
ar
offer
separ
unit
dna
extract
pcr
gcposit
sampl
detect
ar
target
opaa
gene
need
confirm
high
specif
make
ar
suitabl
system
clinic
microbiolog
laboratori
preval
nvct
need
test
cho
j
chung
choi
kwak
seoul
gyeonggi
kr
object
actinomycosi
chronic
infect
caus
anaerob
microaerophil
gramposit
bacteria
actinomyc
spp
classic
involv
cervicofaci
abdominopelv
thorac
mix
organ
includ
skin
brain
pericardium
extrem
recent
studi
reveal
chang
type
actinomycosi
retrospect
studi
describ
clinic
manifest
patient
actinomycosi
studi
durat
iv
antibiot
treatment
rang
day
patient
receiv
oral
antibiot
therapi
without
iv
antibiot
durat
oral
antibiot
treatment
rang
day
one
patient
receiv
surgic
treatment
without
antibiot
conclus
last
three
decad
incid
actinomycosi
declin
markedli
better
oral
hygien
extens
use
antibiot
clinic
pictur
chang
incid
cervicofaci
type
declin
thorac
type
increas
treatment
actinomycosi
also
chang
shortcours
chemotherapi
recent
report
success
renko
h
kukkola
h
kauma
tapiainen
uhari
oulu
fi
background
streptococcu
pneumonia
common
caus
commun
acquir
invas
bacteri
infect
children
adult
infect
previous
healthi
diseas
subject
incid
invas
pneumococc
diseas
differ
age
group
well
known
effect
age
clinic
outcom
invas
pneumococc
diseas
document
want
analyz
whether
clinic
impress
children
recov
quickli
invas
pneumococc
diseas
adult
true
method
review
medic
record
blood
cultur
posit
commun
acquir
case
pneumococc
diseas
admit
univers
hospit
oulu
year
data
clinic
symptom
laboratori
valu
imag
studi
medic
outcom
collect
compar
children
adult
studi
period
vaccin
pneumococc
diseas
recommend
specif
risk
group
patient
immun
defici
peopl
older
year
result
paediatr
year
adult
case
one
hundr
seven
patient
adult
children
previous
healthi
none
children
die
mortal
among
adult
differ
confid
interv
ci
median
length
stay
hospit
lo
day
children
day
adult
differ
median
day
ci
take
account
patient
underli
condit
median
lo
day
children
day
adult
p
cours
outcom
invas
pneumococc
infect
far
sever
adult
patient
compar
children
may
explain
differ
attitud
toward
pneumococc
vaccin
among
physician
take
care
either
children
adult
n
borovkova
j
stsepetova
h
oopkaup
p
korrovit
punab
r
tartu
ee
physiolog
condit
vagin
microflora
vmf
contain
high
number
lactic
acid
bacteria
provid
colon
resist
time
vmf
open
ecosystem
significantli
affect
sexual
intercours
aim
clarifi
influenc
sexual
intercours
partner
vagin
lactoflora
method
studi
group
includ
women
mean
age
year
two
selfcollect
vagin
sampl
taken
follicular
phase
intercours
hour
intercours
vmf
assess
nugent
method
lactobacilli
cultur
mr
agar
type
appcr
method
identifi
sequenc
result
accord
nugent
score
normal
vagin
flora
score
found
women
specimen
intermedi
score
found
women
bacteri
vaginosi
score
woman
women
normal
microflora
found
first
sampl
intermedi
microflora
postintercours
sampl
addit
score
increas
two
women
total
mean
score
higher
intercours
vs
cultur
lactobacilli
found
women
mean
proport
lactobacilli
total
microflora
somewhat
lower
afterintercours
sampl
vs
isol
strain
identifi
lactobacillu
jensenii
women
l
crispatu
l
gasseri
one
third
women
speci
isol
appcr
allow
us
confirm
persist
strain
case
though
quarter
women
strain
speci
differ
fingerprint
reveal
conclus
lactobacillu
speci
composit
estonian
women
coincid
describ
earlier
sexual
intercours
caus
shift
vagin
lactoflora
reveal
increas
nugent
score
decreas
lactobacillu
proport
vmf
j
blocher
eckert
j
elster
j
wiefek
h
eiffert
h
schmidt
de
object
aquaporin
aqp
protein
facilit
water
transport
cell
membran
due
main
local
plexu
choroideu
perivascular
endfeet
astrocyt
brain
channel
suppos
play
pivot
role
oedema
format
cerebr
oedema
format
one
main
contributor
neuron
damag
bacteri
mening
bm
studi
aim
determin
whether
present
cerebrospin
fluid
csf
bm
induc
increas
protein
csf
whether
concentr
correl
routin
csf
paramet
inflamm
p
concentr
csf
bm
patient
invers
intercorrel
r
p
could
find
correl
concentr
routin
csf
paramet
leukocyt
lactat
protein
qalbumin
age
predictionscor
outcomescor
gc
admiss
conclus
bacteri
mening
caus
increas
releas
csf
whether
signific
elev
due
higher
express
intact
choroid
cell
due
destruct
glial
cell
need
determin
coen
passerini
r
terzi
p
zucchi
g
rizzardini
milan
object
aim
studi
evalu
outcom
prosthet
joint
infect
pji
due
differ
microorgan
treat
differ
option
analyz
econom
impact
pji
method
consid
retrospect
patient
pji
isol
microorgan
obtain
blood
cultur
andor
deep
sampl
andor
intraoperatori
sampl
defin
cure
patient
without
sign
local
infect
neg
inflammatori
index
month
antimicrobi
therapi
interrupt
order
quantifi
cost
treatment
consid
averag
weekli
cost
antimicrobi
therapi
result
pji
includ
analysi
obtain
isol
microrgan
case
furthermor
evalu
import
choic
therapeut
option
prosthet
remov
consequ
substitut
cure
vs
patient
underw
debrid
retent
patient
treat
longterm
suppress
antimicrobi
treatment
mean
weekli
cost
pji
analysi
microrgan
involv
mrsamrs
increas
conclus
analysi
signific
proport
pji
pathogen
remain
unidentifi
previous
describ
two
stage
substitut
prosthesi
result
success
option
taken
whole
data
suggest
import
multidisciplinari
approach
manag
prosthet
joint
infect
stage
allow
time
identif
microorgan
whenev
possibl
medic
surgic
approach
allow
favour
outcom
mrsamrs
continu
seriou
challeng
patient
prosthet
infect
associ
wors
outcom
greater
cost
compar
infect
caus
microorgan
h
kim
ns
lee
kwon
yk
kim
uh
j
lee
wonju
chungju
kr
object
evalu
clinic
signific
delta
neutrophil
index
dni
correspond
immatur
granulocyt
peripher
blood
patient
sepsi
method
review
medic
laboratori
record
consecut
hospit
adult
patient
sepsi
may
june
one
tertiari
univers
hospit
dni
measur
blood
cell
analyz
advia
siemen
inc
result
total
patient
sepsi
mean
age
year
mean
dni
valu
rang
mean
apach
ii
score
rang
dni
valu
sepsi
n
sever
sepsi
n
septic
shock
n
respect
p
dni
valu
bacterem
patient
n
higher
nonbacterem
patient
n
vs
p
dni
valu
signific
differ
survivor
n
nonsurvivor
n
vs
p
dni
valu
bacterem
patient
significantli
higher
nonsurvivor
n
survivor
n
vs
p
present
find
indic
dni
may
use
prognost
marker
bacterem
sepsi
gorbich
g
chistenko
gorbich
minsk
object
evalu
epidemiolog
communityacquir
pneumonia
cap
hospit
belarusian
children
method
consecut
immunocompet
children
hospit
main
citi
children
infecti
diseas
hospit
radiograph
confirm
cap
evalu
retrospect
januari
decemb
analyz
age
past
histori
clinic
manifest
length
hospit
stay
sever
diseas
influenc
repeat
case
cap
child
result
patient
studi
month
age
rang
month
year
old
boy
major
pneumonia
case
regist
twoyearsold
children
second
place
occupi
oneyearold
children
third
place
threeyearsold
children
children
younger
year
age
pneumonia
case
major
patient
hospit
first
week
ill
mostli
day
case
children
admit
initi
diagnosi
pneumonia
pneumonia
moder
sever
level
hospit
children
patient
sever
cap
mean
length
hospit
day
rang
day
children
histori
acut
upper
respiratori
tract
infect
bronchiti
respect
patient
experienc
one
cap
episod
past
histori
influenza
regist
anamnesi
patient
studi
patient
attend
preschool
school
organ
analysi
repeat
case
pneumonia
among
studi
patient
nt
reveal
statist
signific
interrel
sever
diseas
presenc
pneumonia
episod
patient
histori
odd
ratio
confid
interv
p
cap
case
regist
round
year
morbid
increas
septemb
slightli
decreas
decemb
anoth
increas
record
januari
maximum
level
note
novemb
case
april
case
conclus
children
cap
signific
problem
belarusian
health
system
main
group
associ
cap
children
age
year
old
futur
immun
use
licens
pneumococc
influenza
vaccin
may
reduc
frequenc
pneumonia
year
old
man
father
first
patient
igg
igm
host
stray
cat
garden
close
longterm
contact
year
old
woman
igg
igm
infect
attribut
eat
raw
meat
conclus
women
test
prove
seroposit
percentag
come
total
complianc
studi
conduct
northern
greec
among
women
reproduct
age
compar
result
previou
studi
clearli
observ
decreas
seroposit
rate
last
decad
women
test
previou
contact
gondii
therfor
suscept
possibl
sourc
infect
suscept
individu
take
account
peopl
habit
drama
provinc
eat
habit
low
consumpt
undercook
meat
high
consumpt
lamp
goat
sheep
smoke
pork
sausag
salad
consist
raw
wild
veget
fruit
well
document
sourc
gondii
great
number
stray
cat
unknown
respons
primari
efficaci
endpoint
microbiolog
respons
defin
erad
presum
erad
secondari
endpoint
global
respons
end
iv
therapi
eoivt
week
eot
time
neg
blood
cultur
surviv
day
advers
event
ae
result
pt
receiv
studi
drug
includ
mitt
popul
candidemia
c
albican
common
caus
pathogen
common
cic
risk
factor
includ
broadspectrum
antibiot
pt
central
venou
cathet
prior
surgeri
total
parenter
nutrit
test
baselin
isol
fulli
suscept
anifluvor
except
c
albican
flu
vor
glabrata
flu
c
parapsilosi
ani
flu
c
krusei
flu
overal
mic
ani
flu
vor
mgml
mgml
mgml
respect
microbiolog
global
respons
differ
time
point
across
select
subpopulationsbaselin
pathogen
infect
site
shown
tabl
mean
time
first
neg
blood
cultur
day
surviv
patient
treatmentrel
ae
led
studi
discontinu
pt
infusionrel
ae
occur
pt
select
icu
popul
ani
effect
safe
well
toler
firstlin
therapi
cic
eot
outcom
incl
microbiolog
respons
similar
across
baselin
pathogen
infect
site
patient
popul
pyloriposit
patient
duoden
ulcer
n
zakharova
v
simanenkov
suvorov
g
belov
saint
petersburg
ru
background
helicobact
pylori
h
pylori
erad
rate
follow
standard
tripl
therapi
decreas
worldwid
lowest
incid
sideeffect
standard
therapi
observ
probiot
combin
antibiot
low
erad
rate
lack
treatment
regimen
altern
approach
h
pylori
explor
assess
efficaci
safeti
synbiot
compar
prebiot
h
pylori
erad
duoden
ulcer
du
patient
method
random
doubleblind
placebocontrol
trial
last
week
pill
contain
either
specif
synbiot
e
faecium
cfug
pectin
soy
protein
hydrolyz
laminaria
saccharina
prebiot
pectin
soy
protein
hydrolyz
laminaria
saccharina
placebo
pill
manufactur
conduct
trial
h
pyloriposit
patient
remiss
du
randomli
assign
three
group
group
receiv
synbiot
group
b
receiv
prebiot
group
c
receiv
placebo
patient
took
three
pill
three
time
daili
gastroscopi
perform
week
end
treatment
du
activ
evalu
h
pylori
detect
carri
rapid
ureas
test
polymeras
chain
reaction
pcr
primer
vaca
ureab
ureac
gastric
biopsi
differ
erad
frequenc
evalu
chisquar
test
intentiontotreat
itt
perprotocol
pp
analys
use
assess
erad
rate
h
pylori
result
h
pylori
erad
rate
group
b
c
patient
patient
patient
respect
accord
pp
itt
synbiot
show
higher
erad
rate
prebiot
p
placebo
p
clinic
endoscop
relaps
du
chronic
gastriti
observ
patient
group
patient
group
b
patient
group
c
though
h
pylori
erad
relaps
still
occur
case
attribut
relaps
risk
respect
relaps
risk
ratio
synbiot
vs
placebo
case
enterococcu
colon
gastric
mucosa
reveal
pcr
e
faecium
specif
primer
conclus
monotherapi
synbiot
base
e
faecium
effect
prebiot
placebo
h
pylori
erad
monotherapi
synbiot
increas
risk
du
relaps
indic
h
pylori
major
caus
du
one
phase
prospect
randomis
studi
investig
daptomycin
mgkg
versu
standard
antibiot
therapi
treatment
staphylococc
prosthet
joint
infect
byren
wheeler
e
campanaro
yankelev
anastasi
g
kuropatkin
r
evan
osmon
oxford
uk
lexington
us
samara
ru
littl
rock
rochest
us
object
evolv
resist
gramposit
organ
support
investig
higher
dose
daptomycin
manag
prosthet
joint
infect
pji
prospect
openlabel
studi
subject
randomis
daptomycin
dap
mgkg
compar
vancomycin
teicoplanin
semisynthet
penicillin
undergo
replac
hip
knee
pji
remov
prosthesi
subject
receiv
week
treatment
week
antibioticfre
period
implant
new
prosthesi
test
cure
toc
week
reimplant
primari
object
evalu
measur
compar
preval
ida
h
pylori
infect
group
result
case
girl
case
control
group
boy
case
group
control
h
pylori
serolog
posit
case
control
group
infect
meaning
differ
pvalu
conclus
result
support
propos
h
pylori
infect
associ
ida
children
herreramartinez
herreramartinez
limper
barquisimeto
amsterdam
nl
background
sexual
transmit
diseas
std
pregnanc
pose
major
risk
fetu
due
vertic
transmiss
congenit
diseas
still
repres
signific
public
health
problem
worldwid
particularli
develop
countri
method
materi
retrospect
investig
perform
compris
pregnant
women
hiv
andor
syphili
infect
admit
central
hospit
cof
two
western
citi
venezuela
januari
pregnant
women
without
std
serv
control
group
epidemiolog
characterist
report
anthropometr
variabl
newborn
consid
statist
signific
defin
p
statist
analys
perform
spss
result
pregnant
hiv
patient
patient
syphili
infect
identifi
three
coinfect
pregnant
women
without
std
serv
control
mean
age
infect
mother
hivsyphili
year
rang
yr
mean
pregnanc
rang
control
group
pregnanc
week
observ
newborn
mean
birth
weight
mean
height
hiv
infect
patient
mean
gestat
week
rang
week
mean
birth
weight
newborn
g
rang
g
low
birth
weight
newborn
mean
birth
height
cm
rang
syphili
infect
patient
mean
gestat
week
rang
week
mean
birth
weight
newborn
g
rang
g
low
birth
weight
newborn
mean
birth
height
cm
rang
cm
matern
vdrl
titer
strongli
associ
birth
weight
higher
mother
vdrl
titer
correl
lower
birth
weight
cephal
thorac
abdomin
circumfer
show
consider
differ
group
conclus
std
caus
consider
morbid
women
gestat
period
congenit
perinat
infect
newborn
miscarriag
low
birth
weight
describ
studi
hiv
syphili
infect
result
lower
birth
weight
particularli
newborn
hiv
infect
patient
treatment
etiolog
agent
consid
effect
prevent
vertic
transmiss
recommend
std
kyratsa
grafako
guahardo
p
giannopoul
f
lykou
zabou
varzakako
voyatzi
e
trikka
athen
gr
parvo
dna
viru
respons
erythema
infectiosum
fifth
diseas
infecti
benign
rash
common
childhood
pregnant
women
may
also
develop
parvo
infect
sever
conjenit
malform
object
studi
epidemiolog
profil
infect
hospit
paediatr
popul
athen
method
two
year
period
igm
igg
antibodi
parvo
viru
detect
blood
sampl
hospit
children
age
month
till
year
fever
suspicion
parvovir
infect
antibodi
titr
detect
immunoassay
reconfirm
indirect
immunofluoresc
bio
germani
result
clinic
sampl
equal
number
patient
acut
infect
diagnos
patient
igg
antibodi
detect
children
slight
differ
observ
incid
antibodi
detect
sex
incid
igg
antibodi
detect
children
age
less
year
inferior
comparison
incid
children
age
year
increas
incid
infect
observ
winter
spring
month
conclus
earli
accur
diagnosi
parvo
infect
base
igm
antibodi
detect
increas
igg
antibodi
titr
crucial
hospit
children
infecti
rash
leukopenia
chronic
haemolyt
anaemia
popul
athen
guahardo
grafako
kyratsa
f
lykou
p
giannopoul
athanasopoulo
varzakako
e
trikka
voyatzi
athen
gr
toxoplasmosi
worldwid
public
health
diseas
nowday
incid
vari
among
differ
countri
depend
live
standard
dietari
habit
socioeconom
statu
popul
object
determin
incid
toxoplasmosi
children
cervic
gener
lymphadenopathi
detect
igm
igg
antibodi
five
year
method
determin
igm
igg
antibodi
titr
toxoplasma
gondii
perform
immunoassay
sera
children
lymphadenopathi
age
till
year
hospit
admit
emerg
depart
everi
child
two
blood
sampl
drawn
distanc
period
day
examin
torch
virul
agent
reconfirm
acut
infect
perform
indirect
immunofluoresc
well
observ
fourth
time
rise
igg
antibodi
titr
result
children
examin
posit
igg
igm
antibodi
toxoplasma
gondii
children
posit
igg
igm
antibodi
rise
seroposit
observ
accord
increas
age
higher
incid
infect
observ
age
group
differ
observ
incid
antibodi
detect
sex
conclus
toxoplasma
gondii
import
caus
lymphadenopathi
childhood
greec
low
incid
probabl
due
habit
eat
wellcook
meat
good
socioeconom
statu
studi
popul
object
isol
candida
spp
cerebrospin
fluid
csf
preterm
neonat
rare
describ
clinic
characterist
diagnosi
two
case
hospit
prematur
neonat
whose
candida
albican
isol
csf
method
first
case
set
femal
dizygot
twin
born
w
gestat
twin
die
within
hour
twin
b
transfer
neonat
intens
care
unit
nicu
mother
treat
cervic
incompet
vagin
candidiasi
trimest
pregnanc
neonat
b
start
empir
antibiot
therapi
elev
crp
low
csf
glucos
level
blood
csf
cultur
neg
day
neonat
look
slightli
unwel
lumbar
punctur
lp
repeat
second
case
male
neonat
born
w
gestat
neonat
present
respiratori
distress
syndrom
neonat
jaundic
transfer
nicu
empir
antibiot
therapi
start
although
univari
binari
logist
regress
model
impact
neonat
matern
factor
sepsi
risk
estim
term
odd
ratio
confid
interv
ci
result
studi
reveal
impact
bacteri
pathogen
neonat
matern
predispos
factor
sepsi
follow
matern
factor
prom
affect
sepsi
risk
p
neonat
factor
mean
age
neonat
earlyonset
sepsi
lower
lateonset
sepsi
differ
statist
signific
p
low
birth
weight
lbw
g
increas
risk
sepsi
p
gestat
age
ga
week
significantli
associ
sepsi
p
septicemia
turn
increas
risk
death
p
half
septic
neonat
posit
result
crp
wherea
neonat
sepsi
crp
neg
differ
statist
signific
p
tashiro
ueda
n
kohda
kohno
otsu
nagasaki
jp
object
fatal
caus
streptococcu
pneumonia
pneumonia
infect
high
young
children
elderli
hostdefens
mechan
pathogen
infect
involv
innat
acquir
immun
system
particular
secretori
immunoglobulin
iga
innat
immun
airway
mucosa
play
princip
role
prevent
infect
lactobacillu
pentosu
screen
excel
igainduc
bacterium
vitro
present
studi
aim
investig
whether
nonviabl
prevent
pneumonia
infect
mice
method
cbaj
mice
administ
week
prior
lethal
pneumonia
infect
surviv
bodi
weight
mice
monitor
daili
week
infect
isol
lung
evalu
sever
pneumonia
number
pneumonia
concentr
inflammatori
cytokin
express
tolllik
receptor
lung
homogen
infect
determin
pneumococc
pneumonia
model
oral
intak
led
prolong
surviv
time
significantli
inhibit
bodi
weight
loss
well
reduc
bronchiti
signific
decreas
secret
level
inflammatori
cytokin
tolllik
receptor
express
promot
mice
result
exhibit
accord
allevi
patholog
sever
pneumonia
conclus
result
suggest
lactobacillu
pentosu
intak
facilit
protect
pneumonia
infect
via
modul
innat
immun
matsumoto
h
ishikawa
e
kutsukak
fukui
sato
shirai
kurihara
n
okada
h
danbara
toba
maeda
n
kohda
tokyo
otsu
uenohara
jp
object
one
benefici
effect
probiot
bacteria
protect
host
infect
variou
enter
pathogen
viabl
lactobacilli
use
probiot
studi
studi
use
heatkil
probiot
bacteria
report
purpos
studi
investig
effect
heatkil
lactobacillu
pentosu
system
infect
salmonella
enterica
serovar
typhimurium
styphimurium
determin
mechan
protect
infect
determin
whether
oral
administr
heatkil
would
affect
surviv
mice
typhimurium
infect
mice
oral
administ
salin
daili
week
typhimurium
oral
inocul
surviv
mice
monitor
day
inocul
studi
effect
bacteri
transloc
typhimurium
mice
treat
oral
salin
daili
week
variou
organ
remov
day
typhimurium
inocul
viabl
number
bacteria
evalu
also
examin
effect
adhes
invas
typhimurium
hela
cell
vitro
assay
mice
treat
significantli
protect
styphimurium
compar
fed
salin
moreov
viabl
number
styphimurium
organ
mice
tend
less
control
mice
vitro
studi
demonstr
inhibitori
effect
bind
invas
styphimurium
cell
oral
administr
lactobacillu
pentosu
protect
mice
styphimurium
infect
inhibit
adhes
invas
styphimurium
intestin
epitheli
cell
associ
reduct
bacteri
system
infect
result
suggest
nonviabl
lactic
acid
bacteria
also
play
import
role
prevent
infect
enter
pathogen
immunogen
pneumococc
conjug
vaccin
impact
pneumococc
carriag
infant
venezuela
sickl
cell
diseas
hiv
infect
ia
riveraolivero
b
del
nogal
mc
sisco
fuent
r
cortez
bogaert
pw
herman
jh
de
waard
caraca
utrecht
nijmegen
nl
object
evalu
immunogen
pneumococc
conjug
vaccin
impact
pneumococc
carriag
infant
sickl
cell
diseas
scd
hiv
infect
method
children
scd
n
hiv
n
list
children
hospit
caraca
venezuela
enrol
studi
vaccin
accord
age
conjug
vaccin
follow
booster
dose
pneumococc
polysaccharid
vaccin
blood
sampl
nasopharyng
swab
determin
antibodi
concentr
vaccin
serotyp
isol
pneumonia
respect
obtain
immedi
month
booster
result
infant
enrol
studi
pneumococc
carriag
prior
first
immun
found
n
children
n
carri
nonvaccin
serotyp
boost
subject
antibodi
titer
mgml
vaccin
serotyp
rang
mgml
serotyp
mgml
serotyp
one
month
complet
vaccin
scheme
pneumococc
carriag
found
n
children
n
carri
non
vaccin
serotyp
conclus
high
antibodi
titer
serotyp
conjug
vaccin
obtain
vaccin
scheme
children
howev
signific
effect
carriag
rate
gener
carriag
rate
vaccin
serotyp
observ
group
consist
healthi
aureu
carrier
mean
level
serum
cytokin
amount
follow
pgml
tnfa
pgml
ifng
pgml
group
first
sampl
level
cytokin
follow
pgml
tnfa
pgml
ifng
pgml
level
ifng
significantli
higher
p
mean
level
group
turn
second
sampl
mean
level
ifng
significantli
higher
p
level
note
upon
first
sampl
amount
pgml
serum
level
tnfa
increas
patient
pgml
p
pgml
p
respect
remain
unalt
remain
patient
time
patient
presenc
aureu
could
detect
throat
smear
obtain
time
second
sampl
conclus
effect
immun
respons
aureu
seem
depend
level
circul
cytokin
tnfa
product
may
stimul
aureu
autovaccin
background
evid
shown
relationship
human
cytomegaloviru
cmv
infect
pregnanc
loss
howev
whether
recurr
latent
cmv
infect
alter
immun
respons
cmv
may
relat
recurr
pregnanc
loss
rpl
unclear
data
avail
regard
evalu
cmv
infect
humor
immunolog
respons
cmv
women
rpl
compar
women
without
histori
abort
crosssect
observ
studi
conduct
clinic
immunolog
outpati
clinic
alzahra
univers
hospit
isfahan
iran
case
women
rpl
refer
obstetr
gynecolog
outpati
clinic
control
randomli
select
healthi
age
match
multipar
women
without
histori
abort
inclus
criteria
least
recurr
spontan
abort
histori
diagnos
underli
diseas
etiolog
rp
l
blood
sampl
obtain
patient
control
evalu
cmv
igg
igm
antibodi
igg
avid
index
enzym
link
immunosorb
assay
method
elisa
data
analyz
spss
version
use
student
ttest
chisquar
test
multivari
analys
result
one
case
posit
igm
group
rpl
control
detect
also
case
posit
igg
rpl
control
p
patient
control
similar
regard
serum
igm
titer
p
igg
titer
significantli
higher
rpl
group
p
differ
found
two
group
igg
avid
index
p
multivari
analys
igg
posit
relat
rpl
p
avid
relat
rpl
p
also
igg
posit
p
igm
posit
p
avid
index
p
relat
number
abort
rpl
patient
conclus
previou
exposur
cmv
detect
posit
igg
antibodi
significantli
relat
rpl
present
studi
howev
found
relationship
igg
avid
index
rpl
whether
latent
cmv
infect
start
indirect
process
autoimmun
etiolog
rpl
women
rpl
recurr
reactiv
cmv
infect
avid
index
best
index
detect
mostli
alter
immun
function
cmv
rpl
patient
need
investig
atrasheuskaya
ia
karpov
gm
ignatyev
minsk
mump
virusneutr
antibodi
believ
predict
surrog
marker
protect
immun
remot
histori
vaccin
also
suggest
wane
immun
could
contribut
vaccine
suscept
mump
outbreak
vaccin
popul
usual
caus
phylogenet
distinct
vaccin
strain
mump
virus
muv
examin
issu
kinet
titer
avid
neutral
activ
level
spectrum
specif
igg
studi
followup
serum
sampl
healthi
volunt
n
vaccin
mump
past
one
vaccin
dose
contain
muv
strain
full
seroconvers
confirm
elisa
prn
vaccin
muv
strain
regist
volunt
month
vaccin
antibodi
induc
vaccin
strain
effect
neutral
five
heterolog
muv
strain
genotyp
b
earlier
isol
local
mump
outbreak
c
h
start
month
vaccin
time
point
test
thereaft
albeit
level
lower
seen
vaccin
strain
differ
specif
igg
titer
measur
elisa
demonstr
earli
decreas
month
post
vaccin
time
specif
igg
function
activ
character
avid
level
spectrum
neutral
activ
reach
maximum
within
month
vaccin
antibodi
capabl
neutral
heterolog
muv
genotyp
absenc
antigen
boost
demonstr
decreas
critic
level
part
vaccine
third
year
post
vaccin
specif
igg
neutral
activ
vaccin
strain
still
demonstr
titer
previous
associ
protect
muv
infect
current
studi
possess
sever
limit
demonstr
first
time
broadspectrum
neutral
activ
specif
igg
recipi
one
dose
vaccin
contain
muv
strain
within
year
vaccin
k
hamuro
kotani
inou
ogasawara
yamahira
saito
toba
n
kohda
otsu
jp
object
foreign
substanc
pathogen
microorgan
usual
invad
intern
bodi
via
mucos
surfac
ingest
breath
thu
activ
mucos
immun
function
essenti
maintain
better
health
secretori
immunoglobulin
siga
play
pivot
role
mucos
immun
system
multipl
protect
role
studi
object
find
lactic
acid
bacteria
lab
promot
iga
method
first
test
lab
strain
iga
product
capabl
vitro
use
murin
peyer
patch
cell
cultur
system
select
lactobacillu
pentosu
addit
comparison
cytokin
profil
low
iga
induc
lab
examin
next
administr
heatkil
mice
week
investig
intestin
iga
enhanc
moreov
attempt
ex
vivo
studi
assess
reactiv
murin
peyer
patch
cell
result
found
exhibit
excel
iga
produc
activ
strain
lab
interestingli
plant
deriv
lab
includ
tend
show
higher
activ
dairi
lab
administr
intestin
iga
significantli
increas
first
vaccin
week
age
respect
vaccin
induc
immun
respons
mainli
type
cytokin
secret
evalu
differ
age
group
follow
booster
dose
equal
time
interv
preliminari
result
show
higher
antigen
specif
ifng
level
respons
heat
shock
protein
famili
member
protein
antigen
observ
effect
age
ifng
produc
capac
anim
differ
age
group
stimul
whole
blood
seb
howev
anim
older
age
group
respond
well
map
multiantigen
might
need
one
booster
compar
younger
anim
find
work
could
interest
determin
appropri
age
vaccin
gener
memori
cell
pool
map
vaccin
challeng
experi
smallpox
caus
variola
viru
consid
dread
scourg
human
smallpox
vaccin
use
strain
vaccinia
viru
vacv
lead
erad
howev
advers
reaction
could
result
abandon
current
bioterror
attack
threat
fear
diseas
reemerg
new
smallpox
vaccin
safe
less
effect
anim
develop
attenu
candid
measur
swiss
nude
scid
mice
mice
vaccin
pfu
virus
tail
scarif
sign
diseas
mortal
follow
week
period
protect
balbc
mice
lethal
challeng
perform
day
vaccin
cowpoxviru
intranas
rout
vacv
neutral
antibodi
ab
serum
sampl
titrat
plaqu
assay
serum
sampl
first
incub
minut
submit
serial
dilut
sampl
mix
equal
volum
vacv
contain
pfu
one
hour
ad
vero
cell
monolay
two
day
later
viru
plaqu
count
measur
lymphocyt
respons
percentag
lymphocyt
express
intracellular
ifng
measur
flow
cytometri
matur
bone
marrow
dendrit
cell
uninfect
balbc
mice
infect
vacv
incub
spleen
cell
suspens
infect
anim
six
hour
brefeldin
mgml
ad
last
four
hour
block
cytokin
secret
cell
stain
fitccoupl
apccoupl
monoclonalab
fix
permeabilis
ifng
stain
pecoupl
antiifng
mab
cell
fix
formaldehyd
vaccin
candid
shown
protect
tradit
vaccin
cowpox
challeng
mice
close
safe
mva
strain
nude
mice
neutral
antibodi
titrat
show
everi
delet
virus
induc
humor
respons
strong
final
intracellular
cytokin
stain
show
similar
specif
respons
slightli
lower
specif
respons
result
show
sever
delet
vaccin
could
advantag
complet
rang
third
gener
vaccin
alreadi
develop
utilis
one
candid
viral
vector
vaccin
ebola
viru
investig
laboratori
luqu
grau
c
serra
p
pisuny
jp
horcajada
n
berengu
urbina
espona
e
sala
barcelona
es
object
sever
strategi
design
increas
adher
vaccin
program
aim
healthcar
profession
though
result
alway
satisfactori
differ
adher
season
pandem
influenza
vaccin
implement
vaccin
program
healthcar
worker
assess
compar
age
gender
profession
categori
workplac
two
differ
prognost
model
predict
adher
season
pandem
influenza
develop
statist
analysi
univari
logist
regress
perform
identifi
risk
factor
associ
adher
vaccin
multipl
regress
analysi
backward
stepwis
variabl
select
use
identifi
independ
risk
factor
adher
intern
valid
predict
model
evalu
measur
calibr
discrimin
power
result
profession
vaccin
pandem
influenza
season
influenza
statist
signific
differ
observ
vaccin
compar
vaccin
unvaccin
profession
age
profession
categori
workplac
sex
differ
relat
pandem
influenza
predict
model
adher
pandem
vaccin
show
good
discriminatori
power
area
roc
curv
includ
variabl
age
profession
categori
workplac
previou
vaccin
season
influenza
independ
predict
factor
contrari
predict
model
adher
season
vaccin
show
poor
discriminatori
power
area
roc
curv
includ
variabl
age
gender
workplac
model
show
good
calibr
tabl
conclus
adher
pandem
season
influenza
vaccin
program
low
suggest
need
implement
new
strategi
vaccin
program
aim
healthcar
profession
good
model
predict
adher
pandem
vaccin
develop
compar
poor
discrimin
power
predict
model
season
influenza
vaccin
object
adenoviru
respons
variou
diseas
human
mani
speci
anim
bird
antivir
drug
treat
adenovir
infect
use
immunoinformat
greatli
revolution
field
vaccin
research
discoveri
develop
henc
approach
made
identifi
relev
bcell
tcell
epitop
design
vaccin
adenoviru
use
bioinformat
fatal
rate
agespecif
estim
among
adult
age
year
among
older
adult
epidemiolog
burden
ipd
greater
among
older
adult
synthes
estim
may
therefor
serv
baselin
measur
evalu
costeffect
new
strategi
prevent
pneumococc
infect
resist
mddc
apoptosi
assess
annexinvpropidium
iodid
stain
chemokinedriven
chemotaxi
also
evalu
cocultur
experi
lymphocyt
perform
assess
antigenpres
activ
thelper
cell
polar
abil
induct
function
suppressor
cell
result
abl
induc
phenotyp
matur
human
mddc
resist
apoptosi
mddc
produc
broad
spectrum
proinflammatori
regulatori
cytokin
effici
migrat
vitro
respons
lymphat
chemokin
due
inactiv
pertussi
toxin
enzymat
activ
mddc
acquir
antigenpres
capac
drive
mix
polar
induc
function
suppressor
cell
suppress
activ
requir
cell
contact
rather
product
solubl
factor
conclus
find
support
potenti
novel
live
attenu
pertussi
vaccin
strongli
activ
matur
dc
fullblown
activ
dc
acquir
capac
surviv
death
signal
migrat
site
infect
lymph
node
dc
abil
orchestr
broad
spectrum
respons
protect
experiment
b
pertussi
infect
regulatori
cell
respons
like
balanc
restor
local
homeostasi
background
patient
receiv
cytotox
therapi
solid
tumor
increas
risk
sever
influenza
data
flu
vaccin
immunogen
need
patient
improv
vaccin
coverag
method
multicentr
prospect
studi
patient
breast
n
prostat
n
cancer
receiv
one
dose
trival
inactiv
influenza
vaccin
day
iv
administr
docetaxel
serum
hemagglutinationinhibit
hi
antibodi
respons
assess
day
vaccin
median
age
studi
popul
year
minmax
femal
baselin
percentag
patient
titer
vaccin
strainspecif
hi
antibodi
b
respect
immunogen
result
day
show
vaccin
poorli
immunogen
see
tabl
seriou
advers
event
ae
report
first
week
vaccin
report
ae
mild
moder
intens
result
show
trival
inactiv
influenza
vaccin
trigger
low
immunogen
adult
receiv
docetaxel
solid
tumor
although
demonstr
good
safeti
profil
strategi
use
immunogen
influenza
vaccin
evalu
patient
cancer
